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Background: Breast cancer is the most frequently diagnosed cancer and a 
leading cause of cancer death among females, both worldwide and in the UK. 
Although, UK incidence of breast cancer is rising, breast cancer mortality rates are 
falling, due largely to early detection and improved treatment. As a result there are 
more women living with a diagnosis of breast cancer than ever before. Due mainly 
to side-effects of adjuvant therapy, breast cancer patients may require diagnostic, 
therapeutic, supportive or palliative services many years post-diagnosis, which 
poses a major challenge to already stretched healthcare services. Accordingly, 
effective and inexpensive interventions that can alleviate treatment side-effects, 
improve health, quality of life and potentially reduce risk of early mortality are 
required for breast cancer patients. Awareness of the positive influence that 
physical activity can have on breast cancer development and outcome is an 
important determinant of physical activity levels. A higher level of physical activity 
before and after breast cancer diagnosis is related to a lower risk of all-cause and 
breast cancer-related mortality. Randomised controlled trials have reported 
beneficial effects of physical activity interventions on outcomes relating to health, 
quality of life and mortality risk among breast cancer survivors. 
Aims: The present project aimed to: 1) assess awareness of the role of physical 
activity on breast cancer risk and the sufficiency of physical activity undertaken in 
women attending the NHS breast screening programme (NHSBSP), 2) compare 
physical activity levels of women at different stages of breast cancer pathway, 3) 
investigate the effects of a low-cost six-month home-based physical activity 
intervention on physical activity, body mass, health-related quality of life (HRQoL), 
insulin resistance and blood lipid profiles of breast cancer survivors and 4) assess 
the effects of our home-based intervention on cardiorespiratory fitness in a subset 
of breast cancer survivors. 
Methods: A total of 309 volunteers (188 NHSBSP attendees, 41 breast cancer 
patients undergoing chemotherapy and 80 post-treatment breast cancer survivors) 
participated in the current project. Physical activity was assessed via the 
International Physical activity Questionnaires (IPAQ). In studies one and two, Body 
mass and body mass index (BMI) were assessed directly in chemotherapy 
patients and breast cancer survivors, and indirectly from self-reported values in 
NHSBSP attendees. While in study three, body fat percentage was measured via 
bioelectrical impedance analysis, HRQoL was assessed using the Functional 
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Assessment of Cancer Therapy-Breast (FACT-B) questionnaire and fasting blood 
samples were taken to measure lipid, glucose and insulin concentrations at 
baseline and post-six month home-based physical activity intervention. In study 
four, a random subsample of 32 breast cancer survivors undertook an exercise 
tolerance test to establish peak oxygen uptake values. 
Results: A high proportion (70%) of NHSBSP attendees engaged in low-moderate 
levels of physical activity and performed low amounts of recreational physical 
activity. Attendees demonstrated high awareness (75%) of the role of physical 
activity in reducing breast cancer risk but those categorised as “low activity” were 
significantly unaware of insufficiency of activity (p<0.05). Chemotherapy patients 
and breast cancer survivors had significantly lower levels of total physical activity 
than NHSBSP attendees (p<0.001 and p<0.05, respectively). The randomised 
controlled trial revealed significant improvements in total physical activity, body 
mass (p<0.05), BMI (p<0.05) HRQoL (breast cancer subscale, p<0.01; trial 
outcome index, p<0.05) and total (p<0.01) and low-density lipoprotein (p<0.05) 
cholesterol concentrations in the intervention group compared to usual care, and 
significant improvements in cardiorespiratory fitness (p<0.05) in a subsample of 
breast cancer survivors allocated to intervention. 
Conclusions: Physical activity interventions that incorporate strategies aimed at 
increasing awareness of recommended physical activity guidelines may be 
required in populations at risk of breast cancer. A relatively large proportion of 
women at risk of breast cancer may not be sufficiently exposed to the potential 
benefits of physical activity on breast cancer outcomes. Post-treatment breast 
cancer patients may be more receptive to physical activity interventions as the 
negative effects of chemotherapy begin to resolve, and therefore, may benefit from 
physical activity interventions. Results suggest that a low-cost home-based 
physical activity intervention with counselling and telephone support can improve 
the health and HRQoL of breast cancer survivors, which may in turn potentially 
reduce risk of breast cancer and cardiovascular disease-related mortality. Given 
the encouraging results and its highly portable and feasible nature, our 
intervention represents a promising tool for use in health and community settings 
to benefit large numbers of breast cancer survivors. The current project supports 
the inclusion of physical activity promotion as an integral component for the 




TABLE OF CONTENTS Page no. 
ACKNOWLEDGEMENTS  
LIST OF FIGURES 
LIST OF TABLES 
LIST OF PUBLICATIONS 
CHAPTER ONE: INTRODUCTION      
CHAPTER TWO: LITERATURE REVIEW     
2.1 DEFINITION, DIAGNOSIS AND CLASSIFICATION OF BREAST 
CANCER 
 2.1.1 Definition of breast cancer 
 2.1.2 Diagnosis and classification of breast cancer 
2.2 EPIDEMIOLOGY OF BREAST CANCER 
 2.2.1 Breast cancer prevalence 
 2.2.2 Breast cancer incidence  
 2.2.3 Breast cancer mortality 
 2.2.4 Breast cancer survival 
2.3 THE AETIOLOGY AND PATHOGENESIS OF BREAST CANCER 
 2.3.1 Genetic and molecular aetiology of breast cancer 
 2.3.2 Pathogenesis of breast cancer 
2.4 GENETIC RISK FACTORS FOR FAMILIAL BREAST CANCER  
2.5 RISK FACTORS FOR SPORADIC BREAST CANCER 
           2.5.1 Exposure to endogenous hormones 
           2.5.2 Obesity and/or overweight 
           2.5.3 Physical activity and sedentary behaviour 
2.6 TREATMENT OF BREAST CANCER AND SIDE EFFECTS 
2.7 PHYSICAL ACTIVITY AND DEATH AND RECURRENCE IN BREAST 
CANCER SURVIVORS; A SYSTEMATIC REVIEW AND META-ANALYSIS 
2.8 PHYSICAL ACTIVITY INTERVENTIONS FOR BREAST CANCER 
SURVIVORS; SYSTEMATIC REVIEW AND META-ANALYSIS  
CHAPTER THREE: AIMS AND HYPOTHESES 
CHAPTER FOUR: METHODOLOGY 
4.1 PARTICIPANTS 
4.2 ASSESSMENTS  
           4.2.1 Anthropometry and body composition 
 4.2.2 Physical activity 
 4.2.3 Health-related quality of life 
 4.2.4 Blood biomarkers 
 4.2.5 Cardiorespiratory fitness  
 4.2.6 Blood Pressure 
4.3 DATA MANAGEMENT AND ANALYSES 
CHAPTER FIVE: STUDIES 
5.1 PHYSICAL ACTIVITY LEVELS AND AWARENESS OF BREAST 
CANCER RISK FACTORS AND SUFFICIENCY OF PHYSICAL ACTIVITY 
IN NHSBSP ATTENDEES 
 5.1.1 Abstract 
5.1.2 Introduction 
 5.1.3 Methods 
 5.1.4 Results 




















































5.2 PHYSICAL ACTIVITY OF NHSBSP ATTENDEES, BREAST CANCER 
PATIENTS RECEIVING CHEMOTHERAPY AND BREAST CANCER 
SURVIVORS 
 5.2.1 Abstract 
5.2.2 Introduction 
 5.2.3 Methods 
 5.2.4 Results 
 5.2.5 Discussion 
 5.2.6 Conclusions 
5.3 HOME-BASED PHYSICAL ACTIVITY INTERVENTION IN BREAST 
CANCER SURVIVORS; A RANDOMISED CONTROLLED TRIAL 
 5.3.1 Abstract 
5.3.2 Introduction 
 5.3.3 Methods 
 5.3.4 Results 
 5.3.5 Discussion 
 5.3.6 Conclusions 
 5.4 EFFECTS OF A HOME-BASED PHYSICAL ACTIVITY INTERVENTION 
ON CARDIORESPIRATORY FITNESS IN BREAST CANCER SURVIVORS  
 5.4.1 Abstract 
5.4.1 Introduction 
 5.4.2 Methods 
 5.4.3 Results 
 5.4.4 Discussion 
5.4.5 Conclusions 
CHAPTER SIX: GENERAL DISCUSSION 
CHAPTER SEVEN: LIMITATIONS 
CHAPTER EIGHT: CONCLUSIONS 
CHAPTER NINE: REFERENCES 
APPENDICES 
Appendix A: Tumour, Node, Metastasis (TNM) classification system  
Appendix B: Epidemiological systematic review search results 
Appendix C: Multivariate analysis in epidemiological studies  
Appendix D: Details of sub-analyses from epidemiological studies 
Appendix E: Funnel plots form epidemiological meta-analysis 
Appendix F: Search strategy and results of RCT systematic review 
Appendix G: Details of studies excluded from RCT systematic review 
Appendix H: Funnel plots from RCT meta-analysis 
Appendix I: Ethics approval documentation (Study 1 and 2) 
Appendix J: Ethics approval documentation (Study 3 and 4) 
Appendix K: PHAST awareness study demographic  information 
Appendix L: PHAB-PILOT Randomisation Form 
Appendix M: Patient Information Sheet 
Appendix N: Informed Consent Form 
Appendix O: Demographic information questionnaire 
Appendix P: International Physical Activity Questionnaire 
Appendix Q: FACT-B (Version 4) 
Appendix R: Blood form for biochemistry request 
Appendix S: Script for face to face and telephonic consultation 























































The present thesis is dedicated to my wife, Yupa, who has given me love, support 
and encouragement throughout this occasionally arduous process. Along with 
Yupa, my stepdaughter, Ruby, and sons, Oisín and Tadhg, allowed me a broader 
perspective, provided a constant source of inspiration, kept me motivated and 
gave me strength to overcome difficulties along the way. My gratitude also to my 
mother for showing me the importance of hard work, and sister, Marie, and 
brother, Edward, for their support along the way. I am also grateful to the Deegan 
aunts, uncles and cousins who have made such an impact on how I think and view 
the world. 
 
Special thanks also to my supervisory team. My supervisor, Dr George Metsios 
has been a close friend, mentor and necessary objective critic of my work and has 
been instrumental in the completion of this thesis. To Prof Amtul Carmichael I 
extend my warmest of thanks for providing me with this opportunity, wise words 
and guidance and unwavering support. My gratitude also goes to Prof Alan Nevill 
for his advice and support on the statistical challenges presented to us during the 
project. Thanks also to Jenny Ensor, Hilary Croydon and Louise Hoole who 
offered me great assistance in the recruitment and administration involved in 
running the randomised controlled trial. In addition, I would like to thank the people 
who without their active involvement there would have been no project, the 
patients. These strong and inspirational women gave our research a sense of 
meaning and have helped make me a better person, for this and more, I will be 
forever in their debt.  
 
This thesis is in memory of my cousin, Jason, beloved and missed by all those he 
has left behind. 
7 
 
LIST OF FIGURES 
FIGURE 1.1 Anatomy of the female breast  
FIGURE 1.2 UK age-standardised incidence for major cancers in females 2007-
2009 
FIGURE 1.3 UK age-standardised mortality for major cancers in females, 2007-
2009  
FIGURE 1.4 Divergent evolutionary pathways of breast cancer progression 
FIGURE 1.5 Average number of new breast cancer cases per year and age-
specific incidence rates, females, UK, 2008-2010 
FIGURE 1.6 Worldwide incidence of breast cancer 
FIGURE 1.7 Biosynthesis of oestrogens and progesterone 
FIGURE 1.8 Hypothesised model of the potential mechanisms by which long-term 
physical activity may decrease breast cancer risk in pre and postmenopausal 
women 
Figure 2.7.1 Forest plot with random effects overall hazard ratio for association 
between lifetime recreational (pre-diagnosis) physical activity (highest vs. lowest 
physical activity categories) and all-cause death in breast cancer survivors 
Figure 2.7.2 Forest plot with random effects overall hazard ratio for association 
between lifetime recreational (pre-diagnosis) physical activity (highest vs. lowest 
physical activity categories) and breast cancer-related death in breast cancer 
survivors 
Figure 2.7.3 Forest plot with random effects overall hazard ratio for association 
between recent (1-5 y) pre-diagnosis recreational physical activity (highest vs. 
lowest physical activity categories) and all-cause death in breast cancer survivors 
Figure 2.7.4 Forest plot with random effects overall hazard ratio for association 
between recent (1-5 y) pre-diagnosis recreational physical activity (highest vs. 
lowest physical activity categories) and breast cancer-related death in breast 
cancer survivors 
Figure 2.7.5 Forest plot with random effects overall hazard ratio for association 
between post-diagnosis recreational physical activity (highest vs. lowest physical 
activity categories) and all-cause death in breast cancer survivors 
Figure 2.7.6 Forest plot with random effects overall hazard ratio for association 
between post-diagnosis recreational physical activity (highest vs. lowest physical 
activity categories) and breast cancer-related death in breast cancer survivors 
8 
 
Figure 2.7.7 Forest plot with random effects overall hazard ratio for association 
between post-diagnosis meeting recommended physical activity guidelines 
(meeting vs. not meeting physical activity guidelines) and all-cause death in breast 
cancer survivors 
Figure 2.7.8 Lifetime pre-diagnosis recreational physical activity and all-cause 
death and funnel plot with 95% CI provided  
Figure 2.8.1 Selection process of eligible trials for inclusion in review 
Figure 2.8.2 Risk of bias graph: review authors' judgements about each risk of 
bias item presented as percentages across all included studies 
Figure 2.8.3 Risk of bias summary: review authors' judgements about each risk of 
bias item for each included study 
Figure 2.8.4 Forest plot: Physical activity vs. Control, analysis 1.1 Physical activity 
levels. 
Figure 2.8.5 Forest plot: Physical activity vs. Control, analysis: 1.2 Physical 
activity (steps/day/week) 
Figure 2.8.6 Forest plot: Physical activity vs. Control, analysis: 1.3 
cardiorespiratory fitness 
Figure 2.8.7 Forest plot: Physical activity vs. Control, analysis: 1.4 Mass (kg) 
Figure 2.8.8 Forest plot: Physical activity vs. Control, analysis: 1.5 BMI (kg/m2) 
Figure 2.8.9 Forest plot: Physical activity vs. Control, analysis: 1.6 Body fat % 
Figure 2.8.10 Forest plot: Physical activity vs. Control, analysis: 1.7 Lean mass  
Figure 2.8.11 Forest plot: Physical activity vs. Control, analysis: 1.8 waist 
circumference (cm) 
Figure 2.8.12 Forest plot: Physical activity vs. Control, analysis: 1.9 hip 
circumference (cm) 
Figure 2.8.13 Forest plot: Physical activity vs. Control, analysis: 1.10 WHR 
Figure 2.8.14 Forest plot: Physical activity vs. Control, analysis: 1.11 Upper body 
strength 
Figure 2.8.15 Forest plot: Physical activity vs. Control, analysis: 1.12 Lower body 
strength 
Figure 2.8.16 Forest plot: Physical activity vs. Control, analysis: 1.13 Resting 
systolic blood pressure 




Figure 2.8.18 Forest plot: Physical activity vs. Control, analysis: 1.15 HRQoL - 
FACT-G 
Figure 2.8.19 Forest plot: Physical activity vs. Control, analysis: 1.16 HRQoL - 
FACT-B  
Figure 2.8.20 Forest plot: Physical activity vs. Control, analysis: 1.17 Physical 
wellbeing 
Figure 2.8.20 Forest plot: Physical activity vs. Control, analysis: 1.18 
Mental/emotional wellbeing 
Figure 2.8.21 Forest plot: Physical activity vs. Control, analysis 1.19 Fatigue 
Figure 2.8.22 Forest plot: Physical activity vs. Control, analysis: 1.20 Self-esteem 
Figure 2.8.23 Forest plot: Physical activity vs. Control, analysis: 1.21 Depression 
Figure 2.8.24 Forest plot: Physical activity vs. Control, analysis: 1.22 Anxiety 
Figure 2.8.25 Forest plot: Physical activity vs. Control, analysis: 1.23 Sleep 
Figure 2.8.26 Forest plot: Physical activity vs. Control, analysis: 1.24 Insulin 
Figure 2.8.27 Forest plot: Physical activity vs. Control, analysis: 1.25 Glucose 
Figure 2.8.28 Forest plot: Physical activity vs. Control, analysis: 1.26 HOMA 
Figure 2.8.29 Forest plot: Physical activity vs. Control, analysis: 1.27 High Density 
Lipoprotein 
Figure 2.8.30 Forest plot: Physical activity vs. Control, analysis: 1.28 Triglycerides 
Figure 2.8.31 Forest plot: Physical activity vs. Control, analysis: 1.29 Insulin-like 
Growth Factor 1 
Figure 2.8.32 Forest plot: Physical activity vs. Control, analysis: 1.30 Insulin-like 
Growth Factor-Binding Protein 3. 
Figure 2.8.33 Forest plot: Physical activity vs. Control, analysis: 1.31 Interleukin-6 
Figure 2.8.34 Forest plot: Physical activity vs. Control, analysis: 1.32 Interferon-
gamma 
Figure 5.2.1 Box-plot for overall physical activity (MET-min·wk-1) of NHSBPS 
attendees, chemotherapy breast cancer patients and post-treatment breast cancer 
survivors 
Figure 5.2.2 Percentage of participants in each physical activity category in the 
NHSBPS attendees, chemotherapy breast cancer patients and post-treatment 
breast cancer survivors 
Figure 5.3.1 Plan of the six month home based physical activity intervention 
Figure 5.3.2 Flow of participants through the trial 
Figure 5.4.1 Flow of participants through the trial  
10 
 
LIST OF TABLES 
 
Table 2.1 Surrogate definitions of intrinsic subtypes of breast cancer   
Table 2.2 Five-year relative survival rates (%) for breast cancer among 
individuals† aged 15 and older in select countries 
Table 2.7.1 Characteristics of included studies 
Table 2.7.2 Physical activity assessment characteristics 
Table 2.7.3 Physical activity and all-cause and breast cancer death and 
recurrence risk; results from epidemiological studies 
Table 2.7.4 Summary of random effects overall hazard ratios (HR) and 95% 
confidence intervals (95% CI) for association between physical activity variables 
and death in breast cancer survivors 
Table 2.8.1 Summary of characteristics of included studies 
Table 2.8.2 Summary of findings; analysis 1: all physical activity interventions vs. 
control    
Table 2.8.3 Summary of findings; analysis 2: aerobic exercise only interventions 
vs. control    
Table 2.8.4 Summary of findings; analysis 3: aerobic and resistance exercise 
combined interventions vs. control    
Table 2.8.5 Summary of findings; analysis 3: resistance training only interventions 
vs. control    
Table 5.1.1 Anthropometric, demographic, and lifestyle characteristics of the 
participants 
Table 5.1.2 Median and IQR physical activity levels of women attending 
NHSBCSP 
Table 5.1.3 Participant’s awareness of physical activity and overweight/obesity 
and the risk of developing breast cancer 
Table 5.1.4 Responses to the question “do you think you do enough physical 
activity?” 
Table 5.2.1 Anthropometric, demographic and lifestyle characteristics of the 
participants 
Table 5.2.2 Mean ± s or median (IQR) for anthropometric measures and physical 
activity variables for NHSBPS participants, breast cancer patients undergoing 
chemotherapy, and breast cancer patients within one-year post-treatment 
Table 5.3.1 Personal characteristics of the participants at baseline 
11 
 
Table 5.3.2 Median (IQR) for anthropometric and physical activity (PA) variables 
at baseline for all participants and for intervention and usual care groups at 
baseline and post-intervention (6-months) 
Table 5.3.3 Median (IQR) HRQoL (FACT-B) variables at baseline for all 
participants, and for intervention and usual care groups at baseline and post-
intervention (6-months) 
Table 5.3.4 Linear mixed model results of log transformed data and delta values 
(6-months minus baseline) of untransformed data for anthropometric and physical 
activity (PA) variables comparing intervention group to usual care group at 
baseline to post-intervention (6-months)  
Table 5.4.1 Personal characteristics of the participants at baseline 
Table 5.4.2 Linear mixed model results for exercise tolerance test (ETT) and 
physical activity (MET-min·wk-1) variables comparing intervention group to usual 
care group at baseline to post-intervention 
Table 5.4.3 Linear mixed model results of anthropometric, blood pressure and 



















LIST OF PUBLICATIONS 
Lahart IM, Reich C, Metsios GS, Nevill AM, Carmichael AR. Physical activity and 
awareness in breast screening attendees in Black Country, UK  (in press). Health 
Promotion International. 
Lahart IM, Metsios GS, Nevill AM, Carmichael AR. (2014) Physical activity levels 
in women attending breast screening, receiving chemotherapy and post-breast 
cancer treatment; a cross-sectional study. International Journal of Environmental 
Research and Public Health. May 20; 11(5):5487-96. 
 
Conference presentations 
Lahart IM, Metsios GS, Carmichael AR. and Nevill AM. Effects of a home-based 
physical activity intervention on body mass, physical activity and health-related 
quality of life in breast cancer patients. British Association of Sport and Exercise 
Sciences Conference; University of Essex, Essex, UK. 06-08th September 2011. 
Lahart, I. Reichl, C., Metsios, G., Carmichael, A. Physical activity, body mass 
index, and awareness of breast cancer risk factors in women attending National 
Health Service Breast Screening Programme in the UK. International Convention 









CHAPTER ONE: INTRODUCTION 
Breast cancer affects both men and women; however, the incidence is much 
higher for women. Overall, women are at 100-fold higher risk of breast cancer than 
men (Thomas, 1993). Therefore, female breast cancer will be the focus of this 
thesis. Worldwide, female breast cancer is the most frequently diagnosed cancer 
and a leading cause of cancer death among females, accounting for 23% of total 
cancer cases and 14% of cancer deaths in 2008 (Jemal et al., 2011). In the UK, it 
has the highest incidence (i.e. number of new cases per year) of all cancers and is 
second only to lung cancer as the highest cause of cancer-related mortality (ONS, 
2012). 
 
Breast cancer results from a single transformed cell that proliferates at an 
unregulated rate and multiplies to form a growth of abnormal cells (tumour) within 
the breast tissue. The transformation of a normal breast cell into a cancerous one 
is initiated by a genetic mutation in a somatic (any cell other than gamete or sex 
cells) breast cell or breast stem cell through exposure to appropriate doses of a 
carcinogenic agent (Porth, 2011). The cancer cell and its subsequent generations 
of daughter cells acquire further mutations during cell division conferring a number 
of capabilities upon the cancer cells, such as sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, reprogramming of energy metabolism, evading immune 
destruction, and activating invasion and potentially spreading to distant parts of the 
body (i.e. metastasis) (Hanahan and Weinberg, 2011). 
 
While the exact cause of the genetic mutations that induce breast cancer is 
unknown, there are a number of risk factors associated with an increased risk of 
breast cancer (see sections 2.4 and 2.5). The strongest risk factors for the 
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development of a first primary invasive breast cancer are older age, previous 
history of breast lesions, a family history of breast cancer (particularly in a first-
degree relative), inheritance of a genetic mutation, such as the Breast Cancer 
genes (BRCA) 1 and 2, and very high breast density (NBOCC, 2009; Weir et al., 
2007; Ellis et al., 2003). Other risk factors that confer a moderate to modest 
increase in risk of breast cancer include living in a ‘developed’ more-affluent 
country, menstrual and reproductive factors, exposure to endogenous (coming 
from within the body) and exogenous (coming from outside the body) hormones, 
dietary fat and alcohol intake, height, being overweight or obese, inactivity and 
increased sedentary behaviour (NBOCC, 2009; Weir et al., 2007). 
 
Because some of these risk factors are either non-modifiable or difficult to modify, 
researchers have focused on inducing change in modifiable risk factors. Alcohol 
intake, overweight/obesity and inactivity/sedentary behaviour are perhaps the 
most modifiable risk factors associated with breast cancer. Investigating and 
reducing inactivity or sedentary behavior (i.e. increased physical activity) in breast 
cancer populations will be the focus of this thesis. There is evidence that physical 
activity can reduce the risk of breast cancer either dependent or independent of 
reducing adiposity (body fat) (Lynch et al., 2010; Neilson et al., 2009). In the most 
recent epidemiological review, physical activity participation of two to three hours 
per week was associated with an average breast cancer risk reduction of 9%, and 
a 30% risk reduction with 6.5 hours of weekly physical activity (Lynch et al., 2010). 
The mechanism for this beneficial role of physical activity on breast cancer risk 
has been attributed to a number of factors, including decreased adiposity, reduced 
exposure to oestrogen and androgens, lower conversion of androgens to 
oestrogens, increased insulin sensitivity and positive influence on inflammatory 
cytokines (Neilson et al., 2009; Key et al., 2002).  
15 
 
In 2008, only 29% of women aged 16 and over were meeting the current 
recommended physical activity guidelines, that is achieving at least 150 minutes of 
moderate intensity activity in bouts of 10 minutes or more over a week, 75 minutes 
of vigorous intensity activity spread across a week, or a combination of moderate 
and vigorous intensity activity throughout a week (Bull and the Expert Working 
Groups, 2010; Roth, 2009). Based on these data, many women are not sufficiently 
active to avail of the potential breast cancer risk-reducing benefits of physical 
activity. However, relevant data from a UK based population at risk of breast 
cancer are lacking. Therefore, the aims of the first study presented in this thesis 
(section 5.1) was to explore, primarily, the physical activity and secondarily, 
overweight/obesity prevalence of a cross-section of women attending National 
Health Service breast screening (NHSBSP), and to examine the awareness levels 
of these women regarding the sufficiency of their physical activity levels and the 
potential breast cancer risk influence associated with physical activity and 
postmenopausal overweight/obesity. 
 
Due to the increasingly early diagnosis of breast cancer and improvements in 
breast cancer treatment, more women are living longer after diagnosis (Ferlay et 
al., 2010). However, the risk of recurrence and development of a second primary 
breast cancer is a continued source of anxiety for breast cancer survivors (i.e. 
patients diagnosed with operable breast cancer who have completed all adjuvant 
therapy apart from hormone therapy). Epidemiological evidence suggests that 
breast cancer survivors who perform the highest amounts of physical activity 
compared to inactive or minimally active breast cancer survivors have a lower risk 
of breast cancer recurrence and improved overall survival (Beasley et al., 2012; 
Ibrahim and Al-Homaidh, 2011) (section 2.8). The mechanisms for this beneficial 
effect on breast cancer progression and mortality appear to be similar to those 
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attributed to breast cancer prevention, such as reduced adiposity, lower exposure 
to both oestrogens and androgens and positive influences on insulin-related 
factors and inflammatory biomarkers.  
 
However, research in the USA has found that physical activity levels are generally 
low among breast cancer survivors with many women decreasing their physical 
activity following diagnosis (Irwin et al., 2003; Irwin et al., 2004). It is unknown 
whether this is also true in UK breast cancer populations. Therefore, we adopted a 
cross-sectional approach to assess whether physical activity levels of breast 
cancer patients undergoing systemic therapy and breast cancer patients post-
systemic therapy (baseline data from participants in study’s 3 and 4) were different 
from those of women not diagnosed with breast cancer (for this the breast 
screening attendees investigated in study 1 were used) (section 5.2).  
 
Breast cancer treatment and in particular the use of adjuvant systemic treatment, 
such as chemotherapy and biologic and hormone therapy, can result in significant 
short- and long-term side effects (section 2.7). Short-term effects such as nausea, 
emesis (vomiting), alopecia (hair loss), myelosuppression (suppression of the 
bone marrow's production of blood cells and platelets), stomatitis (oral 
inflammation), thromboembolism  (blocking of a blood vessel by a particle that has 
broken away from a blood clot), myalgia (pain in one or more muscles), 
neuropathy (abnormal and usually degenerative state of the nervous system or 
nerves), cognitive dysfunction, fatigue, sore eyes, difficulty sleeping and changes 
in sexual functioning have a significant detrimental impact on breast cancer 
patients’ health-related quality of life (HRQoL) (Mishra et al., 2012; Kayl and 




Long-term effects of adjuvant systemic therapy include cardiotoxicity, 
neurotoxicity, secondary leukemia, lymphedema, premature menopause, sexual 
dysfunction, infertility, weight gain and fatigue (Azim et al., 2011; Bovelli et al., 
2010). Particularly worrisome is the cardiotoxicity associated with some forms of 
systemic therapy, which can reduce survival rates in breast cancer patients so that 
the benefits derived by chemotherapy are negated.  
 
Physical activity interventions have been investigated in randomized controlled 
trials (RCTs) as a possible strategy to alleviate some of both the short and long-
term side effects of cancer therapy and improve overall HRQoL and psychological 
well-being in breast cancer survivors (Mishra et al., 2012; Speck et al., 2011; 
McNeeley et al., 2006). These studies have reported potential benefits of physical 
activity interventions in the management and/or rehabilitation of breast cancer 
patients post-treatment including the preservation or restoration cardiorespiratory 
function, muscle and bone strength and mobility, all of which can be adversely 
affected by cancer therapy (Speck et al., 2011). 
 
However, most physical activity intervention trials consist of either entirely or partly 
facility-based supervised interventions, and therefore, the findings of these trials 
have limited generalisability to patients who have limited access to exercise 
facilities because of transportation or time-related difficulties. Home-based 
interventions may be advantageous as they provide a low-cost to alternative 
supervised, facility-based interventions that mitigate most of the transport and 
time-related difficulties. Therefore, a low-cost home-based physical activity 
intervention for breast cancer survivors within 12-months of completion of all 
adjuvant therapy except hormone therapy was developed (section 5.3, study 3). 
Study three adopted a RCT design to compare the effects of six-month home-
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based physical activity intervention on primarily the physical activity levels of 
breast cancer survivors to usual care. Secondary outcomes included 
anthropometric measures, HRQoL and concentrations of blood biomarkers, such 
as blood lipid concentrations and insulin resistance of breast cancer survivors. The 
effects of the home-based intervention on cardiorespiratory fitness compared to 
usual care were assessed in a sub-sample of patients in study four (section 5.4). 
 
Chapter two consists of a comprehensive description of the classification and 
diagnosis of breast cancer, and a presentation of the current knowledge on the 
aetiology, pathogenesis of the disease, risk factors for both familial (inherited) and 
sporadic (non-inherited) breast cancer and the treatment and side effects 
associated with breast cancer therapy. In addition, section 2.7 includes a review of 
the epidemiological research investigating the association between physical 
activity and mortality and recurrence in breast cancer survivors and is followed by 
a systematic review of trials of physical activity interventions in breast cancer 
survivors in section 2.8. The aims and objectives and hypotheses of this current 
thesis are provided in chapter three, while the methods and findings of the studies 
are presented in chapters four and five, respectively. Finally, the applications, 
limitations and future recommendations for practice and research are discussed in 










CHAPTER TWO: LITERATURE REVIEW 
The following chapter includes an overview of the definition, diagnosis and 
classifications of breast cancer. Subsequently, breast cancer prevalence, 
incidence, mortality and survival statistics are outlined in section 2.2. The next 
section (2.3) describes the possible causes of breast cancer and reviews the 
progression of breast cancer from malignancy to metastasis. Section 2.4 and 2.5 
provides a summary of the genetic risk factors for familial breast cancer and risk 
factors of sporadic breast cancer, respectively. In particular, the role of 
endogenous hormone exposure, overweight/obesity and physical activity on the 
effects of breast cancer risk is reviewed. A summary of the treatment and side-
effects associated with breast cancer therapy is included in section 2.6. Finally, 
sections 2.7 and 2.8 comprise of systematic reviews and meta-analyses of the 
effect of physical activity on breast cancer outcomes in breast cancer survivors 
and the effect of physical activity interventions for breast cancer survivors, 
respectively. 
 
2.1 Definition, diagnosis and classification of breast cancer 
2.1.1 Definition of breast cancer 
Cancer is a generic term that encompasses a group of more than two hundred 
diseases sharing common characteristics (Gabriel, 2007). Cancer develops when 
somatic cells acquire mutations which enable them to overcome numerous 
intrinsic and extrinsic barriers allowing them to replicate uncontrollably and spread 
to other parts of the body (Pelengaris and Khan, 2013). Normal cell renewal and 
repair involves two distinct processes: a) cell proliferation, which is the process of 
cell division, and b) cell differentiation, which is the process of specialization 
whereby new cells acquire the structural, microscopic and functional 
characteristics of the cells they replace (Porth, 2011). Tumour and neoplasm 
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(meaning “new growth”) are interchangeable terms used to describe a diverse 
group of conditions associated with uncontrolled cell proliferation. If a tumour is 
confined locally, composed of well-differentiated cells that resemble the structure 
and function of normal original cells but has lost its ability to control proliferation, it 
is described as a benign or non-cancerous tumour. However, if uncontrolled cell 
proliferation is accompanied by a loss of control of differentiation and invasion of 
surrounding tissues or spread to distant sites (metastasis) then the resulting 
neoplasm is described as a malignant or cancerous tumour (Pelengaris and Khan, 
2013).  
 
In malignant tumours, the accumulation of neoplastic cells may result from not only 
uncontrolled cell proliferation but also from evasion of apoptosis (programmed cell 
death that eliminates senescent and damaged or unwanted cells and 
deoxyribonucleic acid, DNA) (Gabriel, 2007). Both benign and malignant tumours 
consist of parenchymal tissue, which is composed of the neoplastic cells, and 
supporting non-neoplastic stromal tissue, which comprises of connective tissue, 
extracellular matrix and blood vessels (Porth, 2011). Tumours can be liquid, as in 
the cases of leukaemia and lymphomas, which comprise of neoplastic cells whose 
precursors are usually mobile, or they can be solid, as in the case of cancers such 
as breast cancer, which arise from the epithelial cells and are usually immobile 
(Vogelstein and Kinzler, 2004).  
 
Pathologically, cancers are defined based on their site of origin. Carcinomas are 
cancers which originate from the epithelial cells in the skin or tissues lining or 
covering internal organs (~70% of cancer cases), sarcomas begin in bone, 
cartilage, fat, muscle, blood vessels or other connective/supportive tissue, 
leukaemia forms in blood-forming tissues such as the bone marrow and causes 
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the production of abnormal blood cells, while lymphomas arise in the cells of the 
immune system (Pelengaris and Khan, 2013). Most breast cancers are 
carcinomas. Although rare, sarcoma’s can develop in the stromal tissues (i.e. 
connective tissues including muscle, fat and blood vessels) within the breast (e.g. 
phyllodes tumour) (Esteva and Gutierrez, 2010). 
 
Breast carcinomas are typically sub-divided into two major categories, in situ 
disease or invasive cancer. In situ disease describes tumours which remain either 
in the ducts (tubes which carry breast milk from the lobes to the nipple), referred to 
as ductal carcinoma in situ (DCIS), and those which remain in the lobules (milk 
producing part of breast), known as lobular carcinoma in situ (LCIS) (Gabriel, 
2007) (see figure 2.1. for anatomy of breast). Although most research uses the 
term DCIS to describe proliferative lesions within the ducts of the breasts, DCIS is 
actually one of four categories, which are collectively defined as intraductal 
proliferative lesions of the breast. Intraductal proliferative lesions are a group of 
diverse proliferations that typically originate from the terminal duct-lobular unit and 
are confined to the mammary duct lobular system (Ellis et al., 2003). The three 
other categories besides DCIS include: a) usual ductal hyperplasia (UDH), which 
describes a benign ductal proliferative lesion typically characterised by secondary 
lumens, and streaming of the central cells, b) atypical ductal hyperplasia, which is 
described as a neoplastic intraductal lesion characterised by proliferation of evenly 
distributed monomorphic cells and c) flat epithelial atypia, a neoplastic intraductal 
alteration and characterized by replacement of the original epithelial cells by a 
single or several layers of mildly atypical cells (Ellis et al., 2003). Due to a lack of 
distinction in the literature between different intraductal proliferative lesion 





Figure 2.1 Anatomy of the female breast 
 
DCIS includes a wide spectrum of diseases ranging from non-life threatening low-
grade lesions to high-grade lesions that may harbour invasive breast cancer foci 
(Virnig et al., 2010). Histologically (investigation of the microscopic structure, 
composition and function of tissues and cells), it is characterized by a proliferation 
of malignant-appearing cells of the duct system and terminal lobular units of the 
breast (Leonard and Swain, 2004). DCIS varies in size and can be extensive, but 
has not spread outside the ductal basement membrane and thus, cannot have 
metastasised (Resetkova, 2012). It is classified according to its architectural 
pattern (solid, cribform, papillary and micropapillary), tumour grade (high, 
intermediate and low) and comedo (presence/absence of cells that appear 
cytologically malignant, with the presence of high-grade nuclei, pleomorphism and 
abundant central luminal necrosis) (Ellis et al., 2013; Vernig et al., 2010). DCIS 
accounts for around 20% of breast cancers detected by mammographic (x-ray of 
the breasts) screening (Virnig et al., 2010). In 2008, 2,500 cases of DCIS were 
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detected by screening in the UK (NHSBSP & ABS, 2010). DCIS is considered a 
precursor lesion to invasive breast cancer, with a relative risk (RR) of developing 
invasive breast cancer of 8.0 to 11.0 (Ellis et al., 2003). Post-DCIS diagnosis, the 
probability of a diagnosis of invasive breast cancer has been estimated at 5.3% 
within five years and 10.9% within 10 years (NBOCC, 2010). 
 
The term LCIS was chosen to emphasis the morphological similarities between the 
cells of LCIS and invasive LCIS (Foote and Stewart, 1941). However, the term 
atypical lobular hyperplasia (ALH) is more appropriately used to describe 
morphologically similar but less well-developed lesions, and an all-encompassing 
term, lobular neoplasia (LN), is used to cover both ALH and LCIS (Haagensen et 
al., 1978). Morphologically LN is defined as a proliferation of generally small and 
often loosely cohesive cells originating in the terminal duct-lobular unit, with or 
without pagetoid (i.e. resembling Paget’s disease, that is any deviation from or 
interruption of the normal structure or function of any body part, organ or system) 
involvement of terminal ducts (Tavassoli et al., 2003).  The term ALH is used when 
there is an incomplete distension of the involved terminal duct-lobular units or 
when residual lumens are present, while LCIS is used to describe fully developed 
lesions (Lakhania et al., 2006). The true incidence of LN is difficult to establish 
because there are no specific clinical abnormalities, and in most cases it is 
undetectable by mammography. However, it has been estimated that its frequency 
ranges from less than 1% to 3.8% of all breast carcinomas (Tavassoli et al., 2003). 
LN has generally been considered a breast cancer risk indicator, conferring an 
increased rate of development of about 1–2% per year, a 10-year risk of 7-8%, 
with a lifetime risk (i.e. the risk of contracting breast cancer by the age of 85 years, 
estimated by cumulating all the annual risks over a woman’s life span up to age 
85) of 30–40% (Chuba et al., 2005; Bauer et al., 1994; Haagensen et al., 1978). 
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Women with LN range in age from 15 to over 90 years old, but most are 
premenopausal (Tavassoli et al., 2003). 
 
When breast tumours infiltrate surrounding tissue they are defined as invasive 
(Pelengaris and Khan, 2009). Breast cancer results from a single transformed cell 
that proliferates at an unregulated rate and multiplies to form a growth of abnormal 
cells within the breast tissue. Within a normal human breast the lobules and ducts 
are lined with a double layer of epithelial cells, of which the inner layer of luminal 
cells and outer layer of basal cells are in direct contact with the basement 
membrane (an extracellular matrix lying between cells and underlying connective 
tissue). The transformation of different epithelial cells within the breast results in 
substantial heterogeneity in breast cancer subtypes (Holstege, 2010). Gene 
expression profiling, using techniques such as DNA microarrays and 
immunohistochemical markers, has classified invasive breast cancers into five 
distinct subtypes: 1) luminal A, which are oestrogen receptor (ER) positive and/or 
progesterone receptor (PR) positive, and human epidermal growth factor receptor 
2 (HER2 or HER-2/neu or erbB2) negative; 2) luminal B, which are ER positive 
and/or PR positive, and HER2 positive; 3) HER2 overexpressing, which are ER 
negative, PR negative, and HER2 positive; 4) basal-like, which are ER negative, 
PR negative, HER2 negative, cytokeratin 5/6 positive and/or epidermal growth 
factor receptor (EGFR) positive; and finally 5) normal breast-like tumours, which 
have relatively high expression of gene expressions of adipose tissue and other 
non-epithelial cell types and relatively low expression of luminal cell types (Carey 
et al., 2006; Rakha et al., 2006; Sorlie et al., 2001; Perou et al., 2000). Luminal 
cancers are the most common invasive breast cancer, accounting for up to 70% of 
cases, HER2 and basal breast cancers account for approximately 15% of cases 
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each, while normal breast-like cancers may account for six to 10% of all breast 
cancers (Schnitt, 2010).  
 
Breast cancer subtypes have different epidemiological risk factors and different 
natural histories, which in turn give rise to differences in clinical presentation, 
histology and responses to systemic and local therapies (Goldhirsch et al., 2011). 
However, at this time, the assessment of breast cancer subtype is not widely used. 
Instead the choice of therapy is based on patient’s age, tumour size, histological 
grade, lymph node involvement, ER, PR and HER2 status (Shnitt, 2010). Better 
methods are therefore required in the future to aid the classification of these 
subtypes in order to help assess prognosis and determine the most appropriate 
treatment for patients on an individual basis. 
 
2.1.2 Diagnosis and classification of breast cancer 
Breast cancer may cause any of the following symptoms, a lump or thickening in 
or near the breast or in the underarm area, a change in the size or shape of the 
breast, a dimple or puckering in the skin of the breast, a nipple retraction, unusual 
discharge such as blood from the nipple, scaly, red or swollen skin on the breast, 
nipple or areola and dimples in the breast that look like the skin of an orange, 
called peau d’orange (Bevers et al., 2009). The majority of breast cancers are 
either detected by women themselves through self-examination, through clinical 
breast examinations or by mammography (Porth, 2011). 
 
The diagnosis of breast cancer is based on clinical, radiological and pathological 
examinations. Clinical breast examinations involve bimanual palpation of the 
breasts and locoregional lymph nodes (NCI, 2013). If the clinician detects an 
abnormality the patient undergoes diagnostic imaging rather than screening. 
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Between 14% and 21% of breast cancers are detected by clinical breast 
examination (Jardines et al., 2013). Radiological examinations include bilateral 
mammography and ultrasound of the breast (and potentially the lymph nodes). 
Usually screening mammography can detect breast tumours two years before they 
are palpable (Banning, 2007), and represents a secondary prevention measure for 
the early recognition of breast cancer which is associated with improvements in 
outcomes (Porth, 2011). In the UK, women aged 50 to 70 years are automatically 
invited for mammographic screening every three years. Women over the age of 70 
are still eligible for screening and by the end of 2012, all women in England aged 
47 to 73 will be invited (Public Health England, 2013). Due to the diminished 
sensitivity of mammography when the breast tissue is dense, breast 
ultrasonography has been used as an adjunct to differentiate cystic from solid 
tissue in women with non-specific thickening (Jardines et al., 2013; Porth, 2011). 
In addition, magnetic resonance imaging (MRI) of the breast may be needed in 
cases involving diagnostic challenges arising, such as dense breast tissue 
especially in young women, familial breast cancer associated with breast cancer 
gene mutations, silicone gel implants, positive axillary lymph node status with 
primary tumor in the breast or where multiple tumor foci are suspected, in 
particular with lobular breast cancer (Sardanelli et al., 2010). Positron emission 
tomography (PET) and computer or digital mammography may also be useful 
diagnostic tools to supplement mammography with women with dense breasts or a 
strong family history of breast cancer and/or known breast cancer gene 1 (BRCA1) 
and breast cancer gene 2 (BRCA2) mutation carriers (Porth, 2011).  
 
Pathological diagnosis involves fine needle aspiration, stereotactic (core) needle 
biopsy or incisional or excisional biopsy. Fine needle aspiration is a simple 
method, involving the aspirating of cells and attendant fluid with a small-bore 
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needle, used for obtaining material for cytologic (i.e. microscopic study of cells to 
determine their structure, and how they form and function) examination (ACS, 
2013). It can identify the presence of malignant cells, but cannot differentiate 
between in situ and invasive cancer. In the past, in order to establish a histologic 
diagnosis of breast cancer either an excisional biopsy (removal of the whole 
tumour) or incisional biopsy (removal of a small part of a large tumour) was 
performed (ACS, 2013). Recently for diagnosis of a suspected malignancy, fine 
needle aspiration, incisional and excisional biopsies have been largely replaced as 
the preferred diagnostic tool by core biopsy. Core biopsy is performed using local 
anesthesia and guided by mammography. It involves the removal of a small 
cylinder of tissue (about 0.16 to 1.27 cm), and cells are available for histological 
evaluation with 96% accuracy in detecting cancer (ACS, 2013). Biopsy specimens 
are then used to grade and stage breast cancers to determine the likely rate of 
tumour growth and spread, estimate prognosis and determine the most effective 
treatment regimen. In addition to grading and staging of breast cancer, ER, PR 
and HER2 receptors analysis is carried out on surgical specimens. The presence 
or absence of ER, PR and HER2 receptors can be used in predicting the 
responsiveness of tumours to hormonal manipulation (Porth, 2011). High levels of 
ER and PR improve the prognosis and increase the likelihood of remission (i.e. a 
decrease in or disappearance of signs and symptoms of cancer), while HER2 
receptor overexpression is associated with a worse prognosis. 
 
The grading of a breast tumour based on its histological and cytological 
characteristics and staging according to the clinical spread of the disease are the 
basic methods of classifying breast cancer. Tumour grade is determined based on 
how abnormal the tumour tissue and cells look under a microscope, and is used 
as a prognostic factor because it provides an indication of how quickly a tumour 
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might grow and spread (NCI, 2013). Breast cancer has its own grading systems, 
and the most commonly used system is the Nottingham grading system (Elston 
and Ellis, 1991). This system grades breast tumours based on tubule formation (or 
gland or acinus formation), which determines how much of the tumour tissue has 
normal breast duct structures, nuclear grade (or nuclear atypia or pleomorphism), 
which evaluates the size and shape of the nucleus in the tumour cells and mitotic 
(i.e. division of somatic cells) rate, which describes how many dividing cells are 
present (which is a measure of how fast the tumor cells are growing and dividing) 
(AJCC, 2010). Each category is scored between one and three, where a score of 
one represents that cells and tumour tissue that are “well-differentiated”, or the 
cells of the tumour and the organization of the tumour’s tissue are most similar to 
normal cells and tissue, and a score of three means the cells and tumour tissue 
are “poorly differentiated”, or they look the most different from normal cells and 
tissue and grow and spread at a faster rate than well-differentiated tumours (NCI, 
2013). The three values from the categories are then added together to produce 
scores of three to nine. Based on these scores three grades are possible; G1 or 
low grade (i.e. well differentiated) from a total score of 3–5; G2 or intermediate 
grade (i.e. moderately differentiated) from a total score of 6–7; and G3 or high 
grade (i.e. poorly differentiated) from a total score of 8–9 (Ollis et al., 2003).  
 
The staging of cancer is important in order to determine the prognosis of patients 
and deciding upon the most appropriate treatment and comparing different 
treatment regimens (Porth, 2011). Most staging systems are based on identifying 
the tissue of origin regardless of organ location, and focus on the similarities in 
cellular structure and function among tumours. The majority of adults with solid 
tumours are staged using the internationally recognised Tumour, Node, Metastasis 
(TNM) classification system (UICC, 2010) (see appendix A). The TNM 
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classification system is a measure of the extent of disease, and is used to guide 
management and determine prognosis (AJCC, 2010). In addition to assessing the 
extent of the primary tumour, the TNM classification assesses the involvement of 
lymph glands and the presence of metastases. The system is a “bin model”, in 
which patients are partitioned using TNM prognostic factors, so that each patient is 
placed in only one bin, and these bins are grouped together into larger bins called 
stages (Burke, 2004). It is based upon retrospective analyses of survival in diverse 
samples of patients representing all stages of disease. For example, if a new 
patient is placed in the T1, N1, M0 bin, then that patient’s 5-year disease specific 
survival is predicted to be the same as the mean survival of patients placed in that 
group years earlier (UICC, 2010; Burke, 2004). The prognostic value of the TNM 
system was revaluated for its latest 7th edition based on 211,645 breast cancer 
cases diagnosed between 2001 and 2002 and entered into the National Cancer 
Data Base (UICC, 2010).  
 
The TNM staging system has been useful for assessing prognosis and risk in 
groups of breast cancer patients, but has had limited success in determining 
prognosis and risk in individual patients (Schnitt, 2010). This system assumes the 
contiguous spread of disease over time (temporal determinism) (Burke, 2004). 
However, ordering does not take into account which patients received adjuvant 
therapy, for example, staged IIB patients who do not undergo adjuvant therapy 
may have a worse prognosis than stage IIA who have received adjuvant therapy. If 
a bin with a better prognosis is placed below a bin with a worse prognosis the 
validity of the system would be questioned. Furthermore, the early detection of 
disease due to improved screening has resulted in an increase in the number of 
patients in the early stages and a reduction in the number of patients in the later 
stages, and changes to surgery and neoadjuvant therapy has further reduced the 
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size of tumours, detection of nodal metastases and the accurate grading of 
tumours (Burke, 2004). The above factors lead to a reduction in the predictive 
ability of the staging system. In addition to these issues, the TNM system does not 
accommodate continuous biomarkers or the addition of new biomarkers, which 
can improve the accuracy of prognosis predictions (Burke, 2004). The problems 
presented above have led some researchers to call for a move away from 
temporal determinism to one of biological determinism (Burke, 2004). This 
approach accepts that carcinogenesis is defined by the characteristics of the 
tumour and the host, and that treatment should be driven by the molecular biology 
of the tumour or the host and not the tumours location at detection. The finding 
that invasive breast cancer is not a single disease but a group of several tumour 
subtypes has been crucial in developing an understanding of differing breast 
cancer prognosis and responses to treatment in individuals within each staging 
category. 
 
Table 2.1 Surrogate definitions of intrinsic subtypes of breast cancer (adapted 
from Goldhirsch et al., 2011) 
Intrinsic Subtype Clinico-pathologic definition 
Luminal A Luminal A 
• ER and/or PR positive 
• HER2 negative 
• Ki-67 low (< 14%) 
Luminal B  Luminal B (HER2 negative) 
• ER and/or PR positive 
• HER2 negative 
• Ki-67 high 
 Luminal B (HER2 positive) 
• ER and/or PR positive, 
• any Ki-67 
• HER2 over-expressed or amplified 
HER2 (Erb-B2) 
overexpression 
HER2 positive, non-luminal 
• HER2 over-expressed or amplified 
• ER and PR negative 
‘Basal-like’ Triple negative (ductal)  
• ER and PR negative 




The 12th St Gallen International Breast Cancer Conference Expert Panel adopted 
a new approach to breast cancer subtype classification based largely on the 
subtypes classification outlined earlier in this section. However, for practical 
purposes the panel (Goldhirsch et al., 2011) proposed that subtypes may be 
approximated using clinicopathological rather than gene expression criteria. This 
new classification is based on expression of ER, PR, HER2 and Ki-67 (a 
monoclonal antibody used to assess uncontrollable cell proliferation). The panel 
reached the following consensus on breast cancer subtypes, 1) luminal A; 2) 
luminal B (HER2 negative); 3) luminal B (HER2 positive); 4) HER2 overexpression 
(HER2 positive, non-luminal); and finally, 5) Basal-like (triple negative, ductal) 
(Goldhirsch et al., 2011). The full subtype classification is provided in table 2.1. 
The differences between each of these subtypes imply that clinician’s should 
consider breast cancer cases within the various distinct subtypes in order to 
properly assess the relevant evidence and arrive at appropriate therapeutic 
advice. The use of breast cancer subtypes to guide treatment decision may offer 
an advantage over the classification systems such as the TNM system, as it allows 
treatment to be driven by the molecular biology of the tumour or the host rather 
than the tumours location at detection. 
 
2.2 Epidemiology of Breast Cancer 
Cancer is a major health issue of our day (Pelengaris and Khan, 2013). Of the 
estimated 57 million global deaths in 2008, non-communicable diseases, including 
cardiovascular diseases (CVD) and certain cancers, were responsible for an 
estimated 36 million deaths worldwide, with 17 (~30% of all deaths) and 7.6 (~13% 
of all deaths) million deaths attributable to CVD and cancer, respectively (Jemal et 
al., 2011). The number of global cancer deaths is projected to almost double to 13 
million by 2030. Breast cancer is the most frequently diagnosed cancer and a 
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leading cause of cancer death among females, accounting for 23% (1.38 million) 
of total cancer cases and 14% (458,400) of cancer deaths in 2008 (Jemal et al., 
2011). Thus, cancer is a major and increasing disease burden worldwide and 
breast cancer represents the largest cancer burden for women. 
 
2.2.1 Breast cancer prevalence 
Cancer prevalence is expressed as the number of people or the proportion of the 
population who are alive on a specified index date and have previously been 
diagnosed with cancer (i.e. cancer survivors) (Maddams et al., 2009). Prevalence 
is used as an indicator of the burden of cancer and can help to inform health care 
service planning. Prevalence figures are presented as simple counts of patients as 
well as crude and age-standardised proportions (ASP). Crude proportions are 
calculated by dividing the number of patients who live in a given area by the 
population of that area. The ASP calculation takes into account the age 
composition and size of a population to allow comparisons between different areas 
to be made (Parkin, 2006). Because cancer is much more common in the elderly, 
a more elderly population will in general have a higher crude proportion. 
Therefore, ASPs should be used to account for differences in the age distribution. 
ASPs are most commonly standardised using the European Standard Population 
or World Standard Population statistics. 
 
The number of persons diagnosed and living with cancer within a five-year period 
(i.e. five-year prevalence) has increased from 22.4 million in 2000 to 28 million in 
2008 (Ferlay et al., 2000; Ferlay et al., 2010). Worldwide, female only breast 
cancer has the highest five-year prevalence of all cancers, with nearly 5.2 million 
women (World ASP=210.7 per 100,000) diagnosed and still living between 2003 
and the end of 2008 (Ferlay et al., 2010).  
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Cancer prevalence is influenced by both the number of new cases each year and 
survival. One-year prevalence is strongly associated with incidence, whereas five-
year and ten-year prevalence is associated with both incidence and survival. The 
most recent UK cancer prevalence data comes from the National Cancer 
Intelligence Network (NCIN, 2011). The NCIN (2011) presented one-year, five-
year and ten-year prevalence of cancer in the UK for the end of 2006. There were 
over 200,000 prevalent cancer patients who were less than a year post-diagnosis, 
at the end of 2006, representing a 5% increase in prevalence compared to the 
NCIN’s previous report (2006). Overall, there were 1.13 million cancer survivors 
(European ASP=1,501 per 100,000 population) in the UK who had been 
diagnosed with cancer in the ten years before the end of 2006. In the UK, breast 
cancer was the most prevalent female cancer. At the end of 2006, the number of 
women that were within one year of breast cancer diagnosis was 40,137 (108.8 
per 100,000), while the five-year prevalence was 175,974 women (475.6 per 
100,000) and the ten-year prevalence was 296,037 women (790.8 per 100,000).  
 
2.2.2 Breast cancer incidence 
Cancer incidence is expressed as the number of new cases of cancer diagnosed 
for a given period, usually a year (Stewart and Kleihues, 2003). The statistics are 
generally provided as the total number of cases or similar to prevalence 
proportions, incidence rates can be crude or age-standardised (AS) using the 
European Standard Population or World Standard Population statistics. The global 
number of new cases of cancer is increasing. In 2000, there was an estimated 
10.1 million new cases of cancer, while in 2008 new cancer cases increased to 
12.4 million, and this is projected to rise to 21.4 million in 2030 (Ferlay et al., 2000; 
Ferlay et al., 2010). There were almost 1.4 million new cases of female breast 
cancer worldwide in 2008, with a world AS incidence rate was 66.4 per 100,000 
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population in developed countries and 27.3 per 100,000 population in less 
developed areas (Jemal et al., 2011).   
 
In 2008, the UK had the 22nd highest cancer incidence in the world (World AS 
rate=266.9 per 100,000) (Ferlay et al., 2010). According to the latest data from the 
Office of National Statistics (ONS, 2012), there were on average 315,100 (158,900 
males and 156,300 females) cases of newly diagnosed cancer each year in the 
UK during the period 2007 to 2009 (see figure 2.2). These data represented an 
increase in the average number of newly diagnosed cases of cancer (147,000 
males and 146,000 females) when compared to the period of 2004 to 2006 (ONS, 
2012; ONS, 2009). Furthermore, the yearly incidence of cancer in England is 
predicted to increase by 33%, from 224,000 cases in 2001 to 299,000 in 2020 
(Moller et al., 2007). 
On average there were 47,809 new incidences of breast cancer each year in the 
period of 2007 to 2009 (ONS, 2012). UK women had the 9th highest breast cancer 
incidence rate (world AS=81.9 per 100,000 population) in the world in 2008 (Ferlay 
et al., 2010). In the UK, breast cancer had the highest incidence rate of all 
cancers, with an average European AS rate of 124.2 cases per 100,000 
population each year between 2007 and 2009 (ONS, 2012). This represented a 
slight increase in incidence compared to 2004 to 2006 figures (122 per 100,000) 
(ONS, 2009). Recent projections have estimated that new cases of breast cancer 
in England will rise to 49,743 cases in 2020, representing a 44% increase from 





Figure 2.2 UK age-standardised 
incidence for the major cancers in 
females, 2007-2009 (ONS, 2012) 
Figure 2.3 UK age-standardised 
mortality for the major cancers in 
females, 2007-2009 (ONS, 2012) 
 
2.2.3 Breast cancer mortality  
Mortality is the number of deaths which have occurred, and the mortality rate is the 
number of deaths per 100,000 persons per year (Stewart and Kleihues, 2003). 
Global cancer mortality rates have increased from 6.2 million deaths in 2000 to 7.6 
million deaths in 2008 (Ferlay et al., 2000; Ferlay et al., 2010). Deaths from cancer 
worldwide are projected to continue rising, with an estimated 13.1 million deaths in 
2030 (Ferlay et al., 2010). There was an estimated 458,400 deaths worldwide 
attributed to breast cancer, and world AS mortality rates for breast cancer was 
higher in more developed countries compared to less developed countries (15.3 
and 10.8 per 100,000 population, respectively) (Jemal et al., 2011). 
 
Between the years of 2007 and 2009, there were on average 156,200 deaths 
(81,600 male and 74,600 female deaths, respectively) from cancer each year in 
the UK (see figure 2.3; ONS, 2012). The equivalent European AS mortality rates 
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were 209 per 100,000 deaths for males and 151 per 100,000 deaths for females 
(ONS, 2012). These mortality rates were higher than those in the period of 2004 to 
2006, on average 154,000 (80,000 males and 74,000 females) died from cancer in 
each of these years in the UK, corresponding to an AS mortality rate of 218 and 
155 per 100,000, respectively. Breast cancer was second only to lung cancer as 
the cause of deaths from cancer in UK females (European AS mortality rate of 
26.1 and 31.5 per 100,000, respectively). In the UK in 2008, 12,122 women died of 
breast cancer. The average mortality rate for breast cancer in 2007-09 was slightly 
lower than that of 2004 to 2006 (European AS mortality rate of 26.1 and 28.3 per 
100,000, respectively) (ONS, 2012; ONS, 2009). 
 
2.3.4 Breast cancer survival 
Cancer survival rates in a population are affected by a number of factors, most 
importantly, the types of cancer that occur, the stages at which cancers are 
diagnosed and whether treatment is available (ACS, 2011). Survival rates can be 
expressed in relative or net terms. Relative survival is the ratio of the observed 
survival and the survival that would have been expected if cancer patients had 
only experienced the background mortality (defined by general population life 
tables) experienced by the general population. It can be interpreted as the survival 
of cancer patients after other causes of death are taken into account (Walters et 
al., 2009). Net survival on the other hand, is estimated with an excess hazard 
model, in which the all-cause mortality is modelled as the sum of the cancer-
related (excess) mortality hazard and the background (expected) mortality (Nur et 
al., 2011). Similar to relative survival, the net survival in a population of cancer 
patients is their survival from the cancer of interest in the absence of other causes 




Table 2.2 Five-year Relative Survival Rates (%) for Breast Cancer among 



























77.3 89.0 80.0 73.7 82.0 52.0 46.0 
* Survival rates are age standardised. Variations in survival rates across countries 
may reflect differences in detection practice, availability of treatment and data 
quality. 
† Survival rates for Asia and Africa are for person’s aged 0-74. 
 
In England, the AS relative survival rate for all cancer site for this period (1995-99) 
was 46.2%. For breast cancer, the five-year (1995-99) AS relative survival rate in 
England was 77.3%. AS relative survival rates in England have improved 
substantially since then, the AS five-year relative survival for women (15-99 y) 
diagnosed with breast cancer during 2001-06 and followed up in 2007 was 81.1%, 
and rose to 82% during the period of 2000 to 2004 and followed up in 2005 
(Walters et al., 2009). Net breast cancer survival rates in England have also 
improved, increasing from 90.8% in 1996 to 95.7% in 2009 (Nur et al., 2011). 
 
The statistics presented in this section highlight the major and growing burden of 
cancer across the world. Both in the UK and worldwide the prevalence and 
incidence of cancer, and particularly relevant to this thesis, breast cancer, is 
growing ever larger. In the UK there are now more women being diagnosed with 
breast cancer each year, and positively, with decreasing mortality rates there more 
women living with breast cancer within five years of diagnosis than there has ever 
been since records began. Incidence and survival rates are projected to rise even 
further in the future. Therefore, there are more women who require diagnostic, 
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therapeutic, supportive or palliative services than ever before. This poses a major 
threat to already stretched healthcare services. The Department of Health (2010) 
has recognised this and has emphasised in their “Cancer Reform Strategy” that 
identifying and addressing the requirements of cancer survivors in UK is a high 
priority. 
 
2.3 The aetiology and pathogenesis of breast cancer 
The aetiology (i.e. causes) of breast cancer can be viewed from two perspectives. 
The first perspective entails an investigation of genetic and molecular mechanisms 
that characterise the transformation of a normal cell into a cancerous cell, while 
the second involves an examination of external factors such as age, heredity and 
environmental factors that contribute to its pathogenesis (development) and 
progression. The first part of this section therefore, includes an exploration of the 
genetic and molecular mechanisms that might explain the origins of cancer cells 
and a description of the development and progression of breast cancer. The 
second part includes a comprehensive review of the literature pertaining to the 
factors associated with the risk of developing familial and sporadic breast cancer 
and a quantification of the level of risk presented by these factors. 
 
2.3.1 Genetic and molecular aetiology of breast cancer 
All cancers are genetic diseases of somatic cells (Knudson, 2001). They begin 
with a mutational event, or in other words a permanent change in the DNA 
sequence of a gene in a single cell.  This alteration in the DNA coding allows the 
cell to overcome the intrinsic and extrinsic restraints imposed on cells within the 
adult organism, and in the case of cancerous cells allows the cell to multiply 
uncontrollably and do so in places where it should not (Khan and Pelengaris, 
2013). Along with the original mutation, subsequent generations acquire further 
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mutations when they divide, and almost universally lose normal DNA repair 
processes, which helps explain why tumours develop from benign growths to 
malignancy (Kinzler and Vogelstein, 1996). 
 
The transformation of a normal cell into a cancerous one has been described in 
three main stages, namely, initiation, promotion and progression (Porth, 2011). 
Initiation describes the irreversible stage in which the cell is altered through 
exposure to appropriate doses of a carcinogenic agent, in such a way that it has a 
neoplastic potential. The promotion stage describes the potentially reversible 
process where potentially malignant cells, which have already undergone initiation, 
go into a phase of excessive growth mediated by various chemical and growth 
factors. The progression stage involves the process by which tumour cells acquire 
invasiveness, metastatic competence, autonomous growth and increased genetic 
instability. This classification does not exclude the possibility that each of the 
stages, in the natural state, may depend on one or several changes in the genetic 
make-up (genotype) of the cells.  
 
As normal cells evolve progressively towards a neoplastic state, they acquire a 
number of capabilities driven by the need of cancer cells to acquire traits that 
enable them to become tumorigenic and ultimately malignant (Hanahan and 
Weinberg, 2011). Hanahan and Weinberg (2000) proposed six hallmarks of cancer 
that comprised of six biological capabilities acquired during the development of 
human cancer. These include sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis and activating invasion and metastasis. The acquisition of these 
hallmarks is expedited by increasing genome instability. In an update, Hanahan 
and Weinberg (2011) added two emerging hallmarks to this list, namely, 
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reprogramming of energy metabolism and evading immune destruction. Adding a 
further dimension of complexity, tumours contain both cancer cells and a collection 
of recruited, normal cells that contribute to the acquisition of hallmark traits by 
creating the “tumour microenvironment” (Hanahan and Weinberg, 2011). These 
acquired hallmark traits of tumours allow single somatic cell mutations to develop 
into malignant cancer tumours by increasing proliferation, resisting death, by 
providing an environment in which cells can replicate uncontrollably and ultimately 
activating invasion of surrounding tissues and metastasis from its site of origin to 
other locations within the organism. The mechanisms for the development of these 
hallmarks in breast cancer will be discussed below. 
 
The transformation of a normal breast cell into a cancerous cell is thought to be a 
result of changes in cell physiology originating from genetic damage or mutations. 
The genes associated with cancers are classified into two broad categories. The 
first category includes “proto-oncogenes”, which are normal genes that become 
cancer-causing “oncogenes” if mutated and as a result become overactive. The 
second category comprises of “tumour-suppressor genes”, which by being less 
active can create an environment in which cancer is promoted (ACS, 2011).  
 
Proto-oncogenes encode for normal cell proteins such as growth factors 
(responsible for regulating the division and proliferation of cells), growth factor 
receptors, growth factor signalling molecules (responsible for transmitting 
information between cells) and transcriptional factors (responsible for turning 
particular gene expressions “on”) that promote cell growth and increase growth 
factor-dependent signalling (Lodish et al., 2000). There are a number of genetic 
events that can cause a mutation which can transform a proto-oncogene into an 
oncogene. Gene amplification is a common event in breast cancer, and involves 
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the multiple copying of certain genes which may cause overexpression with higher 
than normal levels of proteins that promote cell proliferation. In breast cancer, 
genomic amplification of the HER2 proto-oncogene results in elevated levels of 
HER2, and is seen in about 20% of primary invasive breast cancer cases (Wolff et 
al., 2007). Overexpression of HER2 is associated with an aggressive tumour type 
and a negative clinical prognosis in both lymph-node positive (Ravdin and 
Chamness, 1995; Antoniotti et al., 1994; Mansour et al., 1994) and node-negative 
breast cancer patients (Andrulis et al., 1998).  
 
Another genetic event that can cause or activate oncogenes is point mutation, 
which is when a single nucleotide base of DNA changes due to an insertion, 
deletion or substitution. An example of this type of mutation is seen in the RAS 
oncogene, which is common in lung, colorectal and pancreatic cancer but 
relatively rare in breast cancer (Fernández-Medarde and Santos, 2011). Other 
mechanisms of oncogene activation include chromosomal translocation, which 
involves the translocation (swapping) of chromosomal arms between heterologous 
chromosomes (i.e. chromosomes which differ in type, function or size) which 
results in abnormal expression of the translocated genes, the formation of a 
unique fusion gene or the inactivation of tumour suppressor genes (Nambiar and 
Raghavan, 2011). All of these outcomes could promote uncontrolled cell 
proliferation or influence apoptosis. Chromosomal translocation may contribute to 
the mutational burden of many breast cancers, but further research is needed to 
elucidate the contribution of this type of mutation in breast cancer development 
(Stephens et al., 2009).  
 
Tumour suppressor genes are genes that normally help prevent unrestrained 
cellular growth and promote DNA repair and cell cycle checkpoint activation, which 
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slows or arrests cell-cycle progression, thereby allowing time for appropriate repair 
mechanisms to correct genetic lesions before they are passed on to the next 
cellular generation (Lee and Muller, 2010; Abraham, 2001). Therefore, loss of 
function mutations in these genes prevents normal DNA repair and promotes 
unregulated cell proliferation. Mutations of tumour protein 53 (p53), perhaps the 
most studied tumour suppressor gene are estimated to occur in up to half of all 
human cancers and in 20 to 30% of breast cancers (Hollstein et al., 1991).  The 
p53 gene normally acts to prevent the propagation of genetically damaged cells by 
detecting DNA damage and assisting the repair process by arresting the cell cycle 
in G1 (phase of cell growth) and inducing DNA repair or apoptosis if repair is not 
possible. The loss of p53 prevents the repair of DNA, leading to the acquisition of 
mutations during cell division and ultimately to malignant transformation (Porth, 
2011). Other tumour suppressor gene mutations which have a major role in breast 
cancer development include mutations in the BRCA1 and BRCA2 genes, which 
are normally involved in DNA repair. These two genes will be discussed in more 
detail in the discussion of familial breast cancer (section 2.4). 
 
In addition to oncogenes and tumour suppressor gene mutations, micro 
ribonucleic acid (miRNA) genes can promote the transformation from normal cell 
function to malignancy. Instead of encoding proteins, these genes produce a 
single strand of RNA, known as miRNA, which serves to regulate gene expression 
(Porth, 2011). Many miRNA can be found in chromosomal regions that undergo 
rearrangement, deletions and amplifications (Zhang et al., 2013). MiRNA can 
either block protein translation or prevent degradation of messenger RNA (mRNA), 
which carries codes from the DNA to the protein synthesising ribosomes in the 
cytoplasm of cells, by pairing with an mRNA that complements the sequence of 
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mRNA (Dvinge et al., 2013). Furthermore, miRNAs can upregulate (i.e. increase 
activity) or downregulate (i.e. decrease activity) cancer cells (Zhang et al., 2013).  
 
There is considerable evidence indicating that miRNAs play important roles in cell 
proliferation, apoptosis and differentiation (Zhang et al., 2013; Casalini and Iorio, 
2009; Brennecke et al., 2003). Depending on the context, they may function as 
either tumour suppressors or oncogenes (Esquela-Kerscher et al., 2006). 
Overexpression of oncogenic miRNAs by amplification may deregulate (i.e. loss of 
regulation) the target tumour suppressor gene, whereas underexpression of 
tumour suppressor miRNAs by deletion of the miRNA locus can result in the 
upregulation of a target oncogene (Caldas and Brenton, 2005). A number of 
miRNAs are deregulated in breast cancer. For example, deregulation of the 
miRNA, miR-125b, has been observed in invasive breast cancer (Scott et al., 
2007). Scott and colleagues (2007) reported that miR-125b suppressed cell 
proliferation by downregulation of HER2 and HER3 in breast cancer. Breast 
cancer subtypes have deranged miRNA expression signatures, which means 
miRNAs could potentially be used to devise novel molecular classifications of 
breast cancer and ultimately could facilitate the development of more 
individualised treatment strategies for breast cancer patients (Khoshnaw et al., 
2009). 
 
As well as mechanisms involving DNA and changes to chromosomal structure, 
carcinogenic changes can be induced through epigenetic mechanisms, which 
involve changes in patterns of gene expression without any alterations in the DNA 
sequence (Esteller, 2008). Epigenetic mechanisms may “silence” genes (i.e. 
interrupt/suppress the expression of a gene at transcriptional and translation 
levels), such as tumour suppressor genes so that the gene although still present is 
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not expressed and a cancer-suppressing protein is not synthesised (Porth, 2011). 
Epigenetic mechanisms that lead to gene silencing include DNA methylation, 
histone modification, miRNA expression and higher order chromatin structure.  
Methylation, which involves the addition of a methyl group to a cytosine nucleotide 
in DNA, of the promoter region of the DNA (region which the transcription of a 
gene is initiated) prevents transcription and causes gene inactivity (Esteller, 2008). 
Abnormal patterns of methylation have been found in several types of breast 
cancer (Vo and Mills, 2012). In sporadic (non-familial) breast cancers mutations in 
oncogenes are rare, however, epigenetic gene silencing by DNA hypermethylation 
of BRCA1, which prevents BRCA1’s role in DNA repair, is observed frequently 
(Heyn et al., 2013). Furthermore, there is a suggestion that DNA hypermethylation 
resulting from high alcohol consumption and low folate intake has been indicated 
in the development of breast cancer (Christensen et al., 2010). Genes silenced by 
hypermethylation can be inherited, and epigenetic silencing can be considered a 
“first hit” in non-familial breast cancer or as a “second hit” when DNA 
hypermethylation occurs in individuals with inherited cancer (Esteller et al., 2001; 
Grady et al., 2000). 
 
2.3.2 Pathogenesis of breast cancer 
Recent advances in genetic, transcriptomic and epigenetic technologies combined 
with advanced microdissection and ex vivo isolation techniques have provided a 
more detailed understanding of the pathological progression of breast cancer 
subtypes. Observations from epidemiological and morphological studies led to the 
formulation of the classic model of breast cancer initiation, transformation and 
progression. For the ductal subtype, a normal epithelial cell was traditionally 
thought to progress to flat epithelial atypia, atypical ductal hyperplasia and DCIS, 
before evolving into invasive ductal carcinoma and potentially metastatic cancer 
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(Bombonati and Sgroi, 2011). While for the lobular subtype, the traditional model 
involves the progression from normal epithelium to the development of atypical 
lobular hyperplasia, LCIS, invasive lobular carcinoma and to potential metastases 
(Bombonati and Sgroi, 2011).  
 
It now appears that human breast cancers progress along two distinct molecular 
genetic pathways that strongly associate with a low or high tumor grade 
(Bombonati and Sgroi, 2011). The low-grade pathway is characterized by 
recurrent chromosomal loss of 16q, gains of chromosome 1q, a low-grade-like 
gene expression signature and the expression of ER and PR. The progression 
along these pathways culminates with the formation of low and intermediate grade 
invasive ductal and invasive lobular carcinomas (see figure 2.4). Tumours 
resulting from the low-grade pathway consist of either luminal A (HER2 absent) or 
luminal B (HER2 present). The high-grade pathway is characterized by recurrent 
chromosomal gain of 11q13 and loss of 13q, a high-grade-like gene expression 
signature, amplification of 17q12 and a lack of ER and PR expression. 
Progression along the pathway includes intermediate- and high-grade ductal 
carcinomas that are stratified as HER2 or basal-like dependent on the 
expression/amplification of HER2. 
 
The mechanisms underlying the pathogenesis of breast cancer are complex and 
vary among individual tumours (Gasparini et al., 2005). Mechanisms include 
defects in DNA repair mechanisms, disorders in growth factor signalling pathways, 





Figure 2.4 Divergent evolutionary pathways of breast cancer progression 
(Bombonati and Sgroi, 2011) 
 
DNA repair genes influence cell proliferation and survival indirectly through their 
ability to repair non-fatal damage in other genes including proto-oncogenes, 
tumour suppressing genes and gene that control apoptosis (Porth, 2011). 
Exposure of cells to physical and chemical agents results in DNA damage, which 
can potentially cause a loss of genetic stability and elevated cancer risk. The 
action of particular DNA repair enzymes, encoded by genes involved in DNA 
repair, restore the Integrity of the damaged DNA (Vettriselvi et al., 2007; 
Charames and Bapat, 2003). Lower DNA repair capacity has been associated with 
a higher cancer risk (Matta et al., 2013). Mutations in genes involved in DNA repair 
can speed up the accumulation of mutations in these critical other genes. Genes 
implicated in breast cancer oncogenesis involved in DNA repair include p53, 
BRCA1, BRCA2 and ataxia-telangiectasia mutated (ATM) (Venkitaraman, 2001). 
In particular deficiencies in the type of DNA repair known as Nucleotide Excision 
Repair (NER) have been associated with breast cancer incidence, suggesting that 
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NER deficiency may contribute to the aetiology and development of sporadic and 
familial breast cancers (Latimer et al., 2010).  
 
Mutations in genes that control signalling pathways are another relatively common 
pathway by which cancerous cells gain autonomous growth (Porth, 2011). These 
signalling pathways allow communication between growth factor receptors and 
their targets in the cell nucleus. In normal conditions, cell proliferation results from 
the binding of a growth factor to its receptor located on the cell plasma membrane, 
which activates the growth factor receptor resulting in the transfer of a signal 
across the cytoplasm to the nucleus via signal-transducing proteins that function 
as second messengers (Striker and Kumanr, 2011). The transfer of the signal to 
the nucleus triggers the induction and activation of regulatory factors that initiate 
DNA transcription and entry into the cell cycle. Many of the proteins involved in 
signalling pathways exert their influence through enzymes known as kinases, 
which add phosphates to proteins.  
 
Altered patterns of gene expression can influence the activity of specific growth 
factor signalling pathways, and aberrant signalling is a key characteristic of 
cancerous cells that can lead to continuous proliferation and suppressed apoptosis 
(Lo and Hung, 2006). Pathways that have been identified as having aberrant 
signalling networks critical to the development and progression of breast 
carcinomas include HER family of receptor tyrosine kinases (including epidermal 
growth factor receptor, or EGFR/HER1, HER2, HER3 and HER4), ERs, BRCA 1/2, 
c-myc, transforming growth factor (TGF)-α and Wnt (Rosen et al., 2010; Lo and 
Hung, 2006). For example, the EGFR signalling pathway regulates growth, 
survival, proliferation, and differentiation in breast epithelial cells (Oda et al., 
2005). EGFR is known to transmit extra-cellular mitogenic signals, such as EGF 
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and TGF-α, through activating a number of downstream signalling cascades, 
which results in altered gene activities, leading to uncontrolled tumour proliferation 
and avoidance of apoptosis (Lo et al., 2006). EGFR is highly expressed 
particularly in triple negative breast cancers (Eccles, 2011). 
 
The proliferation of cancer cells occurs as a result of mutations in genes that 
regulate cell apoptosis. Under normal conditions, breast development is controlled 
by a balance between cell proliferation and apoptosis (Parton et al., 2001). 
Apoptosis is activated by specific enzymes known as caspases, which are also 
involved in the execution of the cell (Wong, 2011). Three pathways are known to 
activate caspases. The intrinsic (or mitochondrial) and extrinsic (or death receptor) 
pathways of apoptosis lead to a common pathway (the execution phase) of 
apoptosis, while a third less well-known initiation pathway is the intrinsic 
endoplasmic reticulum pathway (Wong, 2011). The failure of cancer cells to 
undergo apoptosis is thought to occur due to a disrupted balance of pro-apoptotic 
and anti-apoptotic proteins due to an over- or under-expression of certain genes, 
reduced caspase function and impaired death receptor signalling.  
 
The p53 is a tumour suppressor gene that plays a key player in cell cycle 
regulation, development, differentiation, gene amplification and also the induction 
of cell apoptosis. In breast cancer, ER suppresses several p53 target genes 
implicated in the p53-mediated cell death response including activating 
transcription factor (ATF3), B-cell translocation gene (BTG2) and tumour necrosis 
factor receptor (TNFR) associated factor 4 (TRAF4) (Bailey et al., 2012).  ATF3 
negatively regulates cell-cycle progression and augments the transcription of p53 
target genes, thus, its repression by ER would contribute to further inhibition of the 
p53 responses (Karmakar et al., 2009). BTG2 is regulated in response to DNA 
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damage in a p53-dependent manner, and has been found to inhibit breast cancer 
cell growth and to be downregulated by ER. Loss of BTG2 gene expression is 
associated with a poor prognosis in breast cancer patients and is a strong 
predictor of tumour grade and size, invasion, recurrence and overall survival 
(Möllerström et al., 2010). TRAF4 is a target gene of p53 which has been indicated 
in the p53-mediated cell death response, is known to be suppressed by ER (Bailey 
et al., 2012). There are numerous possible ways by which breast tumours lose 
normal apoptotic pathways, but all contribute to tumour development and 
progression by allowing DNA-damaged cells to survive and pass on their 
mutations to subsequent generations of daughter cells. 
 
Even with genetic abnormalities described above, tumour growth would not be 
possible without angiogenesis to supply them with blood vessels. Angiogenesis 
allows a tumour to exceed a volume of 1-2 mm2, and also provides a route for 
cancer cells to spread to distant organs (Langley and Fidler, 2007). Thus, 
angiogenesis is a prerequisite to both tumour growth and metastasis (Folkman, 
1971). The exact molecular basis for the angiogenesis switch is unknown but 
appears to involve an increased production of angiogenic factors or loss of 
angiogenic inhibitors (Porth, 2011). For example, hypoxia is a key signal for the 
introduction of angiogenesis, and hypoxia-inducible factors (HIF) are angiogenic 
factors which are expressed increasingly from the progression of normal breast 
tissue to invasive carcinoma (Schneider and Miller, 2005). HIF expression is 
greater in higher grade tumours (i.e. poorly differentiated tumours) and is 
associated with increased cell proliferation and expression of ER and vascular 
endothelial growth factor (VEGF) (Bos et al., 2001). VEGF, a potent angiogenic 
cytokine, stimulates breast endothelial cell proliferation and induces angiogenesis, 
and is associated with reduced disease-free and overall survival (Byrne et al., 
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2007; Gasparini et al., 1997; Obermair et al., 1997). The tumour suppressor gene, 
p53, under normal conditions represses the expression of pro-angiogenic factors, 
such as VEGF. However, when p53 activity is lost as is the case in some breast 
tumours, pro-angiogenic switches are overexpressed (Iovino et al., 2008).  
 
Metastasis is the final stage of multi-step tumour progression, and describes the 
development of a secondary tumour in a distant location from the primary tumour. 
Malignant tumours can metastasise by either spreading into the lymph channels or 
blood vessels. Lymphatic spread is more typical in carcinomas, such as breast 
cancer, whereas haematogenous spread is more common for sarcomas (Porth, 
2011). Once in the initial lymph node (known as the sentinel node) the cells may 
die, lay dormant or grow into a discernible mass and gain access to blood 
vasculature by spreading from more distant lymph nodes or through tumour-
associated blood vessels infiltrating the tumour (Tobler and Detmar, 2006). 
Metastatic breast cancer is largely incurable and along with complications from 
recurrence, accounts for a large majority of breast cancer-related deaths 
(O’Shaughnessy, 2005). Despite advances in cancer treatment, approximately 
30% of women diagnosed with earlier stage primary breast cancer eventually 
develop recurrent advanced or metastatic disease (O’Shaughnessy, 2005).  
 
Evidence suggests that breast cancer stem cells play a major role in breast cancer 
growth and metastases. The origin of breast cancer stem cells is unknown, but 
may result in the transformation of normal stem/progenitor cells (Petersen and 
Polyak, 2010). Stem/progenitor cells are likely candidates for the origin of tumour 
cells (i.e. the origin of the first mutational event) due to their long lifespan, which 
makes them more susceptible to the accumulation of DNA mutations, and their 
capacity to replicate and produce multiple progeny (Takebe and Ivy, 2010). For 
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example, BRCA1 expression is required for the differentiation of ER 
stem/progenitor cells into ER-positive luminal cells, and mutations in BRCA1 
resulting in the loss of DNA repair may contribute to the accumulation of 
genetically unstable breast stem cells, which may lead to carcinogenesis and 
cancer stem cell development (Liu et al., 2008).  
 
Furthermore, genetic programmes operative in stem cells during embryonic 
development may become operant in cancer stem cells, and provide a mechanism 
for metastasis. The epithelial cell to mesenchymal cell (a type of connective tissue 
stem cell that can differentiate into bone, fat, cartilage, tendon and muscle cells) 
transition is a process seen in embryogenesis that guides the transformation of a 
non-mobile epithelial-like cell into mesenchymal-like cell, which is more mobile and 
can travel distant anatomical sites within the developing embryo (Takebe et al., 
2011). Upon arrival at this distant site the epithelial-to-mesenchymal transition is 
reversed and the mesenchymal-like cell regains its epithelial phenotype. This 
process has been observed during tumour formation and may lead to metastasis, 
where migratory cancer cells become anchored at distant sites and then lose their 
migratory potential and begin to accumulate at this new site (Takebe et al., 2011).  
 
In breast cancer, the functional loss of E-cadherin, a protein categorized as a 
tumour suppressor, is critical to the progression towards metastasis. E-cadherin is 
responsible for the formation of intracellular junctions and is involved in the 
downregulation of epithelial-to-mesenchymal transition in epithelial tumours 
(Rodriguez et al., 2012). Without E-cadherin previously stationary tumour cells are 
free to dislodge from their original location and become more mobile. Among other 
mechanisms, hypermethylation and silencing of the E-cadherin promoter is known 
to cause downregulation of the E-cadherin gene, CDH1, and has been associated 
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with the initiation of epithelial-to-mesenchymal transition and metastasis 
(Lombaerts et al., 2006; Graff et al., 1995). 
 
2.4 Genetic risk factors for familial breast cancer 
Assuming that most cancers develop from a single cell, and at least two mutational 
events are required, the findings of Knudson (1971) predicted that all cancers can 
be classified as either a) inherited or familial cancers caused by genetic factors, or 
b) sporadic cancers, those arising as a result of chance and caused by a 
combination of genetic and environmental factors. Both categories involve the 
same genetic mutations, but differ in the timing of the mutation’s occurrence. For 
familial cancers, individuals are born with the first mutation and this mutation is 
carried in all of the cells in their body, while the second mutation is acquired after 
birth in a relevant somatic cell of these individuals. By contrast, in the case of 
sporadic cancers individuals acquire both mutations in somatic cells after birth. 
Therefore, the chances of two independent mutations occurring in the same 
somatic cell during the lifetime of an individual (sporadic) are significantly lower 
than a single mutation occurring in a somatic cell with a pre-existing mutation 
(familial) (Knudson, 1971). This “multiple hit” model predicts that those born with a 
pre-existing cancer inducing mutation are at a higher risk of developing cancer and 
that familial cancer will occur at younger ages and at multiple sites, while sporadic 
cancers will occur in older adults and in single sites (Slijepčević, 2007).  
 
About 15 to 20% of all cases of breast cancer are thought to be familial, that is 
breast cancer characterized by a clear family history of disease (i.e. a mother, 
father, sister, brother, daughter or son who have had breast cancer) (Jacobi, 
2003). The overall RR of breast cancer in a woman with a positive family history is 
1.7, and the risk increases threefold if onset of the disease in a first-degree relative 
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was premenopausal (RR=9 if bilateral and premenopausal) compared to an RR of 
1.5 in the case of a postmenopausal diagnosis (Jardines et al., 2013). Apart from a 
significantly younger age at time of diagnosis and a higher frequency of bilateral 
disease, there are no other obvious differences that affect the clinical and 
pathological presentation of familial and sporadic breast cancer (Slijepčević, 
2007). Thus, the same genetic mutations occur in both and the underlying 
molecular mechanism should be the same, leading to similar clinical and 
pathological presentation. 
 
The heritable component of the disease was first indicated by researchers who 
noticed that some breast cancers tend to cluster in families (i.e. multiple first-
degree relatives were affected) (van der Groep et al., 2011). Since the early 
1990’s, researchers have searched for mutations in genes that could explain 
familial breast cancer cases (Narod and Foukes, 2004). Genes in which mutations 
influence the risk of breast cancer have been described based on their 
penetrance. Penetrance is a measure of the probability of a gene or genetic trait 
(phenotype) being expressed and is based on the proportion of individuals with a 
mutation causing a particular disorder who exhibit clinical symptoms of that 
disorder (Griffiths et al., 2000). Highly penetrant genes will almost always cause 
symptoms irrespective of the environmental effects, while, low penetrance genes 
produce symptoms only some of the time and can be affected by environmental 
factors (Slijepčević, 2007).  
 
Ripperger and colleagues (2009) categorised breast cancer susceptibility genes 
and single nucleotide polymorphisms (SNPs) into three groups. These groups are 
a) rare high penetrance genes, which are rare mutations that confer a high risk of 
developing cancer, b) rare moderate-penetrance breast cancer susceptibility 
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genes, which are uncommon mutations in genes conferring a moderate increases 
in risk, and c), common low-penetrance breast cancer susceptibility SNPs, which 
confer only slight risk alterations but are frequently expressed in the population. 
 
Mutations in rare high penetrance genes were the first to be discovered. In the 
early 1990’s, genetic analyses of multiple breast cancer families revealed a 
common gene located on chromosome 17q that was mutated in some but not all 
families (Hall et al., 1990). This gene was named BRCA1 (Miki et al., 1994). Soon 
after, a second breast cancer predisposing gene was identified and named 
BRCA2 (Wooster et al., 1995). Overall, it has been estimated that 
inherited BRCA1 and BRCA2 mutations account for 20-40% of familial breast 
cancer but 5-10% of breast cancer overall (Ripperger et al., 2009). Women who 
inherit a BRCA1/2 mutations have a 40-65% lifetime risk of breast cancer 
compared to a 12% lifetime risk of women in the general population (Chen and 
Parmigiani, 2007; Antoniou et al., 2003), with a typically younger age of onset 
compared with sporadic cases of breast cancer (Hilgart et al., 2012). Mutation 
carriers are also susceptible to cancers of the ovary, prostate, pancreas and male 
breast (Venkitaraman, 2001). The prevalence of BRCA1 or BRCA2 mutations 
varies considerably among ethnic groups and geographical areas, with population-
specific mutations and recurrent mutations described among Ashkenazi Jews and 
in Iceland, Netherlands, Sweden, Norway, Germany, France, Spain, Canada and 
countries of eastern and southern Europe (Balmana et al., 2010). 
 
BRCA1 and BRCA2 are genes involved in DNA damage response (Gasser and 
Raulet, 2006). This response is activated when cells or organisms are exposed to 
genotoxic stress (Deng, 2006). Cellular mechanisms typically recognise DNA 
damage, signal the presence of DNA damage to other relevant molecules, and 
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activate cell cycle checkpoints and the recruitment of the machinery of DNA repair 
(Venkitaraman, 2001). Failure to activate these checkpoints of DNA repair 
following DNA damage increase the DNA’s sensitivity to genotoxic agents. BRCA 
proteins are involved in a multitude of pivotal cellular processes. As well as 
contributing to DNA repair, specifically DNA double-strand breaks, and 
transcriptional regulation in response to DNA damage, BRCA proteins may be 
required for maintenance of chromosomal stability, thereby protecting the genome 
(i.e. the entirety of an organism’s hereditary information) from damage 
(Venkitaraman, 2001). In addition, BRCAs transcriptionally regulate some genes 
involved in DNA repair, the cell cycle and apoptosis, mediated by a large number 
of cellular proteins that interact with BRCAs (Yoshida and Miki, 2004).  
 
In addition to BRCA 1 and 2, other rare high penetrance genes include mutations 
in p53 gene, which cause the Li–Fraumeni syndrome, serine/threonne protein 
kinase 11 (STK11) causing Peutz–Jeghers syndrome, phosphatase and tensin 
homologue (PTEN) causing Cowden syndrome, neurofibromin (NF1) causing 
Neurofibromatosis type 1, nibrin (NBN) causing Nijmegen breakage syndrome, 
and mutations in cadherin 1 (CDH1) (Ripperger et al., 2009). Although these 
mutations are uncommon causes of breast cancer they may be highly penetrant.  
 
However, high penetrance genes mutations account for only approximately 16-
25% of familial breast cancer cases, and a mutation in the gene which causes a 
potentially high risk of cancer does not necessarily mean cancer will develop, 
therefore, interactions with other genes and environmental factors may influence 
disease development (Beggs and Hodgson, 2009; Rahman and Stratton, 1998). 
Numerous studies have failed to identify another highly penetrant BRCA gene, but 
have instead identified several low penetrance genes involved in familial breast 
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cancer (Beggs and Hodgson, 2009). High penetrance genes, such as BRCA 1/2, 
affect many family members and greatly increases breast cancer risk, whereas low 
penetrance genes do not affect as many family members and they confer a lower 
risk (Slijepčević, 2007).  
 
The discoveries of lower penetrance genes indicates that inherited breast cancer 
susceptibility is due to a number of genetic factors, and it may well be that non-
BRCA1 and BRCA2 familial breast cancer cases are due to a combination of the 
effects of lower penetrance gene mutations and environmental factors (Beggs and 
Hodgson, 2009). Ripperger and colleagues (2009) categorised these lower 
penetrance genes as rare, moderate-penetrance breast cancer susceptibility 
genes. This category consists of mutations in genes involved in the same DNA 
repair pathway that can cause an increased risk of breast cancer (Odds Ratio, 
OR=2-4), and includes ATM, checkpoint kinase 2 (CHEK2), partner and localizer 
of BRCA2 (PALB2), and BRCA1 interacting protein C-terminal helicase 1 (BRIP1) 
(Ripperger et al., 2009). In addition, RAD50 homologue, which has a role in DNA 
repair, telomere integrity and meiosis (i.e. cell division leading to gamete cells), 
may be linked with an increased breast cancer risk, but this is still being debated 
(Beggs and Hodgson, 2009).     
 
The final category presented by Ripperger and colleagues (2009) is common low-
penetrance breast cancer susceptibility SNPs. Each individual’s DNA sequence is 
identical apart from 0.01% (or 1 in 1200 DNA bases).  The DNA bases, at specific 
genomic locations, that differ between individuals are called SNPs. SNPs 
constitute by far the greatest type of genetic variation, and the total number of 
common SNPs in the human genome has been estimated to be at least 10 million 
(Slijepčević, 2007). Although there are studies providing contradictory evidence of 
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the importance of the role of SNPs, there is good evidence now that there are up 
to seven SNPs that have been reproducibly found to influence breast cancer risk 
(Beggs and Hodgson, 2009). Each SNP is expected to impact breast cancer risk 
to a minor extent. However, as most of these variants occur at high frequency in 
the investigated populations they can have a significant impact upon breast cancer 
risk. The current list of SNPs which are thought to increase breast cancer risk are 
fibroblast growth factor receptor type 2 (FGFR2), lymphocyte-specific protein 1 
(LSP1), mitogen-activated protein kinase 1 (MAP3K1), transforming growth factor, 
beta 1 (TGFB1), TOX high mobility group box family member 3 (TOX3), as well as 
a locus on 2q3545 and 8q (Ripperger, 2009).  
 
In summary, the evidence suggests that familial breast cancer is a polygenic 
disease (i.e. a disease caused by multiple genes).  Based on current evidence, the 
greatest breast cancer risk is conferred by high penetrance genes, such as 
BRCA1 and BRCA2, although these mutations are rare in the general population. 
Rare moderate-penetrance genes confer a much lower risk, which can increase by 
inheriting more than one of these genes, while common low-penetrance breast 
cancer susceptibility SNPs have a minor impact upon risk but this risk can 
increase due to their high frequency in the population. However, only 
approximately 50% of familial cancer cases can be explained by high, moderate 
and low penetrance genes and SNPs, the other 50% may be caused by as yet 
unidentified genes (Atoum et al., 2012). Therefore, it seems likely that future 
research will uncover more.  
 
2.5 Risk factors of sporadic breast cancer 
For sporadic breast cancer, which represents the majority of breast cancer cases, 
there is no family history of breast cancer and somatic mutations in BRCA1 or 
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BRCA2 do not frequently occur in these breast cancer cases (Venkitaraman, 
2001). This may suggest that the genetic alterations in sporadic cancers target 
other molecules whose functions are linked to those of BRCA1 or BRCA2, target 
genes other than BRCA1 and BRCA2 or that BRCA1 and BRCA2 are inactivated 
by mechanisms other than somatic mutation (Rahman and Stratton, 1998).  
 
Knowledge of breast cancer risk factors might provide information about a 
woman’s future if risk factors are associated with very large increases in risk 
above the “background” risk of the general populations. They are not necessarily 
“causes” of breast cancer. Risk factors that are extremely strongly associated with 
a disease can be considered as a potential screening test for that particular 
disease (Wald et al., 1999).  A RR or of at least five between the highest and 
lowest quintiles of the distribution of a risk factor is necessary to be considered a 
strong indicator of risk of a particular disease (Wald et al., 1999). For example, 
because women who inherit a BRCA1/2 mutation have a breast cancer lifetime RR 
of 4-6.5, BRCA1/2 screening has been proposed for women. Investigations of 
breast cancer risk factors can help improve awareness of these factors and allow 
women to manage their risk were possible and necessary. Where risk factors are 
modifiable, women may reduce their risk of breast factor by lowering their 
exposures to such factors. 
 
The increase in breast cancer risk associated with a history of in situ disease has 
been discussed earlier in this chapter. But in brief, the RR of developing 
intraductal proliferative lesions such as DCIS is eight to 11. Post-DCIS diagnosis, 
the probability of a woman being diagnosed with invasive breast cancer has been 
estimated at 5.3% within five years and 10.9% within 10 years. LN confers an 
increased rate of development of invasive carcinoma of about 1–2% per year, a 
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10-year risk of 7-8%, with a lifetime risk of 30–40%. Other risk factors that were 
beyond the remit of this review and hence, will not be discussed in this section 
include tobacco smoking, for which the evidence of an effect on breast cancer risk 
is equivocal (Gaudet et al., 2013; Slattery et al., 2008; Roddam et al., 2007; Gram 
et al., 2005; Terry et al., 2002) and other factors for which there is either a lack of 
evidence or an unclear relationship with breast cancer, such as bra wear, use of 
deodorants/antiperspirant, chemical pollutants and stress (NBOCC, 2009). 
Ionising radiation is an established breast cancer risk factor (RR=1.4 to 2.2), 
particularly in young girls in whom differentiation of breast tissue is not completed 
(Ronckers et al., 2005), but is of limited quantitative importance so will not be 
reviewed here. Exposure to electromagnetic fields has not been shown to be 
related to breast cancer (Feychting and Forssen, 2006). 
 
The risk of developing breast cancer may be influenced by a number of factors. 
The risk factors associated with the highest increase in risk (RR≥5.0) includes 
being female, inheritance of BRAC 1/2, having first-degree relatives who have had 
breast cancer, previous invasive breast cancer and history of breast lesions, such 
as in situ carcinomas (NBOCC, 2010; Weir et al., 2007). The RR associated with 
breast densities above 75% compared to 5% have been just below five 
(Cummings et al., 2009; McCormack and dos Santos Silva, 2006). All other risk 
factors offer moderate or modest predictions for breast cancer risk.  
 
High consumption of alcohol (Collaborative Group on Hormonal Factors in Breast 
Cancer, 2002), age over 50 years (Jardines et al., 2013; see figure 2.5), higher 
socio-economic status (Ferlay et al., 2010; see figure 2.6) and being Caucasian 
(Ferlay et al., 2010) are associated with moderate levels of risk of breast cancer 
(RR ~1.5 to >4). While later age at menopause (Trichopoulos et al., 2012), 
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nulliparity (Collaborative Group on Hormonal Factors in Breast Cancer, 2002), 
high intake of saturated fat (Thiebaut et al., 2007; Saadatian-Elahi et al., 2004), 
type II diabetes (Larsson et al., 2007; Lawlor et al., 2004), taller height (Baer et al., 
2006; Lahmann et al., 2004; van Brandt et al., 2000), previous history of other 
cancers (Karahalios et al., 2009; Curtis et al., 2006), exposure to diethylstilboestrol 
in utero (Titus-Ernstoff et al., 2001), current or recent use of hormone replacement 
therapy (HRT) (Chlebowski et al., 2013; Collaborative Group on Hormonal Factors 
in Breast Cancer, 1997) and current use of oral contraceptives (OC) (Marchbanks 
et al., 2012; Hannaford et al., 2007) may confer a more modest risk of developing 
breast cancer (RR=1.1-1.5). There is also evidence that the influence of breast 




Figure 2.5 Average incidence of breast cancer per year and age-specific 
incidence rates, females, UK, 2008-2010 (Cancer Research UK, 2013). 80% 
(39,339 out of 48,975 average new cases across all ages) of new cases of female 






Figure 2.6. Worldwide incidences of breast cancer, countries in the red have the 
highest incidence while those countries in blue and purple have the lowest 
incidence. AS incidence rates can vary five-fold, and are highest in “developed” 
countries, such as USA, UK and other Western European countries and lowest in 
the less-developed countries, such as most African countries and parts of Asia. 
This variation is not fully explained by the quality and scope of screening 
programmes within countries (Ferlay et al., 2010) 
 
A number of risk factors may offer modest to moderate protection against breast 
cancer occurrence. Parous women are at a lower breast cancer risk and each 
subsequent child after the first is thought to confer an additional 7% risk reduction 
(Weir et al., 2007). In addition, other reproductive factors such as a lower age at 
first birth (3% risk reduction for each one-year decrease in a woman's age at first 
birth) and breastfeeding of at least 12 months in duration (4.3% risk reduction for 
every 12 months of breastfeeding) have been associated with lower risk of breast 
cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 2002). High 
vegetable intake and dietary patterns high in raw vegetables, fish and olive oil may 
confer a lower risk of breast cancer (Masala et al., 2012; Brennan et al., 2010; 
Sieri et al., 2004; Gandini et al., 2000). 
 
Many of the risk factors outlined above are either not modifiable or modification of 
risk would lead to a considerable restriction in a woman’s life decisions. Therefore, 
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there has been a focus on breast cancer risk factors that can be more readily 
modified. Modifiable risk factors, such as obesity and low physical activity may 
have only modest effects on breast cancer risk, but because of their high 
prevalence it has been estimated that nearly 40% of breast cancer cases could be 
prevented by these risk factors (Sprague et al., 2008), in addition, reducing obesity 
and physical inactivity can decrease risk of other chronic diseases, such as type II 
diabetes and CVD (Lee et al., 2012; Nocon et al., 2008; Lindstrom and Uusitupa, 
2008). It is thought that the positive effects of these modifiable risk factors are 
mainly due to changes in endogenous hormone exposure (NBOCC, 2010; Weir et 
al., 2007). The next section will therefore, explore the influence of endogenous 
hormone exposure, overweight/obesity and physical activity on breast cancer risk. 
 
2.5.1 Exposure to Endogenous hormones 
The specific cause for the transformation of a normal breast epithelial cell into a 
malignant one is unknown. However, it is known that breast tissues and tumours 
are dependent on oestrogen for their growth. Oestrogens have been shown to 
promote development of breast tumours by promoting proliferation of cells with 
existing mutations and increasing the probability of new mutations (Key and Allen, 
2002). Researchers have moved away from studying the influence of hormones 
indirectly through menstrual and reproductive factors, and have begun to explore 
the direct effects of endogenous (produced within the body) and exogenous 
(introduced from outside) hormones on breast cancer aetiology and pathology.  
 
The steroid hormone group collectively known as oestrogens consist of oestradiol, 
oestrone and oestriol. Each oestrogen has varying levels of oestrogenic activity in 
the body. For premenopausal women, the secretion of oestradiol, produced from 
androgenic precursors (such as by androstenedione or testosterone) by the 
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ovaries, provides the major source of oestradiol (see figure 2.7) (Barrett et al., 
2010). However, for postmenopausal women the ovaries have stopped producing 
oestradiol, and it is the aromatization (i.e. conversion via enzyme aromatase) of 
androgens (mainly dehydroepiandrosterone, DHEA, secreted by the adrenal 
cortex) primarily synthesised in adipose tissue to oestrone, and then to oestradiol 
in periphery tissues account for 90% of circulating oestradiol (Henderson et al., 
1988; Santen, 1986). 
 
Oestradiol, and the other oestrogens to a lesser degree, increase proliferation of 
breast epithelium and stroma, and consequently increase the possibility of 
mutations occurring in rapidly proliferating epithelial cells (Yaghjyan and Colditz, 
2011). Oestrone is considered to have weak oestrogenic activity, but because it 
acts as a precursor to the more powerful oestrogen, oestradiol, for 
postmenopausal women it is of considerable interest to cancer researchers 
(Ottesen and Pedersen, 1996). Whereas most of the body’s oestradiol is bound to 
sex-hormone binding globulin (SHBG) and subsequently unavailable for entry into 
cells, oestriol has a much lower affinity for binding to SHBG and as a result a 
greater proportion is available for biological activity (Longcope, 1984). While, 
increased levels of oestradiol and oesterone has been linked with an increased 
risk of breast cancer, oestriol, the third naturally occurring and weakest oestrogen, 
depending on the situation may exert either agonistic or antagonistic effects on 
oestrogen and may have some beneficial effects such as controlling symptoms of 
menopause, including hot flashes, insomnia, vaginal dryness, and frequent urinary 




Figure 2.7 Biosynthesis of oestrogens (green boxes = sex hormones; grey boxes 
= sex hormone precursors; yellow boxes = enzymes) (adapted from Barrett et al., 
2010; Head, 1998) (Figure abbreviations: P450scc = cytochrome P450scc, 
CYP11A1; CYP17 = Cytochrome P450 17α-hydroxylase/17, 20-lyase; 3b-OH–
SDH = 3b-Hydroxysteroid dehydrogenase; 17-OH-SDH = 17-Hydroxysteroid 
dehydrogenase; 16α–OHase = 16a-Hydroxylase) 
 
The study of hormones in relation to risk has been hampered by a number of 
factors, including proneness to error of laboratory analysis, the ability of clinical 
laboratory to reliably quantify the low circulating concentrations of oestradiol in 
postmenopausal women, and difficulties relating to large intra- and inter-individual 
fluctuations oestrogen concentrations across menstrual cycles and menstrual 
timing of sampling among premenopausal women (Chen, 2008; Kaaks et al., 
2005). Furthermore, it is unclear whether a single sample of hormone 
concentrations is adequate to represent long-term exposure and whether they are 
influenced by samples taken post-diagnosis which may have been affected by the 
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disease process or its treatment (Endogenous Hormones and Breast Cancer 
Collaborative Group, 2002).  
 
Possibly due in part to the problems with sampling premenopausal women 
mentioned above, the association between circulating oestrogen concentrations 
and the risk of breast cancer has been more consistent for postmenopausal 
women than premenopausal (Chen, 2008; Eliassen et al., 2006a; Kaaks et al., 
2005; Collaborative Group on Hormonal Factors in Breast Cancer, 1997). 
However, a study in premenopausal women found significant increases in breast 
cancer risk from total and free oestradiol taken during the follicular stage but not 
the luteal stage of the menstrual cycle (Eliassen et al., 2006b). Moreover, there is 
evidence that androgens, such as testosterone and DHEA secreted by the ovaries 
and adrenal glands, can increase risk of breast cancer in both postmenopausal 
and premenopausal women (Eliassen et al., 2006; Kaaks et al., 2005). 
 
Androgens are thought to indirectly influence breast cancer risk by conversion to 
oestrogens, but also directly by increasing cell proliferation (Endogenous 
Hormones and Breast Cancer Collaborative Group, 2002). The European 
prospective Investigation into Cancer and Nutrition (EPIC) study found similar 
increases in breast cancer risk associated with high levels of androgens in 
postmenopausal and premenopausal women (Kaaks et al., 2005). In a case-
control study nested within the Nurses’ Health Study II, the analysis of blood 
samples collected from 18,521 premenopausal women (including 197 cases of 
breast cancer) revealed that women in the highest (versus the lowest) quartiles of 
total and free testosterone and androstenedione had a modest increase in breast 
cancer risk, which was stronger for invasive breast cancer and for ER and PR-
positive tumours (Eliassen et al., 2006b). 
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An analysis of nine prospective studies on 663 women who developed breast 
cancer and 1,765 women who did not (all were postmenopausal and not using 
HRT) found a significant increase in breast cancer risk with increased 
concentrations of every sex hormone examined including total oestradiol, free 
oestradiol, non-SHBG bound oestradiol (which comprises free and albumin-bound 
oestradiol), oestrone, oestrone sulphate, androstenedione, DHEA, DHEA sulphate 
and testosterone (Endogenous Hormones and Breast Cancer Collaborative 
Group, 2002). The authors (2002) found that breast cancer risk rose with 
increasing concentrations of sex hormones, and an approximately twofold 
increase in risk with both oestrogens and androgens when the highest 
concentrations were compared to the lowest. Higher concentrations of SHGB on 
the other hand was associated with a significantly lower risk of breast cancer. 
Subsequent studies have found similar results (Kaaks et al., 2005; Missmer et al., 
2004; Zeleniuch-Jacuotte et al., 2004; Manjer et al., 2003). 
 
Two other hormones considered as primarily female hormones, progesterone and 
prolactin, have been investigated in relation to the risk of breast cancer. 
Progesterone is a steroid hormone secreted by ovaries from the corpus luteum, 
the placenta and to a lesser extent the follicle, and is an important intermediate in 
the synthesis androstenedione, which can subsequently be converted to oestrone, 
and/or testosterone and oestradiol (see figure 2.7) (Barrett et al., 2010). After 
menopause concentrations of progesterone are extremely low because the 
ovaries stop secreting it. In the breast, progesterone stimulates the development 
of lobules and alveoli, and is hypothesized to increase cell division and thereby, 
lead to the accumulation of DNA damage (Chen, 2008). In support of this, it has 
been noted that breast cell proliferative activity is at its highest during the luteal 
phase of the menstrual cycle, a time when endogenous progesterone 
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concentrations are also high (Graham and Clarke, 1997). Prolactin is secreted by 
the pituitary gland and causes milk secretion from the breast after oestrogen and 
progesterone priming and has a role in stopping ovulation in lactating women 
(Barrett et al., 2010). Similar to progesterone, prolactin concentrations are much 
lower postmenopause. Experimental evidence suggests that prolactin can also 
promote cell proliferation and survival, increase cell motility, and support tumour 
vascularisation (Tworoger and Hankinson, 2006). However, to date, there is not 
enough available evidence to draw conclusions on the association between 
progesterone and prolactin and breast cancer risk (NBOCC, 2010). 
 
In both prospective and retrospective studies conducted in premenopausal 
women, significant associations have been found between blood insulin-like 
growth factor (IGF)-I and breast cancer risk (Hankinson et al., 1998; Toniolo et al., 
2000; Rinaldi et al., 2006; Schernhammer et al., 2006; Sugumar et al., 2004). IGF-
I is a peptide growth factor, secreted by the liver, which acts as a mediator of the 
anabolic and mitogenic activity of human growth hormone (Loran, 2001). IGF-I 
signalling is vital for tumour progression because it stimulates mitogenic and 
metabolic activities that regulate cell proliferation, differentiation and migration, 
and inhibits death of normal breast epithelial cells (Rajski et al., 2010; Massoner et 
al., 2010). In circulation, a small amount of IGF-I is free, while the majority is 
bound to one of six binding proteins, which regulate IGF-I. Up to 90% of circulating 
IGF-I is bound to IGF-binding protein-3 (IGF-BP3) (Laron, 2001). IGF-BP3 can 
have tumour growth promoting and suppressing effects, it can work either IGF-I-
dependently by increasing the half-life of IGF-I and modulating access to the IGF-I 
receptor, or IGF-I-independently by mediating their effects on target cells, where 
they generally have a proapoptotic affect (Canzian et al., 2010). However, 
evidence suggests that an increase in circulating concentrations of both IGF-I and 
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IGF-BP3 is associated with a moderate increase in breast cancer risk (Renehan et 
al., 2004; Shi et al., 2004). 
 
A recent pooled analysis of 17 prospective studies across 12 countries, and 
including 4790 cases and 9428 matched controls, investigated the association 
between IGF-I and breast cancer risk (Endogenous Hormones and Breast Cancer 
Collaborative Group, 2002). The authors (2002) found that when the highest 
concentration of IGF-I was compared with the lowest fifth, IGF-I was associated 
with a 28% (95% confidence intervals, 14 to 44%) increase in breast cancer risk. 
This increase in risk was not modified by IGF-BPs, and did not differ by 
menopausal status, but seemed to be confined to ER-positive tumours.  
 
It is possible that exposure to hormones in utero might affect future breast cancer 
risk, possibly due to an influence on the number or state of cells in the foetus’s 
undeveloped breast (Colditz, 2005). A Danish study of 117,000 women followed 
up for an average of 28 years, examined 334 breast cancer cases and found a 
modest increase in breast cancer risk associated with a high birth weight and other 
factors that potentially indicate exposure to higher concentrations of oestrogens in 
utero (Ahlgren et al., 2004). Higher maternal age and higher paternal age, factors 
thought to increase the foetus’s exposure to hormones, have also been associated 
with a slight increased risk of breast cancer in a recent meta-analysis (Xue and 
Michels, 2007). The same study (2007) also found a 50% reduction in subsequent 
breast cancer risk with maternal- or pre-eclampsia during pregnancy.   
 
2.5.2 Obesity and/or overweight  
Overweight and obesity are defined as the abnormal or excessive accumulation of 
adipose tissue (i.e. body fat) that may impair health (WHO, 2013).  Anthropometric 
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indices, height, mass, body mass index (BMI), waist circumference, hip 
circumference or waist-to-hip ratio (WHR), are commonly used as tools for 
assessing overweight/obesity. BMI is a simple index of mass-for-height (defined as 
a person's mass in kilograms divided by the square of his/her height in meters, 
kg·m2) that is the most commonly method used to classify general overweight and 
obesity in adults (Amadou et al., 2013). The WHO (2013) defines overweight as a 
BMI of greater than or equal to 25 and obesity as a BMI greater than or equal to 
30. Waist circumference and WHR measures used to assess abdominal obesity.  
 
Excess bodyweight is the sixth highest contributor to the overall burden of disease 
worldwide (Haslam and James, 2005). It has been estimated that at least 1.1 
billion adults are overweight and 312 million are obese worldwide (James et al., 
2004). In England, the proportion of adults that were obese increased from 13% in 
1993 to 24% in 2011 for men and from 16% to 26% for women (Health and Social 
Care Information Centre, 2013). The EPIC study investigated the risk of premature 
death associated with overweight and obesity among 359,387 participants from 
nine countries, follow-up on average for 9.7 years (Pischon et al., 2008). The 
authors (2008) found that after adjusting for educational level, smoking status, 
alcohol consumption, physical activity and height, a 24% (95% CI, 14 to 35%) and 
94% (95% CI, 71 to 220%) increased risk of death in those with a BMI of 30.0 to 
<35.0 kg·m2 and a BMI ≥35.0 kg∙m2, respectively. In England, an estimated 34,100 
deaths were attributable to obesity (6.8% of all deaths) in 2004 (Health and Social 
Care Information Centre, 2013). Obesity has been shown to decrease life 
expectancy by seven years at the age of 40 years (Peeters et al., 2003). 
Overweight and obesity have been associated with an increased risk of conditions 
including dyslipidaemia, hypertension and stroke, type II diabetes, coronary heart 
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disease and some cancers including endometrium, colon, kidney, oesophagus and 
breast (postmenopausal) (WCRF/AICR, 2007).  
 
The relationship between body mass and BMI and breast cancer risk appears to 
be dependent on menopausal status. A pooled analysis of cohort studies 
comprising of 337,817 women and 4,385 cases of invasive breast cancer, found a 
significant non-linear positive correlation between BMI and the risk of breast 
cancer in postmenopausal women, but a significant non-linear inverse association 
between BMI and breast cancer risk in premenopausal women (van den Brandt et 
al., 2000). The same study (2000) reported a RR for postmenopausal women with 
BMI above 28 kg·m2 was 1.26 (95% CI, 1.09 to 1.46), while premenopausal 
women with a BMI exceeding 31 kg·m2 had an RR of 0.54 (95% CI, 0.34 to 0.85) 
compared to premenopausal women with a BMI less than 21 kg·m2. However, the 
authors (2000) did not control for physical activity in their analysis. 
 
In a meta-analysis, the RR associated with BMI and breast cancer in 
postmenopausal women was 1.12 and 1.25, respectively for overweight (BMI=25-
30 kg·m2) and obese (BMI=≥30 kg·m2) women (Bergstrom et al., 2001). The 
authors (2001) estimated a 2% increase in risk per unit increase in BMI of 
postmenopausal women (95% CI, 0.69 to 1.52). Similarly, an analysis of cohort 
studies without adjusting for mass and BMI observed a 39% lower risk of breast 
cancer in postmenopausal women with the smallest waist compared to the largest, 
and a 24% lower risk in women with the smallest WHR (Harvie et al., 2003). 
However, with the adjustment for BMI, the relationship between WHR and risk of 
postmenopausal breast cancer was abolished, but introduced an association 
between premenopausal breast cancer women and WHR. The implication of these 
findings suggest that general obesity rather than central obesity should be viewed 
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as a risk factor for breast cancer in postmenopausal women, whereas central 
obesity may be more important for premenopausal breast cancer risk.  
 
The mechanism for the increased breast cancer risk associated with 
postmenopausal overweight and obesity is thought to be caused by abnormally 
high concentrations of free oestrogen in postmenopausal obese women (Rinaldi et 
al., 2006; Key et al., 2003). Because ovarian oestrogen production decreases 
following menopause, the rationale for high concentrations of oestrogen is 
attributed to the peripheral conversion of sex hormones in adipocytes (fat cells), 
which increase in number and size as a result of mass gain, and a fall in the 
concentrations of plasma SHGB (Haslam and James, 2005; Friedenreich, 2001). 
An alternative explanation might be that fat tissue can accumulate fat-soluble 
potential carcinogens, which increases their concentrations adjacent to epithelial 
tissue making them more available within the body (Friedenreich, 2001).  
 
The suggested protective effect of premenopausal obesity on breast cancer risk 
has been attributed to excessive oestrogens and progesterone concentrations, 
which is proposed to interfere with the feedback regulation of the 
hypothalamopituitary axis, disrupt normal reproductive function and cause 
irregular, commonly anovulatory cycle (i.e. a cycle in which ovulation fails to occur) 
(Haslam and James, 2005). However, the Nurses’ Health Study II found that the 
inverse association between obesity and breast cancer risk in premenopausal 
women was not explained by menstrual cycle dysfunction or ovarian disorder 
related infertility, suggesting that factors other than ovulation might contribute to 




It should be noted that although being overweight/obese is associated with a lower 
breast cancer risk in younger women, premenopausal breast cancer is relatively 
rare, and only a small proportion of premenopausal breast cancer might be 
avoided by being overweight/obese for younger women, while increased adiposity 
may confer an increased risk of the much more common postmenopausal breast 
cancer later in life (NBOCC, 2010). In addition, premenopausal obesity is 
associated with an increased risk of diabetes, heart disease and infertility and 
pregnancy related-problems such as pre-eclampsia, gestational diabetes, 
difficulties in labour and delivery, and higher rates of caesarean deliveries with 
more maternal and infant deaths (Haslam and James, 2005). Therefore, 
premenopausal weight gain should be avoided wherever possible.  
 
In summary, postmenopausal overweight and obesity states are both strongly 
associated with an increased risk of developing breast cancer. Conversely, 
premenopausal overweight and obesity appears to confer a slight decrease in 
breast cancer risk. It should be noted that most of the studies in this area did not 
control for breast density and HRT use, which are known to influence the risk of 
breast cancer in postmenopausal women, and therefore, may have influenced the 
precision and magnitude of risk estimates.  
 
2.5.3 Physical Activity and sedentary behaviour 
Physical activity is defined as any bodily movement produced by the contraction of 
skeletal muscle that increases energy expenditure above a basal level, whereas 
exercise, a subcategory of physical activity is defined as planned, structured and 
repetitive and is aimed at improving or maintaining of one or more component of 
physical fitness (Bull and the Expert Working Groups, 2010). There is substantial 
evidence to support a protective role of physical activity against many of the 
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world’s major noncommunicable diseases and a casual role for physical inactivity 
in the development of these diseases (WCRF/AICR, 2007). As a key determinant 
of energy expenditure, physical activity is fundamental to energy balance and 
weight control, but beyond weight control, physical activity can also reduce blood 
pressure, improve the level of high density lipoprotein cholesterol, and improve the 
control of blood glucose in overweight people and is associated with a reduced 
risk of colon, endometrium and postmenopausal breast cancer (WHO, 2003). 
Physical inactivity along with high blood pressure, high concentrations of 
cholesterol in the blood, inadequate intake of fruit and vegetables, overweight or 
obesity and tobacco use, is considered to be amongst the major causes of the 
world’s major noncommunicable diseases, including CVD, type II diabetes and 
certain types of cancer, including colon, endometrium and postmenopausal breast 
(Lee et al., 2012; WHO, 2003). Worldwide, it is estimated that physical inactivity 
can be attributed to 10% (range=5·6-14·1) of the burden of disease from breast 
cancer (Lee et al., 2012). Furthermore, with increased industrialisation, 
urbanisation and mechanisation, populations become less active and become 
more at risk of developing breast cancer and other noncommunicable lifestyle-
related diseases (WRCF/AICR, 2007). 
 
Current physical activity guidelines for UK adults recommend daily activity, and a 
target of at least 150 minutes of moderate intensity activity in bouts of 10 minutes 
or more (e.g. 30 minutes on at least 5 days a week) over the week, or 
alternatively, 75 minutes of vigorous intensity activity spread across the week or a 
combination of moderate and vigorous intensity activity throughout a week (Bull 
and the Expert Working Groups, 2010). In 2008, only 39% of men and 29% of 
women aged 16 and over in England met the government’s recommendations for 
physical activity, compared with 32% and 21% respectively in 1997 (Health and 
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Social Care Information Centre, 2013). Therefore, much of the female population 
are not meeting current recommended physical activity guidelines. The 
consequences for women regarding the risk of breast cancer can be assessed by 
reviewing the available epidemiological research. 
 
An American case-control study, based on a comparison of lifetime exercise 
participation between 545 breast cancer cases to a similar number of women 
without breast cancer, estimated that women who exercised for at least 3.8 hours 
per week had nearly a 60% reduction in risk for breast cancer compared to women 
who reported no exercise participation (OR=0.42; 95% CI, 0.27 to 0.64) (Bernstein 
et al., 1994). Since this study, there have been many studies investigating the 
association between physical activity, physical inactivity and sedentary behaviour 
and breast cancer risk, including a number of systematic reviews. 
 
In a systematic review based on data from 19 cohort and 29 case-control studies, 
Monninkhof et al. (2007) found a 20% to 80% reduction in breast cancer risk in 
postmenopausal women when comparing women with the highest levels of 
leisure-time physical activity to those with the lowest. A weak, indecisive 
association was found between leisure-time physical activity and breast cancer 
risk in premenopausal women. A dose-response relationship (i.e. greater benefits 
with increased physical activity) was evident in around half of the higher quality 
studies. The authors (2007) estimated a 6% reduction in breast cancer risk with 
every additional hour of physical activity assuming the level of physical activity 
would be sustained.  
 
In an update of a previous review of the epidemiological evidence (Friedenreich 
and Cust, 2008), Lynch and colleagues (2011) reviewed 73 studies (33 cohort and 
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40 case-control studies) and reported that 29 studies (40% of studies) found 
statistically significant reductions in breast cancer risk when comparing the highest 
to the lowest level of physical activity. Another eight (11%) found borderline 
significant risk reduction for breast cancer. A decrease in the risk of breast cancer 
was only slightly greater among postmenopausal women (31%) than for 
premenopausal women (27%). The authors (2011) also reported that the greatest 
risk reductions were found for recreational and household activity (21%), followed 
by walking/cycling (18%) and occupational activity (13%). A slightly greater risk 
reduction was found for vigorous intensity (18%) compared to moderate intensity 
physical activity (15%). Risk reduction was lowest in those with a low (<22 kg·m2) 
and medium (22-25 kg·m2) BMI (27% and 24%, respectively) compared to those 
with a high (>25 kg·m2) or very high (>30 kg·m2) BMI (18% and 1%, respectively). 
Furthermore, there was a suggestion of a dose-response relationship between 
physical activity and breast cancer risk. Physical activity participation for two to 
three hours per week was associated with an average risk reduction of 9%, while 
women who reported 6.5 hours of activity per week or more had a decreased risk 
of 30%. The average risk reduction associated with physical activity was the same 
for ER-positive and ER-negative breast cancers (20%). However, average risk 
reductions were greater for women with ER-negative/PR-negative tumours (27%) 
than for women with ER-positive/PR-positive tumours (14%).  
 
The strongest breast cancer risk reductions are observed for long-term physical 
activity sustained throughout life, but there is also evidence that activity performed 
earlier in life (including during puberty or adolescence) as well as after menopause 
reduces breast cancer risk (Vainio et al., 2002). Similarly, in a large cohort study, a 
20% risk reduction in breast cancer was observed with long-term strenuous 
activity (≥5 hours per week per year) compared to inactivity (Dallal et al., 2007). 
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Importantly, the protective association has been noted in women of nearly every 
racial and ethnic background (Lynch et al, 2011). 
 
A number of mechanisms have been proposed to explain the potential association 
between physical activity and breast cancer risk, including reduced exposure to 
oestrogen and androgens, insulin-related factors, and adipokines and 
inflammation (see figure 2.8 for summary). Oestrogens can inhibit apoptosis and 
act as mitogens in the breast, promoting the proliferation of cells through 
oestrogen receptor-mediated transcriptional activity and activation of cellular 
signalling pathways (Key et al., 2002). In postmenopausal women, production of 
ovarian oestrogens and adipose tissue becomes the predominant source of 
endogenous oestrogens. Physical activity may reduce oestrogen concentrations in 
postmenopausal women by facilitating a reduction in body fat. Weight loss induced 
by physical activity may also reduce oestrogen concentrations by lowering 
adipokines (a group of biologically active polypeptides produced by adipocytes or 
adipose tissue) concentrations, which influence oestrogen biosynthesis (Cleary 
and Grossman, 2009) and by lowering blood insulin concentrations, which in turn 
increases the concentrations of SHBG, thereby decreasing oestrogen 
bioavailability (Kaaks et al., 2005). 
 
Biological mechanisms for premenopausal breast cancer: 
For premenopausal women the mechanisms are less understood. However, 
mechanisms may be linked with delayed menarche and menstrual dysfunction, 
although very high levels of activity may be necessary to induce these chances 
(Bernstein, 2009). Alternatively, energy deficiency rather than activity levels may 
be a potential underlying mechanism (Loucks, 2003). Recently, a randomized 
controlled trial found that premenopausal women who participated in an aerobic 
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exercise intervention significantly increased the ratio of two key oestrogen 
metabolites, 2-hydroxyestrone (2OHE1) and 16α-hydroxyestrone (16αOHE1) but 
no other oestrogen, compared with a usual care group (Smith et al., 2013). A 
higher ratio would reflect a dominance of 2OHE1, which has a weak binding 
capacity to the ER and has been assumed to have antioestrogenic properties 
because of its association with normal cell differentiation and apoptosis, whereas, 
16αOHE1 can bind to the ER and has been shown to induce abnormal cell 
proliferation (Obi et al., 2011). Therefore, exercise may positively influence the 
concentrations of antioestrogenic metabolites, and thereby, potentially affect 
breast cancer risk in premenopausal women. 
 
Biological mechanisms for postmenopausal breast cancer: 
For postmenopausal women, androgens, such as testosterone, may act to 
increase breast cancer risk through their conversion to oestrogens in adipose 
tissue, or independently of oestrogen by binding to androgen receptors to 
influence cell growth (Nicolas Diaz-Chico et al., 2007). Physical activity may 
decrease circulating androgens concentrations by decreasing adiposity or by 
decreasing SHBG levels by lowering insulin concentrations (Kaaks, 1996). The 
effect of physical activity on sex hormones may vary according to menopausal 
status (Schmitz et al., 2007), hormone receptor status (Adams et al., 2007) and 
adiposity (McTiernan et al., 2004). Evidence from randomized controlled trials 
consisting of physical activity interventions has shown reduced oestrogen 
(McTiernan et al., 2004; Friedenreich et al., 2010) and androgen concentrations 
(McTiernan et al., 2004; Monninkohf et al., 2009) with reduced body fat. The 
significant reduction in oestrogen concentration reported by Friedenreich and 
colleagues (2010) was still evident after adjusting for weight change, which 
suggests an independent role for physical activity. Observational studies support 
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the view that fat loss may not be necessary for changes in sex hormones (Chan et 
al., 2007; Verkasalo et al., 2001; Madigan et al., 1998). 
 
Insulin may increase the potential for mutagenic events in breast cells by exerting 
a mitotic, anti-apoptotic effect in these cells (Lann and LeRoth, 2008). 
Hyperinsulinemia (excessively high blood concentrations of insulin) may increase 
the bioavailability of sex hormones by decreased SHBG concentrations (Kaaks, 
1996). In addition, insulin-resistance and hyperinsulinemia are both related to 
obesity, intra-abdominal fat and adipokines and inflammatory factors, which have 
all been linked with an increase in breast cancer risk (Vona-Davis et al., 2007; 
Haslam and James, 2005; Kaaks, 1996). Therefore, it is possible that insulin may 
increase the risk of breast cancer independently or indirectly via biomarkers of 
breast cancer risk. Non-insulin dependent diabetes (or type 2 diabetes mellitus), 
subclinical diabetes or hyperinsulinemia with insulin resistance have all been 
associated with a modest increase (~20%) in the risk of breast cancer, 
independent of body mass (Larsson et al., 2007; Lawlor et al., 2004). Exercise in 
combination with weight loss can be an effective way to increase insulin sensitivity 
and preventing diabetes (Warburton et al., 2007; Frank et al., 2005; Ryan, 2000), 
and therefore, may reduce breast cancer risk.  
 
Due to their stimulation of cell proliferation and anti-apoptosis actions, 
concentrations of IGFs have been considered as a potential breast cancer risk 
factor. Evidence from observational studies appears to suggest that an increase in 
circulating concentrations of both IGF-I and IGF-BP3 associates with an increase 
in breast cancer risk (Renehan et al., 2004; Shi et al., 2004). However, RCTs on 
the effects of physical activity on IGF concentrations have shown mixed results. 
Two trials in postmenopausal breast cancer survivors have found decreased 
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concentrations of IGF-I and IGF-BP3 with exercise compared with a no-exercise 
control (Irwin et al., 2009; Fairey et al., 2003), but another trial showed no change 
in IGF-I and IGF-BP3 concentrations in young women after an exercise 
intervention (Arikawa et al., 2010). Another recent trial observed increased serum 
total IGF-I and maintenance of free IGF-I concentrations in premenopausal women 
after weight loss induced through an energy restriction and exercise programme, 
suggesting that weight loss with diet and exercise does not mediate breast cancer 
risk through the circulating IGF-axis (Harvie et al., 2010).  
 
The association between postmenopausal breast cancer and obesity has led to a 
search for the mechanisms that may explain this relationship. Obesity is 
characterised as a condition of chronic low-grade, systematic inflammation with 
elevated concentrations of inflammatory markers (Lee and Pratley, 2005). This 
chronic inflammatory state may promote cell proliferation, microenvironmental 
changes and oxidative stress which could inhibit normal cell growth and promote 
malignancy (Coussens and Werb, 2002). Thus, there has been considerable 
interest in the role of adipokines secreted by adipose tissue as a consequence of 
this inflammation.  
 
Adipokines are produced in adipose tissue by adipocytes, stromal cells, which can 
differentiate to mature adipocytes, and macrophages, which infiltrate the adipose 
cell mass and are sources of the increase in local concentrations of the adipokine, 
tumour necrosis-α (TNF-α), observed in obese individuals (Weisberg et al., 2003). 
Adipokines, such as TNF-α, leptin, adiponectin, hepatocyte growth factor (HGF), 
heparin-binding epidermal growth factor-like growth factor (HB-EGF) and 
interleukin-6 (IL-6), have been implicated in the development of breast 
(postmenopausal) and endometrium cancer (Cymbaluk et al., 2008; Rose et al., 
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2004; Harvie et al., 2003; Petridou et al., 2003). C-reactive protein (CRP) is not an 
adipokine, but along with TNF-α and IL-6 is considered an inflammatory marker 
(Lynch et al., 2011). Leptin, TNF-α, IL-6, HGF and HB-EGF, have been found to 
have a positive relationship with BMI, whereas, adiponectin has been shown to be 
negatively associated with BMI (Rose et al., 2004). 
 
Leptin and adiponectin have received the most attention in the literature, and are 
thought to have opposing biological effects on breast cancer cells. Leptin may 
have a mitogenic effect on breast cancer cell growth, inhibit apoptosis in tumour 
cells and promote tumour angiogenesis, whereas, adiponectin is thought to have 
antimitogenic properties, enhance tumour cell apoptosis and inhibit tumour 
angiogenesis (Rose et al., 20004; Vona-Davis and Rose, 2007). There has been 
conflicting results from studies investigating the relationship between the levels of 
leptin in serum or plasma and breast cancer risk. Four case-control studies found 
an association between high serum leptin concentrations and increased breast 
cancer risk (Cust et al., 2009; Chen et al., 2006a; Han et al., 2005; Tessitore et al., 
2000), but another six case-control studies (Woo et al., 2006; Miyoshi et al., 2006; 
Sauter et al., 2004; Coskun et al., 2003; Ozet et al., 2001; Petridou et al., 2000) 
and one case-control nested within a prospective study (Stattin et al., 2004) found 
no evidence of an association. Although fewer studies have investigated the 
relationship between adiponectin and breast cancer, each study has demonstrated 
an inverse association between serum adiponectin and breast cancer risk (Chen 
et al., 2006b; Mantzoros et al., 2004; Miyoshi et al., 2003). Miyoshi et al. (2003) 
found low concentrations of adiponectin were correlated with large tumours and 
tumours of high histological grade. Further, adiponectin may block leptin-induced 
production of TNF-α by macrophages (Zhao et al., 2005). In addition to leptin, 
HGF may increase tumour growth by facilitating angiogenesis and promotion of 
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cell invasion capacity. In one study, a decrease in HGF concentrations was 
observed after tumour removal, suggesting that HGF concentrations were related 
to tumour and/or excised adipose tissue (Taniguchi et al., 1995). 
 
A recent RCT involving type II diabetics suggested that greater decreases in 
leptin, IL-6, TNF-α and CRP and increases in adiponectin can be achieved using 
high-intensity exercise rather than low-intensity and a combination of aerobic and 
resistance training rather than aerobic training alone (Balducci et al., 2009). In 
addition, a 12-month exercise intervention induced reductions in leptin in 
postmenopausal women and CRP in obese postmenopausal women (Campbell et 
al., 2009; Frank et al., 2005). Some studies have only shown decreases in 
adipokines with fat/weight loss (Campbell et al., 2009; Lee et al., 2009), while 
others have shown decreases independently of fat/weight loss (Friedenreich et al., 
2011; Balducci et al., 2009; You et al., 2004). Figure 2.8 provides a summary of 
the potential mechanisms that may explain the role of physical activity in the 
reduction of breast cancer risk. 
 
Sedentary lifestyles and breast cancer: 
Sedentary lifestyles have been associated with disease-related risk factors such 
as central adiposity, some cancers, elevated blood glucose and insulin, diabetes 
and other cardiometabolic biomarkers in health adults, independent of physical 
activity levels (Lynch, 2010). Sedentary behaviour is defined not simply as a lack 
of physical activity but is a group of individual behaviours where sitting or lying is 
the dominant mode of posture and energy expenditure is very low. The recent 
Health Survey for England (Roth, 2009) reported that women over the age of 16 
years engage in sedentary behaviour for an average of about five hours per day. 
Lynch et al. (2010) associated sedentary behavior with increased colorectal, 
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endometrial, ovarian and prostate cancer risk, in addition to cancer mortality in 
women.  
 
Figure 2.8 Hypothesized model of the potential mechanisms by which long-term 
physical activity may lower breast cancer risk in pre and postmenopausal women 
(adapted from Lynch et al., 2011 and Neilson et al., 2009) 
 
In a recent, case-control study, which included 996 incident cases of breast cancer 
and 1,164 controls, found that sedentary behaviour was significantly associated 
with an increased risk of breast cancer, independent of moderate-to-vigorous 
activity (OR=1.81; 95% CI, 1.26 to 2.6) (Dallal et al., 2012). Similarly, a nested 
case-control study within a cohort study, being in the highest (>12 hours per day) 
versus lowest (<5.5 hours per day) quartile of total sedentary behaviour was 
associated with increased odds of breast cancer among white women (OR=1.94; 
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95% CI, 1.01 to 3.70), but not black women (OR=1.23; 95% CI, 0.82 to 1.83), after 
adjustment for physical activity (Cohen et al., 2013). The hypothesised 
mechanisms for the enhanced risk of cancer associated with sedentary behaviour 
are increased adiposity and metabolic dysfunction (i.e. when abnormal chemical 
reactions in the body disrupt normal metabolism) (Lynch, 2010).  
 
 
In summary, an inverse relationship has consistently been found between 
increased physical activity and breast cancer risk. This association has been found 
in both pre- and postmenopausal women, but is strongest for postmenopausal 
women. Recreational and household-related physical activity appears to confer the 
greatest protective effect. Numerous studies have observed a dose-response 
relationship between physical activity and breast cancer risk. In addition, the 
strongest breast cancer risk reductions are observed for long-term activity 
sustained throughout life. It should be noted that there is considerable diversity in 
the measurement of physical activity in studies of physical activity and breast 
cancer risk, and because most studies rely on self-report to assess physical 
activity levels they are subject to recall bias. Nevertheless, findings have been 
relatively consistent across studies. The mechanisms that may explain the 
proposed reduction in breast cancer risk associated with physical activity include 
reduced exposure to oestrogen and androgens and increased concentrations of 
SHBG, improved insulin sensitivity and decreased concentrations of IGF-1 and 
adipokines and inflammatory markers, with the exception of a beneficial elevation 
in adiponectin concentrations. Sedentary behaviour, independently of physical 
activity, can increase the risk of breast cancer, possibly due to increased adiposity 





2.6 Treatment of breast cancer and short and long-term side effects 
The treatment methods for breast cancer include surgery, chemotherapy, radiation 
therapy, biologic therapy and hormonal therapy. The primary treatment of operable 
early breast cancer is surgery with or without radiotherapy (Whelan et al., 2003). 
Adjuvant chemotherapy (i.e. the treatment of disease by chemical agents after the 
removal of the tumour) following surgery improves survival in pre- and post-
menopausal women with early breast cancer (Early Breast Cancer Trialists’ 
Collaborative Group, EBCTCG, 2005). 
 
Most breast cancer patients have surgery to remove the breast tumour and for 
some the lymph nodes under the arm are extracted and investigated for the 
presence of cancer cells. There has been a major shift towards breast 
conservation surgery (i.e. surgery to remove the cancer but not the breast itself) in 
the last 30 years (Aebi et al., 2011). Breast-conserving surgery includes 
lumpectomy, which is surgery to remove the tumour and a small amount of normal 
tissue around it, partial mastectomy, which is surgery to remove the part of the 
breast that has cancer and some normal tissue around it, and segmental 
mastectomy, which is the removal of the lining over the chest muscles below the 
cancer in addition to a partial mastectomy (NCI, 2013a). A radical mastectomy, 
which is the surgical removal of the entire breast, underlying muscles and all 
axillary lymph nodes, is rarely used as a primary surgery unless the cancer is 
advanced at the time of diagnosis (Porth, 2011). In some instances a modified 
radical mastectomy, which is surgery to remove the whole breast that has cancer, 
many of the lymph nodes under the arm, the lining over the chest muscles and 
occasionally part of the chest wall muscles, may be preferred to a radical 
mastectomy (NCI, 2013a). A sentinel lymph node (i.e. first lymph node or nodes to 
which cancer cells are most likely to spread) biopsy of the affected breast is 
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performed during surgery to determine whether the cancer has spread to the 
lymph nodes. If the lymph node status is positive (i.e. cancer cells are detected) 
then more nodes are removed and more aggressive post-surgery treatment is 
required, while if negative further lymph node evaluation may not be needed.  
 
Although the aim of breast surgery is the removal of detected breast cancer cells, 
undetected deposits of disease may still remain post-surgery either locally (i.e. in 
the residual breast tissue, scar area, chest wall or regional lymph nodes) or at 
distant sites that could, if untreated, develop into life-threatening recurrence 
(EBCTCG, 2005). Radiation therapy can be used either preoperatively or 
postoperatively, and is used either alone as a primary treatment method, with 
chemotherapy or with chemotherapy and surgery (Porth, 2011). In addition, it can 
be used as a palliative treatment to reduce symptoms in patients with advanced 
cancer. For example, it can reduce the pain associated with bone metastasis and 
can shrink the size of tumours which have spread to the brain from other parts of 
the body (NCI, 2010). Radiation therapy exerts its influence through ionising 
radiation produced by high energy x-rays or gamma rays. The two types of 
radiation therapy are external radiation, which uses a machine outside the body to 
send radiation towards to cancer, and internal radiation, which uses a radioactive 
substance sealed within needles, seeds, wires or catheters that are placed directly 
into or near the site of the cancer (NCI, 2013b). Whole-breast radiation therapy of 
between five and seven weeks duration is considered as the standard treatment 
following breast-conserving surgery (Lin and Tripuraneni, 2011). The method of 





Radiation therapy can kill cancer cells by causing DNA damage directly or by 
indirectly causing cellular damage when the x-rays or gamma rays are absorbed 
into tissue, give up their energy by producing fast-moving electrons, which interact 
with loosely bonded or free electrons of the absorber cells to create free radicals 
(Porth, 2011; Lawrence et al., 2008). These free radicals interact with critical cell 
components and can kill cells immediately, delay or halt cell cycle progression or 
can cause damage to the cell nucleus resulting in apoptosis after replication. It is 
thought that radiation therapy is more likely to damage the rapidly proliferating and 
poorly differentiated tumour cells rather than the more slowly proliferating normal 
cells (Sharma et al., 2010). However, radiation is injurious to normal, as well as 
cancerous, rapidly proliferating cells and can cause both acute and chronic side 
effects (NCI, 2010). Acute effects of radiation therapy includes skin toxicity (i.e. 
pain, redness, peeling skin and oedema) in about 30% of women, which is 
associated with a decrease in their quality of life (Kraus-Tiefenbacher et al., 2012), 
and potential damage to the regions exposed to radiation such as heart, lungs, 
spinal cord and ribs (Hanna et al., 2013). Other side effects include fatigue and 
nausea with or without vomiting, while late side effects include fibrosis (formation 
of scar tissue), memory loss, infertility and in rare instances, a second primary 
cancer. The side effects that develop as a result of radiation therapy depend on 
the area of the body treated, the daily and total dose given, the patient’s general 
medical condition and other treatments given at the same time. 
 
Systemic treatment refers to the administration of chemotherapy, biologic therapy 
or hormonal therapy. Chemotherapy is the treatment of disease by chemical 
agents, and enables drugs to reach the site of the cancer as well as at distant 
sites. It can be used as the primary form of treatment, but is most commonly used 
as part of a multimodal treatment plan (Porth, 2013). Chemotherapy is 
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administered systemically or regionally. Systemic chemotherapy is when 
chemotherapy drugs are taken by mouth or injected into a vein or muscle so that 
the drugs can enter the bloodstream and reach cancer cells throughout the body. 
While, regional chemotherapy refers to chemotherapy placed directly into the 
cerebrospinal fluid, an organ or a body cavity, such as the abdomen, so that the 
drugs mainly affect cancer cells in those areas (NCI, 2013c). The way the 
chemotherapy is given depends on the type and stage of the cancer being treated. 
Chemotherapy is given in cycles of treatment days followed by days of rest. The 
cycles vary in length depending on the type of drug used, but typically last 14, 21 
or 28 days long within a regimen of three to six months (NCI, 2013c).   
 
Chemotherapy is designed to stop the growth of cancerous cells, either by 
triggering cell death or by inhibiting cell proliferation. Most chemotherapeutic drugs 
are more toxic to rapidly proliferating cells than to those incapable of replication or 
in phase G0 of the cell cycle. They are particularly effective against tumours with a 
high growth fraction. However, because the growth fraction of tumours is usually 
decreased by the time the cancer tumour is detected, treatment methods such as 
surgical debulking or radiation therapy, which can cause tumour cells residing in 
G0 to re-enter the cell cycle, are used to increase the effectiveness of 
chemotherapy (Porth, 2013).   
 
In most cases, chemotherapy is most effective when combinations of more than 
one drug are used. During the past few decades, clinicians have moved from a 
combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) to 
anthracycline-based (e.g. doxorubicin, AdriamycinR® and epirubicin, EllenceR®) 
regimens, to the subsequent incorporation of taxanes (e.g. paclitaxel, Taxol® and 
docetaxel, Taxotere®), administration of dose-dense regimens (i.e. doses 
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administered over a shorter duration with less recovery between doses) and most 
recently, the use of biological agents (Colozza et al., 2006). Optimal administration 
of adjuvant chemotherapy in combination or in sequence reduces the RR for 
recurrence and death by more than 50%, with long-lasting benefits exceeding 15–
20 years (EBCTCG, 2005). A recent Cochrane collaboration systematic review 
and meta-analysis found, amongst 18,304 women with operable breast cancer 
with 2,483 deaths, a 19% (95% CI, 12% to 25%) increase in overall survival in 
women administered taxane containing regimens compared to non-taxane 
containing regimens (Ferguson et al., 2007). Furthermore, amongst 19,943 
women with 4,800 events, disease-free survival was 19% (95% CI, 14% to 27%) 
higher for those women administered taxane containing regimens. This finding is 
consistent with that of two other major meta-analyses (Qin et al., 2011; De 
Laurentiis et al., 2008). 
 
Short-term effects of chemotherapy typically occur during the course of treatment 
and generally resolve within months of the completion of the therapy (Partridge et 
al., 2001). The frequency and severity of side effects are associated with the dose 
and type of treatment used. In general, a higher dose is associated with a higher 
incidence of side effects. Short-term effects of chemotherapy include nausea, 
emesis, alopecia, myelosuppression, stomatitis, thromboembolism, myalgias, 
neuropathy, cognitive dysfunction, fatigue, sore eyes, difficulty sleeping, changes 
in sexual functioning and reductions in HRQoL ratings (Kayl and Meyers, 2006; 
Partridge et al., 2001; Sitzia and Huggins, 1998). Although the short-term side 
effects of cytotoxic adjuvant chemotherapy are largely outweighed by its beneficial 
influence on breast cancer outcome and short-term patient survival, because of 
the increased survival rates of breast cancer patients due to both earlier diagnosis 
and improved chemotherapy strategies, the long-term complications of this type of 
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therapy has become a major issue as it could counter its effects on patient survival 
(Azim et al., 2011; Bovelli et al., 2010). The fact that adjuvant chemotherapy is 
administered to patients that may not need it has led to the consideration of the 
risks associated with chemotherapy versus the benefits to maximise disease-free 
and overall survival without compromising quality of life (Partridge et al., 2001).  
 
The long-term effects of adjuvant chemotherapy can have a later onset and 
sustained impact sometimes lasting many years and in rare cases symptoms 
develop years after treatment (Partridge et al., 2001). These effects include 
cardiotoxicity, neurotoxicity, secondary leukaemia, lymphedema, premature 
menopause/infertility, sexual dysfunction, cognitive dysfunction and weight gain 
(Bovelli et al., 2010; van Dalen et al., 2010). All of these events would be expected 
to result in a negative impact on HRQoL long after the completion of active 
treatment (Mishra et al., 2012). 
 
Biologic therapy, involving use of the drug trastuzumab (Herceptin®), is 
administered to stop growth of breast tumours that express HER2 receptors on 
their cell surface. Trastuzumab is a form of targeted therapy, which is a type of 
treatment that uses drugs or other substances to identify and attack specific 
cancer cells. The drug is a recombinant DNA derived monoclonal antibody that 
binds to HER2 receptor, thereby inhibiting HER2 overexpressing cancers and 
promoting apoptosis (Fiszman and Jasnis, 2011; Feldman et al., 2000). 
Amplication or overexpression results in the cancer cell gaining aggressive 
behavioural traits, such as enhanced growth and proliferation, increased invasive 
and metastatic capability and stimulation of angiogenesis (Robson and Verma, 
2009). Breast cancers in which HER2 is amplified or overexpressed account for 
15% of breast cancer cases, and are more likely to be poorly differentiated 
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tumours with a greater cell proliferation rate, positive axillary lymph node status 
and decreased ER and PR expression (Hortobagyi, 2005; Slamon et al., 2001). 
These characteristics are associated with an increased risk of disease recurrence 
and reduced survival (Fiszman and Jasnis, 2011; Leonard et al., 2002).  
 
Trastuzumab is usually given by infusion following a three-weekly schedule (6 
mg·kg-1), while the optimum duration of adjuvant trastuzumab is unknown, one 
year is usually recommended (Aebi et al., 2011). When trastuzumab is used in 
combination with other chemotherapeutic agents it has been found to improve the 
chemotherapeutic response rate (Piccart-Gebhart et al., 2005; Romond et al., 
2005). Alternative types of targeted therapy used in the treatment of breast cancer 
include other monoclonal antibodies, such as bevacizumab (Avastin®), an 
antiangiogenic agent (by inhibiting actions of VEGF), tyrosine kinase inhibitors, 
such as lapatinib (Tykerb®), which are targeted therapy drugs that block signals 
needed for tumours to grow, and poly ADP-ribose polymerase (PARP) inhibitors, 
which are a type of targeted therapy that can block DNA repair and promote 
apoptosis and is being studied as a potential treatment of triple-negative breast 
cancer (Colozza et al., 2006).  
 
However, Trastuzumab administration is expected to result in the development of 
some form of cardiac function impairment in 5% of breast cancer patients and 
symptomatic congestive heart failure (CHF) in 2% to 7% of patients, and increases 
with age over 50 years (26% for patients aged 66-70 years), borderline left 
ventricular ejection fraction after treatment, history of CVD and prior treatment with 
anthracyclines (Bartsch and Steger, 2011; Bovelli et al., 2010; Robson and Verma, 
2008). Furthermore, the incidence of CHF rises to 27% when trastuzumab is used 
concurrently with anthracyclines plus cyclophosphamide (Bovelli et al., 2010). It is 
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recommended that trastuzumab use should be avoided in patients with low left 
ventricular ejection fraction (LVEF, <50%) and in patients whose cardiac function 
deteriorates during therapy (Aebi et al., 2011). However, in most cases the systolic 
dysfunction appears to be reversible (Guarneri et al., 2006).  
 
In patients with ER-positive breast cancer, endocrine or hormone therapy is used 
to block the effects of oestrogen on the growth and proliferation of cancer cells 
(Porth, 2011). Hormone therapy is also used as palliative treatment for patients 
with hormone-sensitive metastatic disease, adjuvant treatment for women with 
early stage and locally advanced breast cancer, preventative measure to reduce 
risk of breast cancer in women at high risk, and recently, as a neoadjuvant 
treatment of operable and locally advanced breast cancers (Boughey et al., 2008). 
The two forms of hormone therapy used in breast cancer are selective oestrogen 
receptor modulators (SORMs) and Aromatase inhibitors (AIs).  
 
SORMs, which include tamoxifen (Nolvadex®) and raloxifene (Evista®), are 
pharmacological agents that interact with the ER, and may have both oestrogen-
agonistic and oestrogen-antagonistic properties based on the specific tissue target 
and menopausal status (Lo and Vogel, 2004). SORMs bind to ERs and block the 
effects of oestrogens on the growth of cancerous cells. In premenopausal patients 
tamoxifen alone (20 mg daily for 5 years) or the combination of ovarian function 
suppression or ovarian ablation (through drugs that temporarily stop the 
production of oestrogen by the ovaries, such as luteinizing hormone-releasing 
hormone agonist drugs, or oophorectomy) with tamoxifen are standard therapies 
particularly post-chemotherapy (Aebi et al., 2011; Bush, 2007). Raloxifene has 
anti-oestrogenic effects on the breast and endometrial tissue, and an oestrogenic 
effect on bone, lipid metabolism and blood clotting, and is used to prevent 
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osteoporosis and lower the risk of invasive breast cancer in postmenopausal 
women (Swaby et al., 2007). Unlike tamoxifen, raloxifene is not associated with an 
increased risk of endometrial cancer (Lo and Vogel, 2004). Although SORMs have 
little effect on breast cancer outcomes in ER-negative disease, for the near 80% of 
early breast cancer patients with ER-positive disease, treatment with tamoxifen for 
five years is associated with reduced local, contralateral, and distant recurrence 
rates and lower 15-year breast cancer mortality, with little effects on death from 
other causes (EBCTCG, 1988; 2005).  
 
AIs reduce the amounts of circulating oestrogen in postmenopausal by blocking 
the enzyme aromatase, which converts circulating androstenedione and 
testosterone to oestrogen in peripheral tissues such as adipose tissue (Porth, 
2011). AIs are now first-line adjuvant therapy for postmenopausal women with HR-
positive disease (Boughey et al., 2008). Three AIs are currently licensed, these 
are anastrozole (Arimidex®), which is used instead of tamoxifen for five years, 
letrozole (Femara®), which is used instead of tamoxifen for five years but also for 
three to five years following five years of tamoxifen, and exemestane (Aromasin®), 
which is implemented after a woman survives disease-free for a period on 
tamoxifen (Hind et al., 2007). A meta-analysis by the EBCTC Group (Dowsett et 
al., 2010) found that the use of AIs was associated with improved disease-free 
survival and showed a significant but modest improvement in overall survival for 
postmenopausal patients who took AIs for two to three years after treatment with 
tamoxifen for two to three years. The authors (2010) reported no overall survival 
benefit in those who received AIs as initial therapy. 
 
Hormone therapy is associated with a number of side effects dependent on the 
whether tamoxifen or AIs are used. Fewer hysterectomies (surgical removal of the 
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womb) were required in women receiving AIs (anastrozole®) when compared with 
those receiving tamoxifen (Howell et al., 2005). Although rare, tamoxifen has a 
higher risk of deep vein thrombosis, pulmonary embolus, stroke and uterine 
cancer than AIs (Bush et al., 2007). The most important side effects of AIs, due to 
near total oestrogen depletion, are decreased bone mineral density and increased 
fracture rates compared with tamoxifen and placebo (Boughey et al., 2008). In 
addition, longer duration of AI use is associated with increased odds of developing 
CVD in postmenopausal breast cancer patients (Amir et al., 2011). The 
mechanism for this is unknown, but may be due to the effects of AIs on the 
endothelium which may promote the development of atherosclerosis or may be 
due to an AI-mediated hypercholesterolemia, a well-known risk factor for 
development of CVD (Amir et al., 2011). 
 
The primary importance of adjuvant therapy is to improve recurrence risk and 
disease-free and overall survival, while less attention has been paid to the impact 
of short-term side effects on HRQoL and even less on the long-term toxicity effects 
of treatment. Recently, with the increasing survival rates and longer life of breast 
cancer survivors post-treatment, more focus has been placed on the impact of 
treatment-induced toxicity of treatment. Particularly, given that treatment-induced 
toxicity may counter the survival benefits conferred by cancer treatment. 
Chemotherapy provides relatively moderate reductions in mortality for breast 
cancer patients; therefore, careful considerations of benefit and risk should be 
made when deciding the best course of treatment for breast cancer patients. It is 
also known that chemotherapy is currently given to patients who may not require 
such treatment. In the future, genetic profiling will hopefully lead to more targeted 
therapies, which will help identify patients who benefit most from chemotherapy 
and spare others from potentially devastating long-term adverse events and 
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associated reductions in HRQoL. An increasing area of research is the 
investigation of strategies for improving the HRQoL, disease-free survival and 
overall survival in breast cancer survivors. One such strategy which has been 
proposed for breast cancer patients is physical activity, the particular focus of this 
thesis. The next section will consider the evidence for the potential role of physical 
























2.7 Physical activity and risk of death and recurrence in breast cancer 
survivors; a systematic review and meta-analysis of epidemiological studies 
2.7.1 ABSTRACT 
Introduction: Strong evidence exists supporting the positive role of physical 
activity on breast cancer development risk. However, studies examining the effects 
of physical activity on clinical breast cancer outcomes including survival and 
prognosis have been inconclusive. Therefore, the aim of the current study was to 
provide a systematic review and meta-analysis of studies investigating the 
association between physical activity and breast cancer recurrence and death.  
Methods: A comprehensive literature search identified 21 studies, of which two 
studies were excluded from the meta-analysis. The remaining 19 studies included 
44,201 participants, 6,675 all-cause deaths and 5,485 breast cancer events (i.e. 
breast cancer related-deaths or recurrences).  
 
Results: Lifetime recreational pre-diagnosis reduced all-cause death significantly 
by 19% but only had a borderline significant effect on breast cancer deaths. 
Recent (1-3 years) pre-diagnosis physical activity significantly decreased both all-
case and breast cancer-related deaths (25% and 13%, respectively). Post-
diagnosis physical activity reduced all-cause death by 42% and breast cancer-
related deaths by 39%, and meeting recommended physical activity guidelines 
(i.e. ≥8 MET-h·wk-1) lowered all-cause death by 38%. There were insufficient 
studies including recurrence as an outcome to include in the meta-analysis.  
Conclusion: The current meta-analysis provides evidence for an inverse 
relationship between physical activity and all-cause and breast cancer-related 
death in breast cancer patients and supports the notion that appropriate physical 





Breast cancer is the most commonly diagnosed cancer and a leading cause of 
death from cancer in women, responsible for 23% of total cancer cases and 14% 
of cancer deaths worldwide (Jemal et al., 2011). In the UK, female breast cancer 
had the highest incidence rate of all cancers, with an average European AS rate of 
124 cases per 100,000 population each year between 2007 and 2009 (ONS, 
2012). Recent projections have estimated that new cases of breast cancer in 
England will rise by 44% from 2001 figures to 2020 (Moller et al., 2007). Breast 
cancer was second only to lung cancer as the cause of deaths from cancer in 
females (European AS mortality rate=26.1 and 31.5 per 100,000, respectively). 
 
Risk factors associated with an increased risk of developing breast cancer are 
typically categorised into those which are non-modifiable, such as age and genetic 
predisposition, and those which are modifiable, such as alcohol consumption, 
overweight/obesity and physical activity. Twenty nine observational studies have 
found a statistically significant reduction in breast cancer risk when comparing the 
most physically active women to the least active (Lynch et al., 2011). A number of 
mechanisms have been proposed to explain the potential association between 
physical activity and breast cancer risk, including reduced exposure to oestrogen 
and androgens, insulin-related factors, adipokines and inflammation (Monninkohf 
et al., 2009; McTiernan et al., 2004; Key et al., 2002; Kaaks, 1996). These same 
mechanisms that may explain the association between physical activity and 
reductions in breast cancer risk, may also act to reduce the risk of premature 




Therefore, the aim of this systematic review was to evaluate the available literature 
pertaining to the effects of physical activity on all-cause and breast cancer-related 
death as well as recurrence in women diagnosed with breast cancer. 
 
2.7.3 METHODS 
A review of the epidemiologic literature on the association between physical 
activity and all-cause and breast cancer-related death and recurrence in women 
diagnosed with breast cancer was conducted using PubMed articles from 1966 up 
to June 2013, and a search of the reference lists of previous studies and reviews 
for potentially relevant additional references. The primary search strategy is 
presented in appendix B.  
 
2.7.3.1 Criteria for considering studies for the review  
Based on the current literature search there are at present no RCTs addressing 
the effects of physical activity on all-cause or breast cancer-related death or 
recurrence in breast cancer survivors. Therefore, a priori was given to 
observational studies such as cohort, case-control and cross-sectional studies for 
inclusion in the review. Studies were considered if they included women 
diagnosed with breast cancer. Studies which included cancer patients but did not 
provide a sub-analysis of breast cancer patients were excluded. Studies which 
measured and investigated the effects of either pre and/or post-diagnosis physical 
activity on all-cause death, breast cancer-related death and/or breast cancer 
recurrence were included. Only English language studies were included. 
 
2.7.3.2 Search methods for identification of studies 
All the titles and abstracts of the studies resulting from the searches of PubMed 
and reference lists were reviewed and articles that were clearly irrelevant were 
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excluded. Full-text copies of all trials were retrieved if a trial possibly or definitely 
met the inclusion criteria. The retrieved full-text articles were reviewed using the 
defined eligibility criteria, and were included if eligibility criteria was met. If there 
was a need for clarification of any detail of a trial, the trial authors were contacted 
to obtain such clarification for a complete assessment of the trial’s relevance for 
the review to be made. Missing data were retrieved by asking study authors for the 
necessary data via electronic mail.  
 
2.7.3.3 Data collection and analysis 
For each trial, information on the characteristics of studies, study population, 
physical activity assessment and breast cancer outcomes was extracted, in 
addition to details of the comparisons made within each study. Characteristics of 
studies extracted included study design, country of origin, years patients were 
recruited/diagnosed with breast cancer and follow-up time. Characteristics of study 
population included participants’ age, menopausal status, BMI, race, percentage 
with family history of breast cancer, percentage of participants received 
chemotherapy and hormonal therapy, breast cancer staging information and 
hormone-receptor status. Characteristics of physical activity assessment extracted 
included the time period between diagnosis and assessment, the period(s) of time 
that physical activity was assessed for, the mode of physical activity assessment 
and a description of the assessment tool used. In addition, information on physical 
activity variables and categories, comparisons made and the statistical results 
(hazard ratios and 95% CI) of these comparisons were extracted for the effects on 
all-cause death, breast cancer-related death and breast cancer recurrence. Details 
of any physical activity sub-analyses were also extracted from studies. 




2.7.3.4 Measurement of outcome 
All-cause death, breast cancer-related death and recurrence are described as 
time-to-event data and as such were expressed as a hazard ratio (HR) with 95% 
CI in all studies. The HR is a measure of relative risk over time, and in this case it 
is the risk of suffering death or breast cancer recurrence over a particular time 
period (Spruance et al., 2004). The HR is not computed at any one time point, but 
from all the data in the survival curve. Participants who contribute some period of 
time that does not end in an event (i.e. death or recurrence) are said to be 
“censored”. In the current review, the HR provides a measure of how high the risks 
of these events are in one group (group 1; reference group of those who perform 
no/low levels of physical activity) compared to another group (group 2; those who 
are sufficiently physically active i.e. at least 150 min/week of moderate or 75 
min/week of vigorous physical activity). A HR of greater than one would mean that 
the risk of an event in group two is higher than in group one. A HR of less than one 
would mean that the risk of an event in group two is lower than in group one, while 
a HR equal to one would mean that the risk of an event is approximately equal in 
both groups (Spruance et al., 2004). In all cases, statistical significance is 
assumed if the 95% CI around the HR does not include 1.0. 
 
The HRs for all-cause death, breast cancer-related death or breast cancer 
recurrence of the identified studies were assessed by categorising the HR and 
accompanying 95% CI into the following as adopted from Lynch et al. (2011): 
• Significant reductions=HR below 0.9 and upper limit 95% CI less than 1.0 
• Borderline significant reductions=HR below 0.9 and upper limit 95% CI is 
less than 1.05 




• Null findings=HR is above or equal to 0.9 or if upper limit 95% CI is 1.05 or 
over 
 
In addition to the above synthesis of data, a meta-analysis was conducted to 
summarise the association between higher levels of physical activity and all-cause 
death and breast cancer-related death. It was not possible to include recurrence 
data in the meta-analysis due to a lack of available data.  
 
2.7.3.5 Meta-analysis 
A meta-analysis was conducted to determine the direction and size of the possible 
effect that physical activity has on all-cause mortality and breast cancer-related 
mortality in breast cancer patients. There is conflicting results from the available 
data, and therefore, by combining these data the power (i.e. ability to detect a real 
effect as statistically significant if it exists) and precision (i.e. improve the accuracy 
of the effect estimate) can be improved. The comparisons were made between a) 
lifetime pre-diagnosis physical activity, b) recent (on average 1-3y) pre-diagnosis 
total physical activity and c) post-diagnosis recreational physical activity and 
meeting recommended physical activity guidelines post-diagnosis and all-cause 
and breast cancer-related death. 
 
To date no RCTs or controlled trials address these outcomes, therefore, cohort 
and case-control trials were included in this meta-analysis. To perform meta-
analysis of time-to-event outcomes log HR (intervention relative to control) and its 
standard error (SE) must be obtained. HRs and their confidence intervals were 
extracted from the relevant trials, and were then transformed by taking their 
natural logarithms (log base e, written “ln”). Standard errors (SE) were calculated 
from the corresponding 95% CI as follows: (ln[upper limit of CI] - ln[lower limit of 
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CI])/3.92 (Tierney et al., 2007). This transformation was conducted due to the 
asymmetry of risk ratios. The lowest value that a ratio can be is zero while the 
highest value is infinity. By transforming the HR to their ln the ‘no effect’ value 
becomes 0. To estimate a pooled effect and corresponding 95% CI the ln of the 
HRs were weighted by the inverse of their variance. For ease of interpretation the 
ln transformations of summary estimates and their 95% CI were converted back to 
their ratio (i.e. eln(HR)) and presented in the results section.  
 
Based on the ln of the HRs and the SE of the ln of the HR, the Cochran’s Q test 
and I2 statistics were used to assess heterogeneity among studies (Higgins et al., 
2003). These statistics were used to test whether the differences obtained 
between studies were due to sampling error (i.e. chance). Cochran’s Q test is 
calculated as the weighted sum of squared differences between individual study 
effects and the pooled effect across studies (Cochran, 1954). The significance of 
the Q statistic was interpreted using the χ2 distribution table. For the Q statistic, a p 
value of less than 0.10 was used as an indicator of the presence of heterogeneity 
(i.e. variation in intervention effects beyond chance), while a p-value of greater 
0.10 suggests there is no significant heterogeneity (i.e. effect estimates of studies 
are similar). The I2 statistic expresses the percentage of variability in effect 
estimate due to heterogeneity rather than chance. An I2 value of 0% indicates no 
observed heterogeneity and larger values reflect increasing heterogeneity.  A 
value greater than 50% was considered a measure of substantial heterogeneity 
(Higgins et al., 2003). 
 
Study results were combined using the generic inverse-variance method. This 
method assigns a weight to each study based on the inverse of the variance of the 
effect estimate (i.e. 1 over its SE squared). In this method larger studies with 
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smaller SEs are given more weight than smaller studies with higher SEs, which 
minimises the imprecision of the pooled effect estimate (Deeks et al., 2011). A 
random-effects model (DerSimonian and Laird, 1986) was used to combine data 
where heterogeneity was suspected, while the fixed-effects model was used when 
heterogeneity was not suspected. The summary statistic based on either a fixed or 
random-effects model will be expressed as a HR and 95% CI, and not their ln for 
ease of comparison with other studies and consistency. The random-effects model 
incorporates heterogeneity among studies whereas the fixed-model ignores 
heterogeneity. If substantial heterogeneity is found subanalyses will be conducted 
when there are sufficient numbers of studies involved. These subanalyses will 
stratify breast cancer patients by postmenopausal status/age, BMI and ER status. 
 
The meta-analyses and accompanying forest plots were completed using 
Microsoft Excel employing the method and spreadsheet described in Neyeloff et 
al. (2012). The main limitation of the forest plot developed by this method is that all 
studies are represented by squares of the same size, instead of proportional to 
study weight, however, study weight was provided adjacent to the plots and study 
weight can also be estimated by the confidence interval width. For illustration 
purposes effect estimates were shown on their ratio scale rather than their ln scale 
(see figures 2.7.1 to 2.7.7). 
 
Funnel plots were constructed for each of the comparisons again using Microsoft 
Excel. Funnel plots are commonly used to assess evidence of publication bias in 
studies included in a meta-analysis. If smaller studies without statistically 
significant effects remain unpublished, this can lead to an asymmetrical 
appearance of the funnel plot (Harbord et al., 2009). For each funnel plot, the 
estimate of effect from each study (lnHR) in the meta-analysis was plotted against 
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a measure of its precision (SE of lnHR) (Sterne and Harbord, 2004). To facilitate 
the interpretation of funnel plots, we included diagonal lines (black dashed lines) 
representing the 95% CI around the summary treatment effect, i.e., [summary 
effect estimate − (1.96 × SE)] and [summary effect estimate + (1.96 × SE)] for 
each SE on the vertical axis (Sterne and Harbord, 2004) (see figure 2.7.7). For the 
purposes of displaying the centre of the plot in the absence of bias, we used the 
calculation of the summary In hazard ratio (dashed red line) using fixed rather than 
random-effects because the random-effects estimate gives greater relative weight 
to smaller studies and would, therefore, be more affected if publication bias is 
present (Poole and Greenland, 1999). The 95% CI show the expected distribution 
of studies in the absence of heterogeneity or of selection biases. In the absence of 
heterogeneity, 95% of the studies should lie within the funnel defined by these 
straight lines. Because these lines are not strict 95% limits, they are referred to as 
“pseudo 95% confidence limits” (Sterne and Harbord, 2004).  
 
Tests for funnel plot asymmetry, such as the Peters test (Peters et al., 2006) or the 
Egger regression test (Egger et al., 1997), were not used because there were 
fewer than 10 studies in all of the meta-analysis. The small number of studies 
lowers test power to a point where it is too low to distinguish chance from real 
asymmetry, which leads to an increase in the likelihood of a “statistically 
significant” result when in reality there is no association between study size and 
intervention effects (Sterne and Egger, 2011). Therefore, publication bias was 
interpreted in the context of visual inspection of funnel plots. Effect estimates from 
smaller studies should scatter along the bottom of the funnel plot because these 
studies are usually less precise (i.e. have larger SEs) and are highly subject to 
random variation, while the spread among larger more precise (i.e. smaller SEs) 
studies should narrow (Sterne et al., 2011). Thus, publication was deemed to be 
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absent if the funnel plot resembled a symmetrical inverted funnel shape. 
Publication bias was suspected if there were studies with markedly different 
intervention effect estimates, if smaller studies tended to lead to more or less 
beneficial effect estimates, and if the funnel plot was skewed and asymmetrical 
(i.e. gaps in bottom right and left corners indicating “missing studies”).  
 
2.7.4 RESULTS 
Through a literature search of PubMed, 1,314 potentially relevant references were 
identified and screened for retrieval. Based on the title and abstract 254 
references were retrieved for more detailed evaluation. From the 254, 235 
references were excluded as they did not meet the inclusion criteria and 21 
studies were identified as appropriate for inclusion in the current review. 
 
2.7.4.1 Results of the search 
The final selection based on consensus resulted in 21 studies being included in 
this review (Schmidt et al., 2013; Cleveland et al., 2012; Cadmus-Bertram et al., 
2011; Chen et al., 2011; George et al., 2011; Irwin et al., 2011; Emaus et al., 2010; 
Hellmann et al., 2010; Keegan et al., 2010; Friedenreich et al., 2009; Sternfield et 
al., 2009; West-Wright et al., 2009; Dal Maso et al., 2008; Irwin et al., 2008; Holick 
et al., 2008; Pierce et al., 2007; Abrahamson et al., 2006; Holmes et al., 2005; 
Borugian et al., 2004; Enger and Bernstein, 2004; Rohan et al., 1995). The above 
studies included 19 trials as two publications were secondary publications to two 
of the trials (2 publications each for the WHEL study, Cadmus-Bertram et al., 2011 
and Pierce et al., 2007; and HEAL study, George et al., 2011 and Irwin et al., 
2008). We reviewed and included information on trial characteristics and outcome-
related data from these two secondary publications (George et al., 2011; Pierce et 
al., 2007). We corresponded with and requested additional data from one trial 
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author, and this trial author was able to provide additional data. For trial 
characteristics, physical activity assessment details and outcomes see the 
Characteristics of included studies tables 2.7.1, 2.7.2 and 2.7.3, respectively. 
 
2.7.4.2 Characteristics of included studies 
Of the 21 included studies, 19 were prospective cohort studies and two were case-
control studies (Schmidt et al., 2013; Emaus et al., 2010). The total number of 
participants across all 21 studies was 44,201, and the mean number of 
participants in each study was 2,105 (s=1,470; range=412-4,826). The years in 
which participants were diagnosed with breast cancer ranged from 1974 to 2006. 
The mean average (mean/median) time the participants were followed-up for was 
7.1 (s=2.0) y.  
 
The total number of all-cause deaths observed across all studies was 6,675, and 
the mean number of all-cause death reported was 318 (157). Sixteen studies 
reported a total number of breast cancer-related deaths of 3,526 
(mean±s=196±98). While, one study (Chen et al., 2011) combined the number of 
breast cancer-related deaths and breast cancer recurrences (n=450). Four studies 
(Sternfield et al., 2009; Irwin et al., 2008; Pierce et al., 2007; Holmes et al., 2005) 
reported breast cancer recurrences (total=887; mean=221.8±128.7), while one 
study (Friedenreich et al., 2009) reported a combined breast cancer recurrence, 
breast cancer progression and new primary breast cancer outcome category 
(n=327) and another study (Cadmus-Bertram et al., 2011) reported combined 
breast cancer recurrences and new primary breast cancers (n=295). Only two of 
these studies included breast cancer recurrences in their analyses (Sternfield et 
al., 2009; Holmes et al., 2005). For full details of the characteristics of included 




The eligibility age of participants ranged from 18 to 80y across the 21 included 
studies. From the 17 studies that reported the average age of participants, the 
mean average age was 57 (±6) y. Other studies reported the number of 
participants in various age categories. Enger and Bernstein (2004) reported that 
90% of participants were aged 31 to 40y, all participants in Holmes et al. (2005) 
were aged between 30 and 55y, and 81% and 41% of participants were aged at 
least 50y in Sternfield et al. (2009) and Keegan et al. (2010), respectively. 
Fourteen studies reported the menopausal status of participants and the average 
percentage of postmenopausal patients in these studies was 60 (±25) %. One 
study (Enger and Bernstein, 2004) consisted entirely of premenopausal women 
while one study (Irwin et al., 2011) comprised of only postmenopausal women. 
 
The mean average BMI, in the 13 studies that reported this variable, was 26 (2) 
kg·m2. Other studies reported the number of participants in particular BMI 
categories. In these studies, the number of participants with a BMI of at least 25 
kg/m2 (i.e. overweight or obese) was 49.6% (Hellmann et al., 2010), 43% (Keegan 
et al., 2010), 40.7% (West-Wright et al., 2009), 56.2% (Pierce et al., 2007), 38% 
(Abrahamson et al., 2006), 25.4% (Enger and Bernstein, 2004) and 42% (Rohan 
et al., 1995). Participants in the included studies were mainly 
white/Caucasian/non-Hispanic white participants (number of studies, n=12, mean 
%=82±14.2%). Only eight studies provided the number of participants who 
reported a family history of breast cancer, and the average percentage of women 
with a family history in these studies was 16.3 (6.3) %. Nearly half of the 
participants in the studies had received chemotherapy (n=10, mean 
%=45.0±18.9%) and a similar number reported receiving hormonal therapy (chiefly 
tamoxifen) (n=10, mean %=45.2±18.9%). 
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Table 2.7.1 Characteristics of included studies 
Trial (trial 
name), country  
Sample 
N 







Schmidt et al. 
(2013) (MARIE), 
Germany 










2001-2005 in Hamburg 
and between 2002-




367 243 330 
Cleveland et al. 
(2012) (LIBCSP), 
USA 














196 128 NR 
Cadmus Bertram 
et al. (2011) 
(WHEL), USA 




















name), country  
Sample 
N 







  Stage II=45.2% 
Stage III =14.3% 
HR-status=NR 
    
Chen et al. 
(2011) (SBCSS), 
China 
4,826 Mean age=53.5 (±10)y 
Postmenopausal=51.1% 












436 450**   





Mean age =57.8y 
Postmenopausal=61% 











62 24 NR 









Mean age at enrolment=63.7y 
Postmenopausal=100% 


























name), country  
Sample 
N 















    
Emaus et al. 
(2010), Norway 














diagnosis and end of 
follow-up =8.2±6.6y 
429 355 NR 
Hellmann et al. 
(2010) (CHCS), 
Denmark 

















323 178 NR 















name), country  
Sample 
N 



















1,225 Mean age at diagnosis=56 
(±12.1)y 
Postmenopausal=62.4%  











Minimum follow-up for 
breast cancer 
recurrence and 




341 223 327*** 
Sternfield et al. 
(2009) (LACE), 
USA 


















name), country  
Sample 
N 







  ER-/PR-=17.6% 
ER-/PR+=2.7% 
    
West-Wright et 
al. (2009) (CTS), 
USA 












1995-1996 to 2004, 
Median follow-up =4.3y 
(median follow-up =3.2y 
and 5.3y for all-cause 
death and for women 
alive until study end, 
respectively) 
460 221 NR 







































Holick et al. 
(2008) (CWLS), 
USA 












412 109 NR 











Mean age=55.5 (range=35-64)y 
Postmenopausal=60% 






























Pierce et al. 
(2007) (WHEL), 
USA 
1,490†† Mean age=50y 
Aged 40-59=69% 
Menopausal status=NR 
BMI <20=5.2%  
BMI 20–24.9=38.6%  
BMI 25–29.9=30.7% 








Mean follow-up from 
diagnosis to censor 
point= 
8.7y,  
Mean  follow-up after 
baseline=6.7 (range=6-
11)y 




name), country  
Sample 
N 











    
Abrahamson et 
al. (2006), USA 















290  247  
 
NR 
Holmes et al. 
(2005) (NHS), 
USA 













463 280 370 
Borugian et al. 
(2004), USA 
603 Mean age=55 (±11)y  
Postmenopausal=61% 










name), country  
Sample 
N 







  HT/Tamoxifen=43% 
Stage=NR 
ER+=76.4% 



















Median follow-up=10.4  
(range=0.3-15.1)y 
263 251 NR 
Rohan et al. 
(1995), Australia 












123 112 NR 
Key: NR=not reported, HT=hormone treatment, HR=hormone receptor, ER=oestrogen receptor, PR=progesterone receptor, PA=physical activity 
*Breast cancer recurrence and new breast cancer primaries combined 
**Breast cancer-related deaths and recurrence combined 
***Breast cancer recurrence and breast cancer progression and new breast cancer primaries combined 
† Forms part of cohort from Irwin et al. 2008 post-diagnosis analysis 
†† Consisted of some of the control group of WHEL study, see Cadmus Bertram et al. (2011) for full WHEL cohort analysis 
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Seventeen of the 19 studies reported stage data on the participants. 
However, these data were reported in different ways. Eight of the studies 
reported stage data in the form of the Surveillance, Epidemiology, and End 
Results (SEER) Program “summary staging”, which groups cancer cases 
into four main categories. These categories are in situ (abnormal cells are 
present only in the layer of cells in which they developed), localised 
(cancer is limited to the organ in which it began, without evidence of 
spread), regional (cancer has spread beyond the primary site to nearby 
lymph nodes or tissues and organs) and distant (cancer has spread from 
the primary site to distant tissues or organs or to distant lymph nodes) 
(SEER Program, 2011). In the eight studies using this method the average 
percentage of localised breast cancer cases was 65.5 (8.1) %. Six of the 
studies reported combined regional and distant cases, and the average 
percentage of these combined stages was 31.0 (5.6) %. While, Enger and 
Bernstein (2004) reported 30% regional cases and just 0.9% distant cases 
and Rohan et al., (1995) reported 33.7% regional and 6.3% distant cases 
within their respective populations. In situ or TNM stage 0 breast cancer 
cases were reported in just three studies (Cleveland et al., 2012; 
Friedenreich et al., 2009; Enger and Bernstein, 2004), with an average of 
13 (3.5) % of this stage within these studies.  
 
Eight studies used the TNM staging system, there were an average of 43 
(8) % stage I cases, 44 (5) % stage II cases and 9 (5) % stage III cases. 
Only one study (Emaus et al., 2010) included separate stage IV data and 
reported that this stage accounted for 5.3% of the total population. Another 
study (Dal Maso et al., 2008) combined stage III and IV, and reported 
13.3% stage III/IV breast cancers. Thirteen studies reported participant’s 
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tumour hormonal-status. From these studies there was an average of 66.4 
(10.2) % ER-positive, 20.9 (5.6) % ER-negative, 58.9 (7.7) % PR-positive 
and 27.6 (7.5) % PR-negative breast cancer cases.  
 
Physical activity assessment characteristics 
All 21 studies assessed physical activity via a physical activity 
questionnaire. Twenty of the studies reported that these physical activity 
questionnaires were interview-administered. Twelve of the 21 studies 
reported an actual time between diagnosis of breast cancer and physical 
activity assessment, and there was considerable variation in this duration. 
The mean average time from diagnosis to assessment was 29 (39, 
range=2-138) months. Cadmus-Bertram et al. (2011) reported that 55% of 
participants completed physical activity assessments less than two years 
after diagnosis and the remaining 47% completed their assessment 
between two and four years post-diagnosis, while participants completed 
physical activity assessments within 12, 24 and 39 months of diagnosis in 
Dal Maso et al. (2008), Holmes et al. (2005) and Sternfield et al. (2009), 
respectively. In five studies (Cleveland et al., 2012; Hellmann et al., 2010; 
Friedenreich et al., 2009; West-Wright et al., 2009; Enger and Bernstein, 
2004) the time between diagnosis and assessment was unclear. 
 
Twelve of the 21 studies investigated the effects of only pre-diagnosis 
physical activity (Schmidt et al., 2013; Cleveland et al., 2012; Emaus et al., 
2010; Hellmann et al., 2010; Keegan et al., 2010; Friedenreich et al., 
2009; West-Wright et al., 2009; Dal Maso et al., 2008; Abrahamson et al., 
2006; Borugian et al., 2004; Enger and Bernstein, 2004; Rohan et al., 
1995), seven studies assessed only post-diagnosis physical activity 
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(Cadmus-Bertram et al., 2011; Chen et al., 2011; George et al., 2011; 
Sternfield et al., 2009; Holick et al., 2008; Pierce et al., 2007; Holmes et 
al., 2005)  and two studies measured both pre- and post-diagnosis 
physical activity (Irwin et al., 2011; Irwin et al., 2008). For full details of 
physical activity assessment characteristics see table 2.7.2. 
 
Characteristics of pre-diagnosis physical activity assessments 
Seven of the 14 studies that included an assessment of pre-diagnosis 
physical activity measured lifetime physical activity (Cleveland et al., 2012; 
Keegan et al., 2010; Friedenreich et al., 2009; West-Wright et al., 2009; 
Dal Maso et al., 2008; Abrahamson et al., 2006; Enger and Bernstein, 
2004). Four of these studies assessed physical activity at various age 
ranges. Keegan and colleagues (2010) and West-Wright et al. (2009) 
assessed physical activity during similar age categories (12-17, 18-24, 25-
34, 35-44, 45-54, ≥55y and during 3y pre-diagnosis, and 18-24, 25-34, 35-
44 and 45-54y and during 3y pre-diagnosis, respectively). While Dal Maso 
et al. (2008) and Abrahamson et al. (2006) both assessed lifetime physical 
activity in three age categories (15-19, 30-39 and 50-59y, and 12-13, 20y 
and year before diagnosis, respectively).  
 
The other studies measured only physical activity that was performed for a 
particular frequency and/or duration over a lifetime. Schmidt et al. (2013) 
assessed recreational physical activity that participants performed from 
the age of 50y to diagnosis. Cleveland et al. (2012) measured recreational 
physical activity that participants had engaged in for at least one h·wk-1 for 
at least three months in any year over their entire lifetime, while 
Friedenreich and colleagues (2009) assessed occupational and household 
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physical activity and exercise and/or sport engaged in for at least eight, 
seven and two h·wk-1 for at least four months over participants entire 
lifetime. Enger and Bernstein (2004) asked participants about their 
engagement in competitive team sport or in dance or exercise classes, or 
jogging or running one mile at least twice weekly from menses up to 
breast cancer diagnosis. Borugian et al. (2004) assessed how often (per 
week, month or year) participants performed physical exercise, active 
sports, jogging or running, swimming or taking long walks, and gardening 
or fishing or hunting, as well as blocks walked and flights of stairs climbed 
on average each day pre-diagnosis. Three studies (Irwin et al., 2011; Irwin 
et al., 2008; Rohan et al., 1995) measured physical activity in the year 
prior to breast cancer diagnosis. Emaus et al. (2010) assessed leisure 
time physical activity on the year preceding assessment, which was on 
average 11.5y (range=1-29y) prior to diagnosis. It was unclear what period 
of time pre-diagnosis physical activity data was collected for in Hellmann 
et al. (2010). 
 
All 14 of the studies that measured pre-diagnosis physical activity included 
recreational physical activity, while three studies (Friedenreich et al., 2009; 
Dal Maso; Irwin et al., 2008) also included occupational physical activity 
and three studies (Schmidt et al., 2013; Friedenreich et al. 2009; Borugian 
et al., 2004) included household physical activity. Most of the studies 
(Irwin et al., 2011; Keegan et al., 2010; West-Wright et al., 2009; Dal Maso 
et al., 2008; Irwin et al., 2008; Abrahamson et al., 2006; Borugian et al., 
2004; Enger and Bernstein, 2004; Rohan et al., 1995) provided 




The physical activity variables used in these studies were considerably 
varied. Total lifetime recreational/leisure physical activity in MET-h·wk-1 
units was used in three studies (Cleveland et al., 2012; Keegan et al., 
2010; Friedenreich et al., 2009) and in h/wk-1 units in four studies 
(Hellmann et al., 2010; Dal Maso et al., 2008; Enger and Bernstein, 2004; 
Rohan et al., 1995) and in h·wk-1·y-1 units in one study (West-Wright et al., 
2009). Friedenreich et al. (2009) in addition to recreational lifetime 
physical activity included total lifetime, occupational and household 
physical activity variables in their analysis. Two studies used a recent 
(average 3y pre-diagnosis) physical activity variables in MET-h·wk-1 
(Schmidt et al., 2013; Keegan et al., 2010) and one in h·wk-1 (West-Wright 
et al., 2009). While, one study (Enger and Bernstein, 2004) used average 
h·wk-1 and two studies (Irwin et al., 2011; Irwin et al., 2008) used MET-
h·wk-1 of recreational physical activity in the year prior to diagnosis. Dal 
Maso et al. (2008) assessed occupational physical activity performed from 
age 30 to 39y as a physical activity variable. Borugian et al. (2004) 
included a number of physical activity variables, such as flights of stairs 
climbed per week, number of blocks walked per week and the frequency 
of sports participation, exercise, jogging, swimming and gardening per 
week. Finally, Emaus et al. (2010) categorised physical activity based on 
the time (h·wk-1) spent performing leisure time physical activity (e.g. 







Table 2.7.2 Physical activity (PA) assessment characteristics 
Trial  
(name of trial) 
Diagnosis to 
assessment time 
Time period of 
PA assessment 
Assessment mode and PA domains/items PA variables 










PA was assessed using a detailed interviewer-administered 
questionnaire. Data collected: duration and type of 
occupational PA and time spent doing household tasks. A 
typical week was split into weekdays and weekend; the 
number of hours per week spent walking as well as the 
number of hours per week spent cycling was recorded. 
Participants listed up to 3 sports performed during the 
considered age period, including sport type, duration and 
frequency. MET-h·wk-1 were calculated by summing the 
average hours per week spent walking, cycling, engaged in 
sports or in occupation and household weighted by the 
appropriate MET values. Recreational PA was categorised 
using cutpoints: 0 (no recreational PA), <12 MET-h·week-1 
(e.g., <2 h cycling or moderate exercise per week), 12 to <24 










recreational PA in 
which they had 
engaged for ≥1 
h·wk-1 for ≥3 mo 
in any year over 
their entire 
lifetime. 
Interview; Activity information recorded: name of activity, ages 
the activity was started and stopped, total years of 
participation in the activity, number of months per year and 
number of hours per week the activity was usually performed. 
Time periods: lifetime (h·wk-1 from menarche to diagnosis); 
premenopausal (postmenopausal women only, menarche up 
to menopause); onset of menopause to diagnosis, and recent 
PA (>10 y pre-diagnosis). 
1. Total lifetime recreational 
PA (MET-h·wk-1); 
2. Moderate-intensity 
lifetime PA (MET-h·wk-1); 
3. Vigorous-intensity 
lifetime recreational PA 
(MET-h·wk-1) 
Cadmus-
Bertram et al. 
(2011) (WHEL) 





baseline (at the 
time of 
enrollment) 
and at 12-mo 
follow-up 
Questionnaire; 9-item PA measure adapted from the WHI 
study (see Irwin et al. 2011). Assessed frequency, duration, 
and speed of walking outside the home and frequency and 
duration of participation in each of three intensities (mild, 
moderate, or vigorous) of exercise. Activity levels were 
converted into MET-h·wk-1 (mild PA=3, moderate PA=5, and 
vigorous PA=8 METs). For walking, slow, average, fast, and 
very fast were assessed as 2, 3, 4 and 6 METs, respectively. 
1. Total PA (MET-h·wk-1) 
2. Mod-vig PA (MET-h·wk-1) 
3. Meeting PA guidelines 
(Yes = ≥10 MET-h·wk-1; 
No = <10.MET-h·wk-1) 
4. Change in adherence to 
guidelines (Yes/No) 
5. Change in total PA 
(MET-h·wk-1)  





(name of trial) 
Diagnosis to 
assessment time 
Time period of 
PA assessment 
Assessment mode and PA domains/items PA variables 
Chen et al. 
(2011) 
(SBCSS) 
6 mo At baseline: 6 mo 
post- diagnosis, 
at 18-mo: 
preceding  12 mo 
(i.e. 6-mo to 18-
mo), at 36-mo: 
preceding 18 mo 
(18-mo to 36-mo)  
Interview; Participants asked whether they participated in 
exercise regularly (≥2 h∙wk-1) or not. If the answer was "Yes", 
asked to report up to 5 of the most common activities in which 
she participated. Frequency and duration was obtained for all 
exercise activities. Each activity was assigned a MET score. 
MET-h·wk-1 for each activity was calculated from the hours 
per week the participant reported engaging in that activity 
multiplied by the assigned MET score. 
1. Exercise participation 
(Yes/No) 
2. Exercise participation 
(h·wk-1) 
3. Exercise energy 
expenditure(MET-h·wk-1) 
George et al. 
(2011) (HEAL) 






For PA questionnaire detail see Irwin et al. (2008) below. Diet 
quality scores based on Healthy Eating Index (HEI)-2005 
questionnaire 
1. Recreational PA and diet 
quality combined 
Irwin et al. 
(2011) (WHI) 
Pre-diagnosis: 






PA” at baseline 
(pre-diagnosis) 
and years 3 and 
6 (post-diagnosis) 
PA questionnaire: Walking outside the home  ≥10 min without 
stopping: Categories of frequency: 0 to 1-7 days/wk. Duration 
categories were <20 min, 20 to 39 min, 40 to 59 min, and 1 h 
or more. Four speed categories were created: <2 mph 
(strolling), 2-3 mph (average/normal walking), 3-4 mph (fairly 
fast walking), and >4 mph (very fast walking). 
Recreational PA: frequency of vigorous exercise ranging from 
never to 1 to 5+ days/wk, and session duration categories 
were <20 min, 20-39 min, 40-59 min or ≥1 h). Vigorous 
activities included aerobics, jogging, tennis, and swimming 
laps. Similar questions about moderate-intensity PA (e.g. 
biking, exercise machine, calisthenics, easy swimming, and 
popular or folk dancing. Converted to MET values 
(walking=average, 3 METs; fast, 4 METs; and very fast 4.5 
METs. moderate-intensity recreational, 4 METs, and 
vigorous-intensity recreational, 7 METs) 
1. Moderate-vigorous 
intensity PA (walking + 
recreational PA) (MET-
h·wk-1) 
2. Moderate-intensity PA 
(walking + recreational 
PA) (MET-h·wk-1) 
3. Change in moderate- to 
vigorous-intensity PA 
(MET-h·wk-1) 
Emaus et al. 
(2010) 





activity in the 
year preceding 
each survey 
At inclusion, the participants indicated their usual level of PA 
during leisure time in the year preceding each survey, using 
one of 4 categories: level 1: reading, watching television, or 
engaging in sedentary activities; level 2: at least 4 h/wk 
walking, bicycling, or engaging in other types of physical 
activity; level 3: at least 4 h a week exercising to keep fit and 
participating in recreational athletics; and level 4: regular, 
vigorous training, or competitive sports several times a week. 
1. PA categories 
(sedentary, moderate 
exercise, and regular 






(name of trial) 
Diagnosis to 
assessment time 
Time period of 
PA assessment 
Assessment mode and PA domains/items PA variables 




Self-administered questionnaire; frequency of leisure time 
physical activity as categorised into inactive, moderate=2-4 
h·wk-1, high =>4 h·wk-1) 
1. Moderate PA of 2-4 
h·wk-1 
2. High PA > 4 h·wk-1 








recreational PA at 
Ages 12-17y, 18-
24y, 25-34y, 35-
44y, 45-54y, and 
≥55y, and during 
3y pre-diagnosis 
(recent PA) 
Interview-administered questionnaire: women were asked 
about their lifetime history of recreational PA, including 
moderate exercise activities or sports (i.e., brisk walking, golf, 
volleyball, cycling on level streets, recreational tennis or 
softball) and strenuous exercise activities or sports (i.e., 
swimming laps, aerobics, calisthenics, running, jogging, 
basketball, cycling on hills or racquetball). Data collected for 
each age interval and each type of activity (moderate and 
strenuous): duration of activity (0.5, 1, 1.5, 2, 3, 4-6, 7-10, ≥11 
h·wk-1, don't know; and 1-3, 4-6, 10-12, mo/y, don't know). 
H·wk-1 and mo per y were recoded to the midpoint (highest 
h·wk-1 interval recorded to 15) and multiplied to obtain 
duration of activity in h/y year for each age interval. Lifetime 
average h/y of PA was obtained by summing the duration of 
activity per y across the age intervals (except recent PA, 
which was considered separately), and dividing by the 
number of intervals. Moderate and strenuous activities were 
weighted by MET (5.4 for moderate PA and 8.5 for strenuous 
PA) and combined to obtain MET-h·wk-1. 
1. Lifetime PA (MET-h·wk-1)  





Lifetime PA Questionnaire (Friedenreich et al., 1998); 
Occupational, household and recreational PA separately 
throughout lifetime. For frequency and duration of activities 
assessed number per year, months/year, weeks/ month, 
day/week and hours/day that each activity was performed 
was recorded. Activities were converted into METs.  
1. Total lifetime PA (MET-
h·wk-1) 
2. Occupational PA (MET-
h·wk-1) 
3. Household PA (MET-
h·wk-1) 
4. Recreational PA (MET-
h·wk-1) 
Sternfield et al. 
(2009) (LACE) 
≤39 mo Post-diagnosis 
and post-
treatment, 6 mo 
prior to enrolment 
LACE PA Questionnaire; Job/work-related PA, nonwork 
routine PA (household chores, caregiving, home 
maintenance), recreational PA and transport (motorised & 
active) (frequency, intensity, duration); NHS activity score 
using 8 activities (walking/hiking, jogging/running, bicycling, 
swimming, tennis, calisthenics, aerobics, squash racquetball) 
1. Total PA (MET-h·wk-1) 
2. Mod-vig PA (MET-h·wk-1) 
3. H·wk-1 mod-intensity PA 
4. H·wk-1 vigorous PA 





(name of trial) 
Diagnosis to 
assessment time 
Time period of 
PA assessment 









the ages of 18-
24, 25-34, 35-44 
and 45-54y, and 
during the past 3y 
(recent PA) 
Information provided on recreational PA for 2 intensity levels, 
strenuous and moderate, at each of 6 time intervals. Long-
term PA was defined for this analysis as reported activities 
from high school though age 54 (or the participant's age at 
entry if younger than 54). Recent PA was defined for this 
analysis as reported activity within the 3 y prior to cohort 
entry. Examples of strenuous exercise included running, 
jogging, swimming laps, racquetball, aerobics, calisthenics, 
and cycling on hills. Examples of moderate intensity exercise 
included brisk walking, golf, softball, volleyball, recreational 
tennis, and cycling on flat surfaces. Participants reported an 
average number of h·wk-1 (categories: none, 0.5, 1, 1.5, 2, 3, 
4-6, 7-10, and ≥11) and the average number of mo/y 
(categories: 1-3, 4-5, 7-9, and 10-12) that they engaged in 
such activities. For each intensity level and time period, we 
calculated the average h·wk-1·y-1 by multiplying h·wk-1·y-1 by 
mo per y and dividing by 12 mo. These were summed across 
all eligible years and calculated the average annual h·wk-1 of 
long-term recreational PA for each intensity level. 
1. Long-term PA 
combined(h·wk-1·y-1) 




Dal Maso et al. 
(2008) (PACE) 
≤12 mo Pre-diagnosis, at 
various ages over 
lifetime 
Interview administered questionnaire: PA questions included 
self-reported intensity of activity at work and in leisure time 
separately. Both types of activity were elicited for thee specific 
periods of life: from 15 to 19, 30 to 39, and 50 to 59 y. For 
occupational PA, the scores ranged from 1 to 5, 
corresponding to “very tiring,” “tiring,” “average,” “standing,” 
and “mainly sitting.” PA in leisure time was defined according 
to h·wk-1 of sport and leisure time activity such as walking, 
gardening, and cycling. The cutoffs were defined as <2, 2-4, 
5-7, and >7 h·wk-1. 
1. Occupational PA at age 
30–39 y (h·wk-1) 
2. Leisure time PA (h·wk-1) 
Holick et al. 
(2008) (CWLS) 
Median=5.6y Post-diagnosis 
and treatment in 
the past year (i.e. 
year before 
enrolment) 
Questionnaire modelled on NHS PA questionnaire (Holmes et 
al., 2005); NHS activity score in the past year average time 
per week spent at each of the following 8 activities 
(frequency, intensity duration): walking or hiking, jogging or 
running, bicycling, swimming laps, tennis, calisthenics, 
aerobics, squash or racquetball. 










(name of trial) 
Diagnosis to 
assessment time 
Time period of 
PA assessment 
Assessment mode and PA domains/items PA variables 
Irwin et al. 
(2008) (HEAL) 
Pre-diagnosis PA: 








and treatment: 2 
y post-diagnosis 
Interview-administered questionnaire: Modifiable Activity 
Questionnaire (Kriska, 1997) included recreational, 
occupational, and household PA (type, duration, and 
frequency).  PA categorized: light (<3 MET), moderate (3-6 
MET) or vigorous (>6 MET). Reported recreational PA only. 
1. Recreational PA (MET-
h·wk-1) 




Pierce et al. 
(2007) (WHEL) 











Questionnaire same as Cadmus-Bertram et al. (2011) above. 1. Total PA (MET-h·wk-1) 




Median= 4.2 mo 
 
Pre-diagnosis, 
Ages 12-13 y, 
Age 20 y and 
year before 
diagnosis 
Interview questionnaire; Frequency of vigorous activities (lap 
swimming, dance, basketball, gymnastics, running, fast 
cycling, aerobics, or field hockey). Frequency of moderate 
activities (brisk walking, volleyball, recreational tennis, 
softball, leisurely cycling, or golfing). Relative units of PA were 
derived from frequency/wk times MET scores for vigorous, 9 
METs, and moderate, 5 METs activities. 
1. Relative units of 
recreational PA for each 
time period (MET x 
frequency of activity) 
Holmes et al. 
(2005) (NHS) 
≥24 mo Post-diagnosis 
and post-
treatment, in the 
year before 
enrolment 
Questionnaire; NHS activity score in the past year average 
time per week spent at each of the following 8 activities 
(frequency, intensity duration): walking or hiking, jogging or 
running, bicycling, swimming laps, tennis, calisthenics, 
aerobics, squash or racquetball  
1. Total MET-h·wk-1 (NHS 
activity score) 
Borugian et al. 
(2004) 
Mean=2 mo after 




Questionnaire; How often (per week, month, or year) the 
participant does each of the following: physical exercise, 
active sports, jogging or running, swimming or taking long 
walks, and gardening or fishing or hunting, as well as blocks 
walked and flights of stairs climbed on average each day.  
1. Flights of stairs 
climbed/wk 
2. Number of blocks 
walked/wk 
3. Days sports 
participation/wk 
4. Days exercise/wk 
5. Days jogging/wk 
6. Days swimming per wk 





(name of trial) 
Diagnosis to 
assessment time 
Time period of 
PA assessment 










up to 1-y before 
diagnosis 
Interview; Patients asked if they had ever participated ≥2/wk 
on a competitive athletic team or in dance or exercise 
classes, or if they jogged or ran 1-mile ≥2/wk. For each 
activity the age started and stopped, the type and the average 
number of h·week-1 of participation was recorded. Each 
episode when activities were started and stopped more than 
once or when the amount of time spent in the activity changed 
was recorded. The number of h·wk-1 each patient participated 
in all recreational exercise activities beginning with the year of 
each woman’s first menstrual period and ending at 1y pre-
diagnosis date was computed. 
1. Average hours of PA per 
week from first menses 
to 1-y prior to diagnosis 
2. Average hours of PA per 
week during year before 
1-y prior to diagnosis 
3. H·wk-1 from first menses 
to 1-y prior to diagnosis  
Rohan et al. 
(1995) 





one year prior to 
diagnosis 
Interview-administered questionnaire; Participants were 
asked to report how many h·wk-1 they spend doing light (e.g. 
bowls, walking, golf), moderate (e.g. dancing, horseback 
riding) and vigorous (e.g. competitive squash, tennis) 
recreational activities. H·wk-1 were converted to kcal/min 
expended (5 kcal/min for light, 7.5 kcal/min for moderate and 
10 kcal/min for vigorous activities) 




Studies also analysed the effects of different physical activity intensities on 
breast cancer outcomes. Cleveland et al. (2012) included moderate-
intensity and vigorous-intensity lifetime physical activity (MET-h·wk-1) and 
Irwin et al. (2011) moderate-intensity and vigorous-intensity physical 
activity (MET-h·wk-1) in the year prior to diagnosis. Abrahamson et al. 
(2006) used relative units (METs x frequency) of moderate-vigorous 
recreational physical activity for year before diagnosis and relative units 
averaged over age 13y, age 20y and year pre-diagnosis. 
 
Characteristics of post-diagnosis physical activity assessments 
Three of the nine studies that included post-diagnosis physical activity 
(Cadmus-Bertram et al., 2011; Irwin et al., 2011; Pierce et al., 2007) 
assessed the amount participants “currently” engage in walking outside 
the home for more than 10 min without stopping and recreational physical 
activity separated into moderate-intensity physical activities (including 
biking outdoors, exercise machine, calisthenics, easy swimming and 
popular or folk dancing) and vigorous activities (aerobics, jogging, tennis 
and swimming laps). Two of these studies included multiple physical 
activity assessment points. Cadmus-Bertram et al. (2011) assessed 
physical activity at baseline (within 4y of diagnosis) and at one year follow-
up, while Irwin et al. (2011) measured physical activity at years three and 
six post-diagnosis.  
 
Two of the studies (Holick et al., 2008; Holmes et al., 2005) assessing 
post-diagnosis physical activity measured the amount of leisure-time 
physical activity (chosen from a list of 6-8 activities) participants engaged 
in per week “during the past year” expressed in MET-h·wk-1. The 
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modifiable activity questionnaire, which measures the usual amount of 
recreational and occupational activity performed in the past-year (reported 
month-by-month) and sums and divides this into an average of physical 
activity per week (MET-h·wk-1), was used in the two studies from the HEAL 
trial (George et al., 2011; Irwin et al., 2008).  
 
Sternfield et al. (2009) measured occupational, household, active transport 
and recreational physical activities over the six month period prior to 
enrolment (≤39 month’s post-diagnosis). This study (2009) also included 
the nine-activity assessment used in the NHS trial (Holmes et al., 2005). 
Chen and colleagues (2011) assessed the amount of regular exercise (≥2 
h·wk-1) performed by participants expressed in MET-h·wk-1 at six months 
after breast cancer diagnosis (baseline), during the 12 months between 
baseline and 18-month assessment point and during the 18 months 
between the 18 and 36-month assessment points. 
 
Similar to the studies measuring pre-diagnosis physical activity, studies 
assessing post-diagnosis activity included a variety of activity variables to 
measures their influence on breast cancer outcome.  The two studies of 
the WHEL trial (Cadmus-Bertram et al., 2011; Pierce et al., 2007) both 
used a total physical activity variable expressed in MET-min·wk-1, while 
Cadmus-Bertram et al. (2011) also included variables such as moderate-
vigorous physical activity (MET-h·wk-1), achieving recommended levels 
(≥10 MET-h·wk-1) of physical activity (yes/no), change in meeting 
recommended levels from baseline to one year post-baseline (no 
change/yes to no/no to yes) and change in moderate-vigorous physical 
activity from baseline to one year after baseline. Irwin et al. (2011) used 
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the same physical activity assessment but included moderate-vigorous 
intensity and moderate-intensity physical activity variables expressed in 
MET-h·wk-1 variables in their analysis. 
 
Three studies (Sternfield et al., 2009; Holick et al., 2008; Holmes et al., 
2005) included a total physical activity (MET-h·wk-1) variable based on the 
NHS recreational physical activity assessment. Holick et al. (2008) also 
separated total physical activity into moderate-intensity (MET-h·wk-1) and 
vigorous-intensity (MET-h·wk-1) recreational physical activity. While 
Sternfield et al. (2009) used total activity (MET-h·wk-1), moderate-to-
vigorous physical activity (MET-h·wk-1) and time in moderate-intensity 
activities (h·wk-1) variables from a separate assessment. Of the two 
studies from the HEAL trial, both (George et al., 2011; Irwin et al., 2008) 
included a total recreational physical activity (MET-h·wk-1) variable in their 
analysis. While Chen and colleagues (2011) used the following variables 
to analyse the influence of exercise on breast cancer outcomes, exercise 
participation (yes/no), amount of exercise (h·wk-1) and exercise energy 
expenditure expressed in MET-h·wk-1. 
 
The two studies that assessed pre- and post-diagnosis physical activity 
included change in moderate-vigorous intensity physical activity (MET-
h·wk-1) (Irwin et al., 2011) and change in recreational physical activity 
(MET-h·wk-1) (Irwin et al., 2008). Two studies investigated the combined 
effects of physical activity and diet (George et al., 2011; Pierce et al., 





2.7.4.3 Qualitative synthesis of the results of studies 
Full details of results from the epidemiological studies can be found in 
table 2.7.3. 
 
Lifetime physical activity and all-cause death 
Statistically significant risk reductions for all-cause death in breast cancer 
survivors who performed the highest versus lowest level of pre-diagnosis 
lifetime recreational physical activity was found by two studies (Cleveland 
et al., 2012; West-Wright et al., 2009), borderline significant risk reductions 
was observed in two studies (Dal Maso et al., 2008; Friedenreich et al., 
2008), a non-significant risk reduction was reported by one study (Keegan 
et al., 2010), while two studies reported null-findings (Emaus et al., 2010; 
Abrahamson et al., 2006). Only one study reported a null-finding for the 
association between all-cause death and the highest versus the lowest 
categories of pre-diagnosis total lifetime physical activity (occupational, 
household and recreational physical activity combined) and pre-diagnosis 
lifetime household physical activity (Friedenreich et al., 2008). 
 
In regards to the role of physical activity intensity, two studies investigated 
the association between risk of all-cause death in breast cancer survivors 
who perform the highest versus the lowest amount of moderate-intensity 
pre-diagnosis lifetime recreational physical activity, and one study found a 
significant reduction in risk (Cleveland et al., 2012), while the other found a 
non-significant reduction in risk (Friedenreich et al., 2008). Two studies 
found a non-significant risk reduction in all-cause death with high versus 
low levels of pre-diagnosis lifetime vigorous-intensity physical activity 
(Cleveland et al., 2012; Friedenreich et al., 2008). Two studies observed a 
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null-finding for pre-diagnosis lifetime occupational physical activity and all-
cause death when the highest category was compared to the lowest (Dal 
Maso et al., 2008; Friedenreich et al., 2008).  
 
Lifetime pre-diagnosis physical activity and breast cancer-related death 
One study found a statistically significant reduction in risk of breast 
cancer-related death when comparing the highest versus lowest level of 
pre-diagnosis lifetime recreational physical activity (Friedenreich et al., 
2008), while two studies reported non-significant risk reductions 
(Cleveland et al., 2012; Dal Maso et al., 2008) and three reported null-
findings (Emaus et al., 2010; West-Wright et al., 2009; Enger and 
Bernstein, 2004). Two studies observed null-findings when comparing the 
risk of breast cancer-related death in the highest and lowest occupational 
lifetime physical activity categories (Dal Maso et al., 2008; Friedenreich et 
al., 2008). One study reported a borderline significant reduction in risk of 
breast cancer-related death and the highest versus the lowest categories 
of pre-diagnosis total lifetime physical activity (occupational, household 
and recreational physical activity combined), and a null-finding for the 
association of highest versus the lowest pre-diagnosis lifetime household 
physical activity (Friedenreich et al., 2008). 
 
Regarding physical activity intensity, one study found a statistically 
significant reduction in risk of breast cancer-related death when comparing 
breast cancer survivors who performed the highest versus lowest levels of 
moderate-intensity lifetime physical activity (Friedenreich et al., 2008), 
while another study found a non-significant risk reduction (Cleveland et al., 
2012). One study reported a statistically significant risk reduction for the 
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highest versus the lowest amounts of lifetime vigorous-intensity 
(Friedenreich et al., 2008), and one study reported a non-significant risk 
reduction (Cleveland et al., 2012). 
 
Recent pre-diagnosis physical activity and all-cause death 
Two studies found a statistically significant risk reduction for all-cause 
death when comparing the highest versus lowest level of pre-diagnosis 
recent (1-3y prior to breast cancer diagnosis) recreational physical activity 
in breast cancer survivors (Schmidt et al., 2013; Irwin et al., 2011), two 
found a borderline significant risk reduction (Keegan et al., 2010; West-
Wright et al., 2009), two found a non-significant decrease (Irwin et al., 
2008; Abrahamson et al., 2006), and finally one reported a null-finding 
(Hellmann et al., 2010). One study found a significant risk reduction in all-
cause deaths for the highest versus the lowest levels of pre-diagnosis 
recent moderate-intensity physical activity (Irwin et al., 2011). 
 
Recent pre-diagnosis physical activity and breast cancer-related death 
Of the studies that reported the association between recent pre-diagnosis 
recreational physical activity and breast cancer-related death, one study 
found a statistically significant reduction in risk in the highest physical 
activity category compared to the lowest (West-Wright et al., 2009), one 
observed a borderline significant risk reduction (Irwin et al., 2011), two 
found a non-significant risk reduction (Irwin et al., 2008; Enger and 
Bernstein, 2004), while the remaining four reported null-findings (Schmidt 
et al., 2013; Hellmann et al., 2010; Borugian et al., 2004; Rohan et al., 
1995). One study reported a non-significant reduction in risk of breast 
cancer-related deaths for the highest versus the lowest levels of pre-
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diagnosis recent moderate-intensity physical activity (Rohan et al., 1995). 
The only study that investigated the association between recent pre-
diagnosis vigorous-intensity physical activity and breast cancer-related 
death reported a null-finding comparing the highest versus the lowest 
categories (Rohan et al., 1995).  
 
Lifetime and recent pre-diagnosis physical activity and recurrence 
One study (Friedenreich et al., 2008) reported a statistically significant 
reduction in breast cancer events (combined breast cancer recurrence, 
breast cancer progression and new breast cancer primaries) when 
comparing the highest versus the lowest moderate-intensity lifetime 
recreational physical activity, a borderline statistically significant reduction 
with lifetime recreational physical activity, and null-findings for total lifetime 
physical activity, lifetime occupational physical activity, lifetime household 
physical activity and lifetime vigorous-intensity physical activity. Schmidt et 
al. (2013) found a significant reduction in risk of breast cancer recurrence 
when the highest level of physical activity from age 50y to breast cancer 
diagnosis (i.e. recent physical activity) was compared to the lowest. 
 
Dose-response relationships for lifetime and recent pre-diagnosis physical 
activity 
A statistically significant dose-response relationship between increasing 
levels of physical activity and decreased risk of all-cause death, breast 
cancer-related death and/or breast cancer recurrence was reported in four 
studies including an assessment of pre-diagnosis physical activity and in 




Regarding lifetime physical activity, West-Wright et al. (2009) found a 
significant dose-response relationship between increasing physical activity 
and both all-cause and breast cancer-related death. Similarly, 
Friedenreich and colleagues (2009) observed a significant dose-response 
relationship between increasing lifetime household physical activity and 
all-cause death, increasing lifetime recreational physical activity and 
breast cancer-related death, increasing moderate-intensity recreational 
physical activity and both all-cause and breast cancer-related death and 
breast cancer recurrence and progression and new primaries.  
 
When recent pre-diagnosis physical activity was considered, one study 
(Irwin et al., 2011) reported significant dose-response relationship 
between increasing moderate-vigorous recreational physical activity and 
all-cause death and moderate-intensity and all-cause death and breast 
cancer-related death. Similarly, another study (Irwin et al., 2008) found a 
dose-response relationship between recent pre-diagnosis recreational 
physical activity and all-cause death. 
 
Post-diagnosis physical activity and all-cause death 
Nine studies investigated the association between post-diagnosis physical 
activity and reduced risk of death in breast cancer survivors (Cadmus-
Bertram et al., 2011; Chen et al., 2011; George et al., 2011; Irwin et al., 
2011; Sternfield et al., 2009; Holick et al., 2008; Irwin et al., 2008; Pierce 
et al., 2007; Holmes et al., 2005). Six of the seven studies found 
statistically significant reduced risk of all-cause death when comparing 
breast cancer survivors who performed the highest versus the lowest 
levels of post-diagnosis recreational physical activity (Cadmus-Bertram et 
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al., 2011; Chen et al., 2011; Irwin et al., 2011; Holick et al., 2008; Irwin et 
al., 2008; Holmes et al., 2005), while one study found a non-significant 
reduced risk (Sternfield et al., 2009). Chen and colleagues (2011) 
assessed physical activity at six, 18 and 36 months post-diagnosis, and 
found significant risk reductions in all-cause death six months post-
diagnosis with exercise participation (yes vs. no), and 18 months and 36 
months post-diagnosis when the highest categories was compared to the 
lowest for exercise participation (yes vs. no, and h·wk-1) and exercise 
energy expenditure, but borderline significant reductions were observed 
six months post-diagnosis for highest category of hours per week of 
exercise and exercise energy expenditure versus the lowest. 
 
In regards to the intensity of physical activity, two studies (Irwin et al., 
2011; Holick et al., 2008) found a significant and one study (Sternfield et 
al., 2009) found a borderline significant risk reduction in all-cause death 
when comparing the highest amount of moderate-intensity recreational 
physical activity versus the lowest. Sternfield et al. (2009) and Holick et al. 
(2008) reported a non-significant reduction in risk and null-finding, 
respectively, when comparing the highest amount of vigorous-intensity 
recreational physical activity versus the lowest. Two studies in addition to 
a total physical activity variable, reported a combined moderate and 
vigorous-intensity physical activity variable (Cadmus-Bertram et al., 2012; 
Sternfield et al., 2009). These studies found a significant risk reduction 
(Cadmus-Bertram et al., 2012) and a non-significant reduction in risk 
(Sternfield et al., 2009) of all-cause death when comparing the highest 




An additional variable was created to investigate whether achieving 
recommended physical activity guidelines (150 min/week or ≥9-10 MET-
h·wk-1) conferred a reduction in the risk of all-cause death in breast cancer 
survivors. It was possible to include six studies of the post-diagnosis 
physical activity for this analysis (Cadmus-Bertram et al., 2011; Chen et 
al., 2011; Irwin et al., 2011; Irwin et al., 2008; Holmes et al., 2005). Five of 
the six studies observed a significant reduction in the risk of all-cause 
death when comparing those who achieved the recommended guidelines 
or more versus those who did less than the recommended amount 
(Cadmus-Bertram et al., 2011; Holmes et al., 2005) or those who did no 
physical activity (Chen et al., 2011; Irwin et al., 2011; Irwin et al., 2008), 
while another study found a non-significant reduction in risk in those who 
achieved the guidelines versus those who did not (Sternfield et al., 2009).  
 
Post-diagnosis physical activity and breast cancer-related death 
When the risk of breast cancer-related death in breast cancer survivors 
performing the highest level of recreational post-diagnosis physical activity 
was compared to that of survivors performing the lowest, significant 
reductions in risk was found in three studies (Irwin 2011; Holick et al., 
2008; Holmes et al., 2005), while non-significant decreases in risk was 
found in two studies (Sternfield et al., 2009; Irwin et al., 2008).  When the 
intensity of physical activity was considered, Holick and colleagues (2008) 
found a significant breast cancer-related risk reduction with the highest 
levels of moderate-intensity physical activity compared to the lowest, but 
reported a null-finding with vigorous-intensity physical activity. Irwin et al. 
(2011) observed a non-significant decrease in risk when comparing the 
highest category of vigorous-intensity compared to the lowest. Sternfield 
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and colleagues (2009) found when the highest categories were compared 
to the lowest, non-significant decreases in risk of breast cancer-related 
with moderate-vigorous intensity physical activity (MET-h·wk-1) and hours 
per week of moderate-intensity physical activity, and null-findings for hours 
per week of vigorous-intensity physical activity. Of the three studies that 
investigated the association between meeting recommended guidelines 
and breast cancer-related death, one study each found a significant 
reduction (Irwin et al., 2011), a non-significant reduction (Irwin et al., 2008) 
and a null-finding (Sternfield et al., 2009). 
 
Post-diagnosis physical activity and recurrence 
Chen and colleagues (2011) combined breast cancer-related deaths with 
breast cancer recurrences and found significant risk reductions in these 
breast cancer events 18 and 36 months post-diagnosis when the highest 
categories was compared to the lowest for exercise participation (yes/no 
and h·wk-1) and exercise energy expenditure. Non-significant reductions 
were observed six months post-diagnosis for exercise participation yes 
versus no and exercise energy expenditure highest versus the lowest 
category, while a null-finding was found for the highest compared to the 
lowest number of hours per week of exercise.  
 
One study (Holmes et al., 2005) found a borderline significant while 
another study (Sternfield et al., 2009) reported a null-significant reduction 
in breast cancer recurrences with the highest versus the lowest category 
of total post-diagnosis recreational physical activity. Sternfield and 
colleagues (2009) also observed when the highest categories were 
compared to the lowest, non-significant decreases in risk of recurrence 
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with hours per week of moderate-intensity physical activity, and null-
findings for moderate-vigorous intensity physical activity (MET-h·wk-1), 
hours per week of vigorous-intensity physical activity and performance of 
at least nine MET-h·wk-1 of selected recreational activity. Cadmus-Bertram 
et al. (2011) combined breast cancer recurrences with new breast 
primaries and found non-significant decreases in risk with total 
recreational physical activity and moderate-vigorous intensity physical 
activity when the highest and lowest categories were compared, and also 
when those who achieved at least 10 MET-h·wk-1 of recreational physical 
activity were compared to those who performed less. 
 
Dose-response relationships for post-diagnosis physical activity 
Significant dose-response relationships between total post-diagnosis 
recreational physical activity and all-cause death and breast cancer-
related death was found in seven (Cadmus-Bertram et al., 2011; Chen et 
al., 2011; Irwin et al., 2011; Sternfield et al., 2009; Holick et al., 2008; Irwin 
et al., 2008; Holmes et al., 2005) and three studies (Irwin et al., 2011; 
Holick et al., 2008; Holmes et al., 2005), respectively. Moderate-vigorous 
intensity physical activity was associated with a significant dose-response 
relationship with both all-cause death and breast cancer recurrences and 
new primaries in one study (Chen et al., 2011), while a significant does-
response relationship between moderate-intensity physical activity and all-
cause death in two studies (Irwin et al., 2011; Holick et al., 2008) and 
breast cancer-related death in another study (Holick et al., 2008). Holmes 
and colleagues (2005) observed a dose-response relationship between 
post-diagnosis recreational physical activity and breast cancer recurrence. 
Chen and colleagues (2011) observed a significant dose-response 
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between exercise participation at 36 months post-diagnosis and breast 
cancer-related deaths and breast cancer recurrences combined.  
 
Change in physical activity from pre- to post-diagnosis 
One study (Irwin et al., 2011) assessed the risk of all-cause and breast 
cancer-related death with a change in moderate-vigorous intensity 
physical activity pre-diagnosis to post-diagnosis. A significant reduction in 
all-cause death risk was found when comparing those who increased 
moderate-vigorous intensity physical activity versus those who had no 
change, while a null-finding was observed between breast cancer-related 
death and change in moderate-vigorous intensity physical activity. 
 
Change in post-diagnosis physical activity 
Cadmus-Bertram and colleagues (2011) observed null-findings when 
comparing the risk of all-cause death and breast cancer events 
(recurrences and new primaries combined) in those who went from non-
adherence at baseline (post-diagnosis) to adherence to physical activity 
guidelines one-year post baseline versus those who did not adhere to 
guidelines at either assessment point. However, those who adhered to the 
guidelines at both assessment points had a significantly reduced risk of 
all-cause death compared to non-adherers at both points. The authors 
(2011) also reported non-significant reductions in all-cause death risk and 
a null-finding for breast cancer events when comparing the highest versus 
the lowest change in total physical activity. Similarly, no significant 
reductions were found in risk of all-cause death and breast cancer events 
when comparing the highest versus the lowest change in moderate-
vigorous intensity physical activity.  
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Table 2.7.3 Physical activity and all-cause and breast cancer death and recurrence risk; results from epidemiological studies† 
Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
Schmidt et al. 
(2013) (MARIE) 
Pre-diagnosis recreational PA  
(Met-h·wk-1) 
• 0 
• >0 to <12  
• 12 to <24  
• 24 to <42  
• ≥42 
a) High vs. low PA 
category 




a) HR=0.65  
(0.44-0.97) 
Cleveland et al. 
(2012) 
(LIBCSP) 
a) Total pre-diagnosis  lifetime 
recreational PA (Met-h·wk-1) categories: 
• 0  
• >0-8.9 
• ≥9 
a) Highest vs. lowest 
category 





 b) Pre-diagnosis  moderate-intensity 
lifetime PA (Met-h·wk-1) categories: 
• 0  
• >0-8.9 
• ≥9  
b) Highest vs. lowest 
category 





 c) Pre-diagnosis  vigorous-intensity 
lifetime recreational PA (Met-h·wk-1) 
categories: 
•  0  
• >0-8.9 
• ≥9 
c) Highest vs. lowest 
category 
c) HR=0.68  
(0.31-1.50) 




Bertram et al. 
(2011) (WHEL) 
a) Total PA (Met-h·wk-1): 
• Q1: 0-2.5 
• Q2: 2.5-7.5 
• Q3: 7.5-14.9 
• Q4: 14.9-24.7 
• Q5: 24.7-107 
a) Highest vs. lowest total 
PA quintile 
a) HR=0.47  
(0.26-0.84)** 
 a) HR=0.74  
(0.50-1.10) 
 b) Moderate-vigorous PA (Met-h·wk-1): 
• Q1: 0-1.3 
• Q2: 1.3-6.3 
b) Highest vs. lowest 
moderate-to-vigorous PA 
quintile 
b) HR=0.39  
(0.21-0.72)** 




Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
 • Q3: 6.3-12.5 
• Q4: 12.5-22.9 
Q5: 22.9-107 
    
 c) Meeting PA guideline:  
• Yes (≥ 10 Met-h·wk-1)  
• No (<10 Met-h·wk-1) 
c) Meeting PA guideline 
vs. not meeting PA 
guideline 
c) HR=0.65  
(0.47-0.91)** 
 c) HR=0.89  
(0.70-1.14) 
 d) Change in adherence to guideline:  
• No  No 
• No  Yes 
• Yes  No 
• Yes  Yes 
d) 
i. No  Yes vs. No  No 
ii. Yes  Yes vs. No  
No 
d) 
i. HR=1.21  
(0.77-1.90) 
ii. HR=0.60  
(0.40-0.88)** 
 d) 
i. HR=1.44  
(1.02-2.03)* 
ii. HR=0.93  
(0.70-1.24) 
 e) Change in total PA (Met-h·wk-1) 
• Q1: -68.8, -5.5 
• Q2: -5.5, -0.3 
• Q3: -0.3, 2.3 
• Q4: 2.3, 7.5 
• Q5: 7.5, 92.3 
e) Highest vs. lowest 
change in total PA 
quintile 
e) HR=0.89  
(0.49-1.64) 
 e) HR=1.19  
(0.80-1.77) 
 f) Change in moderate-to-vigorous PA 
(Met-h·wk-1) 
• Q1: -68.8, -5.5 
• Q2: -5.5, -0.3 
• Q3: -0.3, 2.3 
• Q4: 2.3, 7.5 
• Q5: 7.5, 92.3 
f) Highest vs. lowest 
change in moderate-to-
vigorous PA quintile 
f) HR=0.92  
(0.51-1.66) 
 f) HR=1.23  
(0.83-1.80) 
Chen et al. 
(2011) 
(SBCSS) 




a) Yes vs. no exercise 
participation for i. First 6 
mo post-diagnosis 
ii. First 18 mo post-
diagnosis 
iii. First 36 mo post-
diagnosis 
a)  
i. HR=0.80  
(0.65-0.97) 
 
ii. HR=0.70  
(0.56-0.87) 
 
iii. HR=0.70  
(0.56-0.88) 
a)  
i. HR=0.91  
(0.75-1.11) 
 
ii. HR=0.71  
(0.57-0.90) 
 
iii. HR=0.60  
(0.47-0.76) 
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Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
 b) Exercise participation (h·wk-1) 
• No exercise 
• <2.5 
• ≥2.5 
b) ≥2.5 h∙wk-1 exercise 
vs. no exercise 
i. First 6 mo post-
diagnosis 
ii. First 18 mo post-
diagnosis 
iii. First 36 mo post-
diagnosis 
b)  
i. HR=0.82  
(0.64-1.04) 
 
ii. HR=0.66  
(0.51-0.84)** 
 
iii. HR=0.64  
(0.49-0.82)** 
b)  
i. HR=1.01  
(0.80-1.27) 
 
ii. HR=0.73  
(0.57-0.94) 
 
iii. HR=0.57  
(0.44-0.74)* 
 
 c) Exercise energy expenditure (Met-
h·wk-1) 
• No exercise 
• <8.3 
• ≥8.3 
c) ≥8.3 Met-h·wk-1 vs. no 
exercise 
i. First 6 mo post-
diagnosis 
ii. First 18 mo post-
diagnosis 
iii. First 36 mo post-
diagnosis 
c)  
i. HR=0.80  
(0.63-1.02) 
 
ii. HR=0.65  
(0.51-0.83)** 
 
iii. HR=0.65  
(0.51-0.84)** 
c)  
i. HR=0.98  
(0.78-1.24) 
 
ii. HR=0.72  
(0.57-0.93) 
 
iii. HR=0.59  
(0.45-0.76) 
 
George et al. 
(2011) (HEAL) 
a) Recreational PA (Met-h·wk-1) 
categories: 
•  0 
• >0  
Diet quality quartiles: 
• Q1. Poor quality 
• Q2-3. Mixed quality 
• Q4. Better quality 
a) 0 Met-h·wk-1 and poor 
quality diet vs. >0  Met-
h·wk-1 and poor quality 
diet category  
a) HR=0.53  
(0.21-1.34)  
a) HR=1.05  
(0.25-4.45) 
NR 
 b) 0 Met-h·wk-1and poor 
quality vs.>0  Met-h·wk-1 
and better quality 
category 
b) HR=0.11  
(0.04-1.36) 
b) HR=0.09  
(0.01-0.89) 
 
Irwin et al. 
(2011) (WHI) 
a) Pre-diagnosis moderate-vigorous 





a) Highest vs. lowest 
category  
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Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 






b) Highest vs. lowest 
category 
b) HR=0.58  
(0.44-0.78)** 
b) HR=0.60  
(0.4-0.9)* 
 
 c) Post-diagnosis moderate-vigorous 


















 d) Post-diagnosis moderate-intensity 









d) HR=0.66  
(0.36-1.21) 
 
 e) Change in moderate- to vigorous-
intensity PA from pre-diagnosis to post-
diagnosis 
• No change (stayed in either >0 to 
<9 Met-h·wk-1 or ≥9 Met-h·wk-1) 
• Decrease (went from ≥9 Met-h·wk-1 
pre-diagnosis to >0 to <9 Met-h·wk-
1 post-diagnosis) 
• Increase (went from >0 to <9 Met-
h·wk-1 pre-diagnosis to ≥9 Met-
h·wk-1 post-diagnosis)  
e) Increase vs. no 
change in PA category 
e) HR=0.67 
 (0.46-0.96) 
e) HR=0.91  
(0.51-1.64) 
 
Emaus et al. 
(2010) 
Pre-diagnosis recreational PA 
• Sedentary 
• Moderate 
• Regular exercise 









Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
Hellmann et al. 
(2010) (CHCS) 
a) Pre-diagnosis recent recreational PA 
categories: 
• Inactive 
• Moderate PA of 2-4 h·wk-1 
• High PA of >4 h·wk-1 
a) High PA > 4 h·wk-1 vs. 
inactive 
a) HR=1.00  
(0.69-1.45) 
a) HR=1.01  
(0.62-1.63) 
NR 
Keegan et al. 
(2010) (BCFR) 
a) Lifetime recreational PA (Met-h·wk-1) 
quartiles: 
• Q1: ≤6.7 
• Q2: 6.8-16.3 
• Q3: 16.4-26.1 
• Q4: 26.2-46.0 
a) Highest vs. lowest 




 b) Pre-diagnosis recent PA (Met-h·wk-1) 
(3y pre-diagnosis) 
• 0 
• Q1: ≤9.9 
• Q2: 10-17.7 
• Q3: 17.8-38.2 
• Q4: >38.2 
b) Highest vs. lowest 







a) Total pre-diagnosis  lifetime PA (Met-
h·wk-1·y-1) 
• Q1: ≥95 
• Q2: >95-≤120 
• Q3: >120-≤151 
• Q4:>151 
a) Highest vs. lowest 
quartile 






 b) Pre-diagnosis occupational PA 
(MET-h·wk-1·y-1) 
• Q1: ≥27 
• Q2: >27-≤43 
• Q3: >43-≤62 
• Q4:>62 
 
b) Highest vs. lowest 
quartile 
 b) HR=0.97 (0.69-
1.36) 
b) HR=0.90  
(0.58-1.39) 




Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
 c) Pre-diagnosis  household PA (MET- 
h·wk-1·y-1) 
• Q1: ≥36 
• Q2: >36-≤58 
• Q3: >58-≤87 
• Q4: >87 
c) Highest vs. lowest 
quartile 
c) HR=1.46  
(1.02-2.09)*† 




 d) Pre-diagnosis  recreational PA (MET-
h·wk-1·y-1) 
• Q1: ≥5 
• Q2: >5-≤10 
• Q3: >10-≤19 
• Q4:>19 
d) Highest vs. lowest 
quartile 




d) HR=0.76  
(0.55-1.03) 
 e) Moderate-intensity (3-6 METs) 




e) Highest vs. lowest 
category 






 f) Vigorous-intensity (>6 METs) 
recreational PA (h·wk-1·y-1) categories: 
• <0.03 
• ≥0.03 
f) Highest vs. lowest 
category 
f) HR=0.86  
(0.68-1.07) 
f) HR=0.74  
(0.56-0.98) 
f) HR =0.95 
 (0.76-1.19) 
Sternfield et al. 
(2009) (LACE) 
a) Total PA (Met-h·wk-1) quartiles: 
• Q1: <29 
• Q2: 29-<44 
• Q3: 44-<62 
• Q4: ≥62 









 b) Moderate-vigorous PA (Met-h·wk-1) 
quartiles: 
• Q1: <5.3 
• Q2: 5.3-<15 
• Q3: 15-<27 
• Q4: ≥27 
b) Highest vs. lowest 










Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
 c) h·wk-1of moderate PA:  
• <1 h·wk-1 
• 1–<3 h·wk-1 
• 3–<6 h·wk-1 
• ≥6 h·wk-1 
c) Highest vs. lowest 












d) Highest vs. lowest 
vigorous PA category 
d) HR=1.02  
(0.70-1.47) 
d) HR=1.10  
(0.68-1.80) 
d) HR=1.12  
(0.81-1.56) 
 e) NHS activity score (Met-h·wk-1):  
• <9  
• ≥9 
e) Highest vs. lowest 
NHS activity score 
category 
e) HR=0.98  
(0.71-1.35) 







a) Lifetime PA (h·wk-1·y-1): 
• Low PA (>0.5) 
• Intermediate PA (>0.5 and ≤3 but 
not >3) 
• High PA (≥1 of moderate or 
strenuous activity >3) 







 b) Pre-diagnosis recent PA (h·wk-1·y-1) 
• Low PA (>0.5) 
• Intermediate PA (>0.5 and ≤3 but 
not >3) 
• High PA (≥1 of moderate or 
strenuous activity >3) 







Dal Maso et al. 
(2008) (PACE) 
a) Pre-diagnosis  occupational PA at 
age 30-39y 
• Sitting, standing 
• Medium 
• Heavy, strenuous 
a) Heavy, strenuous vs. 











b) ≥2 vs. <2 h∙wk-1 of 








Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
Holick et al. 
(2008) (CWLS) 
a) Post-diagnosis total recreational PA 
(Met-h·wk-1) quartiles: 
• Q1: <2.7 
• Q2: 2.7-7.9 
• Q3: 8.0-20.9 
• Q4: ≥21.0 
a) Highest vs. lowest total 







 b) Post-diagnosis moderate-intensity 
recreational PA (Met-h·wk-1) quartiles: 
• Q1: <2.0 
• Q2: 2.0-3.9 
• Q3: 4.0-10.2 
• Q4: ≥10.3 









 c) Post-diagnosis vigorous-intensity PA 
(Met-h·wk-1) quartiles: 
• Q1: 0.0 
• Q2: 0.1-5.9 
• Q3: 6.0-15.0 
• Q4: ≥15.1 





c) HR=1.02  
(0.53-1.97) 
 
Irwin et al. 
(2008) (HEAL) 

































Pierce et al. 
(2007) (WHEL) 
a) Total PA (Met-h·wk-1) quartiles:  
• Q1: 0-3.75 
• Q2: 3.75-10.6 
• Q3: 10.6-22 
• Q4: 22-107 
a) Highest vs. lowest total 
PA quartile 





Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 
 b) Diet and PA categories:  
• Low vegetables and fruit (VF) and 
low PA 
• Low VF and high PA 
• High VF and low PA 
• High VF and high PA 
b) Low VF and low PA vs. 
high VF and low PA 
b) HR= 0.86  
(0.51-1.45) 
  
c) Low VF and low PA vs. 
high VF and high PA 




Average recreational PA 1 year pre-
diagnosis quartiles (relative units): 
• Q1: 1.6-3.4  
• Q2: 3.5-13.5 
• Q3: 13.6-35.0 
• Q4: 35.1-98.0 
a) Highest vs. lowest 












 b) Average  recreational PA age 13y, 
age 20y and year before diagnosis 
quartiles (relative units): 
• Q1: 1.6-16.6 
• Q2:16.7-29.4 
• Q3: 29.5-43.0 
• Q4: 43.1-98.0 
b) Highest vs. lowest 
quartile for average of 3 
periods pre-diagnosis 
 
b) HR=1.16  
(0.84-1.60) 
  
Holmes et al. 
(2005) (NHS) 
a) Post-diagnosis recreational PA (Met-
h·wk-1) categories: 
• < 3 
• 3 to 8.9  
• 9 to 14.9, 
• 15 to 23.9 
• ≥24 
a) Highest vs. lowest PA 
category 
a) HR=0.65  
(0.48-0.88)** 
a) HR=0.60  
(0.40-0.89)** 
a) HR=0.74  
(0.53-1.04)* 
Borugian et al. 
(2004) 
Pre-diagnosis:   





a) Highest vs. lowest 









Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 
HR (95% CI) 





b) Highest vs. lowest 
category walking 




 c) Sports:  
• none 
• a few times a year 
• a few times a month  
• about once a week 
• more than once a week 
c) Highest vs. lowest 
category sports 
 




 d) Exercise: 
• none 
• few times/year, few times /month 
• about once a week 
• more than once a week 
d) Highest vs. lowest 
category exercise 
 




 e) Jogging: 
• none 
• a few times a year 
• a few times a month  
• about once a week 
• more than once a week 
e) Highest vs. lowest 
category jogging 
 




 f) Swimming: 
• none 
• few times/year, few times /month 
• about once a week 
• more than once a week 
f) Highest vs. lowest 
category swimming 
 




 g) Gardening 
• none 
• a few times a year 
• a few times a month 
• about once a week 
• more than once a week 
g) Highest vs. lowest 
category gardening 
 





Trial  PA categories Comparisons All-cause 
deaths 
HR (95% CI) 
Breast cancer 
deaths 
HR (95% CI) 
Recurrences 




a) Average hours of PA per week from 
first menses to 1-y prior to diagnosis 
a) 3.8 average h·wk-1 of 
PA vs. 0 average h·wk-1  
PA 
 a) HR=1.30  
(0.81-2.09) 
 
 b) Average hours of PA per week 
during year before 1-y prior to diagnosis  
b) 5+ average h·wk-1  vs. 
0 average h·wk-1 of PA 
 b) HR=0.78  
(0.45-1.34) 
 
 c) h·wk-1from first menses to 1-y prior to 
diagnosis and year before 1-y pre-
diagnosis 
c) 3.8 h·wk-1 from first 
menses to 1-y prior to 
diagnosis and 1+h·wk-1 in 
the year before 1-y pre-
diagnosis vs. 0 and 0 
h·wk-1 
 c) HR=1.26  
(0.68-2.32) 
 
Rohan et al. 
(1995) 






a)  >4,000 vs. 0 kcal·min-1 
of recreational activity 
 a) HR=0.98  
(0.5-1.94) 
 





b) >2,000 total light 
recreational PA vs. 0 
recreational PA 
b) HR=1.07  
(0.61-1.89) 




c) >0 moderate 
recreational PA vs. 0 
recreational PA 
c) HR=0.51  
(0.24-1.06) 




d) >0 vigorous 
recreational PA vs. 0 
recreational PA 
d) HR=1.75  
(0.68-4.47) 
† Only results from multivariate adjusted comparisons are reported. Full multivariate analysis details can be found in appendix C. 
* P-value ≤ 0.05 ** P-value ≤ 0.01  
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Sub-analyses by menopausal status or age 
Only one of the studies (Emaus et al., 2010) that assessed pre-diagnosis 
physical activity included sub-analyses of overall and/or breast cancer 
mortality stratified by age or menopausal status.  Emaus and colleagues 
(2010) reported a significant reduction in the risk of all-cause death in the 
highest physical activity group versus the lowest in postmenopausal but 
not for premenopausal participants. Four studies that assessed post-
diagnosis physical activity included this sub-analyses (Chen et al., 2011; 
Holick et al., 2008; Irwin et al., 2008; Holmes et al., 2005) (see appendix D 
for full details of subanalyses).  However, the definition of menopausal 
status differed across studies. Two of these studies separated breast 
cancer survivors into used self-reported menopausal status (Chen et al., 
2011; Holmes et al., 2005), while the other two studies (Holick et al., 2008; 
Irwin et al., 2008) separated women depending on the study populations 
average age (above or below 59 and above or below 55, respectively). 
One study (Irwin et al., 2008) observed significant reductions in all-cause 
death in participants aged 55y or under who performed any amount of 
physical activity versus women who performed no physical activity. One 
study reported a significant reduction in breast cancer-related death in 
participants aged 59y or under when comparing those who engaged in 
eight MET-h·wk-1 or above versus those who performed less (Holick et al., 
2008), while another reported borderline significant reductions in pre-
menopausal women when comparing those who achieved 9 MET-h·wk-1 or 
above versus those who performed less (Holmes et al., 2005).  
 
Significant reductions in all-cause death were found in two studies (Chen 
et al., 2011; Irwin et al., 2008) and significant reductions in breast cancer-
151 
 
related death was found in one study (Holmes et al., 2005) for 
postmenopausal or those breast cancer survivors aged above the average 
study population when comparing engagement in higher levels of physical 
activity versus lower or no physical activity. Chen et al. (2011) found 
significant and borderline significant reductions in breast cancer events 
(breast cancer-related deaths + recurrences) in post-menopausal and 
premenopausal participants, respectively, in the highest physical activity 
group compared to the lower physical activity group.  
 
Sub-analyses by BMI 
Three studies that assessed lifetime pre-diagnosis physical activity 
included subanalyses of overall and/or breast cancer mortality stratified by 
BMI (Cleveland et al., 2012; West-Wright et al., 2009; Abrahamson et al., 
2006) (see appendix D). These studies reported mixed results. Two 
studies (Cleveland et al., 2012; West-Wright et al., 2009) found significant 
risk reductions in all-cause death for women with a BMI <25 m·kg2 
performing the highest amount of physical activity versus those performing 
the lowest. Cleveland and colleagues (2012) reported a borderline 
significant reduction for those with a BMI ≥25 m∙kg2, but non-significant 
reductions in breast cancer-related death for women with a BMI above and 
below 25 m·kg2 for women. West-Wright et al. (2009) found significant risk 
reductions in breast cancer-related death for those with a BMI ≥25 m∙kg2 
for women categorised as high activity versus low activity, but null-findings 
for with BMI <25 m·kg2, and non-significant reductions in all-cause 
regardless of BMI category. Abrahamson et al. (2006) found significant risk 
reductions in all-cause death for women with a BMI ≥25 m∙kg2 and 
achieving above the median physical activity level of the study population 
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versus those performing below the median physical activity, but null-
findings for women with a BMI <25 m·kg2. Keegan et al. (2010) compared 
women who performed any physical activity in the three years pre-
diagnosis versus those who performed no physical activity, and reported 
null-findings for effects on all-cause death regardless of BMI categories. 
 
Seven studies that assessed post-diagnosis physical activity included 
subanalyses of overall and/or breast cancer mortality stratified by BMI 
(Schmidt et al., 2013; Chen et al., 2011; Irwin et al., 2011; Sternfield et al., 
2009; Holick et al., 2008; Irwin et al., 2008; Holmes et al., 2005). Two of 
these studies (Irwin et al., 2011; Sternfield et al., 2009) stratified based on 
three BMI categories (<25, ≥25-29.9 and ≥30 kg∙m2), and both found 
significant reductions in risk of all-cause death for breast cancer survivors 
with BMI below 25 when comparing breast cancer survivors with higher 
levels of physical activity versus those with lower levels. However, Irwin 
and colleagues (2011) found significant reductions for the ≥25 to 29.9 
kg·m2 category also.  No other significant risk reductions were found in any 
of the other BMI categories in the two studies.  
 
The remaining five studies stratified BMI based on two categories (<25 
and ≥25 kg∙m2). Of these four studies, one study (Chen et al., 2011) 
observed significant reductions in all-cause death in women with BMI less 
than 25 kg·m2 when comparing survivors who performed 8.3 MET-h·wk-1 of 
physical activity or above versus those who performed none, while 
conversely another (Irwin et al., 2008) observed significant reductions with 
BMI of 25 kg·m2 or above in survivors who engaged in any physical activity 
versus those who engaged in none. Conflicting results were also observed 
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in those studies that analysed breast-cancer related death stratified by 
BMI (Holick et al., 2008; Holmes et al., 2005). Holick et al. (2008) found no 
difference in breast cancer-related death between BMI categories when 
comparing women performing 8 MET-h·wk-1 or above of physical activity 
versus those performing under this amount, while, Holmes et al. (2005) 
found significant reductions in only the <25 kg·m2 BMI category when 
comparing women with ≥24 MET-h·wk-1 of physical activity versus those 
performing less than three MET-h·wk-1. Schmidt et al. (2013) reported null-
findings for the risk of all-cause and breast cancer-related death in each of 
the BMI categories when comparing the most active participants versus 
the least. Finally, Chen et al. (2011) found significant reductions in breast 
cancer events (breast-cancer-related deaths + recurrences) for women in 
both BMI categories when women who performed 8.3 MET-h·wk-1 of 
physical activity or above were compared to those who performed none.  
 
Sub-analyses by breast cancer stage 
One study (West-Wright et al., 2009) that assessed pre-diagnosis physical 
activity and five studies that assessed post-diagnosis physical activity 
included sub-analyses of overall and/or breast cancer mortality stratified 
by breast cancer stage (Chen et al., 2011; Irwin et al., 2011; Holick et al., 
2008; Irwin et al., 2008; Holmes et al., 2005). West-Wright and colleagues 
(2009) reported significant reductions in breast cancer-related death for 
both localised and non-localised breast cancer when comparing women 
who achieved over three hours of lifetime physical activity per week per 
year versus women who performed less than 30 min of lifetime physical 
activity per week per year, but only borderline significant reductions and 
non-significant reductions in all-cause death for localised and non-
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localised breast cancer, respectively. The authors (2009) also compared 
women who achieved over three hours of physical activity per week per 
year in the three years pre-diagnosis versus women who performed less 
than 30 minutes of physical activity per week per year in the same period, 
and found no significant reductions in all-cause or breast cancer related-
death for either for localised and non-localised breast cancer. 
 
Of the five studies involving post-diagnosis physical activity that stratified 
by breast cancer stage, four (Chen et al., 2011; Irwin et al., 2011; Irwin et 
al., 2008; Holmes et al., 2005) used the TNM classification system while 
the other study SEER Programme summary staging (Holick et al., 2008). 
Only one study (Irwin et al., 2011) found a significant reduction in all-cause 
death and none of the studies found significant reductions in breast 
cancer-related death for early stage (stage I, stage I-IIa or localised) 
breast cancer when the higher physically active participants were 
compared to the lower or lowest physically active. Conversely, three of the 
studies found significant reductions in all-cause death (Chen et al., 2011; 
Irwin et al., 2011; Irwin et al., 2008) and two (Holick et al., 2008; Holmes et 
al., 2005) found significant reductions in breast cancer-related death in 
more advanced (Stage II-III or regional) when comparing the more 
physically active participants versus the lower or lowest. In addition, 
Holmes and colleagues (2005) found a higher reduction in breast cancer-
related death in those physically active participants with stage III breast 
cancer than those physically active participants with stage II or I. Chen et 
al. (2011) found a significant reduction in breast cancer events (recurrence 
+ breast cancer-related deaths) in women with both stage I-IIa and IIB-III 
with higher levels of physical activity versus lower or no physical activity.  
155 
 
Sub-analyses by ER status 
Two studies that assessed pre-diagnosis physical activity included sub-
analyses of overall and/or breast cancer mortality stratified by ER status 
(Keegan et al., 2010; West-Wright et al., 2009). Both studies assessed 
physical activity in the three years prior to diagnosis, while one study also 
included lifetime physical activity (West-Wright et al., 2009). In these two 
studies, only Keegan et al. (2010) found a significant reduction in all-cause 
death in women diagnosed with ER-positive breast cancer when 
comparing women who achieved over 38.2 MET-h·wk-1 of physical activity 
versus women who performed no physical activity. However, West-Wright 
and colleagues (2009) found significant reductions in breast cancer-
related death in women diagnosed with ER-positive breast cancer and 
significant reductions in both all-cause and breast cancer-related death in 
women with ER-negative when comparing women who achieved over 
three hours of lifetime physical activity per week per year versus women 
who performed <30 min of lifetime physical activity per week per year. 
 
Four studies assessing post-diagnosis physical activity included sub-
analyses of overall and/or breast cancer mortality stratified by ER and/or 
PR status (Chen et al., 2011; Irwin et al., 2011; Sternfield et al., 2009; 
Irwin et al., 2008; Holmes et al., 2005). No significant reductions in all-
cause death for ER-positive was found in the four studies when comparing 
higher amounts of physical activity to either low physical activity or no  
activity. Although, Holmes et al. (2005) found significant reductions in 
breast cancer-related death for ER-positive breast cancer. Conversely, 
three (Chen et al., 2011; Irwin et al., 2011; Irwin et al., 2008) of the four 
studies found significant reductions in all-cause death in women with ER-
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negative and/or PR-negative breast cancer when comparing higher 
physical activity to either low physical activity or no  activity. The other 
study (Sternfield et al., 2009) found a non-significant decrease in all-cause 
death. Holmes et al. (2005) found no significant reductions breast cancer-
related death for ER-negative, whereas, Chen et al., (2011) found a 
significant reduction in breast cancer events (recurrence + breast cancer-
related deaths) in women with ER-negative breast cancer with higher 
levels of physical activity versus lower or no physical activity.  
 
Sub-analyses of other characteristics 
In Irwin et al. (2008) other sub-analyses included by race (African 
American, Hispanic white and non-Hispanic white women) and adjuvant 
treatment received (surgery only, radiation and any chemotherapy). From 
the race analyses, reduced all-cause mortality risk with physical activity 
two years post-diagnosis was found only in non-Hispanic white women 
(HR=0.26; 0.10 to 0.65). While, there was no significant association 
between all-cause mortality and physical activity in any of the treatment 
sub-analyses (Irwin et al., 2008). Chen and colleagues (2011) analysed 
associations of exercise over the first 36 months after breast cancer 
diagnosis with total mortality and relapse/disease-specific mortality, 
stratified by HRQoL and co-morbidities. The authors reported that exercise 
of at least 8.3 MET-h·wk-1 compared to no exercise had a stronger effect 
on those women with a HRQoL score below the median than those 
women with scores equal to or above the median (HR=0.50; 0.35- to 0.71, 
ptrend <0.001 vs. 0.83; 0.58 to 1.21). The effect of exercise was also slightly 
stronger for women with a score on less than one on the Charlson co-
morbidity index compared to women who scored at least one (HR=0.68; 
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0.50 to 0.90, ptrend=0.003 vs. HR=0.62 (0.37 to 1.05, ptrend=0.05). Schmidt 
et al. (2013) reported null-findings for the risk of all-cause and breast 
cancer-related death in those who smoked versus those who did not when 
comparing the most active participants to the least. 
 
2.7.4.4 Meta-analysis of the results of studies 
Lifetime pre-diagnosis recreational physical activity 
Forest plots for each comparison are shown between figures 2.7.1 and 
2.7.7. The summary HR (95% CI) was 0.81 (0.68 to 0.93) in a random 
effects model for all-cause death for breast cancer survivors with the 
highest levels of self-reported lifetime pre-diagnosis recreational physical 
activity compared to the lowest. Although, there was evidence of some 
heterogeneity among these studies, this did not reach statistical 
significance (Q=10.37, P>0.10, I2=42.13%). The summary HR (95% CI) 
was 0.77 (0.57 to 1.04) in a random effects model for breast cancer-
related death for breast cancer survivors with the highest levels self-
reported lifetime pre-diagnosis recreational physical activity compared to 
the lowest. There was statistically significant heterogeneity among these 
studies (Q=16.54, P<0.10, I2=69.77%), suggesting that systematic effect 
size variability was unaccounted for.  
 
Recent pre-diagnosis recreational physical activity 
The random effects model average effect size for all-cause death was 
0.75 (0.68 to 0.84) when the highest levels of self-reported recent pre-
diagnosis recreational physical activity was compared to the lowest. There 
was no evidence of statistically significant heterogeneity across studies 
(Q=4.93, P>0.1, I2=-21.65%). For breast cancer-related death, the random 
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effects model summary HR was 0.87 (0.76 to 0.99) when comparing the 
highest levels of self-reported recent pre-diagnosis recreational physical 
activity to the lowest. There was evidence of substantial heterogeneity 
among these studies (Q=12.74, P<0.10, I2=-69.74%). 
 
Post-diagnosis recreational physical activity 
The random effects model average effect size for all-cause death was 
0.57 (0.48 to 0.67) when the highest level of self-reported post-diagnosis 
recreational physical activity was compared to the lowest. There was no 
evidence of statistically significant heterogeneity across studies (Q=8.25, 
P>0.1, I2=-27.28%). For breast cancer-related death, the random effects 
model summary HR was 0.61 (0.55 to 0.68) when comparing the highest 
levels of self-reported post-diagnosis recreational physical activity to the 
lowest. Although the Q value was not statistically significant, the I2 statistic 
revealed evidence of substantial heterogeneity among these studies 
(Q=1.72, P>0.10, I2=-132.34%). 
 
Post-diagnosis meeting recommended physical activity guidelines 
The summary HR was 0.65 (0.53 to 0.79) in a random effects model for 
all-cause death for breast cancer survivors meeting recommended 
physical activity guidelines post-diagnosis compared to those who were 
not. There was statistically significant heterogeneity among these studies 
(Q=10.10, P<0.10, I2=50.51%). An analysis of the effects of meeting 
recommended physical activity guidelines post-diagnosis on breast 
cancer-related death was not possible as there were not enough studies 














Cleveland et al. 2012 
0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6
<1 favours PA ≥1 favours no/low PA
 
0.57 (0.39 to 0.83) 1508/196 12.97 
Emaus et al. 2010 0.74 (0.51 to 1.08) 
 
1364/429 20.66 
Keegan et al. 2010 0.93 (0.72 to 1.21) 
 
3833/623 13.21 
West-Wright et al. 2009 0.73 (0.55 to 0.96) 
 
3539/460 15.41 
Friedenreich et al. 
2009 0.73 (0.53 to 1.00) 
 
1225/341 16.63 
Dal Maso et al. 2008 0.82 (0.67 to 1.01) 
 
1453/503 10.61 
Abrahamson et al. 
2006 1.16 (0.84 to 1.6) 
 
1264/290 10.51 
Overall 0.81 (0.68 to 0.93) 14186/2768 100.00 
Random effects model    








Figure 2.7.1 Forest plot with random effects overall hazard ratio for association between lifetime recreational (pre-diagnosis) physical 















Cleveland et al. 2012 
0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
<1 favours PA ≥1 favours no/low PA
 
0.66 (0.42 to 1.06) 1508/128 15.19 
Emaus et al. 2010 0.75 (0.49 to 1.15) 1364/355 19.16 
West-Wright et al. 2009 1.53 (0.35 to 0.80) 
 
3539/221 17.18 
Friedenreich et al. 2009 0.54 (0.36 to 0.79) 
 
1225/223 16.67 
Dal Maso et al. 2008 
1.11 (0.81 to 1.52) 1453/398 16.34 
 
Enger and Bernstein, 
2004 
1.30 (0.81 to 2.09) 717/251 15.45 
Overall: 0.77 (0.57 to 1.04) 9806/1576 100.00 
Random effects model     




 Figure 2.7.2 Forest plot with random effects overall hazard ratio for association between lifetime recreational (pre-diagnosis) physical 
















Schmidt et al. 2013 
 
0.66 (0.47 to 0.92) 3393/367 7.97 
Irwin et al. 2011 0.61 (0.47 to 0.81) 4643/350 19.63 
Hellman et al. 2010 1.00 (0.69 to 1.45) 528/323 9.19 
Keegan et al. 2010 0.77 (0.60 to 1.00) 
 
3833/623 23.29 
West-Wright et al. 
2009 0.78 (0.60 to 1.02) 
 
3539/460 21.00 
Irwin et al. 2008 0.69 (0.45 to 1.06) 933/115 6.66 
Abrahamson et al. 
2006 0.78 (0.56 to 1.08) 1264/290 12.26 




Random effects model 
(I2=-21.65%) 




 Figure 2.7.3 Forest plot with random effects overall hazard ratio for association between recent (1-3 y) pre-diagnosis recreational 






Study Hazard Ratio                                                                                          
(95% CI) 








Schmidt et al. 2013 
 
0.80 (0.53 to 1.21) 3393/243 17.38 
Irwin et al. 2011 0.71 (0.49 to 1.03) 4643/194 33.39 
Hellman et al. 2010 1.01 (0.62 to 1.63) 528/323 8.97 
West-Wright et al. 
2009 1.08 (0.73 to 1.58) 3539/221 25.39 
Irwin et al. 2008 0.83 (0.49 to 1.38) 933/115 5.56 
Enger and Bernstein, 
2004 0.78 (0.45 to 1.34) 717/251 6.02 
Rohan et al. 1995 0.98 (0.50 to 1.94) 412/112 3.29 







 Figure 2.7.4 Forest plot with random effects overall hazard ratio for association between recent (1-3 y) pre-diagnosis recreational 








Study Hazard Ratio (95% CI) Hazard Ratio                      
(95% CI) 
Cohort/Deaths Weight (%) 
random effects 
analysis 
Cadmus Bertram et al. 
2011 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2
<1 favours PA ≥1 favours no/low PA
 
0.47 (0.26 to 0.84) 2361/163 7.10 
Chen et al. 2011 0.65 (0.51 to 0.84) 4826/436 24.60 
Irwin et al. 2011 0.54 (0.38 to 0.79) 2910/186 15.11 
Sternfield et al. 2009 0.76 (0.48 to 1.19) 1970/187 10.89 
Irwin et al. 2008 0.33 (0.15 to 0.73) 688/53 4.14 
Holick et al. 2008 0.44 (0.32 to 0.60) 4482/412 18.63 
Holmes et al. 2005 0.63 (0.48 to 0.81) 2987/463 19.53 
Overall 0.58 (0.45 to 0.64) 20224/1900 100.00 
 




 Figure 2.7.5 Forest plot with random effects overall hazard ratio for association between post-diagnosis recreational physical activity 



















Irwin et al. 2011 
0.10.20.30.40.50.60.70.80.9 1 1.11.21.31.41.51.61.71.81.9
<1 favours PA ≥1 favours no/low PA
 
0.61 (0.35 to 0.99) 2910/86 15.01 
Sternfield et al. 2009 0.87 (0.48 to 1.59) 1970/102 7.03 
Irwin et al. 2008 0.65 (0.25 to 1.87) 688/30 9.58 
Holick et al. 2008 0.51 (0.29 to 0.89) 4482/109 1.42 
Holmes et al. 2005 0.60 (0.38 to 0.95) 2987/280 66.96 
Overall 0.61 (0.55 to 0.68) 15015/916 100.00 
Random effects model 
(I2= -132.34%)    
 
   
Figure 2.7.6 Forest plot with random effects overall hazard ratio for association between post-diagnosis recreational physical activity 
























Cadmus Bertram et al. 
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0.65 (0.47 to 0.91) 2361/163 17.56 
 
Chen et al. 2011 0.64 (0.49 to 0.82) 4826/436 21.80 
 
Irwin et al. 2011 0.54 (0.38 to 0.79) 2910/186 15.79 
 
Sternfield et al. 2009 0.98 (0.71 to 1.35) 1970/187 18.05 
 
Irwin et al. 2008 0.33 (0.15 to 0.73) 688/53 5.25 
 
Holmes et al. 2005 0.63 (0.48 to 0.81) 2987/463 21.54 
 
Overall 0.62 (0.50 to 0.74) 15742/1488 100.00 
 




 Figure 2.7.7 Forest plot with random effects overall hazard ratio for association between post-diagnosis meeting recommended physical 







Table 2.7.4 Summary of random effects overall hazard ratios (HR) and 
95% confidence intervals (95% CI) for association between physical 











0.81 (0.68-0.93) 14186/2768 42.1% 
Breast cancer-
related death 
0.77 (0.57-1.04) 9806/1576 69.8% 






0.75 (0.68-0.84) 18133/2506 21.7% 
Breast cancer-
related death 






0.58 (0.45-0.64) 20224/1900 27.3% 
Breast cancer-
related death 







0.62 (0.50-0.74) 15742/1488 51.5% 
 
Publication bias 
Publication bias was difficult to describe because of the relatively small 
number of studies included in the current meta-analysis (figure 2.7.8 is 
presented as an example below; for remaining funnel plots see appendix 
E). Visual inspection of funnel plot did not suggest publication bias for 
lifetime recreational physical activity and all-cause death and recent pre-
diagnosis recreational physical activity and breast cancer-related death 
funnel plots as the studies were distributed symmetrically (i.e. inverted 
funnel shape) about the summary effect size. There was a suggestion of 
publication bias for lifetime recreational physical activity and breast 
cancer-related death as there were studies with markedly different effect 
estimates. However, there was a lack of high precision studies for this 
comparison and lower precision studies were scattered along the bottom 
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of the graph, which suggests that publication bias may not be a plausible 
explanation for funnel plot asymmetry.  
 
There were asymmetrical distributions about the summary effect size for 
recent pre-diagnosis recreational physical activity and all-cause death, 
post-diagnosis recreational physical activity and breast cancer-related 
death and achieving recommended physical activity guidelines post-
diagnosis and all-cause death funnel plots. This was due largely to a lack 
of smaller, less precise studies in the bottom corners of each plot, 
suggesting the possibility of “missing” studies. However, all of the more 
precise studies suggested a beneficial effect. For both post-diagnosis 
recreational physical activity and all-cause death and post-diagnosis 
recreational physical activity and breast cancer-related death there were 
no studies showing no effect, which could represent either ‘missing’ less 
precise studies or a “true” beneficial effect.  
 
 
Figure 2.7.8 Lifetime pre-diagnosis recreational physical activity and all-
cause death and funnel plot with 95% CI provided (black diagonal lines). 
Line of no effect is shown as a black dashed line and the effect estimate 
line is shown as a red dashed line. 
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2.7.5 DISCUSSION  
Of the 21 included prospective cohort and case-control studies, 12 of the 
studies measured only pre-diagnosis physical activity, nine studies 
included only post-diagnosis and two studies investigated both pre-
diagnosis and post-diagnosis physical activity. We used HRs and 95% CI 
(HR <0.9 and upper limit 95% CI <1) to determine significant risk 
reductions. Concerning the role of pre-diagnosis lifetime physical activity, 
we found significant risk reductions in all-cause death for recreational 
physical activity in two studies (out of 7) and for moderate-intensity 
physical activity in one study (out of three). Significant risk reductions in 
breast cancer-related death was found for lifetime recreational physical 
activity in one study (out of 5), moderate-intensity lifetime physical activity 
in two studies (out of 4) and vigorous-intensity lifetime physical activity in 
one study (out of 3). Two studies reported a statistically significant 
reduction in breast cancer events risk when comparing the highest versus 
the lowest moderate-intensity lifetime recreational physical activity. Two 
studies found a significant dose-response relationship between lifetime 
recreational physical activity and all-cause death and breast cancer-
related death. 
 
In regards to recent pre-diagnosis physical activity, significant reductions 
in risk of all-cause death were reported for total recreational physical 
activity in two studies (out of 6) and for moderate-intensity physical activity 
in one study (out of 1). One study (out of 7) reported significant risk 
reductions in breast cancer-related death for recent pre-diagnosis 
recreational physical activity, one study found recent pre-diagnosis 
moderate physical activity (out of 2), and one study (out of 1) also found 
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risk reductions for recent pre-diagnosis vigorous-intensity physical activity. 
Two studies found a significant dose-response relationship between 
recent recreational physical activity and all-cause death and breast 
cancer-related death. 
 
When considering the role of post-diagnosis physical activity, six studies 
out of seven reported significant reductions in all-cause death for 
recreational physical activity, two studies (out of 3) with moderate-intensity 
recreational physical activity and five studies (out of 6) for adherence to 
recommended physical activity guidelines. Significant reductions in breast 
cancer-related death were found in three studies (out of 5) for post-
diagnosis recreational physical activity, while one study (out of 3) found 
significant risk reductions in those participants meeting recommended 
physical activity guidelines. Significant risk reductions were found in a 
study combining breast cancer-related deaths and recurrences with post-
diagnosis recreational physical activity. A significant dose-response 
relationship between total post-diagnosis recreational physical activity and 
all-cause death and breast cancer-related death was found in seven 
studies (out of 7) and three studies (out of 5), respectively.  
 
Sub-analyses from individual studies produced conflicting results. For pre-
diagnosis physical activity, one study found significant reductions in all-
cause death and breast cancer-related death in only post-menopausal 
breast cancer patients, while no consistent differential effect of physical 
activity was found between BMI categories or between ER-positive and 
ER-negative breast cancer. For post-diagnosis physical activity, we found 
slightly stronger effect of physical activity on risk all-cause and breast 
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cancer-related death in breast cancer patients with BMI <25 kg·m2, greater 
breast cancer-related death risk reductions in breast cancer patients 
diagnosed with more advanced or regional breast cancer compared to 
early stage or local breast cancer and greater risk reducing effect on all-
cause death in breast cancer patients with ER-negative and/or PR-
negative breast cancer. 
 
The results of the meta-analysis suggest that higher levels of lifetime pre-
diagnosis physical activity are significantly associated with a reduction in 
the risk of all-cause death (19% risk reduction) but this association was of 
borderline significance for risk of breast cancer-related death. Significant 
reductions in the risk of all-cause death (25%) and breast cancer-related 
death (13%) were found with recent pre-diagnosis recreational physical 
activity. Post-diagnosis recreational physical activity was associated with 
significant reductions in both all-cause (42%) and breast cancer-related 
death (39%), while breast cancer survivors meeting current recommended 
physical activity guidelines was associated with significant reductions in 
risk of all-cause death (38%). However, substantial heterogeneity (i.e. 
>50%) was found for associations between risk of all-cause death and 
meeting recommended physical activity guidelines, and for risk of breast 
cancer-related death and lifetime and recent pre-diagnosis recreational 
physical activity and post-diagnosis recreational physical activity. 
 
Previous meta-analyses (Beasley et al., 2012; Ibrahim and Al-Homaidh, 
2011), which consist of many of the prospective cohort studies included in 
this current study, support the positive role of physical activity on breast 
cancer outcomes and are in agreement with the findings of the current 
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review. A meta-analysis of six studies found an 18% reduction in the risk 
of all-cause but no reduction in risk of breast cancer-related death with 
pre-diagnosis physical activity, while post-diagnosis physical activity was 
associated with 41% and 34% reductions in all-cause death and breast 
cancer-related death, respectively, and a reduction in breast cancer 
recurrence of 24% (Ibrahim and Al-Homaidh, 2011). A pooled analysis of 
four studies, which were all part of the current study, found that post-
diagnosis physical activity of at least 10 MET-h·wk-1 was associated with 
similar reductions in the risk of all-cause and breast cancer-related death 
(27% and 25%, respectively), but found no reduction in breast cancer 
recurrence risk (Beasley et al., 2012).  
 
The stronger risk reductions in all-cause death associated with physical 
activity was unsurprising, given the evidence regarding the role of physical 
activity in reducing the risk of CVD (Kodama et al., 2013; Wen et al., 2011; 
Myers, 2003), which is the major cause of death in women worldwide 
(WHO, 2013). Furthermore, a recent cohort study reported a significant 
association between poor physical health (characterised by obesity and 
physical inactivity) and all-cause mortality and shorter time to additional 
breast cancer events (Saquib et al., 2011). 
 
The biological mechanism for the reductions in the risk of breast cancer 
outcomes associated with physical activity is unknown, but is likely to be 
similar to the mechanisms thought to reduce the risk of first primary breast 
cancer. Namely, physical activity may reduce the risk of breast cancer 
outcomes by reducing adiposity, improving insulin sensitivity, reduced 
exposure to sex hormones, increased levels of adipokine and decreased 
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concentration of inflammatory markers (Friedenreich et al., 2010). 
Stronger risk reductions in breast cancer outcomes with post-diagnosis 
physical activity may be associated with effects of physical activity on the 
above biological factors in postmenopausal women, who constitute the 
majority of breast cancer survivors in these studies. However, it should 
also be noted that because participants had a lesser duration in which to 
recall post-diagnosis physical activity, the accuracy of this physical activity 
may be better than that of pre-diagnosis physical activity.  
 
From visual inspection of the funnel plots, there was a suggestion of 
publication bias for recent pre-diagnosis recreational physical activity and 
all-cause death, post-diagnosis recreational physical activity and breast 
cancer-related death and achieving recommended physical activity 
guidelines post-diagnosis and all-cause death funnel plots. Publication 
bias could have influenced the results of the current review and analysis. 
Although it is important to note that funnel plot asymmetry can result from 
reasons other than publication bias, such as selective outcome reporting, 
poor methodological quality leading to inflated effects in smaller less 
precise studies, true heterogeneity (i.e. size of effects differs according to 
study size, different populations or differing intensities of intervention), 
artefactual (i.e. where sample variation leads to an association between 
the effect estimate and its SE) and random error (i.e. chance).  
 
The inclusion of only published studies in this review and meta-analysis 
could have increased the risk of publication bias. In addition to this, we 
searched only one electronic database. Unpublished studies, such as 
abstract or reports, often report smaller treatment effects (Hopewell et al., 
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2007), however, these types of studies are often of poor quality and may 
not provide sufficient data for pooled or meta-analysis. To minimise the 
risk of missing possibly relevant studies we carefully examined all relevant 
meta-analysis and systematic reviews, including three recent reviews 
(Beasley et al., 2012; Ellsworth et al., 2012; Ibrahim and Al-Homaidh, 
2011). We were not aware of any relevant unpublished studies when this 
current study was conducted. Only studies published in the English 
language were included, which could have led to an increased risk of 
language bias. Although the exclusion of non-English language studies 
might result in smaller effect estimates, language bias is generally small 
(Juni et al., 2002). Researchers who abstracted and reviewed the data in 
this current study were not blinded to authors, institutions and journals. 
However, this may only introduce a small risk of bias, and requires a large 
amount of administration time (Berlin, 1997).  
 
Substantial heterogeneity was found in several comparisons, including 
lifetime pre-diagnosis physical activity and meeting recommended physical 
activity guidelines, and risk of all-cause death and recent pre-diagnosis 
recreational physical activity and post-diagnosis recreational physical 
activity and risk of breast cancer-related death. Due to the small number of 
studies available, subgroup analyses was not possible. Therefore, the 
results of these comparisons should be treated with caution. This 
heterogeneity may have resulted from the variation in the methods of the 
included studies.  
 
In this current study for each comparison made we used the highest and 
the lowest physical activity categories. However, there was a variation in 
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how each study categorised the highest and lowest physical activity 
categories. Therefore, the strength of the association between the physical 
activity variables and breast cancer outcomes may be dependent on these 
cut-off points. Furthermore, physical activity outcomes were assessed 
differently across studies, which make comparisons between studies 
difficult. For lifetime physical activity some of the studies asked 
participants to recall physical activity performed over their entire lifetime up 
to the time of breast cancer diagnosis or one-year pre-diagnosis, while 
others collected physical activity data from specific age ranges pre-
diagnosis. Recent pre-diagnosis physical activity was assessed from one 
year to three years prior to diagnosis, while post-diagnosis physical activity 
data was taken from six months to six years after diagnosis and 
participants were required to recall physical activity during different 
duration’s post-diagnosis.  
 
All studies assessed physical activity using either questionnaires or 
interviews. Both of these methods are known to be prone to biases, due 
mainly to recall errors and social desirability (Prince et al., 2009). 
Validation of these questionnaires is disputed and is difficult to establish 
due to a lack of a current gold standard criterion method for measuring 
habitual physical activity (Helmerhorst et al., 2012). Often physical activity 
questionnaires are validated against accelerometer data which itself has 
questionable validity. In addition to this, most of the physical activity data 
related to moderate and vigorous-intensity physical activity, but not low-
intensity physical activity. As result, only a small fraction of an individual’s 
physical activity may be measured in a given study, possibly leading to 
175 
 
misclassification of some participants within studies. Moreover, studies 
varied in the information on types of activities requested from participants.  
 
Observational studies provide insights into aetiology and allow us to make 
associations between certain factors and disease. However, these types 
of studies are not able to establish direct, casual links between physical 
activity and breast cancer outcomes (Carlson and Morrison, 20009). There 
are currently no RCTs available that have examined physical activity and 
all-cause death, breast cancer-related death and recurrence in breast 
cancer survivors. The on-going DIANA (Diet and Androgens)-5 
randomized controlled trial of the effectiveness of a Mediterranean diet 
and moderate physical activity in reducing additional breast cancer events 
in women with early stage invasive breast cancer at high risk of recurrence 
because of metabolic or endocrine milieu, may provide important 
information regarding the effects of diet and exercise on breast cancer 
outcomes (Villarini et al., 2012). However, RCTs are needed that can 
isolate the effects of physical activity on breast cancer outcomes.  
 
2.7.6 CONCLUSIONS 
There were significant associations between lifetime and recent pre-
diagnosis recreational physical activity and risk of all-cause death and 
recent pre-diagnosis recreational physical activity and risk of breast 
cancer-related death. Post-diagnosis physical activity was found to 
significantly reduce the risk of both all-cause death and breast cancer-
related death. One study each found a significant reduction in breast 
cancer recurrences with pre-diagnosis lifetime and recent physical activity, 
while another study found significant reductions in recurrences and breast 
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cancer-related deaths combined with post-diagnosis physical activity. 
However, effect estimates for association between all-cause death and 
adherence to recommended physical activity guidelines, and breast 
cancer-related death and lifetime and recent pre-diagnosis physical 
activity and post-diagnosis recreational physical activity should be treated 
with caution due to evidence of substantial heterogeneity. Future studies 
are needed to elucidate the mechanisms by which physical activity may 
improve survival among breast cancer survivors. There is a need for RCT 
investigating the role of physical activity on all-cause death and breast 
cancer outcomes. This current review provides evidence to support the 
role of physical activity and in particular recent pre-diagnosis and post-
diagnosis physical activity in potentially improving and extending overall 













2.8 Physical activity for women with breast cancer after adjuvant 
therapy; systematic review and meta-analysis of Interventions 
This systematic review is currently in the protocol stage of being written up 
as a Cochrane systematic review. 
2.8.1 ABSTRACT 
Background: Recent observational and trial evidence suggests that 
physical activity may reduce mortality and improve physical and 
psychological function in breast cancer survivors. Physical activity 
prescriptions for breast cancer survivors rely on evidence as to whether 
activity during or after treatment results in improved health outcomes. 
Therefore, the aim of this study was to assess the effects of physical 
activity interventions in post-adjuvant therapy breast cancer survivors. 
 
Methods: We searched the Cochrane Central Register of Controlled 
Trials (CENTRAL) (The Cochrane Library 2012, Issue 10), and the 
following electronic databases: MEDLINE (1966 to October 2012), 
EMBASE (1980 to October 2012), PsychINFO (1872 to October 2012), 
Global Health (1973 to October 2012), Health Management Information 
Consortium (1979 to October 2012), CINAHL (1937 to October 2012), 
PeDRO (1929 to October 2012) and SPORT Discus (1975 to October  
2012), OPENGrey (1880 to October 2012), ProQuest Dissertations and 
Theses (1861 to October 2012) and Conference Papers and Proceedings 
Index (1973 to October 2012), and the Web of Knowledge Citation 
databases, Science Citation Index Expanded (1970 to October 2012), 
Social Sciences Citation Index (1970 to October 2012), Arts and 
Humanities Citation Index (1975 to October 2012), and Conference 
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Proceedings Citation Index of Science (1990 to October 2012) and Social 
Science (1990 to October 2012). In addition to this, we screened 
references in relevant reviews and clinical trials and handsearched 
relevant journals. We included randomised and non-randomised controlled 
trials that examine interventions aimed effects of physical activity 
interventions in breast cancer survivors after adjuvant therapy. The 
researcher extracted data and assessed the adequacy of the trials. Study 
authors were contacted for further information if necessary.  
 
Results: We included 34 trials with a total of 3,051 participants 
randomised to the physical activity intervention (n = 1,720) or the 
comparison (n = 1,319) groups. All trials consisted of stage 0-III breast 
cancer patients who had completed all active treatment except hormone 
therapy. Mode of the physical activity intervention differed across trials and 
included aerobic exercise (walking, cycling, step-aerobics or a variety of 
aerobic activities), resistance training, aerobic and resistance exercise 
combined, Greek dance, yoga and Tai Chi. Outcome measurements 
included physical activity levels, cardiorespiratory fitness, anthropometric 
measurements, HRQoL outcomes, fatigue, psychological health 
outcomes, blood biomarkers and bone health-related outcome measures. 
 
The results suggest that physical activity interventions compared with 
control interventions have a significant positive impact on physical activity 
levels (assessed by questionnaire), cardiorespiratory fitness, BMI, body fat 
percentage (%), lower and upper body strength, systolic blood pressure at 
rest, general health-related quality of life (HRQoL), physical and 
mental/emotional well-being, fatigue, self-esteem, depression, anxiety, 
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Insulin-like Growth Factor (IGF)-Binding Protein 3 (IGF-BP3) and 
interferon-γ. No significant effect of physical activity was found for 
accelerometer-derived physical activity levels, mass, lean mass, waist and 
hip circumferences, waist-hip ratio (WHR), sleep disturbance, plasma 
insulin, glucose, Homeostatic Model Assessment (HOMA), High-density 
Lipoprotein, triglycerides, IGF-1 or IL-6. There was insufficient number of 
trials with common bone-related outcome measures to be included in the 
meta-analysis and results reported in these trials were inconsistent. 
 
The effect of physical activity on outcome measures differed according to 
the mode of exercise, the instruments used to assess the various 
outcomes, the presence of a psychological support component. Aerobic 
exercise only interventions compared with controls had a positive effect on 
physical activity levels (both questionnaire and accelerometer-derived), 
cardiorespiratory fitness, upper body strength, general HRQoL, physical 
and mental/emotional well-being and depression. While aerobic and 
resistance exercise combined trials suggested positive effects on mass, 
BMI, general HRQoL, physical well-being, fatigue, depression and anxiety. 
Resistance training exercise trials improved upper and lower body 
strength significantly. The measurement instrument used influenced the 
effects of physical activity compared to controls on physical activity level, 
cardiorespiratory fitness, body fat %, general HRQoL, mental/emotional 
well-being and fatigue. Trials with a psychological support component 
suggested that physical activity interventions with this component can 
positively affect physical activity levels (assessed by questionnaire), 
cardiorespiratory fitness, mass, BMI, body fat %, upper body strength, 
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general HRQoL, physical and mental/emotional  well-being, self-esteem 
and depression compared to controls.  
 
Results of the review need to be interpreted cautiously owing to the risk of 
bias and heterogeneity of the interventions assessed and the 
measurements instruments used across studies. All the trials reviewed 
were at high risk for performance bias. In addition, the majority of trials 
were at high risk for attrition bias and at a high or unclear risk of detection 
and selection bias. 
 
Conclusions: This systematic review indicates that physical activity may 
have beneficial effects on physical activity levels (assessed by 
questionnaire), cardiorespiratory fitness, BMI, body fat %, lower and upper 
body strength, systolic blood pressure at rest, general HRQoL, physical 
and mental/emotional  well-being, fatigue, self-esteem, depression, 
anxiety, IGF-BP3 and interferon-γ. The positive results must be interpreted 
cautiously due to the heterogeneity of physical activity interventions 
assessed, measurement instruments used to assess the various 
outcomes and the risk of bias in many trials. Further research is required 
to investigate how to sustain positive effects of physical activity over time 
and to determine optimal prescription of physical activity (mode, intensity, 
frequency and duration) for breast cancer survivors. In addition, there is 
currently a lack of research regarding the effects of physical activity in 






2.8.2 BACKGROUND  
Worldwide, breast cancer is the most frequently diagnosed cancer and a 
leading cause of cancer death among females, accounting for 23% (1.38 
million) of the total cancer cases and 14% (458,400) of the cancer deaths 
in 2008 (Jemal et al., 2011). Of newly-diagnosed cases of cancer in the 
UK during 2006-08, breast cancer had the highest incidence rate of all 
cancers in females (46,840 cases or 123 cases per 100,000 females) and 
was the second highest cause of death from cancer in females (12 122 
deaths or 25.9 deaths per 100,000 females). Despite improved one-year 
and five-year mortality rates for women with breast cancer, the incidence 
of breast cancer is projected to rise by 44% (22% due to risk increase and 
21% due to population change) by 2020 (Moller et al., 2007). Many 
women still die as a result of breast cancer and given the projected 
increases in breast cancer incidence, it is important that interventions are 
explored that can improve both the survival rates of women diagnosed 
with breast cancer and the quality of life of those living with breast cancer. 
 
Due to the increasing incidence of breast cancer and improved survival 
rates, there has been an increased attention to tertiary prevention among 
women with breast cancer. In addition to the risk of a cancer recurrence, 
breast cancer patients often experience numerous short- and long-term 
disease- or treatment-related adverse physiologic and psychosocial 
outcomes, such as cardiotoxicity, neurotoxicity, secondary leukaemia, 
lymphedema, premature menopause, sexual dysfunction, infertility, weight 
gain, difficulty sleeping and fatigue (Azim et al., 2011; Bovelli et al., 2010; 
de Jong et al., 2002; Beisecker et al., 1997). These adverse effects would 
be expected to result in a negative impact on HRQoL and physical 
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function. In addition, these unwanted effects can be prolonged after the 
completion of active treatment and hinder the patients’ return to normal life 
(Fong et al., 2012). 
 
Physical activity (any bodily movement produced by the contraction of 
skeletal muscle that increases energy expenditure above a basal level) 
and exercise (planned, structured and repetitive physical activity, aimed at 
improving/maintaining one or more component of physical fitness) 
represents a modifiable health behaviour that could alleviate the sequelae 
related to breast cancer and assist patients in returning to the health 
status they had prior to treatment (Physical Activity Guidelines Advisory 
Committee Report, 2008). Evidence suggests that higher levels of post-
diagnosis physical activity in breast cancer survivors can significantly 
reduce the risk of dying from breast cancer and/or all-causes (Cadmus 
Bertram et al., 2011; Chen et al., 2011; Irwin et al., 2011; Holick et al., 
2008; Irwin et al., 2008; Holmes et al., 2005). Increased physical activity is 
associated with reduced exposure to oestrogen and androgens and 
increased concentrations of SHBG, improved insulin sensitivity and 
decreased concentrations of IGF-1 and adipokines and other inflammatory 
markers, with the exception of a beneficial elevation in adiponectin 
concentrations (Lynch et al., 2011). In addition to the above, a recent 
study (Santos et al., 2014) has observed, using in-vitro and in-vivo 
methods, that LDL-C promotes cell proliferation through overexpression of 
HER2 and migration and decreased expression of cadherin-related family 
members, both hallmarks of the epithelial to mesenchymal transition 
implicated in metastasis. Physical activity can lower LDL-C concentrations 
and positively influence HDL-C concentrations and therefore, potentially 
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lower the risk of breast cancer events. The effects of increased physical 
activity outlined above may provide the mechanisms that explain the 
associated reductions in all-cause and breast cancer-related mortality. 
Furthermore, a lack of physical activity has been shown to relate to weight 
gain post-breast cancer diagnosis, which has in turn been linked to poorer 
survival in some studies (Kroenke et al., 2005; Camoriano et al., 1990). 
More active women have been found to possess a lower BMI and were 
less likely to have gained weight after diagnosis, thus improving their 
survival chances (Holmes et al., 2005; Lahmann et al., 2005). 
 
In a recent meta-analysis, physical activity was associated with important 
positive effects on physical functions, body mass, BMI and both physical 
and social functioning domains of HRQoL in patients who had completed 
their treatment for cancer (Fong et al., 2012). There is evidence to suggest 
that physical activity can facilitate positive physiological and psychological 
benefits in cancer survivors during and after treatment (Galvao et al., 
2005; Ingram and Visovsky, 2007; Knols et al., 2005; Schmitz et al., 
2005). The results from a recent Cochrane review, indicated that physical 
activity may have beneficial effects on overall HRQoL and certain HRQoL 
domains including cancer specific concerns (e.g. breast cancer), body 
image/self-esteem, emotional well-being, sexuality, sleep disturbance, 
social functioning, anxiety, fatigue and pain at varying follow-up periods 
(Mishra et al., 2012). 
 
Despite the proposed benefits of physical activity, there is a lack of a 
consensus regarding the most effective delivery mode and prescription of 
physical activity in this population. Physical activity interventions are 
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typically delivered under supervised conditions (Littman et al., 2012; Milne 
et al., 2008) or under self-directed, home-based conditions (Pinto et al., 
2008; Matthews et al., 2007; Vallance et al., 2007). They consist of a 
comparison between either solely or a combination of aerobic exercise 
training (Courneya et al., 2003; Herrero et al., 2006; Hutnick et al., 2005), 
walking (Matthews et al., 2007), and/or resistance training (Schmitz et al., 
2009; Schmitz et al., 2005) and standard or usual care. Their duration can 
vary from less than 10 weeks (Fillion et al., 2008; Daley et al., 2007) to up 
to 12 months (Saarto et al., 2011; Schmitz et al., 2009). 
 
Previous systematic reviews and meta-analyses have either included 
studies involving all cancer patients (Brown 2012; Fong 2012; Mishra 
2012a; Mishra 2012b; Cramp 2010; Knols 2010; Speck 2010) rather than 
those only consisting of breast cancer patients, have studied cancer 
patients receiving adjuvant therapy (Carayol 2013; Mishra 2012b; Markes 
2009; McNeely 2006), have focused only on a particular physical activity 
mode, such as walking (Knols 2010), yoga (Cramer 2013), dance (Bradt 
2011) and resistance training (Cramp 2010; Cheema 2008) or have 
investigated only a particular outcome, such as HRQoL (Cramp 2010; 
Mishra 2012a; Mishra 2012b) and upper-limb dysfunction (McNeely 2010). 
Therefore, there is a need for a systematic review and meta-analysis 
investigating the effects of physical activity on the large range of outcomes 
reported in trials including post-adjuvant therapy breast cancer patients.  
 
OBJECTIVE(S)  
To assess the effects of physical activity interventions for women with 
breast cancer after adjuvant therapy 
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2.8.3 METHODS  
2.8.3.1 Criteria for considering studies for this review  
Types of studies  
All RCTs investigating the effects of physical activity interventions for 
female breast cancer patient’s post-adjuvant therapy were included. 
Quasi-randomized controlled trials and controlled clinical trials will also be 
considered for inclusion in this review. 
 
Types of participants  
Studies including women of all ages diagnosed with breast cancer were 
reviewed. Studies including cancers other than breast cancer were 
excluded unless separate data were available for the breast cancer 
subgroup. Studies including patients with metastatic breast cancer (stage 
IV and above breast cancer) were excluded. Studies including patients 
undergoing adjuvant therapy (radiotherapy, biological therapy and 
chemotherapy but not endocrine therapy) for breast cancer during the 
exercise intervention were also excluded. 
 
Types of interventions  
Interventions in which physical activity/exercise was promoted and/or 
measured as an outcome and/or its effects assessed were included. We 
excluded studies with an additional treatment arm or combined 
intervention (e.g. exercise with diet modification) where the effects of 
exercise could not be isolated, trials of single exercise sessions that 
measured acute effects, trials investigating effects of physiotherapy and 
trials restricted to stretching or local muscular endurance (e.g. training of 
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shoulders, back/legs only) or therapeutic exercise regimens addressing 
only specific impairments related to the shoulder, arm or both. 
 
Types of outcome measures  
Outcome measures did not form part of the criteria for including studies in 
a review. All outcomes assessed in relevant studies were included. It was 
expected that the amount of outcomes would be broad and not all directly 
related to breast cancer, therefore, it was an aim of the review to highlight 
the need for agreement between researchers regarding relevant outcomes 
in breast cancer and physical activity studies. 
 
Expected primary outcomes: 
• Physical activity,  defined as any bodily movement produced by the 
contraction of skeletal muscle that increases energy expenditure 
above a basal level, and measured by self-report via questionnaires 
or objectively via accelerometers 
• Cardiorespiratory fitness, defined as the ability to engage in 
physical activities that rely on oxygen consumption as the primary 
source of energy, and measured either directly or indirectly to 
obtain an individual’s maximal oxygen uptake (VO2 max) 
 
Expected secondary outcomes: 
• Body mass, BMI and body composition (e.g. measures such as 
body fat percentage, fat-free/lean mass and/or fat mass) 
• Other anthropometric measurements (e.g. waist and/or hip 
circumference and waist-hip ratio, WHR)  
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• HRQoL, defined as a subjective and multidimensional concept 
encompassing physical and occupational function, psychological 
state, social interaction and somatic sensation 
• Muscular strength, defined as the maximal force (expressed in 
newtons, kilograms or pounds) that can be generated by a specific 
muscle or muscle group 
• Blood biomarkers, such as glucose-insulin dynamics, lipid profiles, 
insulin-like growth factors and inflammatory cytokines 
• Bone health-related outcomes such as bone mineral density and 
bone mineral content 
• Adverse events such as musculoskeletal injuries, lymphedema and 
illness (such as bronchitis and influenza) 
 
2.8.3.2 Search methods for identification of studies  
Electronic searches  
• The electronic databases, MEDLINE, EMBASE and CENTRAL 
were searched. The subject-specific electronic databases CINAHL, 
PsychINFO, PeDRO and Sports Discus were also searched. 
Citation indexes such as the Science Citation Index and SCOPUS 
were searched to identify additional studies. Relevant dissertations 
and theses were searched for on the databases PROQuest and 
theses.com. 
 
Searching other resources  
• A search for relevant grey literature was conducted using the 
OPENGrey and Healthcare Management Information Consortium 
(HMIC) and PsycExtra databases.  
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• After the initial search, key journals were handsearched. Journals 
were identified and prioritized according to where most of the trial 
reports appeared based on earlier searches.  
• The reference lists of relevant studies, previous relevant reviews 
and evidence-based guideline papers were scanned for additional 
relevant studies.  
• Key researchers in the subject area were contacted and asked 
whether they know of any previous studies not identified by this 
current reviews search or any forthcoming studies they may be 
aware of. 
Full details of the search strategy can be found in the appendix F. 
 
2.8.3.3 Data collection and analysis  
Selection of studies  
The search results from the searches described above were merged and 
duplicate records of the same report were removed. The titles and 
abstracts were examined to remove obviously irrelevant reports. Full texts 
of potentially relevant reports were retrieved and multiple reports of the 
same study were linked together. Full text reports were examined for 
compliance of studies with eligibility criteria. Correspondence with 
investigators was sought where appropriate to clarify study eligibility or to 
seek further information, such as missing data. A list of studies that were 
close to inclusion but after further inspection would not meet criteria was 
included. Non-English language trials were included and these trials were 
translated where necessary so that eligibility could be assessed and 
subsequently data could be extracted. After final decisions on study 
inclusion were made data collection commenced. 
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Data extraction and management  
A checklist of items to consider in data collection was devised. This 
checklist included the source of report, confirmation of eligibility or reason 
for exclusion, methods such as study design, total duration, sequence 
generation, allocation sequence concealment, blinding, and other sources 
about bias, participant information such as total numbers, diagnostic 
criteria, demographic information, and date of study, intervention details, 
for each outcome of interest the definition, unit of measurement, and 
scales, results including number of participants allocated to groups, 
sample size, missing data, summary of data for each group, effect 
estimates with confidence intervals, and miscellaneous information such 
as funding sources, key conclusions, and details of any correspondence. 
Multiple publications for the same trial were collated and the earliest 
publication was used as the primary reference. 
 
Assessment of risk of bias in included studies  
Data collected from the reports were summarized in a “characteristics of 
included studies” table. The Cochrane collaboration “risk of bias” tool was 
used to assess possible sources of bias in the included reports (Higgins 
and Green, 2011). The assessment of risk of bias is a two part tool 
addressing six specific domains, such as sequence generation, allocation 
concealment, blinding, incomplete outcome data, selective reporting bias 
and “other issues”. The first part describes what was reported to have 
happened in a study, while the second part includes the judgment relating 
to the risk of bias for each domain in that study. If there was evidence of 
heterogeneity, a large risk of bias and/or low quality of evidence the 
findings were interpreted cautiously. The assessment of risk of bias was 
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displayed in a “risk of bias” table. Data tables, forest plots and summary of 
findings table were used to present the results of the systematic review. 
 
Measures of treatment effect  
We originally planned to assess the effects of physical activity on breast 
cancer outcomes (i.e. rates of survival and recurrence), physical outcomes 
and psychological outcomes. However, none of the eligible studies 
provided data on breast cancer outcomes. We anticipated that some 
outcomes may not be assessed by multiple studies, therefore, we 
performed a meta-analysis only on an outcome if it was assessed in at 
least two studies and if outcomes were not too diverse, studies were not at 
risk of serious bias and if there was no evidence of serious publication or 
reporting bias. The end of intervention outcome values were used in the 
analysis in preference to change values or end of follow-up values. 
 
Continuous outcomes (such as cardiorespiratory fitness, physical activity, 
anthropometric measures, muscular strength, blood biomarkers and bone 
health-related outcomes) were combined using a weighted mean 
difference (WMD) when trials measured an outcome using either the same 
measurement method or scale to generate continuous data. We used a 
standardized mean difference (SMD) when trials used different 
instruments to measure the same outcome. The SMDs (or effect sizes) 
were interpreted as follows: 0.2 and below represented a small effect, 
above 0.2 to below 0.5 a low to moderate effect, 0.5 a moderate effect, 
above 0.5 to below 0.8 a moderate to large effect and 0.8 and above a 
large effect (Cohen, 1998). For dichotomous outcomes (such as adverse 
events), risk ratios (RR) with 95% confidence intervals (CIs) were used. 
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Data presented as odds ratios (OR) will be transformed using the method 
outlined in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins and Green, 2011). For time-to-event outcomes such 
as mortality and recurrence, hazard ratios (HR) with 95% CI were used. 
We reported the ratios of treatment effects for response so that a HR less 
than 1.0 signified a reductive effect on an outcome and a HR greater than 
1.0 represented an additive effect on an outcome. 
 
Unit of analysis issues  
In the case of trials that have more than one applicable physical activity 
group and more than one relevant control group, where possible we 
created a single pair-wise comparison by combining outcome data 
recommended in the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins and Green, 2011). 
 
Dealing with missing data  
Missing data were requested from authors. If variability was presented by 
measures other than standard deviations we obtained s using standard 
approaches for transforming data. We transformed confidence intervals, t 
values, and P values into s using the methods described in the Cochrane 
Handbook for Systematic Reviews of Interventions (Deeks et al., 2011); 
when F-statistics were reported for comparing two groups, we transformed 
F-statistics into t-statistics using the following formula: t=√F and continued 






Assessment of heterogeneity  
For each outcome, we first assessed study heterogeneity with Cochran’s 
Q test (Cochran, 1954), with P<0.10 indicating evidence of heterogeneity. 
Inconsistency of results across studies was evaluated by the I2 statistic. I2 
describes the percentage of variability in the point estimates that is due to 
heterogeneity rather than sampling error (Higgins et al., 2003). Following 
Higgins and Green (2011), we interpreted I2 values of 0% to 40% as 
“might not be important”, 30% to 60% as “may represent moderate 
heterogeneity”, 50% to 90% as “may represent substantial heterogeneity” 
and 75% to 100% as “considerable heterogeneity”. However, the 
importance of the observed value of I2 was dependent on the magnitude 
and direction of effects and the strength of evidence for heterogeneity (e.g. 
P value from the Q test, or a CI for I2). In addition to the presence of 
random error (i.e. chance), heterogeneity can result from differences 
between physical studies after adjuvant breast cancer treatment can also 
result from real differences between study populations, adjuvant breast 
cancer treatments received and the training stimulus. The random-effects 
model considers these additional sources of between-study variability as 
well as within-study variability.  
 
Assessment of reporting biases  
To investigate publication bias, we prepared funnel plots and visually 
examined them for signs of asymmetry. We followed the 
recommendations in the Cochrane Handbook for Systematic Reviews of 
Interventions (Sterne et al., 2011) for identification of publication bias. 
Publication bias was deemed to be absent if the funnel plot resembled a 
symmetrical inverted funnel shape. Publication bias was suspected if there 
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were studies with markedly different intervention effect estimates, if 
smaller studies tended to lead to more or less beneficial effect estimates, 
and if the funnel plot was skewed and asymmetrical (i.e. gaps in bottom 
right and left corners indicating “missing studies”).  
 
Data synthesis  
The pooled intervention effect estimates and their 95% CI were presented. 
Continuous data were combined using either the inverse-variance fixed-
effect method or the inverse-variance random-effects method, depending 
on the presence of heterogeneity. For RR data a random-effects model 
(Der Simonian and Laird, 1986) was used to combine data where 
heterogeneity was suspected, while the fixed-effects Mantel-Haenzel 
methods (Mantel and Haenzel, 1959; Greenland and Robins, 1985) was 
used when heterogeneity was not suspected. For HR data, study results 
were combined using the generic inverse variance method for both 
random- and fixed effect models. All analyses were carried out using 
RevMan (version 5.2).  
 
Subgroup analysis and investigation of heterogeneity  
We considered the following study characteristics for heterogeneity: mode 
of physical activity, measurement instrument used and presence of a 
psychological support component.  
 
Sensitivity analyses 
We also conducted a sensitivity analysis to assess the effects of including 





2.8.4.1 Description of studies  
Results of the search  
Through a comprehensive literature search, 1,519 potentially relevant 
references were identified and screened for retrieval. After duplicates were 
removed, a total of 639 references were excluded based on the title and 
abstract with 349 references retrieved for more detailed evaluation. From 
these, 96 trials were excluded as they did not meet the inclusion criteria 
and 34 trials were identified as appropriate for inclusion in the current 
review (figure 2.8.1).  
 
Included studies 
The final selection resulted in 34 trials being included in this review (Bower 
et al., 2011; Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; 
Carson et al., 2009; Cho et al., 2006; Courneya et al., 2003; Daley et al., 
2007; DeNysschen et al., 2011; Fillion et al., 2008; Heim et al., 2007; 
Herrero et al., 2006; Hutnick et al., 2005; Kaltsatsou et al., 2011; Ligibel et 
al., 2008; Littman et al., 2012; Matthews et al., 2007; Mefferd et al., 2007; 
Mehnert et al., 2011; Milne et al., 2008; Musanti, 2012; Mustian et al., 
2004; Niemen et al., 1995; Nikander et al., 2007; Payne et al., 2008; Pinto 
et al., 2003; Pinto et al., 2005; Rahnama et al., 2010; Rogers et al., 2009; 
Saarto et al., 2011; Schmitz et al., 2005; Schmitz et al., 2009; Sprod et al., 
2010; Vallance et al., 2007; Winters-Stone et al., 2011) (earliest 
publication of each trial was used as the trial reference). We reviewed and 
included information on trial characteristics and outcome-related data from 
an additional 40 publications that were secondary publications to several 
of the 34 trials. We corresponded with and requested additional data from 
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seven trial authors, and only one of these trials authors replied to requests 
for additional data. For trial characteristics and outcomes see the 
summary characteristics of included studies table (table 2.8.1). 
 
 
Figure 2.8.1 Selection process of eligible trials for inclusion in review 
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Table 2.8.1 Summary of characteristics of included studies 





Stage Mode Intervention 
duration 
Intervention details Control 
group details 
Bower et al. 
2011 






groups of 4-7 
Cadmus et al. 
2009 
75 (37/38) 56 0-III Aerobic  6 mo or 12 
mo 
3-5 x 15-30 min/wk aerobic exercise at 50%, 60%-
80% of predicted HRmax (220-age). Supervised 3 
days/wk and additional 2 days/wk either at the 





78 (38/40) 49 I-III Aerobic + 
resistance 
8 wks 3 x 60 min/wk of aerobic (intensity not reported) 
and resistance training, consisting of fit-ball and 
bodyweight exercises, and resistance bands, at 
75% of maximum load for resistance exercises, 
progression, increase 5% per week. Resistance 
exercises, 10-12 repetitions x 2-3 sets; 30 s rest in 
between sets. 
Usual care 
Carson et al. 
2009 
37 (17/20) 54 I-II Yoga 8 wks 1 x 120 min/wk of Yoga of Awareness: yoga 
postures, breathing techniques, meditation, study 
of pertinent topics, group discussion 
Wait list 
control 
Cho et al. 2006 65 (34/31) 49 I-II Aerobic  10 wks 2 x 90 min/wk consisting of aerobic exercise at 
40%-60 of HRmax. Additional psychology-based 
education and peer support group activity provided 
Wait list 
control 
Courneya et al. 
2003 
53 (25/28) 59 I-III Aerobic  15 wks 3 x 15-35 min/wk of aerobic exercise (upright or 




Daley et al. 
2007 







100 (66/34) 51  Aerobic 4-6 mo 3-5 x 30 min/wk of aerobic exercise at Borg Scale 




Fillion et al. 
2008 
94 (48/46) 53 0-III Walking 4 wks 4 x 60 min/wk walking and 1.5 hours of psycho-









Stage Mode Intervention 
duration 
Intervention details Control 
group details 
Heim et al. 
2007 




2 x 30 min/wk of aerobic exercise (walking) 
3 x 30 min/wk of resistance training (9 exercises 
for all large muscle groups). Educational program, 







Herrero et al. 
2006 
20 (10/10) 51 I-II Aerobic + 
resistance 
8 wks 3 x 90 min/wk of 20-30 min cycling at 70-80% age 
predicted HRmax and resistance exercise 
progressively increased intensity of 12-15 
repetitions at 12–15 repetition max. 
Usual care 
Hutnick et al. 
2005 
49 (28/21) 50 I-III Aerobic + 
resistance 
6 mo 3 x 40–90 min/wk (20 min Aerobic training: 60–
75% functional capacity based on VO2 max; 4 x 
upper and lower body resistance exercises: 8–12 
repetitions x 1–3 sets) 
"Non-
exercisers" 
Kaltasou et al. 
2009 
27 (14/13) 57 NR Greek 
dance + 
resistance 
24 wks 3 x 60 min/wk (25 min of Greek traditional dances 
at 65 and 80% of age predicted HRmax. Upper 
body exercise training and the cool-down lasted 25 
min; resistance machines. 
Usual care 
Ligibel et al. 
2008 
101 (51/50) 53 I-III Aerobic + 
resistance 




Littman et al. 
2012 
63 (32/31) 59 0-III Yoga 6 mo 1-3 x 75 min/wk of Viniyoga: yoga postures, 
breathing techniques, deep relaxation, meditation 
Wait list 
control 
Matthews et al. 
2007 
36 (23/13) 54 I-III Walking 12 wks 3–5 x 20–40 min/wk of walking at RPE 11-13 
(home-based, unsupervised – +1 x 30 min in-
person counselling visit and five brief phone calls 
over the 12 weeks) 
Wait list 
control 
Mefferd et al. 
2007 
85 (56/29) 56 I-III Aerobic + 
resistance 
16 wks 7 x 1 h/day of moderate to vigorous physical 
activity. 
2-3 sessions per wk of muscle strengthening 
exercises (duration or intensity not provided). 
Participants also attended group sessions covering 
elements of cognitive behavioural therapy for 
obesity. Telephone contact was made 4 times in 
the initial 2 weeks and once weekly  
Wait list 
control 
Mehnert et al. 
2011 
63 (35/28) 52 I-III Aerobic  10 wks 2 x 90 min/wk of aerobic exercise at 60% VO2 max Usual care 
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Stage Mode Intervention 
duration 
Intervention details Control 
group details 
Milne et al. 
2008 
58 (29/29) 55 I-III Aerobic 
and 
resistance  
12 wks 3 x 60 min/wk (20 min aerobic and 30 min 
resistance training: 2 sets of 10-15 repetitions of 
light weights; progressed to heavier weights once 













12 wks Aerobic exercise group: 3 x 15-30 min/wk walking 
at 40-65% HRmax, progressing to 85% HRmax;  
Resistance exercise group: 3 sessions of 
resistance training per wk at RPE (0-10) 3-5 
progressing to 7-8. 
Aerobic and resistance combined: 4-5 times per 
week aerobic (15-30 min at 40%-65% and up to 
85% HRmax) and 2 times per week resistance 







Mustian et al. 
2004 
31 (17/14) 52 0-III Tai Chi 
Chaun 
12 wks Tai Chi Chuan 3 x 60 min/wk Supportive 
expressive 
group 
Niemen et al. 
1995 
16 (8/8) 56 NR Walking 
and 
resistance 
8 wks 3 x 60 min/wk (30 min of walking at 75% maximum 
intensity plus 30 min of resistance training at 2 
sets of 12 repetitions for 7 exercises). 
Sedentary 
control group 
Nikander et al. 
2007 
29 (15/14) 52 I-III Aerobic  12 wks 1 x supervised and 2–3 x home-based 
unsupervised exercise for 50-60 min/wk at RPE 
11–16 of step aerobics consisted 150 to 180 
jumps and leaps and circuit-training consisted of 3 
rounds of 8-10 different vigorous movements such 
as rope-jumping and skate-jumping resulting in a 
total of 100 to 150 jumps and leaps during each 
session. In addition to this, home-based circuit 
training and aerobic exercise. 
Usual care 
Payne et al. 
2008 
20 (10/10) 65 NR Walking 14 wks 4 x 20 min/wk of moderate home-based walking 
with pedometers 
Usual care 
Pinto et al. 
2003 
24 (12/12) 53 0-II Aerobic  12 wks 3 x 50 min/wk consisting of 30 min of aerobic 
exercise at 60%-70% HRmax. During the last 
month, participants performed strength training 










Stage Mode Intervention 
duration 
Intervention details Control 
group details 
Pinto et al. 
2005 





Rahnama et al. 
2010 
29 (14/15) 50-65 I-III Walking 
and 
resistance 
15 wks 2 x 25-35 min/wk of supervised walking at 45%-
65% HRmax 
2 x 60 min/wk of resistance training (9 resistance 
training exercises including Cybex strength training 
equipment and free weights exercises)  
Usual care 
Rogers et al. 
2009 
41 (21/20) 52 I-III Aerobic 12 wks Intervention consisting of 6 discussion group 
sessions; 12 individual supervised exercise 
sessions; 3 individual ‘‘face-to-face’’ update 
counselling sessions Behaviour change 
intervention with goal of gradually increasing all 
participants to 150 min/wk of moderate walking. 
Wait list 
control 
Saarto et al. 
2011 




12 mo 1 x supervised and 2–3 x home-based 
unsupervised exercise for 50-60 min/wk at RPE 
11–16 of step aerobics consisted 150 to 180 
jumps and leaps and circuit-training consisted of 3 
rounds of 8-10 different vigorous movements such 
as rope-jumping and skate-jumping resulting in a 
total of 100 to 150 jumps and leaps during each 
session. In addition, home-based circuit training 
and aerobic exercise. 
Usual care 
Schmitz et al. 
2005  
86 (43/43) 53 0-III Resistance  6 mo 2 x 60 min/wk of 9 common weight-training 
exercises using variable resistance machines and 
free weights (for muscles of the chest, back, 
shoulders, and arms, buttocks, hips, and thighs). 
Starting at lightest weight; progressed 1 set to 3 
sets of 8–10 repetitions 
Wait list 
control 
Schmitz et al. 
2009  
295 (148/147) 56 0-III Resistance  12 mo 2 x 90 min/wk of resistance training consisting of 
upper and lower body exercises. Weight was 
increased for each exercise by the smallest 
possible increment after 2 sessions of completing 











Stage Mode Intervention 
duration 
Intervention details Control 
group details 
Sprod et al. 
2010 
114 (97/29) 59 NR Aerobic 
and 
resistance 
3 and 6 mo 2-3 x 60 min/wk of aerobic exercise at 30 to 55% 
of heart rate reserve, and resistance training and 
flexibility exercises emphasizing all of the major 
muscle groups. 
Usual care 
Vallance et al. 
2007 




et al. 2011 
106 (52/54) 63 0-III Resistance  12 mo 3 x 45-60 min/wk of resistance training at loads 
corresponding to 60–70% of 1-RM for 1–3 sets of 
8–12 repetitions of upper and lower body 
exercises, and Impact exercise consisted of jumps 
from the ground to a target height 1″ from the floor, 
performed with weighted vests and in sets of 10. 
Participants performed 1–6 jump sets, 1–2 sets of 







Overall study characteristics 
Of the 34 included trials, 31 were RCTs, one study (Heim et al., 2007) 
used a quasi-randomised design to allocate participants to treatment and 
two were controlled clinical trials (Hutnick et al., 2005; Sprod et al., 2010). 
All trials, except for four (DeNysschen et al., 2011; Daley et al., 2007; 
Sprod et al., 2010; Vallance et al., 2007), randomized eligible participants 
to either the exercise or comparison arm. The additional study group in 
three of the four trials comprised variations in the exercise intervention 
arm, such as six or three month exercise groups (Sprod et al., 2010), an 
exercise-related print material group or a pedometer group or a 
combination of print material and pedometer group (Vallance et al., 2007), 
and an exercise during and after treatment group or an exercise after 
treatment only group (DeNysschen et al., 2011). In all, 3,051 (mean=90; 
range=16-573) participants were randomized to an exercise intervention(s) 
(n of participants=1,720; mean=52; range=8-302) or the comparison group 
(n=1,319; mean=40; range=8-271). 
 
Study participants 
Twenty three trials reported cancer stage data (Cadmus et al., 2009; 
Cantarero-Villanueva et al., 2011; Carson et al., 2009; Cho et al., 2006; 
Courneya et al., 2003; DeNysschen et al., 2011; Fillion et al., 2008; 
Herrero et al., 2006; Hutnick et al., 2005; Ligibel et al., 2008; Littman et al., 
2012; Matthews et al., 2007; Mefferd et al., 2007; Mehnert et al., 2011; 
Milne et al., 2008; Musanti, 2012; Pinto et al., 2003; Pinto et al., 2005; 
Rogers et al., 2009; Schmitz et al., 2005; Schmitz et al., 2009; Vallance et 
al., 2007; Winters-Stone et al., 2011). Of these 23, eight included 
participants with stage 0 breast cancer (n=73, range=1-28) (Cadmus et al., 
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2009; Fillion et al., 2008; Littman et al., 2012;  Pinto et al., 2003; Pinto et 
al., 2005; Schmitz et al., 2005; Schmitz et al., 2009; Winters-Stone et al., 
2011), all 23 trials consisted of participants with both stage I and II breast 
cancer (n=784, range=7-194 and n=753, range=3-161, respectively), and 
18 trials included stage III breast cancer patients (n=175, range=1-50) 
(Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; Courneya et al., 
2003; DeNysschen et al., 2011; Fillion et al., 2008; Hutnick et al., 2005; 
Littman et al., 2012; Ligibel et al., 2008; Matthews et al., 2007; Mefferd et 
al., 2007; Mehnert et al., 2011; Milne et al., 2008; Musanti, 2012; Rogers 
et al., 2009; Schmitz et al., 2005; Schmitz et al., 2009; Vallance et al., 
2007; Winters-Stone et al., 2011). Six of the trials that included 
participants stage data reported missing stage data (n=38, range=2-15) 
(Herrero et al., 2006; Hutnick et al., 2005; Ligibel et al., 2008; Matthews et 
al., 2007; Schmitz et al., 2009; Winters-Stone et al., 2011). 
 
Fourteen trials reported the participants’ average time since cancer 
diagnosis, ranging from 3.5 to 62.5 months (Cadmus et al., 2009; Carson 
et al., 2009; Cho et al., 2006; Fillion et al., 2008; Ligibel et al., 2008; 
Littman et al., 2012; Matthews et al., 2007; Mefferd et al., 2007; Pinto et 
al., 2003; Pinto et al., 2005; Schmitz et al., 2005; Schmitz et al., 2009; 
Vallance et al., 2007; Winters-Stone et al., 2011). Twelve trials reported 
the average time beyond active treatment, which ranged from one week 
after the end of treatment to 41.8 months beyond the end of active cancer 
treatment (Courneya et al., 2003; Daley et al., 2007; Herrero et al., 2006; 
Hutnick et al., 2005; Milne et al., 2008; Mustian et al., 2004; Pinto et al., 
2003; Rogers et al., 2009; Saarto et al., 2011; Schmitz et al., 2005; Sprod 
et al., 2010).  
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Twenty eight trials reported the number of participants who had received 
chemotherapy (Bower et al., 2011; Cadmus et al., 2009; Cantarero-
Villanueva et al., 2011; Carson et al., 2009; Cho et al., 2006; Courneya et 
al., 2003; Daley et al., 2007; DeNysschen et al., 2011; Fillion et al., 2008; 
Heim et al., 2007; Herrero et al., 2006; Hutnick et al., 2005; Ligibel et al., 
2008; Matthews et al., 2007; Milne et al., 2008; Musanti, 2012; Mustian et 
al., 2004; Nikander et al., 2007; Pinto et al., 2003; Pinto et al., 2005; 
Rahnama et al., 2010; Rogers et al., 2009; Saarto et al., 2011; Schmitz et 
al., 2005; Schmitz et al., 2009; Sprod et al., 2010; Vallance et al., 2007; 
Winters-Stone et al., 2011). The mean percentage of participants who had 
received chemotherapy was 68.3% (range=30-100%). Three trials 
consisted entirely of participants who had received chemotherapy (Herrero 
et al., 2006; Hutnick et al., 2005; Rahnama et al., 2010).  
 
Twenty five of the 34 trials reported participant’s hormone therapy details 
(Bower et al., 2011; Cadmus et al., 2009; Carson et al., 2009; Cho et al., 
2006; Courneya et al., 2003; Daley et al., 2007; Fillion et al., 2008; Heim 
et al., 2007; Ligibel et al., 2008; Matthews et al., 2007; Mefferd et al., 
2007; Milne et al., 2008; Musanti, 2012; Mustian et al., 2004; Nikander et 
al., 2007; Payne et al., 2008; Pinto et al., 2003; Pinto et al., 2005; 
Rahnama et al., 2010; Rogers et al., 2009; Saarto et al., 2011; Schmitz et 
al., 2005; Schmitz et al., 2009; Vallance et al., 2007; Winters-Stone et al., 
2011). The total number of participants who received hormone therapy in 
these 25 trials was 1,600 (mean=64; range=16-442). Selective oestrogen 
receptor modulator (SORM) use was reported in 10 trials (Cadmus et al., 
2009; Carson et al., 2009; Ligibel et al., 2008; Matthews et al., 2007; 
Mefferd et al., 2007; Rogers et al., 2009; Schmitz et al., 2005; Schmitz et 
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al., 2009; Vallance et al., 2007; Winters-Stone et al., 2011), while 
aromatase inhibitors (AI) use was reported in eight trials (Cadmus et al., 
2009; Carson et al., 2009; Ligibel et al., 2008; Rogers et al., 2009; Schmitz 
et al., 2005; Schmitz et al., 2009; Vallance et al., 2007; Winters-Stone et 
al., 2011). A total of 469 participants (mean=47; range=11-182) had taken 
SORMs, and a total of 188 had taken AI (mean=24; range=2-43). 
 
The mean age of participants in the 32 trials that reported this 
characteristic was 54.3 (mean age range=49-65) y, while two trials 
reported the age ranges of participants (Heim et al., 2007; Rahnama et al., 
2010). Postmenopausal status was reported in 18 of the trials (Bower et 
al., 2011; Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; Carson 
et al., 2009; Courneya et al., 2003; DeNysschen et al., 2011; Fillion et al., 
2008; Ligibel et al., 2008; Matthews et al., 2007; Mefferd et al., 2007; 
Milne et al., 2008; Pinto et al., 2003; Payne et al., 2008; Rogers et al., 
2009; Saarto et al., 2011; Schmitz et al., 2005; Vallance et al., 2007; 
Winters-Stone et al., 2011), and the mean percentage of postmenopausal 
participants in these trials was 72.2% (average range=0-100). Five of the 
trials had exclusively postmenopausal participants (Cadmus et al., 2009; 
Courneya et al., 2003; Matthews et al., 2007; Payne et al., 2008; Winters-
Stone et al., 2011), while Bower et al. (2011) consisted of only pre- and 
peri-menopausal participants. One trial stated the number of participants 
who reported menopause symptoms rather than menopausal status (Heim 
et al., 2007).  
 
The ethnicity of the participants was reported by 15 trials (Bower et al., 
2011; Cadmus et al., 2009; Carson et al., 2009; Daley et al., 2007; 
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DeNysschen et al., 2011; Littman et al., 2012; Matthews et al., 2007; 
Mefferd et al., 2007; Musanti, 2012; Mustian et al., 2004; Payne et al., 
2008; Pinto et al., 2005; Rogers et al., 2009; Schmitz et al., 2005; Schmitz 
et al., 2009). The majority of the participants were white (mean %=87.6%, 
range=64.5-98%), while black participants were the next highest ethnic 
group (n trials=11; mean %=10.3%, average range=1-31%).  
 
Eighteen trials reported the education of the participants (Bower et al., 
2011; Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; Carson et 
al., 2009; Cho et al., 2006; Courneya et al., 2003; Daley et al., 2007; 
Fillion et al., 2008; Hutnick et al., 2005; Littman et al., 2011; Mehnert et al., 
2011; Mustian et al., 2004; Payne et al., 2008; Pinto et al., 2003; Pinto et 
al., 2005; Schmitz et al., 2005; Schmitz et al., 2009; Vallance et al., 2007), 
with an average of 46% (range=22-70.3%) of participants reporting 
educational attainment of a university degree or more. Three additional 
trials reported number of years in education (mean=15y, mean range=14-
16y) (Matthews et al., 2007; Rogers et al., 2009; Saarto et al., 2011).  
 
Eleven trials reported on the socio-demographic status of the participants 
(Bower et al., 2011; Courneya et al., 2003; DeNysschen et al., 2011; 
Fillion et al., 2008; Littman et al., 2012; Mustian et al., 2004; Payne et al., 
2008; Pinto et al., 2003; Pinto et al., 2005; Rogers et al., 2009; Vallance et 
al., 2007). Four trials reported the specific co-morbidities of participants 
(Cadmus et al., 2009; Daley et al., 2007; Saarto et al., 2011; Vallance et 
al., 2007), while an additional two trials reported a co-morbidity index 
score (Rogers et al., 2009; Winters-Stone et al., 2011), and one trial 
consisted of a study arm of participants with lymphedema (Schmitz et al., 
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2009). Sixteen trials reported on the past physical activity history or 
baseline physical activity of the participants (Cadmus et al., 2009; 
Cantarero-Villanueva et al., 2011; Courneya et al., 2003; Daley et al., 
2007; Fillion et al., 2008; Heim et al., 2007; Ligibel et al., 2008; Littman et 
al., 2012; Matthews et al., 2007; Mehnert et al., 2011; Musanti, 2012; Pinto 
et al., 2005; Saarto et al., 2011; Schmitz et al., 2009; Vallance et al., 2007; 
Winters-Stone et al., 2011).  
 
Twenty one trials reported the mean body mass of participants (Cadmus 
et al., 2009; Courneya et al., 2003; Daley et al., 2007; DeNysschen et al., 
2011; Heim et al., 2007; Herrero et al., 2006; Hutnick et al., 2005; Ligibel 
et al., 2008; Littman et al., 2012; Matthews et al., 2007; Mefferd et al., 
2007; Musanti, 2012; Nieman et al., 1995; Nikander et al., 2007; Pinto et 
al., 2003; Rahnama et al., 2010; Saarto et al., 2011; Schmitz et al., 2009; 
Sprod et al., 2010; Vallance et al., 2007; Winters-Stone et al., 2011) and 
21 trials reported participants mean BMI scores (Bower et al., 2011; 
Cadmus et al., 2009; Courneya et al., 2003; Daley et al., 2007; Herrero et 
al., 2006; Hutnick et al., 2005; Ligibel et al., 2008; Littman et al., 2012; 
Matthews et al., 2007; Mefferd et al., 2007; Milne et al., 2008; Mustian et 
al., 2004; Nikander et al., 2007; Pinto et al., 2003; Pinto et al., 2005; 
Rahnama et al., 2010; Rogers et al., 2009; Saarto et al., 2011; Schmitz et 
al., 2009; Vallance et al., 2007; Winters-Stone et al., 2011). The average 
mean body mass in these trials was 74.9 kg (range=67.2-84.7 kg), and the 
average mean BMI was 28.3 (range=24.6-30.9 m·kg2). One additional trial 
reported the number of participants that fell into particular BMI ranges 





Intervention length ranged from four weeks (Fillion et al., 2008) to 12 
months (Cadmus et al., 2009; Schmitz et al., 2009; Winters-Stone et al., 
2011). The modal intervention length was 12 weeks (Bower et al., 2011; 
Courneya, et al., 2003; Matthews et al., 2007; Milne et al., 2008; Musanti, 
2012; Mustian et al., 2004; Nikander et al., 2007; Pinto et al., 2003; Pinto 
et al., 2005; Rogers et al., 2009; Vallance et al., 2007). Eight trials had a 
follow-up period beyond the end of the intervention length (Bower et al., 
2011; Cantarero-Villanueva et al., 2011; Carson et al., 2009; Daley et al., 
2007; Fillion et al., 2008; Mefferd et al., 2007; Pinto et al., 2005; Rogers et 
al., 2009; Vallance et al., 2007). Follow-up duration ranged from two 
weeks to 12 months.  
 
Mode of exercise differed across trials. Only three trials consisted of 
resistance training interventions with no form of aerobic exercise (i.e. any 
activity that uses large muscle groups, can be maintained continuously 
and is rhythmic in nature) included (Schmitz et al., 2005; Schmitz et al., 
2009; Winters-Stone et al., 2011). Thirteen trials involved interventions 
that combined resistance training and aerobic exercise (Cantarero-
Villanueva et al., 2011; Heim et al., 2007; Herrero et al., 2006; Hutnick et 
al., 2005; Kaltsatsou et al., 2011; Ligibel et al., 2008; Mefferd et al., 2007; 
Milne et al., 2008; Musanti, 2012; Niemen et al., 1995; Pinto et al., 2003; 
Rahnama et al., 2010; Sprod et al., 2010). Of these trials seven consisted 
of an intervention in which the resistance training and aerobic exercise 
was performed in the same training session (Herrero et al., 2006; Hutnick 
et al., 2005; Kaltsatsou et al., 2011; Milne et al., 2008; Niemen et al., 
1995; Pinto et al., 2003; Sprod et al., 2010), while in three trials the 
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resistance training and aerobic exercise were performed on separate days 
(Heim et al., 2007; Ligibel et al., 2008; Rahnama et al., 2010) and in two 
trials this information was unclear (Cantarero-Villanueva et al., 2011; 
Mefferd et al., 2007). Interventions in 18 of the trials consisted of aerobic 
exercise only (Bower et al., 2011; Cadmus et al., 2009; Carson et al., 
2009; Cho et al., 2006; Courneya et al., 2003; Daley et al., 2007; 
DeNysschen et al., 2011; Fillion et al., 2008; Littman et al., 2012; 
Matthews et al., 2007; Mehnert et al., 2011; Mustian et al., 2004; Nikander 
et al., 2007; Payne et al., 2008; Pinto et al., 2008; Rogers et al., 2009; 
Saarto et al., 2011; Vallance et al., 2007). One trial had separate aerobic 
exercise, resistance exercise and combined aerobic and resistance 
exercise intervention groups (Musanti, 2012). 
 
The frequency of exercise ranged between two days to seven days per 
week and in some trials participants attended exercise sessions at a 
facility such as a gym, community centre, or university or hospital facility, 
while in others, participants were instructed to perform home-based 
exercise. Duration of exercise sessions ranged from 15 to more than 95 
minutes, with a modal duration of 60 minutes (n=11; Cantarero-Villanueva 
et al., 2011; Fillion et al., 2008; Mefferd et al., 2007; Milne et al., 2008; 
Mustian et al., 2004; Niemen et al., 1995; Nikander et al., 2007; Saarto et 
al., 2011; Schmitz et al., 2005; Sprod et al., 2010; Winters-Stone et al., 
2011). Two studies gave participants a goal total number of minutes of 
physical activity to achieve each week (range=90-150 min) (Rogers et al., 
2009; Ligibel et al., 2008). In some trials the frequency of the exercise 
programme and duration of each exercise session increased during the 
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course of the trial. The total number of exercise sessions ranged between 
12 and 260.  
 
In 31 trials that consisted of aerobic exercise, eight consisted of walking 
only (Fillion et al., 2008; Heim et al., 2007; Matthews et al., 2007; Musanti, 
2012; Niemen et al., 1995; Payne et al., 2008; Rahnama et al., 2010; 
Rogers et al., 2009), two involved primarily walking (Cadmus et al., 2009; 
Vallance et al., 2007), one trial involved treadmill or outdoor walking or 
running only (Hutnick et al., 2005) and one consisted of walking with 
gymnastics (Mehnert et al., 2011). Other aerobic intervention modes 
involved cycling only (Courneya et al., 2003; Herrero et al., 2006), “fast 
working arm movements” (Cantarero-Villanueva et al., 2011), step 
aerobics and circuit training (Nikander et al., 2007; Saarto et al., 2011), 
Greek dance (Kaltsatsou et al., 2011), Tai Chi Chaung (Mustian et al., 
2004) and Yoga (Bower et al., 2011; Carson et al., 2009; Littman et al., 
2012). In all other trials participants chose their preferred option from a 
range of modes (Daley et al., 2007; DeNysschen et al., 2011; Mefferd et 
al., 2007; Milne et al., 2008; Pinto et al., 2003; Pinto et al., 2005; Sprod et 
al., 2010). 
 
The frequency of aerobic exercise ranged from one to seven days per 
week. The frequency of aerobic exercise was between three and five days 
for 20 of the trials (Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; 
Courneya et al., 2003; Daley et al., 2007; DeNysschen et al., 2011; Fillion 
et al., 2008; Herrero et al., 2006; Hutnick et al., 2005; Kaltsatsou et al., 
2011; Littman et al., 2012; Matthews et al., 2007; Milne et al., 2008; 
Musanti, 2012; Mustian et al., 2004; Nikander et al., 2007; Niemen et al., 
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1995; Pinto et al., 2003; Payne et al., 2008; Saarto et al., 2011; Vallance 
et al., 2007). Duration of aerobic exercise ranged between 10 to 90 
minutes. Nine trials included aerobic exercise sessions with durations that 
either progressed to or was set at 30 minutes throughout (Cadmus et al., 
2009; Courneya et al., 2003; DeNysschen et al., 2011; Heim et al., 2007; 
Herrero et al., 2006; Musanti, 2012; Pinto et al., 2003; Pinto et al., 2005; 
Rahnama et al., 2010; Vallance et al., 2007).  
 
The intensity of the aerobic exercise varied substantially between trials as 
did the methods used to measure and monitor intensity. Three of the trials 
did not provide the intensity at which the aerobic exercise was performed 
(Cantarero-Villanueva et al., 2011; Fillion et al., 2008; Heim et al., 2007). 
Twelve trials set intensity based upon percentage of maximum heart rate 
(MHR range: 40% to 80%) (Cadmus et al., 2009; Cho et al., 2006; Daley 
et al., 2007; Herrero et al., 2006; Kaltsatsou et al., 2011; Ligibel et al., 
2008; Milne et al., 2008; Musanti, 2012; Niemen et al., 1995; Pinto et al., 
2003; Pinto et al., 2005; Rahnama et al., 2010), one used percentage of 
heart rate reserve (HRR range: 30 to 55%) (Sprod et al., 2010), three 
studies used percentage of directly measured maximal oxygen uptake 
(VO2 max range: 60 to 75%) (Courneya et al., 2003; Hutnick et al., 2005; 
Mehnert et al., 2011), five studies utilised rate of perceived exertion (RPE 
range: 11-16) (Daley et al., 2007; DeNysschen et al., 2011; Matthews et 
al., 2007; Nikander et al., 2007; Saarto et al., 2011), and five trials 
measured intensity subjectively (either moderate or moderate to vigorous 
intensity) (Mefferd et al., 2007; Mustian et al., 2004; Payne et al., 2008; 




The frequency of resistance training interventions ranged between two 
and three days, with a modal frequency of three days (n=8; Cantarero-
Villanueva et al., 2011; Kaltsatsou et al., 2011; Heim et al., 2007; Herrero 
et al., 2006; Hutnick et al., 2005; Milne et al., 2008; Musanti, 2012; 
Niemen et al., 1995; Pinto et al., 2003; Winters-Stone et al., 2011). Two 
trials started with two days and progressed to three days (Mefferd et al., 
2007; Sprod et al., 2010). Duration of resistance training sessions ranged 
between 25 and 90 minutes. The number of resistance exercises ranged 
between four and 12, with a modal exercise number of nine (n=4; Heim et 
al., 2007; Rahnama et al., 2010; Schmitz et al., 2005; Schmitz et al., 
2009). Nine trials consisted of resistance training exercises for both the 
upper and lower body (Cantarero-Villanueva et al., 2011; Herrero et al., 
2006; Hutnick et al., 2005; Milne et al., 2008; Musanti, 2012; Rahnama et 
al., 2010; Schmitz et al., 2005; Schmitz et al., 2009; Winters-Stone et al., 
2011), one targeted the lower body and abdominals (Ligibel et al., 2008), 
one targeted the upper body and abdominals (Pinto et al., 2003) and one 
targeted the upper body only (Kaltsatsou et al., 2011), while the remaining 
studies did not report the areas of the body that the exercises targeted 
(Heim et al., 2007; Mefferd et al., 2007; Niemen et al., 1995; Sprod et al., 
2010). One study combined resistance training with jump exercises with 
added resistance ranging from 0% to 10% of bodyweight (Winters-Stone 
et al., 2011).  
 
Eight trials reported the equipment that was utilized in the resistance 
training sessions. Resistance machines were used in five trials (Kaltsatsou 
et al., 2011; Ligibel et al., 2008; Rahnama et al., 2010; Schmitz et al., 
2005; Schmitz et al., 2009), free weights (i.e. dumbbells and barbells) 
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were utilised in five trials (Rahnama et al., 2010; Schmitz et al., 2005; 
Schmitz et al., 2009; Pinto et al., 2003; Winters-Stone et al., 2011), and 
resistance bands was used in four trials (Cantarero-Villanueva et al., 2011; 
Hutnick et al., 2005; Musanti, 2012; Winters-Stone et al., 2011). The 
number of sets per resistance exercise ranged from one to four, and the 
number of repetitions per set ranged between eight and 15. The intensity 
of resistance exercises was set according to the percentage of maximum 
weight a participant can lift for a set number of repetitions in four trials 
(Cantarero-Villanueva et al., 2011; Herrero et al., 2006; Ligibel et al., 
2008; Winters-Stone et al., 2011) and RPE in one trial (Musanti, 2012). 
 
In six of the trials, participants in the intervention group took part in 
psychosocial or behavioural counselling sessions or discussion groups 
(Carson et al., 2009; Cho et al., 2006; Fillion et al., 2008; Matthews et al., 
2007; Mefferd et al., 2007; Rogers et al., 2009). The number of 
counselling sessions ranged from one to 16 in the five trials that reported 
this information (Carson et al., 2009; Cho et al., 2006; Fillion et al., 2008; 
Matthews et al., 2007; Rogers et al., 2009), and the duration of these 
sessions was 30 to 90 minutes in the four trials which reported session 
duration (Carson et al., 2009; Cho et al., 2006; Fillion et al., 2008; 
Matthews et al., 2007). Two trials claimed to integrate cognitive 
behavioural therapy techniques or behavioural coping strategies during 
exercise sessions (Daley et al., 2008; Mustian et al., 2004), one trial 
incorporated individual meetings designed to outline goals and provide 
feedback on participants progress (Courneya et al., 2003), one trial mailed 
physical activity tips to participants in the intervention (Pinto et al., 2005), 
while in another trial both intervention and control groups received an 
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educational programme, physical therapy, group exercise and psycho-
oncological interventions (Heim et al., 2007). In three of the trials 
incorporating psychosocial or behavioural counselling sessions into the 
intervention, these sessions were complimented with telephone 
counselling during the intervention period (Fillion et al., 2008; Matthews et 
al., 2007; Mefferd et al., 2007). The number of telephone counselling 
sessions ranged between four and 18, and their duration ranged from five 
to 15 minutes. Five additional trials involved telephone calls in order to 
track and review the progress of participants in the intervention groups 
(Courneya et al., 2003; DeNysschen et al., 2011; Hutnick et al., 2005; 
Musanti, 2012; Pinto et al., 2005). 
 
Interventions in 27 trials involved a supervised component, while 19 trials 
involved a home-based exercise component. In terms of the format of 
implementing the exercise programme, each used a group or individual 
format and an additional ten trials used a combined group and individual 
format (Bower et al., 2011; Cantarero-Villanueva et al., 2011; Carson et 
al., 2009; Cho et al., 2006; Courneya et al., 2003; Littman et al., 2012; 
Mefferd et al., 2007; Nikander et al., 2007; Rogers et al., 2009; Winters-
Stone et al., 2011). The majority of trials (n=25; Bower et al., 2011; 
Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; Carson et al., 
2009; Cho et al., 2006; Courneya et al., 2003; Daley et al., 2007; 
Kaltsatsou et al., 2011; Fillion et al., 2008; Herrero et al., 2006; Hutnick et 
al., 2005; Ligibel et al., 2008; Littman et al., 2012; Mefferd et al., 2007; 
Mehnert et al., 2011; Milne et al., 2008; Mustian et al., 2004; Niemen et 
al., 1995; Pinto et al., 2003; Rahnama et al., 2010; Saarto et al., 2011; 
Schmitz et al., 2005; Schmitz et al., 2009;  Sprod et al., 2010; Winters-
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Stone et al., 2011) implemented the exercise programme in a facility such 
as a gym/sports club, community centre, or university or hospital facility. 
Fourteen trials involved a combination of facility and home-based exercise 
(Cadmus et al., 2009; Carson et al., 2009; Cho et al., 2006; Cantarero-
Villanueva et al., 2011; Fillion et al., 2008; Heim et al., 2007; Hutnick et al., 
2005; Ligibel et al., 2008; Littman et al., 2012; Mefferd et al., 2007; 
Nikander et al., 2007; Rogers et al., 2009; Saarto et al., 2011; Winters-
Stone et al., 2011), while six trials were solely home-based (DeNysschen 
et al., 2011; Heim et al., 2007; Mathews et al., 2007; Musanti, 2012; 
Payne et al., 2008; Pinto et al., 2005; Vallance et al., 2007). The majority 
of the trials (n=25; Bower et al., 2011; Cadmus et al., 2009; Cantarero-
Villanueva et al., 2011; Carson et al., 2009; Cho et al., 2006; Courneya et 
al., 2003; Daley et al., 2007; DeNysschen et al., 2011; Kaltsatsou et al., 
2011; Fillion et al., 2008; Heim et al., 2007; Herrero et al., 2006; Hutnick et 
al., 2005; Ligibel et al., 2008; Littman et al., 2012; Matthews et al., 2007; 
Mehnert et al., 2011; Milne et al., 2008; Mustian et al., 2004; Rogers et al., 
2009; Saarto et al., 2011; Schmitz et al., 2005; Schmitz et al., 2009; Sprod 
et al., 2010; Winters-Stone et al., 2011) enlisted the services of exercise 
physiologists, exercise/sports trainers/specialists, fitness/exercise 
instructors, physical and sports therapists, kinesiologists, yoga instructors 
or other professionals to lead the exercise programme. 
 
In the majority of trials (n=25) the comparison arm was described as 
“usual” or “standard” care, “no intervention” or “sedentary control” and for 
14 of these trials the comparison arm was a ‘waiting list’ control wherein 
participants were offered either a portion or the full exercise programme at 
the completion of the trial (Cadmus et al., 2009; Carson et al., 2009; Cho 
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et al., 2006; Courneya et al., 2003; Ligibel et al., 2008; Littman et al., 
2012; Matthews et al., 2007; Mefferd et al., 2007; Milne et al., 2008; Pinto 
et al., 2003; Pinto et al., 2005; Rogers et al., 2009; Schmitz et al., 2005; 
Schmitz et al., 2009). The comparison group in eight trials received an 
intervention that included health education (Bower et al., 2011), phone 
calls (DeNysschen et al., 2011), educational programme, physical therapy, 
group discussion exercises and psycho-oncological interventions (Heim et 
al., 2007), psychosocial support therapy (Mustian et al., 2004), light-
intensity body conditioning/stretching (e.g. flexibility and passive 
stretching) exercises (Daley et al., 2007; Musanti, 2012; Winters-Stone et 
al., 2011) and an attention control (Milne et al., 2008; Pinto et al., 2005).  
 
Outcome measures 
Physical activity outcomes: 
Physical activity was assessed using either self-report or objectively by 
pedometers or accelerometers. Self-report questionnaires used included 
the Leisure Score Index (LSI) of Godin leisure time exercise questionnaire 
(Courneya et al., 2003; Musanti, 2012; Rogers et al., 2009; Vallance et al., 
2007), the Community Health Activities Model Programme for Seniors 
(CAMPS) questionnaire (Mathews et al., 2007; Winters-Stone et al., 
2011), the Minnesota Leisure Time Physical Activity Questionnaire 
(MLTPAQ) (Cantarero-Villanueva et al., 2011), a 7-day Physical Activity 
Log (PAL) (Cadmus et al., 2009), a 7-day physical Activity Recall (7-day 
PAR) (Mefferd et al., 2007; Pinto et al., 2005), the Baecke physical activity 
questionnaire (Schmitz et al., 2005), the International Physical Activity 
Questionnaire (IPAQ) (Schmitz et al., 2009), the Modifiable Activity 
Questionnaire (Littman et al., 2012) and self-developed physical activity 
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measures (e.g. exercise logs) were used in four trials (Daley et al., 2007; 
Heim et al., 2007; Hutnick et al., 2005; Saarto et al., 2011). Three trials 
used pedometers to objectively measure physical activity (Cadmus et al., 
2009; Nikander et al., 2007; Vallance et al., 2007), while another three 
used accelerometers (Matthews et al., 2007; Pinto et al., 2005; Rogers et 
al., 2009). Ten trials did not report participants’ physical activity data 
(DeNysschen et al., 2011; Fillion et al., 2008; Herrero et al., 2006; Mehnert 
et al., 2011; Milne et al., 2008; Mustian et al., 2004; Niemen et al., 1995; 
Pinto et al., 2003; Rahnama et al., 2010; Sprod et al., 2010).    
 
Cardiorespiratory fitness outcomes: 
Cardiorespiratory fitness was assessed using maximal or submaximal 
tests for either direct or indirect measurement of VO2 max/peak. Six trials 
directly measured VO2 peak using a maximal exercise test (Courneya et 
al., 2003; DeNysschen et al., 2011; Fillion et al., 2008; Herrero et al., 
2006; Hutnick et al., 2005; Mehnert et al., 2011), two trials used the Bruce 
protocol (Musanti, 2012; Sprod et al., 2010) and one trial used the 
modified Bruce protocol (Rahnama et al., 2010) to measure VO2 max 
indirectly. Other cardiorespiratory assessments included 8-min single 
stage walking treadmill test (Daley et al., 2007), single stage walking 
treadmill test (Fillion et al., 2008), 6-min walking treadmill test (Kaltsatsou 
et al., 2011; Mustian et al., 2004; Nieman et al., 1995), 2-km walking test 
(Nikander et al., 2007; Saarto et al., 2011), Rockport 1-mile walk test 
(Pinto et al., 2005), Aerobic Power Index (API) cycle test (Milne et al., 
2008), Naughton protocol (Rogers et al., 2009), 3-min step test (Mefferd et 
al., 2007) and Harvard step test (Heim et al., 2007). One trial used a peak 
graded exercise stress test on a cycle ergometer to assess exercise 
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tolerance (Pinto et al., 2003). Pulmonary function (forced vital capacity and 
forced expiratory volume in one second) was assessed in one trial (Sprod 
et al., 2010). 
 
Anthropometric outcomes: 
Anthropometric outcomes included body mass (Cadmus et al., 2009; 
Courneya et al., 2003; Daley et al., 2007; DeNysschen et al., 2011; Ligibel 
et al., 2008; Littman et al., 2012; Matthews et al., 2007; Mefferd et al., 
2007; Musanti, 2012; Nikander et al., 2007; Rahnama et al., 2010; Rogers 
et al., 2009; Saarto et al., 2011; Schmitz et al., 2005; Schmitz et al., 2009; 
Winters-Stone et al., 2011), BMI (Cadmus et al., 2009; Courneya et al., 
2003; Daley et al., 2007; Ligibel et al., 2008; Littman et al., 2012; 
Matthews et al., 2007; Nikander et al., 2007; Rahnama et al., 2010; 
Rogers et al., 2009; Schmitz et al., 2005; Schmitz et al., 2009), waist 
circumference (Cadmus et al., 2009; Ligibel et al., 2008; Littman et al., 
2012; Musanti, 2012; Rahnama et al., 2010; Rogers et al., 2009; Schmitz 
et al., 2005), hip circumference (Cadmus et al., 2009; Ligibel et al., 2008; 
Littman et al., 2012; Rahnama et al., 2010; Rogers et al., 2009), and arm 
circumference (Musanti, 2012). Body composition was assessed using 
Dual Energy X-ray Absorptionometry (DEXA) (Cadmus et al., 2009; 
DeNysschen et al., 2011; Matthews et al., 2007; Mefferd et al., 2007; 
Rogers et al., 2009; Saarto et al., 2011; Schmitz et al., 2005; Schmitz et 
al., 2009; Winters-Stone et al., 2011), Bioelectrical Impedance Analysis 
(BIA) (Daley et al., 2007; Ligibel et al., 2008; Matthews et al., 2007; 
Musanti, 2012; Mustian et al., 2004), skinfold thickness (SKF) Courneya et 
al., 2003; Herrero et al., 2006), and multi-slice Magnetic Resonance 
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Imaging (MRI) (Herrero et al., 2006). One trial reported body fat 
percentage but did not provide the method used (Hutnick et al., 2005).  
 
Muscular strength and endurance outcomes: 
Thirteen trials measured muscular strength or muscular endurance as an 
outcome. Maximal isometric leg/back strength was assessed in three trials 
(Heim et al., 2007; Nikander et al., 2007; Rogers et al., 2009; Saarto et al., 
2011), leg extension in one trial (Niemen et al., 1995), maximal grip 
strength was assessed in five trials (Kaltsatsou et al., 2011; Hutnick et al., 
2005; Mustian et al., 2004; Rogers et al., 2009; Saarto et al., 2011) and 
maximal isometric arm flexor strength was measured in two trials (Heim et 
al., 2007; Nikander et al., 2007). Other muscular strength tests included 
“multifunction’s test” (Heim et al., 2007), biceps and triceps curls (Hutnick 
et al., 2005), “maximal weight lifted for each exercise during strength 
training sessions” (Ligibel et al., 2008), “recording the weight used during 
the performance of specific exercises (i.e. bicep curls, leg presses and 
chest extensions)”, six repetition maximum (6-RM) (Musanti, 2012) and 1-
RM chest press and leg press (Schmitz et al., 2005; Schmitz et al., 2009). 
 
Muscular endurance tests included trunk curl static endurance test 
(Cadmus et al., 2009), multiple sit-to-stand test (Cadmus et al., 2009; 
Herrero et al., 2006), maximal number of repetitions at 30-35% and 100-
110% of bodyweight (Herrero et al., 2006), curl-up test (Musanti, 2012; 
Sprod et al., 2010), YMCA bench press endurance test (Musanti, 2012), 
and muscular endurance tests using leg press, bench press, lat pull-down 
and shoulder press machines and crunches with resistance dependent on 
body weight and age of participants and repetitions performed at a rate of 
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12.5 repetitions per minute until volitional fatigue (Sprod et al., 2010). 
Other physical fitness tests included a countermovement vertical jump 
(Nikander et al., 2007; Saarto et al., 2011), the figure-8 running agility test 
(Nikander et al., 2007; Saarto et al., 2011) and timed chair stands (Bower 
et al., 2011).  
 
Cardiovascular function outcomes: 
Resting systolic blood pressure was measured in three trials (Kaltsatsou et 
al., 2011; Rahnama et al., 2010; Musanti, 2012; Courneya 2003). Resting 
heart rate was reported in two of these studies (Kaltsatsou et al., 2011; 
Rahnama et al., 2010; Musanti, 2012) and HRR in one trial (Courneya et 
al., 2003). 
 
HRQoL, fatigue and other psychosocial outcomes: 
HRQoL assessment included a wide range of measures including the 
Functional Assessment of Cancer Therapy-General (FACT-G) (Cadmus et 
al., 2009; Courneya et al., 2003; Daley et al., 2007; Heim et al., 2007; 
Littman et al., 2012; Milne et al., 2008; Rogers et al., 2009), Functional 
Assessment of Cancer Therapy-Breast (FACT-B) (Cadmus et al., 2009; 
Courneya et al., 2003; Daley et al., 2007; Littman et al., 2012; Milne et al., 
2008; Rogers et al., 2009; Vallance et al., 2007), European Organization 
for Research and Treatment of Cancer (EOTRC) Quality of Life 
Questionnaire-C30 (QLQ-C30) (Herrero et al., 2006; Mehnert et al., 2011; 
Saarto et al., 2011), Medical Outcomes Study Short Form-12 (MOS SF-
12) (Fillion et al., 2008), MOS SF-36 (Cadmus et al., 2009; Mehnert et al., 
2011; Schmitz et al., 2009), Cancer Rehabilitation Evaluation System 
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Short Form (CARES-SF) (Schmitz et al., 2005) and a 27-item developed 
by Chae-Choe (Cho et al., 2007). 
 
Fatigue was measured using the Functional Assessment of Cancer 
Therapy-Fatigue (FACT-F) (Courneya et al., 2003; Heim et al., 2007; 
Littman et al., 2012; Mustian et al., 2004; Rogers et al., 2009; Saarto et al., 
2011; Vallance et al., 2007), Revised Piper Fatigue Scale (PFS) 
(Cantarero-Villanueva et al., 2011; Daley et al., 2007; Musanti et al., 2012; 
Payne et al., 2008; Sprod et al., 2010), Multidimensional Fatigue Inventory 
(MFI) (Bower et al., 2011; Fillion et al., 2008; Heim et al., 2007), Schwartz 
Cancer Fatigue Scale (SCFS) (Milne et al., 2008), fatigue subscale of 
Profile of Mood States (POMS) (Cantarero-Villanueva et al., 2011; Pinto et 
al., 2003), fatigue subscale of HIV Self-Efficacy Questionnaire adapted for 
breast cancer (Bower et al., 2011), linear analog scale for fatigue (Pinto et 
al., 2005) and on a 0 to 9 scale (Carson et al., 2009). Body image/self-
esteem was measured using the Rosenberg Self-Esteem Scale (RSE) 
(Cadmus et al., 2009; Courneya et al., 2003; Musanti, 2012; Mustian et al., 
2004), Body Esteem Scale (Pinto et al., 2003; Pinto et al., 2005), physical 
self-perception profile (Daley et al., 2007; Musanti, 2012), Body Image 
Questionnaire (BIQ) (Mehnert et al., 2011), Body Image and Relationships 
Scale (BIRS) (Schmitz et al., 2009) and Social Physique Anxiety Scale 7 
(SPAS-7) (Milne et al., 2008). 
 
Of the 13 trials that measured depression, three trials used the Centres for 
Epidemiological Studies Depression scale (CES-D) (Cadmus et al., 2009; 
Payne et al., 2008; Schmitz et al., 2005), five trials used the Beck 
Depression Inventory (BDI) (Bower et al., 2011; Daley et al., 2007; 
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Kaltsatsou et al., 2011; Saarto et al., 2011; Sprod et al., 2010), three trials 
used the Hospital Anxiety and Depression scale (HADS) (Heim et al., 
2007; Mehnert et al., 2011; Musanti, 2012), and one trial used the 
depression subscale of POMS (Fillion et al., 2008; Pinto et al., 2003). 
Anxiety was measured using the HADS (Heim et al., 2007; Mehnert et al., 
2011; Musanti, 2012), State-Trait Anxiety Scale (STAI) (Cadmus et al., 
2009) and the anxiety subscale of POMS (Fillion et al., 2008; Pinto et al., 
2003). Two trials assessed happiness (Cadmus et al., 2009; Courneya et 
al., 2003) and both of these trials used the Happiness Measure (HM).  
 
Four trails (Bower et al., 2011; Carson et al., 2009; Payne et al., 2008; 
Rogers et al., 2009) assessed sleep quality and three of these four trials 
(Bower et al., 2011; Payne et al., 2008; Rogers et al., 2009) used the 
Pittsburgh Sleep Quality Index (PSI), while one used a sleep disturbance 0 
to 9 scale (Carson et al., 2009). Other self-report HRQoL related 
outcomes included stress assessment using Cohen’s 10-item perceived 
stress scale (Bower et al., 2011; Cadmus et al., 2009; Cantarero-
Villanueva et al., 2011), Satisfaction with Life Scale (SWLS) (Daley et al., 
2007), Life Satisfaction Inventory (LSI) (Kaltsatsou et al., 2011), 
Symptoms of Stress Inventory (SOSI) (Mehnert et al., 2011), Symptom 
Checklist-90 Revised (SCL-90R) (Mehnert et al., 2011), Symptom 
Checklist (DeNysschen et al., 2011), Karnofsky Performance Scale (KPS) 
(DeNysschen et al., 2011), Brief Pain Inventory (BPI) (Fillion et al., 2008), 
Social Barriers Scale (Mehnert et al., 2011), POMS (vigor-activity) (Fillion 
et al., 2008; Pinto et al., 2005), POMS total mood disturbance (Pinto et al., 
2003; Pinto et al., 2005), emotional function using Positive and Negative 
Affect Scale (PANAS) (Pinto et al., 2003), basic psychological needs 
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satisfaction scale (BNS) (Milne et al., 2008), revised psychosocial 
adjustment questionnaire (Cho et al., 2007), Menopausal symptoms 
(Carson et al., 2009), Behavioral Regulation for Exercise Questionnaire 2 
(BREQ-2), joint pain, stiffness, and physical function via 5-point Likert 
scale version (i.e., 1 = none to 5 = extreme) of 24-item Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC) (Rogers et al., 
2009) and perceived general health perspective measured  based on a 
single question on health (Rogers et al., 2009).  
 
Two trials (Schmitz et al., 2005; Schmitz et al., 2009) reported outcomes 
related to lymphedema. One trial (Schmitz et al., 2005) reported arm-
circumference measurements, self-report of diagnosis and self-report of 
symptoms. While the other trial (Schmitz et al., 2009) assessed arm and 
hand swelling at one year, as measured through displaced water volume 
of the affected and unaffected limbs, incidence of exacerbations of 
lymphedema and number and severity of lymphedema symptoms 
(Schmitz et al., 2009).  
 
Blood biomarker outcomes: 
Insulin was assessed in five trials using a variety of different methods 
including an enzyme-linked immunosorbent assay (ELISA) kit (Cadmus et 
al., 2009), immunochemiluminometric assay (Ligibel et al., 2008; 
Rahnama et al., 2009; Schmitz et al., 2005), and radioimmunoassay (RIA) 
(Mustian et al., 2004). Glucose was determined by hexokinase ultraviolet 
assay (Ligibel et al., 2008; Rahnama et al., 2009), and colorometric 
reflectance spectrophotometry (Schmitz et al., 2005). Insulin resistance 
was assessed by the Homeostasis Model Assessment (HOMA) in three 
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trials (Ligibel et al., 2008; Rahnama et al., 2009; Schmitz et al., 2005). 
Total cholesterol (TC) was assessed in two trials (Courneya et al., 2003; 
Mefferd et al., 2007), high-density lipoprotein cholesterol (HDL-C) and 
triglycerides were measured in three trials (Courneya et al., 2003; Mefferd 
et al., 2007; Rahnama et al., 2009), low-density lipoprotein cholesterol 
(LDL-C) was calculated using the Friedewald formula (Friedewald et al., 
1972) in two trials (Courneya et al., 2003; Mefferd et al., 2007) and finally 
the TC:HDL-C ratio was calculated as total cholesterol divided by HDL-C 
in one trial (Courneya et al., 2003). All cholesterol outcomes were 
determined by assayed plasma using enzymatic methods. One trial 
determined haematocrit and haemoglobin levels using a Sysmex NE-1500 
haematology analyzer (Herrero et al., 2006). 
 
Additional blood biomarker outcomes included IGF-I (Cadmus et al., 2009: 
Mustian et al., 2004; Schmitz et al., 2005) determined via ELISA in two of 
these trials (Cadmus et al., 2009; Schmitz et al., 2005) and 
immunoradiometric assay in one (Mustian et al., 2004), and its binding 
proteins, IGFBP-1 by ELISA (Schmitz et al., 2005) and immunoradiometric 
assay (Mustian et al., 2004), IGFBP-2 by ELISA (Schmitz et al., 2005), 
and IGFBP-3 by ELISA (Cadmus et al., 2009; Schmitz et al., 2005) and 
immunoradiometric assay (Mustian et al., 2004). IGF-II was also 
measured in one trial via ELISA (Schmitz et al., 2005). Other blood 
biomarkers included leptin and adiponectin, assessed via 
radioimmunoassay and high molecular weight adiponectin (HMWA) by 
ELISA (Ligibel et al., 2008), cortisol by radioimmunoassay (Payne et al., 
2008), and serotonin radioimmunoassay (Payne et al., 2008). One trial 
assessed salivary cortisol and IgA concentrations, and α-amylase activity 
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using a commercial luminescence immune assay (Cantarero-Villanueva et 
al., 2011). 
 
Blood borne inflammatory biomarkers were assessed in five trials 
(Courneya et al., 2003; Hutnick et al., 2005; Mefferd et al., 2007; Mustian 
et al., 2004; Payne et al., 2008). Courneya (2003) assessed serum C-
reactive protein (CRP) by ELISA, change in natural killer (NK) cell 
cytotoxic activity in isolated peripheral blood mononuclear cells, white 
blood cell counts and differential measured using a Coulter STKS 
instrument, whole blood neutrophil function quantified by flow cytometry, 
the phenotypes of isolated mononuclear cells by an immunofluorescence 
assay, estimations of unstimulated and phytohemagglutinin (PHA)-
stimulated mononuclear cell function, rate of (3H)-thymidine uptake, and 
the production of proinflammatory cytokines, interleukin (IL)-1α, Tumour 
Necrosis Factor-alpha (TNF-α) and IL-6 and anti-inflammatory cytokines 
IL-4, IL-10 and transforming growth factor-β1, by ELIZA. Hutnick et al. 
(2005) measured the numbers of CD3+, CD4+, CD8+, B, and NK cells in 
fresh blood using immunochemistry and flow cytometry, lymphocyte 
proliferation determined by mitogen assays over a range of concentrations 
of the T-cell activators concanavalin A (ConA), phytohemagglutin (PHA) or 
pokeweed mitogen (PWM), and blood plasma concentration of IL-6, 
soluble IL-6 receptor (sIL-6R), soluble glycoprotein 130 (sgp130) and 
interferon-gamma (IFN-γ) as well as the activated lymphocyte supernatant 
concentration of IFN- γ and IL-6 were determined by ELISA. Mefferd et al. 
(2007) assessed levels of IL-6, TNF-α, IL-8 and Vascular Endothelial 
Growth Factor (VEGF) by ELISA. Mustian et al. (2004) assessed serum 
cytokines, IL-2, IL-6 and IFN-γ, by ELISA. Niemen et al. (1995) assessed 
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natural killer cell cytotoxic activity by chromium release assay and 
concentration of circulating immune cells, including percent total NK, total 
leukocytes, neutrophils, lymphocytes and T-cell subsets. Finally, Payne et 
al. (2008) determined IL-6 and bilirubin by radioimmunoassay.  
 
Bone-related outcomes: 
Bone mineral density (BMD) was assessed by DEXA in four trials 
(Cadmus et al., 2009; Rogers et al., 2009; Saarto et al., 2011; Winters-
Stone et al., 2011). Bone turnover was assessed in one trial (Winters-
Stone et al., 2011) by serum osteocalcin, a byproduct of bone formation 
and urinary deoxypyrodinoline cross-links (nmol/l), a byproduct of bone 
degradation adjusted for urine volume (creatinine: mmol/l), both 
determined by ELISA. Another trial assessed bone resorption using serum 
levels of N-telopeptides of type I collagen (NTx) determined by an 
enzyme-linked immunosorbent assay and a specific monoclonal antibody 
for NTx (osteomark serum NTx), and a marker of bone formation using 
serum levels of bone-specific alkaline phosphatase (BSAP), determined 
by a chemiluminescent immunoassay (Mustian et al., 2004). The authors 
of this trial (2004) investigated the balance between bone formation and 
bone resorption by using a formula developed by Eastell et al. 1993 to 
calculate a bone remodeling index (BRI). The formula is: Δ ZBSAP − Δ 
ZNTx, where ZBSAP = (BSAPObserved − BSAPμ at baseline)/σ at 
baseline, and ZNTx = (NTxObserved − NTxμ at baseline)/σ at baseline. 
 
Joint range of motion outcomes: 
Joint range of motion assessments were included in four trials (Cantarero-
Villanueva et al., 2011; Cho et al., 2007; Musanti, 2012; Mustian et al., 
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2004). Cantarero-Villanueva et al. (2011) measured shoulder flexion, 
extension, horizontal abduction and external rotation was assessed using 
a 41 cm plastic universal 2-arm goniometer and assessed cervical mobility 
using a cervical goniometric device. Musanti (2012) assessed hip flexion, 
hip backward extension, shoulder flexion, shoulder posterior elevation, 
and shoulder abduction using a goniometer. Finally, Mustian et al. (2004) 
measured shoulder flexion, extension, abduction, and adduction using 




The 96 trials retrieved and subsequently excluded did not meet the 
inclusion criteria for the following reasons. Trials were excluded if it was a 
single group trial or did not compare an exercise with a no exercise, 
exercise placebo (e.g. stretching), or usual care group (n=47), when 
breast cancer participants were not analysed separately (n=17), the trial 
included participants with metastatic disease (n=7), participants 
undergoing radiotherapy and/or chemotherapy (n=7) or participants who 
were pre-cancer therapy (n=1). Trials including interventions that did not 
promote or measure physical activity as an outcome (n=5), involved 
interventions that included therapeutic exercise regimes addressing only 
specific impairments related to the shoulder and arm or exercises 
restricted to stretching and/or local muscular endurance (n=7), or 
consisted of exercise combined with diet/medication where the effects of 
physical activity could not be isolated (n=2) were ineligible. Full details of 




2.8.4.2 Risk of bias in included studies 
The included studies were assessed for risk of bias using the “risk of bias” 
assessment tool and recommendations for judging risk of bias provided in 
Chapter eight of the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins et al., 2011). For each trial the risk of bias was 
detailed in the “risk of bias” tables included with the Characteristics of 
included studies and the “risk of bias” summary (Figure 2.8.2). In addition, 
an overall assessment of risk of bias is presented in Figure 2.8.3. 
 
Figure 2.8.2 Risk of bias graph: review authors' judgements about each 





Figure 2.8.3 Risk of bias summary: review authors' judgements about 




Thirteen trials were at a low risk of selection bias due to adequate 
generation of the randomized sequence as the trials used a random 
component to generate their sequence (Cadmus et al., 2009; Cantarero-
Villanueva et al., 2011; Carson et al., 2009; Courneya et al., 2003; Daley 
et al., 2007; Fillion et al., 2008; Milne et al., 2008; Musanti, 2012; Mustian 
et al., 2004; Rogers et al., 2009; Schmitz et al., 2005; Schmitz et al., 2009; 
Vallance et al., 2007). Four trials had a high risk of selection bias as they 
used a non-random component to generate their sequence (Cho et al., 
2006; Heim et al., 2007; Hutnick et al., 2005; Sprod et al., 2010). 
Seventeen trials were considered to have an unclear risk of selection bias, 
mainly because the generation of the random sequence was not described 
(Bower et al., 2011; DeNysschen et al., 2011; Herrero et al., 2006; 
Kaltsatsou et al., 2011; Ligibel et al., 2008; Littman et al., 2012; Matthews 
et al., 2007; Mefferd et al., 2007; Mehnert et al., 2011; Nikander et al., 
2007; Niemen et al., 1995; Payne et al., 2008; Pinto et al., 2003; Pinto et 
al., 2005; Rahnama et al., 2010; Saarto et al., 2011; Winters-Stone et al., 
2011).  
 
Fourteen trials were at a low risk of selection bias due to inadequate 
concealment of allocation to the intervention as the participants and 
investigators could not foresee assignment to the study groups (Bower et 
al., 2011; Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; 
Courneya et al., 2003; Daley et al., 2007; Herrero et al., 2006; Milne et al., 
2008; Mehnert et al., 2011; Musanti, 2012; Rogers et al., 2009; Schmitz et 
al., 2005; Schmitz et al., 2009; Vallance et al., 2007; Winters-Stone et al., 
2011). Five trials were at a high risk of selection bias because there was a 
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possibility that participants and/or investigators could foresee assignment 
to the study groups (Carson et al., 2009; Heim et al., 2007; Hutnick et al., 
2005; Mustian et al., 2004; Sprod et al., 2010). Fifteen trials were 
adjudged to have an unclear risk of selection bias due to allocation 
concealment, predominantly, because the allocation concealment was not 
described or not described in adequate detail for a decision to be made 
(Cho et al., 2006; DeNysschen et al., 2011; Fillion et al., 2008; Kaltsatsou 
et al., 2011; Ligibel et al., 2008; Littman et al., 2012; Matthews et al., 2007; 
Mefferd et al., 2007; Nikander et al., 2007; Nieman et al., 1995; Payne et 
al., 2008; Pinto et al., 2003; Pinto et al., 2005; Rahnama et al., 2010; 
Saarto et al., 2011).  
 
Blinding 
All trials included in this review were at high risk for performance bias 
because, owing to the nature of the intervention (i.e. physical activity), it 
was not possible to blind the trial personnel and participants. Ten trials 
were considered to be at a low risk of detection bias, because the 
outcome assessors were blinded to the allocation of participants to the 
study groups (Bower et al., 2011; Cadmus et al., 2009; Carson et al., 
2009; DeNysschen et al., 2011; Herrero et al., 2006; Musanti, 2012; 
Rahnama et al., 2010; Schmitz et al., 2005; Schmitz et al., 2009; Winters-
Stone et al., 2011), however, this was typically for outcome assessors 
measuring physical fitness and haematological outcomes rather than for 
self-report outcomes, such as HRQoL and psychological outcomes. 
Fifteen trials were at high risk for detection bias (Cho et al., 2006; Daley et 
al., 2007; Fillion et al., 2008; Heim et al., 2007; Hutnick et al., 2005; 
Littman et al., 2012; Mefferd et al., 2007; Mehnert et al., 2011; Milne et al., 
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2008; Mustian et al., 2004; Payne et al., 2008; Pinto et al., 2003; Pinto et 
al., 2005; Saarto et al., 2011; Sprod et al., 2010). Nine trials had an 
unclear risk of detection bias (Cantarero-Villanueva et al., 2011; Courneya 
et al., 2003; Kaltsatsou et al., 2011; Ligibel et al., 2008; Matthews et al., 
2007; Nikander et al., 2007; Niemen et al., 1995; Saarto et al., 2011; 
Vallance et al., 2007). 
 
Incomplete outcome data 
Six trials were at a low risk of attrition bias due to the amount, nature, or 
handling of incomplete outcome data. The decision of a high risk of 
attrition bias was based on the exclusion of participants with missing data, 
a lack of description of how missing data was handled or due to 
inappropriate methods of handling missing data, such as use of the last-
observation-carried-forward (LOCF). Twenty trials had a high risk of 
attrition bias (Cadmus et al., 2009; Cantarero-Villanueva et al., 2011; 
Carson et al., 2009; Cho et al., 2006; Fillion et al., 2008; Heim et al., 2007; 
Hutnick et al., 2005; Littman et al., 2012; Matthews et al., 2007; Mefferd et 
al., 2007; Mustian et al., 2004; Niemen et al., 1995; Pinto et al., 2003; 
Pinto et al., 2005; Rahnama et al., 2010; Saarto et al., 2011; Schmitz et 
al., 2005; Schmitz et al., 2009; Vallance et al., 2007; Winters-Stone et al., 
2011). Six trials were considered to be at a low risk of attrition bias either 
because the trials had no missing data or used an acceptable method for 
handling missing data (e.g. multiple imputation) (DeNysschen et al., 2011; 
Courneya et al., 2003; Milne et al., 2008; Musanti, 2012; Rogers et al., 
2009; Sprod et al., 2010). Eight trials had an unclear risk of bias (Bower et 
al., 2011; Daley et al., 2007; Herrero et al., 2006; Kaltsatsou et al., 2011; 
232 
 




Of the 34 trials, 31 were at a low risk of reporting bias, and based on the 
information provided by the trial authors, there was no reason to believe 
that there was selective reporting of the primary and secondary outcomes. 
Due to the incomplete reporting of outcome variables two trials 
(DeNysschen et al., 2011; Musanti, 2012) were considered at high risk for 
reporting bias, while one trial had an unclear risk (Littman et al., 2012). 
 
Other potential sources of bias 
Seventeen trials were at a low risk for other biases. Ten trials were 
considered to be at high risk for other biases (Carson et al., 2009; 
Kaltsatsou et al., 2011; Littman et al., 2012; Mehnert et al., 2011; Milne et 
al., 2008; Musanti, 2012; Payne et al., 2008; Pinto et al., 2003; Pinto et al., 
2005; Winters-Stone et al., 2011) and seven trials were at unclear risk for 
other biases (DeNysschen et al., 2011; Heim et al., 2007; Hutnick et al., 
2005; Ligibel et al., 2008; Matthews et al., 2007; Mefferd et al., 2007; 
Niemen et al., 1995) due to issues surrounding sample size, description of 
study sample and generalizability of findings.  
 
For detailed information on outcomes, number of trials reporting the 
outcomes, number of participants on whom the outcomes were reported, 
statistical methods used for analysis, and effect estimates see the 
summary of findings table (table 2.8.2). The summary of findings from the 
subgroup analysis by intervention mode is presented in tables 2.8.3, 2.8.4 
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and 2.8.5. We based the meta-analysis on post-intervention values rather 
than change in score from baseline. Although using the change scores 
can remove a component of between-person variability from the analysis, 
it involves measurement of the outcome twice, which may make it less 
efficient for outcomes which are unstable or difficult to measure precisely 
(Deeks et al., 2008). We only included outcome assessments made 
immediately upon intervention completion rather than follow-up 
assessments made weeks or months after the post-intervention 
assessments. When heterogeneity was found, subgroups were 
investigated by intervention mode (aerobic, resistance training, 
combination of both, yoga or tai chi), method of measurement and 
presence of a psychological component. Sensitivity analysis of studies 
where the allocation concealment scored as low risk of bias versus 
unclear or with a high risk of bias was also conducted. Data was combined 
using a weighted MD when trials measured outcomes using either the 
same measurement method or scale to generate continuous data. We 
used an SMD analysis to combine data from different measurement 
methods measuring the same outcome. 
 
For the meta-analysis, three of the intervention groups of Vallance et al. 
(2007) and the 3-month and 6-month intervention groups of Sprod and 
colleagues (2010) were combined using the methods outlined in chapter 
seven of the Cochrane handbook (Higgins and Deeks, 2010). Musanti 
(2012) consisted of aerobic exercise only, resistance training only and 
aerobic and resistance exercise combined intervention groups and a 
control group, therefore, for the combined physical activity analysis, the 
three intervention groups were combined, while when modes were 
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analysed separately the relevant interventions data were included. 
Schmitz et al. (2009) was separated into two studies, one study 
randomised breast cancer survivors with lymphedema into intervention 
and control groups, while the other separated breast cancer survivors at 
risk of lymphedema into intervention and control groups. Both studies 
were entered into the meta-analysis separately as Schmitz et al. (2009) (1) 
(with lymphedema) and Schmitz et al. (2009) (2) (at risk of lymphedema). 
Only data from a subgroup of 77 participants could be extracted from 
another study (Saarto et al., 2011), therefore, the data from this subgroup 
was included in the analysis.  
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2.8.4.3 Effects of interventions 
 
Table 2.8.2 Summary of findings; analysis 1: all physical activity interventions vs. control    
Outcome  Trial 
N 
Sample N Statistical Method Effect Estimate 
(95% CI) 
p-value/I2 
1.1 Physical activity levels (questionnaire 
data) 
10 982 SMD (IV, Random, 95% CI) 0.57 (0.26, 0.89)  0.0004/79% 
1.2 Physical activity (steps/day/week) 4 518 SMD(IV, Random, 95% CI) 0.29 (-0.20, 0.77)  0.25/75% 
1.3 Cardiorespiratory fitness 16 734 SMD (IV, Random, 95% CI) 0.30 (0.05, 0.55)  0.02/61% 
1.4 Mass (kg) 18 1103 MD  (IV, Fixed, 95% CI (kg)) -1.61 (-3.38, 0.16) 0.07/0% 
1.5. BMI (kg/m2) 14 916 MD  (IV, Fixed, 95% CI (kg/m2)) -0.86 (-1.59, -0.13) 0.02/0% 
1.6 Body Fat % 16 1025 SMD (IV, Fixed, 95% CI (%)) -0.15 (-0.28, -0.03) 
 
0.02/9% 
1.7. Lean mass (kg) 9 662 MD (IV, Fixed, 95% CI) 0.26 (-0.69, 1.21)  0.59/0% 
1.8 Waist circumference (cm) 6 380 MD  (IV, Fixed, 95% CI (cm)) -0.16 (-2.67, 2.35) 0.90/0% 
1.9 Hip circumference (cm) 5 325 MD  (IV, Random, 95% CI (cm)) 0.56 (-5.30, 6.43) 0.85/82% 
1.10 Waist-to-hip ratio (cm) 3 196 MD  (IV, Fixed, 95% CI (cm)) -0.01 (-0.03, 0.02) 0.49/0% 
1.11 Upper body strength 12 667 SMD (IV, Random, 95% CI) 0.61 (0.27, 0.94)  0.0004/76% 
1.12 Lower body strength 8 549 SMD (IV, Random, 95% CI) 0.46 (0.12, 0.80)  0.008/72% 
1.13 Resting systolic blood pressure 
(mm/Hg) 
3 108 MD  (IV, Fixed, 95% CI) -4.69 (-7.45, -1.93) 0.0009/0% 
1.14 HRQoL – General 11 657 SMD (IV, Random, 95% CI) 0.54 (0.22, 0.86) 0.0009/72% 
1.15 HRQoL – FACT-G 5 354 MD  (IV, Random, 95% CI) 7.94 (-0.51, 16.39) 0.07/90% 
1.16 HRQoL – FACT-B 5 590 MD  (IV, Random, 95% CI) 8.06 (-3.62, 19.75) 0.18/93% 
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Outcome  Trial 
N 
Sample N Statistical Method Effect Estimate 
(95% CI) 
p-value/I2 
1.17 Physical well-being 15 989 SMD (IV, Fixed, 95% CI) 0.35 (0.22, 0.47) <0.001/72% 
1.18 Mental/emotional well-being 15 978 SMD (IV, Fixed, 95% CI) 0.16 (0.03, 0.29)  0.01/51% 
1.19 Fatigue 16 1261 SMD (IV, Random, 95% CI) -0.33 (-0.59, -0.07)  0.01/76% 
1.20 Self-esteem 8 441 SMD (IV, Random, 95% CI) 0.29 (0.01, 0.57)  0.04/50% 
1.21 Depression 8 454 SMD (IV, Fixed, 95% CI) -0.41 (-0.61, -0.21)  <0.001/4% 
1.22 Anxiety 5 275 SMD (IV, Random, 95% CI) -0.64 (-1.03, -0.26) 0.001/57% 
1.23 Sleep 3 126 SMD (IV, Random, 95% CI) -0.06 (-0.56, 0.44)  0.82/49% 
1.24 Plasma Insulin 6 328 SMD (IV, Random, 95% CI) -0.46 (-1.12, 0.21)  0.18/88% 
1.25 Blood glucose 4 240 SMD (IV, Random, 95% CI) -0.11 (-0.44, 0.22)  0.52/37% 
1.26 HOMA 3 186 SMD (IV, Fixed, 95% CI) -0.05 (-0.34, 0.24)  0.74/0% 
1.27 High-density lipoprotein 3 158 SMD (IV, Random, 95% CI) 0.18 (-0.26, 0.62)  0.42/45% 
1.28 Triglyceride 3 158 SMD (IV, Random, 95% CI) -0.17 (-0.80, 0.45)  0.59/72% 
1.29 Insulin-like Growth factor-1 4 219 SMD (IV, Random, 95% CI) -0.20 (-0.54, 0.14)  0.25/33% 
1.30 Insulin-like Growth Factor-Binding 
Protein 3 
3 165 SMD (IV, Random, 95% CI) -2.06 (-3.99, -0.12)  0.04/95% 
1.31 Interleukin-6 4 132 SMD (IV, Fixed, 95% CI) -0.05 (-0.41, 0.30)  0.76/0% 





Table 2.8.3 Summary of findings; analysis 2: aerobic exercise only interventions vs. control    
Outcome  Trial N Sample 
N 
Statistical Method Effect Estimate 
(95% CI) 
p-value/I2 
2.1 Physical activity levels (questionnaire 
data) 
5 600 SMD (IV, Random, 95% CI) 0.55 (0.21, 0.88) 0.001/61% 
2.2 Cardiorespiratory fitness 9 446 SMD (IV, Fixed, 95% CI) 0.30 (0.11, 0.49) 0.002/20% 
2.3 Mass (kg) 7 380 MD (IV, Fixed, 95% CI (kg)) -1.62 (-4.80, 1.57) 0.32/0% 
2.4 BMI (kg/m2) 5 267 MD (IV, Fixed, 95% CI (kg/m2)) -0.52 (-2.00, 0.95) 0.49/0% 
2.5 Percentage Body Fat 7 379 SMD (IV, Fixed, 95% CI) -0.08 (-0.28, 0.12) 0.45/0% 
2.6 Lean mass (kg) 3 169 MD (IV, Fixed, 95% CI (kg)) 0.12 (-1.84, 2.07) 0.91/0% 
2.7 Upper body strength  4 155 SMD (IV, Random, 95% CI) 0.43 (0.11, 0.75) 0.009/0% 
2.8 Lower body strength  4 191 SMD (IV, Random, 95% CI) 0.19 (-0.20, 0.58) 0.34/43% 
2.9 HRQoL – General 6 343 SMD (IV, Fixed, 95% CI) 0.41 (0.19, 0.62) 0.0002/0% 
2.10 HRQoL - FACT-G 4 214 MD (IV, Random, 95% CI) 9.32 (-0.94, 19.57) 0.07/91% 
2.11 HRQoL - FACT-B 4 532 MD (IV, Random, 95% CI) 2.77 (-2.60, 8.14) 0.31/52% 
2.12 Physical well-being 7 456 SMD (IV, Random, 95% CI) 0.27 (0.02, 0.51) 0.03/42% 
2.13 Mental/emotional well-being 8 511 SMD (IV, Fixed, 95% CI) 0.24 (0.06, 0.41) 0.008/28% 
2.14 Fatigue 8 833 SMD (IV, Random, 95% CI) -0.21 (-0.45, 0.04) 0.10/58% 
2.15 Self-esteem 6 345 SMD (IV, Random, 95% CI) 0.21 (-0.14, 0.56) 0.23/60% 





Table 2.8.4 Summary of findings; analysis 3: aerobic and resistance exercise combined interventions vs. control    
Outcome  Trial N Sample N Statistical Method Effect Estimate 
(95% CI) 
p-value/I2 
3.1 Cardiorespiratory fitness 8 346 SMD (IV, Random, 95% CI) 0.32 (-0.16, 0.81) 0.19/76% 
3.2 Mass (kg) 5 237 MD (IV, Fixed, 95% CI (kg)) -4.10 (-7.65, -0.55) 0.02/0% 
3.3 BMI (kg/m2) 4 230 MD (IV, Fixed, 95% CI (kg/m2)) -1.78 (-3.17, -0.38) 0.01/0% 
3.4 Percentage Body Fat 5 230 SMD (IV, Random, 95% CI) -0.25 (-0.60, 0.11) 0.18/38% 
3.5 Waist circumference (cm) 3 187 MD (IV, Fixed, 95% CI (cm)) -1.03 (-4.84, 2.78) 0.53/0% 
3.6 Hip circumference (cm) 3 187 MD (IV, Random, 95% CI (cm)) 1.16 (-9.64, 11.97) 0.83/91% 
3.7 Upper body strength (kg) 4 141 SMD (IV, Random, 95% CI) 0.53 (-0.44, 1.50) 0.28/86% 
3.8 Physical well-being 3 98 SMD (IV, Random, 95% CI) 1.21 (0.01, 2.41) 0.05/84% 
3.9 Mental/emotional well-being 3 98 SMD (IV, Random, 95% CI) 0.27 (-0.68, 1.23) 0.57/78% 
3.10 Fatigue 5 273 SMD (IV, Random, 95% CI) -0.72 (-1.40, -0.04) 0.04/81% 
3.11 Self-esteem 3 99 SMD (IV, Random, 95% CI) 0.17 (-0.81, 1.16) 0.73/78% 
3.12 Depression 4 225 SMD (IV, Fixed, 95% CI) -0.39 (-0.70, -0.08) 0.01/36% 
3.13 Anxiety 3 143 SMD (IV, Random, 95% CI) -0.96 (-1.31, -0.61) <0.001/0% 






Table 2.8.5 Summary of findings; analysis 3: resistance training only interventions vs. control    
Outcome Trial N Sample N Statistical Method Effect Estimate 
 
p-value/I2 
4.1 Mass (kg) 4 410 MD (IV, Fixed, 95% CI (kg)) -0.12 (-3.07, 2.82) 0.93/0% 
4.2 BMI (kg/m2) 4 343 MD (IV, Fixed, 95% CI (kg/m2)) -0.32 (-1.47, 0.83) 0.58/0% 
4.3 Percentage Body Fat 5 419 SMD (IV, Random, 95% CI) -0.25 (-0.68, 0.18) 0.25/76% 
4.4 Lean mass (kg) 4 398 MD (IV, Fixed, 95% CI (kg)) 0.30 (-0.98, 1.59) 0.64/0% 
4.5 Lower body strength 4 358 SMD (IV, Random, 95% CI) 0.70 (0.23, 1.16) 0.003/77% 
4.6 Upper body strength 5 374 SMD (IV, Random, 95% CI) 0.84 (0.43, 1.25) <0.001/68% 
3.8 Physical well-being 4 379 SMD (IV, Random, 95% CI) 0.22 (-0.07, 0.51) 0.14/50% 




Physical activity levels 
Post-intervention follow-up values showed a significant moderate to large 
improvement in physical activity assessed via questionnaires compared 
with control in 982 trial participants (SMD 0.57; 95% CI 0.26, 0.89) 
(Analysis 1.1). There was a significant moderate to large effect when 
aerobic exercise only interventions were analysed separately (SMD 0.55; 
0.21, 0.88). The two resistance training only trials that included follow-up 
physical activity data found no significant difference compared to controls 
(SMD 0.13; -0.23, 0.50). Similarly, the two aerobic exercise and resistance 
training combined trials found no significant effect (SMD 1.24; -0.28, 2.77). 
The four trials (all aerobic exercise only interventions) that included follow-
up accelerometer (steps/day/week) physical activity data found no 
significant difference compared to controls (SMD 0.29, -0.29, 0.77) 
(Analysis 1.2). There was significant statistical heterogeneity when 
combining all studies in an SMD model. Subgroup investigation by 
intervention mode did not affect heterogeneity. Similarly, the presence of a 
psychological component did not alter the significance of the effect on 
physical activity (questionnaire-derived) or reduce heterogeneity to 
acceptable levels.  
 
A sensitivity analysis of studies where the allocation concealment scored 
as low risk of bias versus unclear or with a high risk of bias was 
conducted. When three trials with unclear or high risk of allocation bias 
were removed the effect was moderate to large and remained significant 




Two trials for which we were unable to extract data also reported on 
physical activity (Saarto et al., 2011; Schmitz et al., 2009). Two of these 
studies reported no significant differences in physical activity in the 
intervention compared to the control group. 
 
Cardiorespiratory fitness 
A significant low to moderate improvement in post-intervention scores 
were found in the intervention group (412 participants) compared with the 
control group (322 participants) (SMD 0.30; 0.05 to 0.55) (Analysis 1.3). 
Similarly, a significant low to moderate effect was found when the aerobic 
exercise only interventions (SMD 0.30; 0.11, 0.49) were analysed 
separately, but no effect was found when aerobic and resistance exercise 
combined (SMD 0.32; -0.16, 0.81). There were insufficient resistance 
training only trials to analyse effects on cardiorespiratory fitness. 
 
There was significant statistical heterogeneity when combining all studies 
in a SMD model. The omission of two trials (Sprod et al., 2010; Rahnama 
et al., 2010) that showed markedly different effects of physical activity 
compared to the other trials reduced heterogeneity to 0%. Subgroup 
investigation of aerobic exercise only interventions reduced heterogeneity 
to 0%. The inclusion of only trials that measured cardiorespiratory fitness 
directly via VO2 max also reduced heterogeneity to 0% and remained 
significant (SMD 0.33; 0.11, 0.54). Subgroup analysis by presence of a 
psychological component reduced heterogeneity to 8% and remained 




A sensitivity analysis of studies where the allocation concealment scored 
as low risk of bias versus unclear or with a high risk of bias found that 
when seven trials with unclear or high risk of allocation bias were removed 
the precision of the effect estimate was improved and the effect was low to 
moderate and remained significant (SMD 0.32; 0.08 to 0.55; I2= 11%).  
 
Three trials for which we were unable to extract data also reported on 
cardiorespiratory fitness (Heim et al., 2007; Mefferd et al., 2007; Niemen 
et al., 1995). Mefferd et al. (2007) and Niemen et al. (1995) found a 
significant improvement in cardiorespiratory fitness in the intervention 
group compared to the control group. Heim and co-workers (2007) 
reported no significant improvement in either intervention or control 
groups.  
 














There was no evidence of heterogeneity in the combined comparisons for 
mass, BMI, body fat %, lean mass, waist circumference or WHR. Evidence 
of heterogeneity was found only for hip circumference (I2=82%). Post-
intervention values showed no significant improvement in body mass 
compared with control in an analysis of 1103 trial participants (MD -1.61 
kg; -3.38, 0.16 kg) (Analysis 1.4). Similarly, aerobic training only trials and 
resistance training only found no significant differences compared to 
controls (MD -1.62 kg; -4.80, 1.57 kg and MD -0.12 kg; -3.07, 2.82 kg, 
respectively). However, trials which combined aerobic training and 
resistance training significantly reduced body mass compared to controls 
(MD -4.10 kg; -7.65, -0.55 kg). There was no evidence of heterogeneity in 
the combined comparisons and comparisons by intervention mode. 
Subanalyses of only trials which included a psychological support 
component showed a significant reduction in body mass and 0% 
heterogeneity (MD -5.06 kg; -9.45, -0.68 kg). When 10 trials with unclear 
or high risk of allocation bias were removed in a sensitivity analysis the 
effect remained non-significant (MD -0.18 kg; -2.76 to 2.40 kg).  
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Physical activity was associated with a significantly reduced BMI (MD -0.4; 
-1.59, -0.13) compared to controls in 916 participants (Analysis 1.5). When 
the mode of training was considered, only the trials which combined 
aerobic training and resistance training reduced BMI significantly (MD -
1.78; -3.17, -0.38). Analyses of six interventions that included a 
psychological support component also showed a significant reduction in 
BMI (MD -1.44; -2.62, -0.26). When six trials with unclear or high risk of 
allocation bias were removed the effect on BMI was not significant (MD -
0.40; -1.33, 0.50).  
 
Physical activity was associated with a low but significant reduction in 
body fat (SMD -0.15 %; -0.28, -0.03) and a non-significant effect on lean 
mass assessed via DEXA (MD 0.26 kg; -0.69, 1.21 kg) compared to 
controls in 1025 and 662 participants, respectively (Analysis 1.6 and 1.7, 
respectively). When intervention modes were analysed separately none 
had a significant effect on body fat or lean mass. Analysis of 10 trials that 
assessed body fat % by DEXA revealed a significant effect of physical 
activity compared to controls (MD -1.02; -1.97, -0.08). Analysis of two trials 
that assessed body fat % via BIA and SKF did not show a significant 
effect. Analysis of five trials consisting of a psychological support 
component showed a low to moderate significant reduction in body fat % 
(SMD -0.32; -0.57, -0.08), while the effect on lean mass in the two trials 
that measured lean mass included psychological support was non-
significant (MD 0.08; -0.18, 0.34). The exclusion of eight and four trials 
with unclear or high risk of allocation bias for the sensitivity analysis of 
body fat % and lean mass, respectively, resulted in non-significant effects 
of physical activity compared to control.  
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No significant effect of physical activity compared to controls were found 
for waist circumference (n=380; MD -0.16 cm; -2.67, 2.35 cm), hip 
circumference (n=325; MD 0.56 cm; -5.30, 6.43 cm) or WHR (n= 196; MD 
-0.01; -0.03, 0.02) (Analysis 1.8 to 1.10). There were insufficient studies to 
compare the effects of intervention mode on each of these outcomes. In 
the hip circumference analysis one of the five trials reported a substantial 
increase compared to the other four. The removal of this trial reduced 
heterogeneity to 2%, but the effect on WHR remained non-significant after 
we removed this study from the meta-analysis. There were insufficient 
numbers of trials to conduct subanalyses of trials including a psychological 
support component for these anthropometric outcomes. The exclusion of 
trials with unclear or high risk of allocation bias did not change the effects 
of physical activity on these outcomes compared to control. 
 
 




























Figure 2.8.13 Forest plot: Physical activity vs. Control, analysis: 1.10 
WHR 
 
Upper and Lower Body Strength 
Evidence of heterogeneity was found for both lower and upper body 
strength (I2=72% and 76%, respectively). Physical activity was associated 
with a low to moderate significant effect on lower body and moderate to 
large effect on upper body strength (SMD 0.46; 0.12, 0.80 and SMD 0.61; 
0.27, 0.94, respectively) compared to controls in 667 and 549 participants, 
respectively (Analysis 1.11 and 1.12, respectively). When analysing the 
four aerobic exercise only trials we found no significant effect on lower 
body strength (SMD 0.19; -0.20, 0.58; I2=43%), while analysis including 
four of the aerobic exercise only trials revealed a low to moderate 
significant increase in upper body strength (SMD 0.43; 0.11, 0.75; I2=0%). 
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Analysis of the four trials that consisted of combined aerobic and 
resistance exercise revealed no significant effect on upper body strength 
(SMD 0.53; -0.44, 1.50; I2=86%), while there were insufficient trials to 
conduct analysis on lower body strength in these trials. Unsurprisingly, 
analysis of all resistance exercise only interventions had a moderate to 
large significant effect on lower and a large effect on upper body strength 
(SMD 0.70; 0.23, 1.16; I2=77% and SMD 0.84; 0.43, 1.25; I2=68%, 
respectively). 
 
When trials that measured upper body strength using isometric hand grip 
dynamometers were analysed separately the effect remained significant 
but heterogeneity was reduced to 26%. However, analysing trials using 
chest/bench press to measure upper body strength did not alter the effect 
or heterogeneity. The method of measurement of lower body strength did 
not alter the effect or heterogeneity. There were only two trials and one 
trial that had a psychological support component in the upper body 
strength and upper body strength analysis, respectively. In the analysis of 
the two trials including a psychological support component, the effect of 
physical activity on upper body strength remained significant. The 
exclusion of trials with unclear or high risk of allocation bias did not alter 
heterogeneity or change the effect of physical activity on these outcomes 














Resting Systolic Blood Pressure 
There was no evidence of heterogeneity for resting systolic blood 
pressure. Physical activity was associated with significantly reduced 
resting systolic blood pressure (MD -4.69 mmHg; -7.45, -1.93 mmHg) 
compared to controls in 108 participants (Analysis 1.13). As only three 
trials included this outcome a subgroup analysis was not performed. Two 
of the three trials were combined aerobic and resistance exercise 
interventions and one was an aerobic exercise only intervention. The two 
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combined aerobic and resistance exercise interventions had an unclear 
risk of allocation bias, while the other trial had a low risk.  
 
 
Figure 2.8.16 Forest plot: Physical activity vs. Control, analysis: 1.13 
Resting systolic blood pressure 
 
Health-related quality of life 
There was evidence of substantial to considerable heterogeneity in 
general HRQoL, FACT-G, FACT-B and both physical and 
mental/emotional well-being, with heterogeneity ranging from 51% to 93%. 
Post-intervention values showed significant moderate to large 
improvements in general HRQoL compared with control in 657 trial 
participants (SMD 0.54; 0.22, 0.86) (Analysis 1.14). When aerobic 
exercise only interventions were analysed separately heterogeneity was 
reduced to 0% and there was a similar low to moderate significant effect 
(SMD 0.41; 0.19, 0.62). Analysis of two aerobic and resistance exercise 
combined trials resulted in a significant effect but substantial 
heterogeneity. There were insufficient resistance only trials for a subgroup 
analysis to be performed. In five trials with a psychological support 
component general HRQoL was significantly improved (SMD 0.43; 0.19, 
0.67) compared to controls, with no statistical heterogeneity. The removal 
of three trials with a high or unclear risk of allocation bias did not alter the 




Separate analysis of HRQoL assessed via FACT-G and FACT-B 
questionnaires, did not reveal a significant improvement in HRQoL with 
physical activity, and showed considerable heterogeneity (I2=90% and 
93%, respectively) (Analysis 1.15 and 1.16, respectively). When FACT-G 
was analysed in the aerobic exercise only trials, the effect became 
significant (MD 4.51; 0.61, 8.41). However, this analysis was conducted in 
only three trials. Only the aerobic exercise alone trials had a psychological 
support component, therefore, the result of this subgroup analysis was the 
same as above. There were insufficient aerobic and resistance exercise 
and resistance only trials for a subgroup analysis to be performed. The 
removal of one trial with a high or unclear risk of allocation bias did not 
show a significant effect and revealed evidence of substantial 
heterogeneity. Of the five trials included in the FACT-B analysis four were 
aerobic exercise only trials. The removal of the one aerobic and resistance 
exercise combined trial did not alter the non-significant finding or reduce 
heterogeneity below substantial. Similarly, the inclusion of three of the five 
trials that included a psychological support component did not alter the 
effect or heterogeneity. All included trials were at a low risk of allocation 
bias. 
 
Physical activity was associated with a low but significant improvement in 
physical and mental/emotional well-being (SMD 0.35; 0.22, 0.47 and SMD 
0.16; 0.03, 0.29) compared to controls in 989 and 978 participants, 
respectively (Analysis 1.17 and 1.18, respectively). However, there was 
evidence of possibly substantial heterogeneity in both analyses (I2=72% 
and 51%, respectively). The inclusion of aerobic exercise only trials did not 
alter the significance of the effect and lowered heterogeneity (I2=42% and 
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30%, respectively). Aerobic and resistance exercise trials were associated 
with a significant effect for physical well-being but not for mental/emotional 
well-being, while resistance only trials showed a significant effect with no 
evidence of heterogeneity for physical well-being but no effect and 
substantial heterogeneity for mental/emotional well-being. Inclusion of 
trials that assessed these HRQoL domains using the FACT questionnaire, 
showed a significant effect on physical well-being but not for 
mental/emotional well-being, with evidence of substantial heterogeneity for 
both analyses. Analysis of the five trials with a psychological support 
component showed a significant effect on physical well-being for physical 
activity versus controls but with substantial heterogeneity, while analysis of 
six trials with this component revealed a significant effect on 
mental/emotional well-being but with moderate heterogeneity. Removal of 
four trials with a high or unclear risk of allocation bias did not alter the 
effect on physical well-being, but the removal of five trials due to the same 
reason produced a non-significant effect on mental/emotional well-being.  
 
One trial for which we were unable to extract data also reported on 
HRQoL (Heim et al., 2007). This trial reported that physical activity 
resulted in an increase in HRQoL, although the trial also showed an 





Figure 2.8.17 Forest plot: Physical activity vs. Control, analysis: 1.14 
HRQoL – General 
 
 
Figure 2.8.18 Forest plot: Physical activity vs. Control, analysis: 1.15 
HRQoL - FACT-G. 
 
 
Figure 2.8.19 Forest plot: Physical activity vs. Control, analysis: 1.16 
HRQoL - FACT-B  
 










There was evidence of considerable heterogeneity in the fatigue analysis 
(I2=76%). Physical activity was associated with significant low to moderate 
reductions in fatigue (SMD -0.33; -0.59, -0.07) compared to controls in 
1261 participants (Analysis 1.19). This effect was not evident when the 
aerobic exercise only trials were analysed separately (SMD -0.21; -0.45, 
0.04; I2=58%). Analysis of five trials that assessed aerobic and resistance 
exercise combined showed a moderate to large significant effect but with 
substantial heterogeneity (SMD -0.72; -1.40, -0.04; I2=81%).  
 
Analysis by fatigue instrument type, revealed no significant effect in the 
four trials using FACT-F, in three trials using PFS or in each of two trials 
using MFI and Schwartz fatigue scale. However, significant reductions in 
fatigue were shown only in trials using POMS and the QLQ-C30 to 
measure fatigue, with no evidence of heterogeneity in either analysis. 
Analysis including the five trials with a psychological component did not 
show a significant effect on fatigue, while the removal of five trials at a 
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high or unclear risk of allocation bias revealed a significant reduction in 
fatigue but evidence of substantial heterogeneity.  
 
Among trials for which we could not extract data, one found a significant 
reduction in fatigue (Carson et al., 2009), one reported no group 
differences in fatigue (Payne et al., 2008), while one observed an initial 
improvement in both physical activity and control groups but found that 
over time the activity group improved slightly more while the control group 
became worse (Heim et al., 2007). Musanti (2012) assessed the change in 
clinically significant and non-significant fatigue in the total sample post-
intervention, showing a significant reduction in clinically significant fatigue.   
 
Psychological health outcomes and sleep 
There was evidence of statistical heterogeneity across studies for the 
analyses of self-esteem and anxiety (I2=50% and 57%, respectively), but 
not for depression (I2=4%). Physical activity was associated with a low but 
significant increase in self-esteem compared to controls (SMD 0.29; 0.01, 
0.57) in 441 participants (Analysis 1.20). However, the inclusion of aerobic 
exercise only trials changed the effect to non-significant (SMD 0.21; -0.14, 
0.56 and SMD 0.17; -0.81, 1.16, respectively) and increased the 
heterogeneity across studies. No resistance exercise only trials were 
available in this analysis. The removal of one trial which showed a more 
marked effect on self-esteem (Musanti, 2012) reduced heterogeneity to 
0%. Separate analysis by instrument type, found that two trials assessing 
self-esteem via BES and two by RSE, showed no significant effect on self-
esteem. Inclusion of four trials with a psychological support component 
revealed low to moderate significant increases in self-esteem in the 
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physical activity group compared to controls (SMD 0.41; 0.16, 0.66) with 
no evidence of statistical heterogeneity. Including only studies with a low 
risk of bias for allocation concealment resulted produced a non-significant 
effect (SMD 0.20; -0.12, 0.53) and substantial heterogeneity. 
 
We observed a significant low to moderate reduction in depression in the 
physical activity compared to the control group (SMD -0.41; -0.61, -0.21) in 
454 participants (Analysis 1.21). This effect remained significant 
regardless of intervention mode, although, there were no resistance only 
trials included in the analysis. It was not possible to analyse according to 
the measurement instrument used because of an insufficient number of 
trials using the same instrument. The effect was not altered when the trials 
were analysed by the presence of a psychological support component or 
by the inclusion of only trials with a low risk of allocation bias.   
 
There was a moderate to large significant reduction in anxiety in the group 
exposed to physical activity compared with the control group in 275 
participants (SMD -0.64; -1.03, -0.26) (Analysis 1.22). However, this effect 
only remained significant when aerobic and resistance exercise combined 
trials were included (SMD -0.96; -1.31, -0.61). Examination by individual 
instrument assessing anxiety was not possible due to an insufficient 
number of trials using separate instruments. Similarly, only one trial that 
included a psychological support component was available in this analysis. 
Including only studies with a low risk of bias for allocation concealment 
resulted in a low to moderate effect that remained significant (SMD -0.26; -




Among trials for which we could not extract data, Payne et al. (2008) 
reported that exercise had no effect on depression, while two trials (Fillion 
et al., 2008; Heim et al., 2007) reported a combined anxiety and 
depression score. One trial (Heim et al., 2007) reported a significant 
reduction in the physical activity group but not the control group, while the 
other (Fillion et al., 2008) reported no effect.  
 
Only three trials reported sleep disturbance, of which two assessed 
aerobic exercise only and one assessed yoga. No significant effect on 
sleep disturbance was found for physical activity compared to control 
(SMD -0.06; -0.56, 0.44) in 126 participants (3 studies; 2 aerobic exercise 
only and 1 yoga) (Analysis 1.23). The exclusion of the yoga trial or the 
inclusion of only trials with a psychological support component from the 
analysis did not alter the analysis. No subanalyses were performed on 
different measurement instruments due to inadequate number of trials. All 
three trials had a low risk of allocation bias. Among trials for which we 
could not extract data, one reported a large significant effect of exercise 
on sleep that was not present in the control group (Payne et al., 2008). 
 
 






















Nine blood biomarkers were included in the meta-analysis: insulin, 
glucose, HOMA, HDL-C, triglyceride, IGF-1, IGFBP-3, IL-6 and interferon-
gamma (analysis 1.24 to 1.32). There was no substantial study 
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heterogeneity in five (glucose, HOMA, HDL-C, IGF-1 and IL-6) blood 
biomarkers.  
 
In six trials, of which two assessed aerobic exercise, two assessed aerobic 
and resistance exercise combined and one each assessed resistance 
training and Tai Chi, physical activity was not associated with a significant 
reduction in plasma insulin (SMD −0.46; −1.12, 0.21; I2=88%) compared to 
controls. The removal of one trial (Cadmus et al., 2009) that found a much 
more marked reduction in plasma insulin compared to the other five, 
reduced heterogeneity to 8%. Analysis by intervention mode, 
psychological support component or risk of allocation bias did not alter the 
effect. There was no effect in plasma glucose or HOMA in the group 
exposed to physical activity compared with the control group (SMD -0.11; -
0.44, 0.22 and SMD -0.05; -0.34, 0.24, respectively) in 240 and 186 
participants, respectively. The result did not alter in subgroup and 
sensitivity analysis. In two combined aerobic and resistance exercise trials 
and one aerobic exercise only trial, physical activity was associated with 
no effect on HDL-C or triglycerides (SMD 0.18; -0.26, 0.62 and SMD -0.17; 
-0.80, 0.45) compared to controls in 158 participants. Analysis of the 
combined aerobic and resistance exercise trials reduced heterogeneity in 
both analyses to 0% and resulted in a significant moderate reductions in 
triglycerides (SMD -0.50; -0.89, -0.10), but the effect on HDL-C remained 
non-significant. Similarly, analysis by psychological support component 
and risk of allocation bias did not alter the effect. 
 
We observed no significant effect of physical activity on IGF-1 compared 
to controls (SMD -0.20; -0.54, 0.14) in 218 participants, although inclusion 
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of two aerobic exercise only trials resulted in a significant low to moderate 
reductions (SMD -0.41; -0.77, -0.05). In three trials, of which one each 
assessed aerobic exercise only, Tai Chi and resistance training only, 
physical activity was associated with a significant large reduction in 
IGFBP-3 (SMD -2.06; -3.99, -012). However, there was considerable 
heterogeneity in this analysis (I2=95%), and removal of any one of the 
included trials did not reduce heterogeneity. None of the included trials 
consisted of a psychological component, while inclusion of two studies 
with a low risk of allocation bias did not alter the effects on either marker, 
but this was based on just two trials. 
 
In four trials, three of which assessed combined aerobic and resistance 
exercise and one assessed Tai Chi, physical activity was associated with 
no significant reduction in IL-6 (SMD -0.05; -0.41, 0.30). There was no 
evidence of statistical heterogeneity. Separate analysis of the three 
combined aerobic and resistance exercise trials and two trials which 
included a psychological support component did not alter the effect. Three 
of the trials were at a high risk of allocation bias. In three trial, physical 
activity was associated with a significant large reduction in interferon-γ 
(SMD -1.35; -2.71, 0.02) compared to controls in 62 participants. There 
was evidence of substantial heterogeneity. However, the removal of a 
study (Herrero et al., 2006) that reported more substantial decreases than 
the other two studies reduced heterogeneity to 0%. Including only studies 
which combined aerobic and resistance exercise resulted in this result 
becoming non-significant, although two studies contributed to this 
analysis. Only one of the studies included a psychological support 



























Figure 2.8.31 Forest plot: Physical activity vs. Control, analysis: 1.29 
Insulin-like Growth Factor 1 
 
 
Figure 2.8.32 Forest plot: Physical activity vs. Control, analysis: 1.30 
Insulin-like Growth Factor-Binding Protein 3. 
 








There were an insufficient numbers of trials with common bone-related 
outcome measures to be included in the meta-analysis. BMD was 
assessed by DEXA in four trials (Cadmus et al., 2009; Rogers et al., 2009; 
Saarto et al., 2011; Winters-Stone et al., 2011), bone turnover was 
assessed in one trial (Winters-Stone et al., 2011) by serum osteocalcin 
and urinary deoxypyrodinoline cross-links (nmol/l) and in  another trial 
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(Mustian et al., 2004) assessed bone resorption using serum levels of 
NTx, bone formation using serum levels of BSAP and bone remodeling 
index (BRI). Cadmus and colleagues (2009) found no significant difference 
between a physical activity intervention and control group for total BMD 
(g/cm2) and BMC (g/cm). Rogers and co-workers (2009) reported no 
significant post-intervention differences in BMD of the femoral neck and 
lumbar spine between physical activity and control groups. Similarly, no 
significant differences between physical activity intervention and control 
groups were found for BMC of femoral neck, distal tibia or tibial shaft in 
another trial (Saarto et al., 2011). A resistance training only trial (Winters 
et al., 2011) found that the intervention group significantly preserved BMD 
of the spine compared to the control group, but reported no significant 
changes in total hip, greater trochanter and femoral neck in either 
intervention or control groups. The same trial (Winters et al., 2011) also 
found small but significant post-intervention increases in osteocalcin and a 
non-significant decrease in deoxypyrodinoline in the intervention group 
compared to the control group. Finally, Mustian et al. (2004) reported a 
non-significant increase in bone formation and a non-significant increase 
in bone resorption and a significant increase in bone metabolism 




2.8.5.1 Summary of main results 
We included 34 trials with a total of 3,051 participants randomised to the 
physical activity intervention (n=1,720) or the comparison (n=1,319) 
groups. The results suggest that physical activity interventions compared 
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with control interventions have a significant positive impact on physical 
activity levels (assessed by questionnaire), cardiorespiratory fitness, BMI, 
body fat %, lower and upper body strength, systolic blood pressure at rest, 
general HRQoL, physical and mental/emotional well-being, fatigue, self-
esteem, depression, anxiety, IGFBP-3 and interferon-γ. No significant 
effect of physical activity was found for accelerometer-derived physical 
activity levels, mass, lean mass, waist and hip circumferences, WHR, 
sleep disturbance, plasma insulin, glucose, HOMA, HDL-C, triglycerides, 
IGF-I or IL-6. The findings from bone-related outcome measures were 
inconclusive. 
 
Analysis by intervention mode suggested that aerobic exercise only 
interventions compared with controls had a positive effect on physical 
activity levels (both questionnaire and accelerometer-derived), 
cardiorespiratory fitness, upper body strength, general HRQoL, physical 
and mental/emotional well-being and depression. Analysis of aerobic and 
resistance exercise combined trials suggested positive effects on mass, 
BMI, general HRQoL, physical well-being, fatigue, depression and anxiety. 
In the four resistance training exercise trials included in the analyses, only 
upper and lower body strength improved significantly.  
 
The positive results must be interpreted with caution owing to the 
heterogeneity of physical activity interventions tested, the diversity of 
measures used to assess the various outcomes included and the risk of 
bias in many trials. Further research is required to investigate how to 
sustain positive effects of physical activity over time and to determine 
essential attributes of physical activity (mode, intensity, frequency, 
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duration and timing) for optimal effects on the outcomes included. The 
Summary of findings table 2.8.2, 2.8.3, 2.8.4 and 2.8.5 provides a 
summary of the main results. 
 
2.8.5.2 Overall completeness and applicability of evidence 
This systematic review included 34 trials, 31 of which were RCTs, one trial 
used a quasi-randomized design to allocate participants to treatment and 
two were non-randomised controlled clinical trials. These trials allocated 
3,051 participants to either the physical activity or comparison groups. All 
trials included breast cancer survivors who had completed all treatment 
except for hormone therapy. Physical activity interventions tested in the 
trials varied greatly and included walking by itself or in combination with 
cycling and other aerobic activity, resistance training by itself or combined 
with aerobic activities, yoga or Tai Chi. A variety of outcomes were 
assessed using a wide range of measures. 
 
The review draws upon studies from across the world, but predominantly 
from Europe and North America. The comprehensive search strategy 
obtained information from several electronic databases, citations through 
Web of Science and Scopus, grey literature through OPENGrey and 
review of reference list of other reviews in the field and reference lists of all 
included trials. There were no language or date restrictions in the search 
strategy. See search methods for identification of studies for details on the 
search strategy. 
 
In terms of applicability of evidence, all of the trials included women with 
non-metastatic breast cancer, therefore, the results presented in this 
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current review cannot be generalised to metastatic breast cancer. 
Furthermore, many trials provided incomplete information on participant 
characteristics (staging, breast cancer treatment details, age, menopausal 
status, ethnicity, education level, annual income, physical activity history, 
mass and BMI) that would enable better comparisons between trials and 
assess generalizability of findings. Based on participant characteristics 
presented in trials, participants were generally white and with “University” 
level of education or higher. These characteristics would limit applicability 
of evidence to ethnic populations of breast cancer survivors and potentially 
those of a lower socioeconomic status. Furthermore, we only included the 
assessments made at the end of the intervention. Thus, it is unclear about 
how sustainable the positive effects of a physical activity intervention 
would be. The physical activity interventions varied greatly in their mode, 
frequency, intensity and duration of activity. These variations make it 
difficult to make informed decisions regarding the optimal prescription of 
physical activity, in terms of mode, frequency, intensity and duration of 
sessions and interventions.  
 
The various outcomes were assessed using a diverse range of 
instruments with various degrees of precision, reliability and validity. 
Furthermore, reliance on self-report measures in some of the outcomes 
can open interpretation of findings to bias. There were differences in the 
effect of physical activity across trials using different outcome 
measurement instruments, which may undermine the results of the meta-
analysis. In addition, none of the trials assessed the effects of physical 
activity on breast cancer recurrence and breast cancer-related and overall 
mortality within a RCT design. Finally, the trials provided no data on cost 
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or cost-effectiveness of physical activity interventions on outcome 
measures among breast cancer survivors. 
 
2.8.5.3 Quality of the evidence 
Results of the review need to be interpreted with caution owing to the risk 
of bias. All the trials reviewed were at high risk for performance bias 
because blinding of participants is not possible in physical activity 
interventions. Performance bias becomes accentuated in trials where 
participants are asked to provide self-report or subjective assessments of 
outcomes such as physical activity, HRQoL and psychological health 
outcomes. In addition, many trials were at high risk for detection bias, 
because outcome assessors were not blinded, were at high risk for 
attrition bias owing to inadequate handling of incomplete data, were at 
high or unclear risk for selection bias owing to inadequate random 
sequence generation or concealment of allocation to the intervention, 
and/or were at a high or unclear risk of other bias, mainly due to a lack of 
statistical power due to higher attrition rates than expected.  
 
2.8.5.4 Potential biases in the review process 
The strength of this review is the comprehensive search strategy that 
included a search of a number of electronic databases and review of 
reference lists of other reviews in the field and reference lists of all 
included trials. The comprehensive search strategy was designed and 
implemented to ensure the identification and retrieval of the maximum 
number of available published trials and trials in the grey literature. The 
search strategy also ensured no language restrictions. All trials published 
in non-English language were assessed for eligibility and, if eligible, had 
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data abstracted by native speakers of the language in which the trial was 
published. Only one non-English language trial (D’Attilio et al., 2007) could 
not be excluded by reviewing the title and abstract. This trial was 
translated by a native speaker (Italian) and did not meet eligibility criteria.  
 
Despite a comprehensive literature search, it is possible that this current 
review may be at risk of publication bias. We prepared funnel plots to 
assess publication bias for follow-up values of physical activity, 
cardiorespiratory fitness, mass, BMI, body fat %, upper body strength, 
HRQoL-general, physical wellbeing, mental/emotional wellbeing and 
fatigue (see Figure 2.8.35 as an example; see appendix H for all funnel 
plots). Visually these figures showed there may be some slight asymmetry 
indicating that there is some publication bias in this area of research. We 
did not complete funnel plots for all outcomes, because too few studies 
contributed to some outcome measures. It is important to note that funnel 
plot asymmetry can result from reasons other than publication bias, such 
as selective outcome reporting, poor methodological quality leading to 
inflated effects in smaller less precise studies, true heterogeneity (i.e. size 
of effects differs according to study size, different populations or differing 
intensities of intervention), artefactual (i.e. where sample variation leads to 
an association between the effect estimate and its standard error) and 
random error (i.e. chance).  
 
It is possible this review missed some potentially eligible trials in the grey 
literature. It is unclear whether the addition of trials only in the grey 
literature would have a significant impact on the results, given that trials 
reported only in the grey literature tend to have small sample sizes and 
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inconclusive results (McAuley et al., 2000). Furthermore, we corresponded 
with and requested additional data from seven trial authors (Carson et al., 
2009; Daley et al., 2007; Heim et al., 2007; Mefferd et al., 2007; Niemen et 
al., 1995; Payne et al., 2008; Saarto et al., 2011), and only one of the trials 
authors (Daley et al., 2007) were able to provide additional data. The 
inability to obtain additional data from these trials resulted in an incomplete 
analysis and reduced the robustness of the meta-analysis. In addition, 
only the author assessed the eligibility of trials for this review, which may 
have increased the risk of selection bias.  
 
 
Figure 2.8.35 Funnel plot for analysis 1.4; Mass, all physical activity 
interventions vs. controls. The funnel plot shows evidence of possible 
publication bias due to a lack of symmetry (i.e. no inverted funnel shape). 
 
2.8.5.5 Agreements and disagreements with other studies or reviews 
Similar to this current review, in a meta-analysis of physical activity 
interventions for cancer survivors, Fong et al. (2012) found that trials 
including breast cancer survivors were associated with improvements in 
upper and lower body strength, HRQoL, fatigue and depression. While in 
another recent meta-analysis, Speck and colleagues (2010) also found 
improvements in physical activity levels, cardiorespiratory fitness, mass, 
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BMI, body fat %, upper and lower body strength, overall HRQoL, fatigue 
and depression. In a recent Cochrane review (Mishra et al., 2012) of the 
effects of physical activity interventions on HRQoL of breast cancer 
survivors, found that physical activity compared to control led to significant 
improvements in global HRQoL, body image/self-esteem, emotional well-
being, sleep disturbance, social functioning, sexuality, anxiety, fatigue and 
pain. However, these significant effects occurred at different follow-up 
periods. The results of the current review is similar to that of the three 
recent meta-analyses in that we also found that physical activity 
interventions compared with control interventions may have a significant 
positive impact on physical activity levels (assessed by questionnaire), 
cardiorespiratory fitness, BMI, body fat %, lower and upper body strength, 
systolic blood pressure at rest, general HRQoL, physical and 
mental/emotional well-being, fatigue, self-esteem, depression and anxiety.  
 
However, this is the first systematic review to analyse only studies where 
breast cancer survivors were analysed separately to other cancer 
survivors and includes all outcomes assessed in breast cancer survivors.  
Unlike the current review, two meta-analyses (Fong et al., 2012; Speck et 
al., 2010) also found reductions in IGF-I. Both this current review and 
Fong and colleagues (2012) used the same four trials in this analysis, 
while Speck did not include one of the trials used in this current analysis 
(Mustian et al., 2004). However, Fong et al. (2012) used only the 
difference between the change scores for physical activity and control 
groups for one (Mustian et al., 2004) of the four trials included, instead of 
the follow-up means for both groups that was used for this current review. 
The use of the change values for one trial in Fong and co-workers (2012) 
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led to a more favourable result than the result reported in this current 
analysis. In Mustian et al. (2004) the physical activity group reduced their 
IGF-I more than the control group; however, because there was an 
imbalance in the IGF-I levels of the physical activity intervention compared 
to the controls, the follow-up values of the physical activity group were still 
below that of the controls. Raised levels of IGF-I have been proposed as a 
possible mechanism that may increase the risk of developing breast 
cancer and recurrence (Lynch et al., 2011). Therefore, a significant 
reduction in IGF-I by physical activity could potentially imply a lower risk of 
recurrence. However, given the low number of studies investigating this 
outcome and the conflicting results, suitably powered RCTs are required 
to establish the effects of physical activity on IGF-I and the impact of IGF-I 
on risk of recurrence.  
 
We found significantly increased IGFBP-3 with physical activity 
interventions compared to controls, a finding which contradicts Speck et 
al. (2010). However, there was a difference in the eligibility criteria of 
studies which led to different trials being used in the analysis of this 
outcome. The role of IGFBP-3 on the risk of recurrence is conflicting, with 
some studies reporting lower risk with increased levels (Allen et al., 2005), 
while others reported lower risk with reduced levels (Yu et al., 1998; 
Goodwin et al., 2002a). Similar to the current review, both Fong et al. 
(2012) and Speck et al. (2010) found no significant positive effects of 
physical activity compared to controls on plasma insulin, glucose or 
HOMA. As in the current review, Speck and colleagues (2010) also found 
no significant positive effects on triglycerides and HDL-C. We found mixed 
results for the analysis of the two cytokines included in this analysis (IL-6 
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and interferon-γ. Similarly, Speck and co-workers (2010) found no 
significant effect of physical activity on immune parameters. Although the 
cancer treatment received is associated with pronounced immune 
deficiency and blood immune function is positively associated with 
progression-free and overall survival (Fairey et al., 2005), the effects of 
physical activity on immune parameters in post-treatment breast cancer 
requires further investigation.  
 
Differences between this current review and previous reviews may be a 
result of the different eligibility criteria used for the current review 
(exclusion of trials with patients undergoing treatment, patients with 
metastatic disease or involving patients with cancers other than breast 
cancer and the inclusion of trials that assessed outcomes other than 
quality of life). In addition, this current review also included more recent 
trials not included in the other two reviews. 
 
2.8.6 CONCLUSIONS 
This current systematic review finds that physical activity interventions 
compared with control interventions have a significant positive impact on 
physical activity levels (assessed by questionnaire), cardiorespiratory 
fitness, BMI, body fat %, lower and upper body strength, systolic blood 
pressure at rest, general HRQoL, physical and mental/emotional  well-
being, fatigue, self-esteem, depression, anxiety, IGFBP-3 and interferon-γ 
among breast cancer survivors. Physical activity could be considered as 




However, the positive results must be interpreted cautiously owing to the 
heterogeneity of physical activity interventions, measures used to 
outcomes and the risk of bias in many trials. Furthermore, a lack of 
understanding about important elements of physical activity interventions 
(mode, frequency, duration of sessions and interventions, intensity and 
settings) for optimal effects on physical, physiological, psychological and 
psycho-social outcomes would preclude informed decision-making in 
clinical settings and limit practical applicability of findings. 
 
No evidence of effect was found for accelerometer-derived physical 
activity levels, mass, lean mass, waist and hip circumferences, WHR, 
sleep disturbance, plasma insulin, glucose, HOMA, HDL, triglycerides, 
IGF-I, IL-6 or bone-related outcomes. The lack of evidence may be due to 
few trials assessing these outcomes, small number of participants in trials 
measuring these outcomes and substantial heterogeneity between trials 
measuring these outcomes on the physical activity interventions 
implemented and measures used to assess the outcomes. Owing to these 
limitations, no conclusions can be drawn at this time regarding the effects 
of physical activity interventions on these outcomes. 
 
From a practice perspective, it would be important to understand whether 
certain attributes of physical activity, such as intensity, duration and 
frequency of activity, have more or less optimal effects on particular 
outcomes among breast cancer survivors. In addition, an understanding of 
which modes are optimal for particular outcomes desired in breast cancer 
survivors. For example, elucidation of the optimal mode of physical activity 
(aerobic exercise alone, resistance exercise alone or aerobic and 
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resistance exercise combined) for decreasing BMI or body fat % in 
overweight post-menopausal breast cancer survivors would be valuable, 
and could potentially improve recurrence-free and overall survival. 
 
Further research is required to investigate whether the effect of a physical 
activity intervention can be maintained beyond the active intervention 
period, and if so, how to sustain changes in physical activity behaviours 
and positive effects of physical activity on important breast cancer-related 
outcomes. Empirical evidence is also needed to determine the optimal 
follow-up period from the end of the intervention. In addition to this, the 
effects of physical activity outcomes needs to assessed longitudinally in 
order to investigate effects on breast cancer recurrence and breast 
cancer-related and overall mortality with a RCT design. More research is 
needed to determine optimal prescription of physical activity (mode, 
intensity, frequency, duration, setting) for breast cancer survivors for 
optimal effects on breast cancer-related outcomes. Due to problems with 
the heterogeneity of measurement instruments used in physical activity 
trials which make comparisons of findings between trials extremely 
difficult, more consistency is needed when measuring breast cancer-
related outcomes. When assessing the validity of measurement tools used 




CHAPTER THREE: AIMS AND HYPOTHESES 
The principle aims of the present project were to: 
1. Assess the amount of physical activity undertaken by NHSBSP 
attendees, their levels of awareness of the role of physical activity and 
overweight/obesity in breast cancer risk and awareness of whether 
they engaged in sufficient amounts of physical activity. 
2. To explore the physical activity levels in women at different stages of 
breast cancer pathway, that is, during breast screening (i.e. pre-
diagnosis of breast cancer), during chemotherapy and within one year 
post-breast cancer treatment (breast cancer survivors). 
3. Investigate the effects of a six-month home-based physical activity 
intervention on physical activity levels, mass and BMI, HRQoL, insulin 
resistance and blood lipid profiles of breast cancer survivors. 
4. Examine the effects of a home-based physical activity intervention 
focused on the cardiorespiratory fitness of breast cancer survivors.  
 
For each of the above aims the following hypotheses were made: 
1. NHSBSP attendees were predicted to perform low levels of physical 
activity, have poor awareness of the role of physical activity and 
overweight/obesity on breast cancer risk and poor awareness of 
whether they engaged in sufficient amounts of physical activity. 
2. We hypothesised that breast cancer patients undergoing 
chemotherapy would have the lowest levels of physical activity levels 
of the three participant groups, while breast cancer survivors who had 
completed treatment were expected to have lower physical activity 
levels than the NHSBPS attendees. 
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3. We predicted that breast cancer survivors allocated to a six-month 
home-based physical activity intervention would increase physical 
activity levels, maintain mass and BMI, improve HRQoL, reduce 
glucose, insulin and insulin resistance, lower TC, LDL-C and TG and 
raise HDL-C concentrations compared to breast cancer survivors 
allocated to usual care. 
4. We expected that hypothesised improvements in physical activity in 
breast cancer survivors allocated to the home-based physical activity 
intervention would in turn increase cardiorespiratory fitness (VO2 peak) 
compared to usual care. 
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CHAPTER FOUR: METHODOLOGY 
4.1 PARTICIPANTS 
For the purposes of this PhD project a total of 309 volunteers were 
assessed for the included studies. Of these participants 188 were women 
attending breast screening and 121 were breast cancer patients. In the 
first study (see 5.1) data was derived from 188 NHSBP attendees. In study 
5.2 data was also derived from 41 breast cancer patients undergoing 
chemotherapy and 80 post-treatment breast cancer patients, in addition to 
the NHSBPS attendees. Study 5.3 consisted of the 80 post-treatment 
breast cancer patients and study 5.4 included a subset of 32 of the same 
80 breast cancer patients. The Centre for Disease Control and Protection 
(CDC, 2013) defines a breast cancer survivor as anyone who has been 
diagnosed with breast cancer, from the time of diagnosis through the 
balance of her life. We have used this term to describe the post-treatment 
breast cancer patient. 
 
Each study within the project had local research ethics committee 
approval by Dudley Ethics Committee. All participants were given verbal 
and written information about the project and signed an informed consent 
according to the declaration of Helsinki (World Medical Association, 2000). 
Due to the specific requirements of each study, details about the eligibility 
criteria and participants are presented in the methods section of the 
respective studies. Similarly, given the different designs and data 
collection methods utilised in this current project, the procedures of each 






4.2.1. Anthropometry and body composition 
Standing height was measured to the nearest 0.5 cm on a portable 
stadiometer (Seca 214 Road Rod, Seca gmbh & co. kg., Hamburg, 
Germany). Body composition was assessed by bioelectrical impedance 
analysis (BIA) using a Tanita BC-418 MA Segmental Body Composition 
Analyser, which incorporates eight tactile electrode (Tanita Corporation, 
Tokyo, Japan). Body composition was assessed in terms of body fat %, fat 
mass, fat free mass (FFM) and total body water. The specific device has a 
standard error of <3% when standard procedures are followed (Demura et 
al., 1999). Standard procedures aim at reducing fluctuations in the 
hydration status of participants. BIA assesses water and electrolyte 
content of different parts of body (Bolanowski and Nilsson, 2001). Thus, 
participants were asked to refrain from excessive fluid consumption the 
day before the assessment and were instructed to drink two pints of water 
one to two hours prior to the assessment. After the initial manual entry of 
gender, height and age, participants stood bare-footed on the analyser 
and held the handgrips provided until the body composition analysis was 
completed. Body mass was also measured via the Tanita analyser and 
was recorded to the nearest 0.1 kg. BMI (kg·m2) was calculated on the 
basis of measured height and mass (mass in kg multiplied by height in m 
squared).  
 
4.3.2 Physical activity  
The International Physical activity Questionnaire (IPAQ) is a standardized, 
culturally-adaptable questionnaire that measures the intensity and time of 
physical activity. It was developed to allow comparisons of physical activity 
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data to be made across different countries (Hallal et al., 2010). There are 
two versions of IPAQ, including IPAQ-short form (IPAQ-SF), which is 
generally suitable for population surveillance purposes, and the IPAQ-long 
form (IPAQ-LF), which is recommended for research activities (Bauman et 
al., 2009). The IPAQ-LF version was utilised in the current thesis and 
provides detailed and comprehensive information on daily activity habits 
done in four different domains, including occupational, transportation, 
gardening and housework (domestic) and leisure activities. The 
questionnaire also includes questions about time spent sitting as an 
indicator of sedentary behaviour. In each of the four domains the number 
of days per week and time per day spent in both moderate and vigorous 
activity are recorded. At work, during transportation and in leisure time, 
walking time is also included. Practical examples of culturally relevant 
activities of moderate and vigorous intensity are given. Physical activity 
undertaken by participants in these domains was recorded for the seven 
days prior to assessments. Individuals first indicated the number of days 
(or “none”) in which they engaged in different intensities of activity in each 
of the four contexts for more than 10 min. If a number of days was 
entered, individuals were then asked to specify the total time in hours and 
minutes usually spent in the activity on one of those days. For purposes of 
data analysis, time was converted to minutes. 
 
For standardised evaluation of physical activity, the metabolic equivalent 
(MET) time was estimated. One metabolic equivalent was defined by 
Ainsworth et al. (2011) as the metabolic turnover of 3.5 ml oxygen per 
kilogram body mass per minute in males and 3.15 ml·kg-1·min-1 in females. 
The weighted MET minutes per week were calculated as duration × 
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frequency per week × MET intensity, which were summed across activity 
domains to produce a weighted estimate of total physical activity from all 
reported activities per week (MET-min·wk-1) (Craig et al., 2003). Using 
MET-min·wk-1 as a means to combine aerobic activities of different types 
and intensities into a single measure of amount of activity. The IPAQ 
physical activity categories allow the categorisation of individuals into 
those who are meeting the current recommended physical activity 
guidelines (i.e. a minimum of 150 min of moderate-intensity physical 
activity per week) and those who are not (Bull and the Expert Working 
Groups, 2010).  
 
The low activity category includes individuals who do not meet the criteria 
for moderate and high activity categories, and therefore, are not 
performing the recommended amount of physical activity. The moderate 
activity category represents those meeting current recommended 
guidelines for physical activity, and identifies individuals performing five or 
more days of moderate-intensity activity and/or walking of at least 30 min 
per day, three or more days of vigorous-intensity activity of at least 20 min 
per day or at least five days of any combination of walking, moderate- or 
vigorous-intensity activities achieving a minimum of at least 600 MET-
min·wk-1. This minimum 600 MET-min·wk-1 is based on quantification of 
moderate-intensity physical activity as 3.0 to less than 6.0 METs. 
Therefore, an adult can achieve 600 MET-min·wk-1 by performing 
moderate-intensity physical activity (4 METs) for ~150 min per week. The 
high activity category comprises of individuals achieving at least seven 
days of walking, moderate- and vigorous-intensity activities and a 
minimum of a least 3000 MET-min·wk-1 or those accumulating at least 
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1500 MET-min·wk-1 by performing at vigorous-intensity activity on at least 
three days. 
 
The concurrent validity of IPAQ-LF was originally assessed in 12 
countries, including the UK, against accelerometer data (Craig et al., 
2003). The IPAQ-LF showed moderate concurrent validity (Spearman’s 
rho=0.33) when compared to accelerometer data with around four-fifths of 
all individuals being similarly classified by the IPAQ and accelerometer 
data when physical activity data was categorised, which is similar to other 
self-report physical activity questionnaires (Craig et al., 2003). The two 
modes of administration for IPAQ-LF are self-administration and telephone 
administration. Each of these modes has its own specific questionnaire, 
which can be freely accessed online at http://www.ipaq.ki.se. For the 
purposes of the current study the self-administration version of the 
questionnaire was used (for IPAQ see Appendix P).  
 
4.2.3 Health-related quality of life 
Functional Assessment of Cancer Therapy-Breast (FACT-B) is a 36-item 
compilation of questions subdivided into four primary HRQoL domains, 
including physical well-being (PWB; 7-items), social/family well-being 
(SWB; 7-items), emotional wellbeing (EWB; 6-items) and functional well-
being (FWB; 7-items), and a disease specific domain, which in this case 
was the “additional concerns for breast cancer” (breast cancer subscale; 
9-items) (see Appendix Q). The four primary HRQoL domains are 
combined to provide a 27-item general HRQoL assessment (FACT-G). 
The total FACT-G score, which is the sum of the scores for the four 
HRQoL domains, is computed if the total item response is greater than 
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80%. The PWB, SWB, EWB, and FWB subscales and the FACT-G total 
score have a lowest possible score of 0. The highest possible score is 28 
for the PWB, SWB, and FWB subscales; 24 for the EWB subscale; and 
108 for the FACT-G total score. The total FACT-B score is calculated by 
the sum of FACT-G and breast cancer subscale scores. For these scales 
it is also possible to calculate a Trial Outcome Index (TOI). The TOI is the 
sum of the PWB, FWB and breast cancer subscale scores. The TOI 
endpoint provides an efficient summary index of physical/functional 
outcomes, particularly in clinical trials (Webster et al., 2003). Higher 
scores for the scales and subscales indicate better quality of life.  See 
www.facit.org for full description and scoring. Social and emotional well-
being domains are very important for HRQoL, which are not so likely to 
change quickly or dramatically over time or in response to therapy. The 
instrument has been validated in the breast cancer setting, with good 
internal consistency, reliability, patient acceptability and sensitivity to 
clinically significant change (Brady et al., 1997). 
 
4.2.4 Blood biomarkers 
Venipuncture blood samples were taken at baseline and at six months by 
hospital phlebotomists at the Phlebotomy clinic at Russells Hall Hospital. 
Blood sample analysis was performed at the biomedical laboratory in 
Russells Hall Hospital (see Appendix R). The blood samples were 
analysed for the following biomarkers. 
 
Blood Lipids 
Total cholesterol (TC), high-density lipoprotein (HDL-C) cholesterol and 
triglycerides (TG) were measured using the Vitros® 5.1 FS chemistry 
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system (Johnson and Johnson Inc., Langhorne, PA, USA). This system 
uses a slide, specific for each biochemical test, which is a multi-layered 
analytical element coated on a polyester support. A drop of the patient’s 
serum/plasma is deposited on the slide and is evenly distributed by the 
spreading layer to the underlying layers. The fluid penetrates the reagent 
layer, which contains a dye that binds to the chemical to be measured 
from the sample. The binding results in a shift in wavelength of the 
reflectance maximum of the free dye. The colour complex that forms is 
measured by reflectance spectrophotometry. The amount of chemical-
bound dye is proportional to the concentration of the chemical being 
measured in the sample e.g. calcium. For low-density lipoprotein 
cholesterol (LDL-C), the kit is a dual chamber package instead of a plate 
and contains ready to use reagents. The first reagent selectively 
eliminates non-LDL-C. When the second reagent is added surfactants 
dissociate cholesterol from cholesterol esters and proteins and promote 
the reaction with cholesterol esterase and cholesteroloxidase. Hydrogen 
peroxide is a by-product, which is then dyed and measured 
spectrophotometrically at 600nm. 
 
Patients with increased levels of TG (>1.7 mmol/L), TC (>6.2 mmol/L), 
LDL-C (>4.13 mmol/L), decreased levels of HDL-C (<1.03 mmol/L) or 
receiving cholesterol-lowering therapy were characterised as 
dyslipidaemic (Expert Panel on Detection Evaluation and Treatment of 
High Blood Cholesterol in Adults, 2001). Patients with any of these 
measures were referred to the Head of Phlebotomy at the hospital and 





Plasma glucose was measured by the standardised procedure using the 
same VITROS® 5.1 FS chemistry system (Johnson and Johnson Inc., 
Langhorne, PA, USA) as described above and the same procedure as 
with cholesterol (but not LDL-C) was followed. Insulin was estimated from 
serum stored at -20°C. The method of detection is a solid phase two-site 
chemi-luminescence immunometric assay. The Immunolite 2000 insulin 
was used on the Immulite 2000 Analyser (Siemens Healthcare 
Diagnostics, Deerfield, IL, USA). This is a solid phase, competitive 
chemiluminescent enzyme immunoassay with an analytical range of 14.0-
2,165 pmol/L. Insulin resistance (IR) was evaluated from fasting glucose 
and insulin using the HOMA of IR, and defined as HOMA ≥2.5, presence 
of diabetes mellitus or use of anti-diabetic medication (Radikova, 2003). 
 
4.2.5 Cardiorespiratory fitness 
Cardiorespiratory fitness was assessed in a random subset of the 
randomised patients (n=25, intervention; n=25, usual care) via an exercise 
tolerance test. All exercise tolerance tests were performed on a treadmill 
using the validated Bruce test protocol (Bruce et al., 1963). The Bruce test 
was started at 2.74 km·h-1 (1.7 m·h-1) and at incline of 10% for three 
minutes. At three minute intervals the incline of treadmill increased by 2% 
and speed increase to 4.02, 5.47, 6.76, 8.05, 8.85, 9.65, 10.46, 11.26 and 
12.07 km·h-1 in each stage (10 stages in total), respectively. Ventilatory 
gas exchange was determined using a calibrated breath-by-breath system 
(Metalyzer 3B, CORTEX Biophysik GmbH, Leipzig, Germany) allowing 
continuous measurement of gas variables, including VO2, VCO2, minute 
ventilation (VE) and respiratory exchange ratio (RER). Moreover, during 
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the test heart rate was also monitored using a heart rate monitor and strap 
(Polar USA, Woodbury, NY). Testing was terminated when the participant 
reached voluntary exhaustion. The test was also discontinued if the 
participants showed signs of sudden paleness, change in heart rate, 
dizziness or cold sweat. Peak oxygen consumption was determined by 
taking the highest values during a 20-s period during the test. The 
assessment was conducted in controlled conditions in the cardiovascular 
laboratory of the Research and Development Unit of the hospital. 
 
4.2.6 Blood Pressure 
Prior to performing and three minutes after the exercise tolerance test, 
blood pressure (BP) was assessed three times on the brachial artery using 
a Datascope Accutorr Plus (Datascope, Montvale, NJ, USA), while the 
participant was resting in a seated position. Patients were given five 
minutes of sitting at rest before the first BP measurement was taken. The 
average of the three measurements is reported herein. Patients with a 
resting systolic BP of 140 mmHg or greater and/or diastolic BP of 90 
mmHg or greater and/or receiving antihypertensive medication were 
characterised as hypertensive (Williams et al., 2004).  
 
4.3 DATA MANAGEMENT AND ANALYSES 
For all studies data were inserted in purpose-designed spreadsheets 
(Microsoft Excel™ 2008) and audited for accuracy weekly. All data was 
exported for analysis to the IBM® Statistical Package for Social Sciences® 
(version 20.0 for Windows, SPSS, Inc., Chicago, IL, USA). Due to the 
complexity of the project several different analyses were used. These 
analyses are described in detail in the respective studies. 
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CHAPTER FIVE: STUDIES 
Study 5.1 has been accepted for publication in Health Promotion 
International. 
Study 5.2 has been published in International Journal of Environmental 
Research and Public Health, 2014, 11, pp. 5487-96. 
5.1 Physical activity levels and awareness of breast cancer risk 
factors and sufficiency of physical activity in NHS breast cancer 
screening programme attendees 
5.1.1 ABSTRACT 
Introduction: This study aimed to determine the physical activity levels 
and awareness of the influence of physical activity and overweight/obesity 
on breast cancer risk among NHS breast screening programme 
(NHSBSP) attendees.  
Methods: One hundred and eighty-eight (white British=95%; 
postmenopausal=80%) attendees completed a demographic and 
anthropometric data questionnaire, International Physical Activity 
Questionnaire (IPAQ) and awareness of breast cancer risk factors 
questionnaire. IPAQ data were reported as continuous measures (MET-
min·week-1) and as categorical variables (low, moderate and high 
activities).  
Results: The highest median physical activity levels were reported in the 
domestic physical activity domain (756 MET-min·week-1). Most participants 
were categorized as ‘moderately active’ (45%), while 30% were classified 
in the ‘high activity’ and 25% as ‘low activity’ categories. Almost a third of 
participants (30%) reported no leisure-time physical activity and 83% 
reported no vigorous physical activity. There was high awareness of the 
effects of physical activity (75%) and obesity (80%) on breast cancer risk. 
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No significant differences were found between physical activity categories 
and awareness that physical activity can reduce breast cancer risk 
(p>0.05). However, compared with moderate and high activity categories, 
participants in the ‘low activity’ category were significantly more likely to 
respond that they thought they achieved recommended physical activity 
levels (p<0.05).  
Conclusions: Participants who are unaware of their inadequate physical 
activity levels may have a less positive intention to increase physical 
activity levels. Practical strategies aimed to increase knowledge of the 
recommended physical activity guidelines and facilitate the achievement of 
these guidelines may be required for NHSBSP attendees. 
 
5.1.2 INTRODUCTION  
In the UK, female breast cancer had the highest incidence rate of all 
cancers, with an average European age standardised (AS) rate of 124 
cases per 100,000 population each year between 2007 and 2009 (ONS, 
2012). Breast cancer is second only to lung cancer as the cause of death 
from cancer in UK women (European AS mortality rate=26.1 and 31.5 per 
100,000, respectively) (ONS, 2012). Furthermore, the mortality of breast 
cancer increases proportionately with age (Walters et al., 2011).  
 
Most risk factors associated with breast cancer are not readily amenable 
to intervention (Hill et al., 1997; Sprague et al., 2008; Begum et al., 2009), 
but lifestyle factors such as physical inactivity and postmenopausal obesity 
are potentially modifiable (Vainio et al., 2002; Lahmann et al., 2005; 
Begum et al., 2009). There is strong evidence for an inverse association 
between physical activity and breast cancer risk (Monninkhof et al., 2007; 
288 
 
Friedenreich and Cust, 2008; Lynch et al., 2011), with physical activity 
leading to an average relative risk reduction (RRR) of 25% when 
comparing the most physically active to the least active women (Lynch et 
al., 2011). Obesity is a risk factor for postmenopausal breast cancer, and 
obesity at the time of breast cancer diagnosis is associated with adverse 
outcomes in terms of lower quality of life and both disease-free and overall 
survival (Irwin et al., 2011). Greater breast cancer risk reduction has been 
found in those with a low (≤22 kg∙m2) and moderate (22-25 kg·m2) body 
mass index (BMI) (RRR=27% and 24%, respectively) compared to those 
in the overweight (>25 kg·m2) and obese (>30 kg·m2) BMI ranges 
(RRR=18% and 1%, respectively) (Lynch et al., 2011). 
 
Such evidence makes it imperative that concerted and targeted efforts are 
undertaken to enhance physical activity and reduce overweight/obesity in 
women to decrease the risk of breast cancer. According to most 
behavioural change theoretical models, the intention or motivation to 
change is one of the most important predictors of actual change (Bandura, 
1986; Prochaska and DiClemente, 1983; Azjen and Fishbein, 1980). 
However, the intention or motivation to change is dependent on both the 
belief that a change in behaviour will reduce health risks and the extent to 
which an individual perceives his/her behaviour as ‘unhealthy’ (van Sluijs 
et al., 2007; Weinstein, 1980). Physical activity is a complex, 
multidimensional behaviour that occurs in a variety of different domains, 
which makes it difficult to assess the adequacy of one’s own activity level. 
Therefore, individuals who are not sufficiently physically active may not 
perceive themselves as such, incorrectly believing themselves to be 
active. As much as 60% of adults who do not meet recommended 
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guidelines for physical activity may overestimate their own level (van Sluijs 
et al., 2007). Furthermore, 27% of individuals who are unaware they are 
not meeting recommended guidelines report a positive intention to change 
behaviour compared to 43% among those who accurately assess their 
inactivity (van Sluijs et al., 2007). Therefore, those who are unaware they 
are insufficiently active may be less likely to change behaviour and may be 
less susceptible to health promotion strategies. Hence, the rationale of this 
current study was to assess whether breast screening attendee’s 
awareness of the effect of physical activity and overweight/obesity on 
breast cancer risk influenced their physical activity levels and whether 
participants were aware of the adequacy of their physical activity levels. 
 
The UK NHS Breast Screening Programme (NHSBSP) currently reaches 
75% of women between the ages of 47 and 73 y. Breast screening 
presents health professionals with many “teachable moments” that could 
be used to assess and raise, where necessary, awareness and promote 
changes in physical activity and weight management behaviours, and may 
offer an important opportunity to contribute to the reduction of the overall 
burden of breast cancer and other chronic non-communicable diseases 
(Fisher et al., 2007; Anderson et al., 2013). Despite this, at present, there 
is little data available regarding the levels of physical activity and 
awareness of breast cancer risk factors in NHSBSP attendees. Therefore, 
the aim of this study was to determine the amount of physical activity 
undertaken by women attending NHSBSP, their levels of awareness of the 
effects of physical activity and overweight/obesity on breast cancer risk 




5.1.3 METHODS  
Participants  
Over a four week period (April-May, 2009) women attending routine breast 
screening were invited by the mammography practitioner to take part in 
this cross-sectional study. All women attending a single mobile screening 
unit in the Black Country (West Midlands, UK) were eligible. A total of 188 
consecutive women attending the unit during the study period agreed to 
take part and provided informed consent after a verbal explanation. None 
of the women declined to participate. Ethical approval was obtained from 
Black Country NHS Research Ethics Committee in 2008. 
 
Measures and procedures 
After their routine screening mammogram, each participant completed two 
self-administered questionnaires; one was related to demographic 
characteristics while the other was a questionnaire designed by the 
research team, which assessed the participant’s awareness of the role 
that physical activity and overweight/obesity can play in breast cancer risk. 
Participants responded whether they believed physical activity and 
overweight/obesity “increased risk”, “decreased risk”, had “no effect” on 
risk, or that they “do not know”. Participants who responded that physical 
activity can result in a “decreased risk” of breast cancer were said to be 
aware that physical activity reduces breast cancer risk, and those who 
responded “increased risk” to the overweight/obesity awareness question 
were deemed to be aware that overweight/obesity can increase risk of 
breast cancer. In addition, after participants were informed of the current 
physical activity recommendation stating that “all adults should accumulate 
30 min or more of moderate-intensity physical activity on at least five days 
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each week”, participants were asked to respond “yes” or “no” to the 
following question; “do you think you do enough physical activity?” 
Participants were told that “enough physical activity” was defined as 
meeting the current physical activity recommendations. Participant’s 
physical activity levels were assessed using validated long form 
International Physical Activity Questionnaire (IPAQ-LF) (Craig et al., 
2003). IPAQ was administered during face-to-face interviews by the same 
specifically trained researchers (Hallal et al., 2010). Self-reported height 
and mass was used to calculate participants BMI.  
 
Statistical analysis 
Standard methods for the cleaning and treatment of IPAQ datasets were 
undertaken in accordance with IPAQ guidelines, which are available at 
http://www.ipaq.ki.se/scoring.pdf. Data that were normally distributed were 
reported as mean (±s), while data not normally distributed were expressed 
as median (interquartile range, IQR). Categorical data was expressed as 
number of responses/participants and percentages. The frequency of risk 
factors such as postmenopause, BMI 25 and over, non-parity, aged 30 
and over at birth of first child, family history of breast cancer, previous or 
current HRT use and alcohol consumption was recorded. 
 
For standardised evaluation of physical activity, the metabolic equivalent 
(MET) time was estimated. One metabolic equivalent was defined by 
Ainsworth et al. (2011) as the metabolic turnover of 3.5 ml oxygen per 
kilogram body mass per minute in males and 3.15 ml·kg-1·min-1 in females. 
The weighted MET-minutes per week were calculated as duration × 
frequency per week × MET intensity, which were summed across activity 
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domains to produce a weighted estimate of total physical activity from all 
reported activities per week (MET-min·wk-1) (Craig et al., 2003). Using 
MET-min·wk-1 enables aerobic activities of different types and intensities to 
be combined into a single measure of amount of activity, and allows the 
categorisation of participant’s physical activity. Physical activity categories 
were classified using the recommendations outlined in the IPAQ manual. 
Low activity represented individuals who do not meet the criteria for 
moderate and vigorous intensity categories (< 599 MET-min·wk-1). 
Moderate activity represented those who reported at least five days of 
moderate or vigorous intensity activities achieving a minimum of at least 
600 MET-min·wk-1. This minimum 600 MET-min·wk-1 is based on 
quantification of moderate-intensity physical activity as approximately 4 
METs. High activity represented achieving at least five days of moderate 
and vigorous intensity activities and a minimum of a least 3000 MET-
min·wk-1. The moderate activity category was used to identify those 
meeting current recommended guidelines for physical activity, that is, over 
a week, activity should add up to at least 150 minutes of moderate 
intensity activity in bouts of 10 minutes or more, e.g. 30 minutes on at 
least five days a week (Bull et al., 2010). In addition, BMI was recorded in 
a categorical score, classified into three levels "normal" (<25 kg·m2), 
"overweight" (25–29.9 kg·m2) and "obese" (≥30 kg∙m2).  
 
Chi-square analyses were conducted to compare demographic and 
behavioural characteristics of sufficiently active (moderate and high 
activity categories) versus insufficiently active (low activity category) 
participants, and awareness (correct answer vs incorrect answer) of 
effects of physical activity and overweight/obesity on breast cancer risk. 
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Comparisons between awareness of physical activity and 
overweight/obesity roles in breast cancer risk and physical activity 
categories (low=insufficient; moderate-high=sufficient) and BMI categories 
(“normal” vs. either “overweight” or “obese”) were analysed using chi-
square tests. In addition, chi-square analysis was conducted to compare 
the response (“yes” or “no” or “don’t know”) to the question “do you think 
you do enough physical activity?” to self-reported physical activity 
categories (low, moderate and high). Odds ratios were calculated from 2 x 
2 contingency tables for significant chi-square associations and was 
computed by OR=ad/bc. For example, the OR was the odds of a 
participant in the sufficient physical activity category answering “yes” to the 
“do you think you do enough physical activity?” question relative to the 
odds of a participant in the insufficient physical activity category answering 
“yes” to this question. Statistical analyses were performed using IBM® 
statistical Package for Social Sciences® for windows version 20.0; the 
level of significance was set at p<0.05. 
 
5.1.4 RESULTS 
Demographic details of participants are presented in Table 5.1.1. In 
summary, all of the women were aged 50 years or over (mean ± s; height 
= 1.6±0.1 m; mass = 70.7±14 kg; BMI = 26.9±5 kg·m2) and the majority of 
the sample were postmenopausal (85%; n=146/182), white (95%; 
n=178/188) and British (77.5%; n= 146/188). Most of the women were 
categorised as overweight/obese (58%). There were a greater number of 
parous women (86%; n=160/188) in the sample and of these women most 
had one or two children (76%; n=121/188) and were aged between 21 and 
30 years at the time of their first full term pregnancy (77%; n=122/188).  
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Table 5.1.1 Anthropometric, demographic, and lifestyle characteristics of 
the participants 
 Number of 
Participants 
Percentage 
• BMI (kg·m2) (n=142): 
o Obese (BMI=> 30) 
o Overweight (BMI=25-29.9) 
o Normal (BMI=18-24.9) 











• Ethnic Origin (n=188):  
o White British 
o Indian 
o Black Caribbean 
o White Irish 
o One each of other White 





























• Number of Children (n=186) 
o Nulliparous 
o 1-2 









• Age at birth of first child (n=160): 
o Under 20 
o 21 to 25 years 
o 26 to 30 years 









































• Alcohol Intake (n=188): 
o Do not drink alcohol 
o Drinks alcohol 
• Drink type drank mostly (n=132): 
o Wine 













• Smoking (n=188): 
o Currently/previously 
o No 
• Number of years smoking: 
o 1 to 15 years 
o 16 to 35 years 
o Over 35 years 
• Number of cigarettes per day: 
























There were an equal number (50%; n=94/188) of women who had 
previously or currently received hormone replacement therapy (HRT) as 
those who had never received it. Those with a history of HRT received it 
for a mean (s) duration of 80 (82) weeks. A minority (14%; n=27/188) of 
the sample had a family history of breast cancer. Over a quarter of women 
reported that they currently or have previously suffered from other medical 
conditions (27%; n=51/188), with hypertension (21%; n=39/188) being the 
most common. Almost three quarters (n=133/188) of the participants 
reported that they drank alcohol and a minority (12%; n=23/188) of the 
participants were current or ex-smokers.  
 
The majority of participants (68%, n=128/188) reported three or more of 
the following risk factors, postmenopausal, BMI 25 and over, non-parous, 
aged 30 years and over at birth of first child, positive family history of 
breast cancer, previous or current HRT usage, alcoholic drinks consumer 
and insufficient physical activity. Only two participants had none of these 
risk factors. 
 
The median and IQR for each of the IPAQ variables are presented in table 
5.1.2. The greatest amount of physical activity was reported in the 
domestic physical activity domain (median, IQR=756, 1232 MET-min·wk-
1). There was a relatively low level of leisure time physical activity (median, 
IQR=330, 1020 MET-min·wk-1). Almost a third of women (30%; n=57/188) 
reported no leisure-time activity. The majority of participants (83%; 
n=155/188) reported no vigorous physical activity. The application of the 
IPAQ criteria for categorical scores revealed that 25% (n=46/188) of the 
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participants were classified as low activity, while 45% (n=85/188) and 30% 
(n=57/188) were categorised as moderate and high activity, respectively. 
 
Table 5.1.2 Median and IQR physical activity levels of women attending 
NHSBCSP 
IPAQ continuous variables Median IQR 
Overall physical activity (MET-min·wk-1) 
Work physical activity (MET-min·wk-1) 
Transport physical activity (MET-min·wk-1) 
Domestic physical activity (MET-min·wk-1) 
Leisure physical activity (MET-min·wk-1) 
Walk physical activity (MET-min·wk-1) 
Moderate physical activity (MET-min·wk-1) 
Vigorous physical activity (MET-min·wk-1) 
Over physical activity (min) 
Walk physical activity (min) 
Moderate physical activity (min) 


























We conducted chi-square analyses to compare demographic and 
behavioural characteristics of participants who were sufficiently active 
(moderate to high activity) versus those insufficiently active (low activity). 
Only family history was significantly different between the two physical 
activity categories (χ2 (1) =4.05, p=0.04). This appeared to represent the 
fact that based on the odds ratio; the odds of participants being sufficiently 
active were 38.79 times higher in those with a family history of breast 
cancer compared to those with no family history. No significant differences 
were found between any other demographic or behavioural characteristic, 
when comparing sufficiently active participants with those insufficiently 
active. No significant differences in the above characteristics were 
observed when the high activity category was compared to a combined 
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low and moderate activity category or when those with a “normal” BMI 
were compared to those classified as either “overweight” or “obese”. 
 
The majority (75%; n=136/188) of participants responded that they 
believed physical activity decreases the risk of breast cancer, while 25% 
believed that it either increases, had  no effect, or did not know whether 
physical activity can influence breast cancer risk (see table 3). Similarly, 
most (80%; n=137/188) of the women believed that being overweight or 
obese increases the risk of breast cancer, only 20% (n=38/188) believed 
that being overweight or obese either decreases risk, had no effect, or did 
not know whether overweight/obesity affects breast cancer risk (see table 
5.1.3). 
 
We analysed differences in awareness across demographic and 
behavioural characteristics. There was a significant association between 
family history and awareness of physical activity effects on breast cancer 
risk (χ2 (1)=7.33, p=0.005). Based on the odds ratio, the odds of 
participants being aware of effects of physical activity were 9.29 times 
higher in those with a family history of breast cancer compared to those 
with no family history. Similarly, family history was significantly associated 
with awareness of effects of overweight/obesity on breast cancer risk (χ2 
(1)=6.61, p=0.01). According to the odds ratio, the odds of participants 
being aware of effects of overweight/obesity were 7.67 times higher in 
those with a family history of breast cancer compared to those with no 
family history. No significant differences in awareness were observed 




Table 5.1.3 Participant’s awareness of physical activity and 





No effect Don’t know 
Physical activity 
(n=188) 
136 (75) 3 (1) 14 (8) 29 (16) 
Overweight/obesity 
(n=188) 
3 (1) 147 (80) 5 (3) 29 (16) 
 
Chi square analysis using three categories of physical activity status 
revealed no significant associations between awareness of the effects of 
physical activity and overweight/obesity on breast cancer risk. Similar 
findings were observed when the high activity category was compared to a 
combined low and moderate activity category. There was no association 
between BMI categories (normal and overweight/obese) and awareness of 
obesity as a breast cancer risk factor.  
 
Table 5.1.4 Responses to the question “do you think you do enough 
physical activity?” 
 Do you think you do enough physical activity? 
Physical activity 
Categories 
Yes No Don't 
Know 
Total 
Low physical activity 33 6 3 42 
Exp 25.2 10.9 5.9  
Moderate physical activity 51 21 16 88 
Exp 52.8 22.83 12.37  
High physical activity 27 21 7 55 
Exp 33 14.27 7.73  
Total 111 48 26 185 
Exp=Expected assuming independence (null-hypothesis) 
χ2=11.65, df=4, p-value=0.02 
 
Chi-square analysis using three categories of physical activity (low, 
moderate and high) revealed significant associations between physical 
activity categories and the response to the question “do you think you do 
enough physical activity?” (χ2 (4)=11.65, p=0.02). Those in the low 
physical activity category were more likely to respond that they thought 
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they do enough physical activity, while conversely those in the high 
physical activity were more likely to respond that they thought they did not 
do enough physical activity (see table 5.1.4).  
 
5.1.5 DISCUSSION  
To the authors’ knowledge, this current study is the only study that has 
assessed the levels of physical activity and awareness of the influence of 
physical activity and overweight/obesity on breast cancer risk amongst 
breast screening populations in the UK. Although, the majority of the 
women were categorised into the moderate and high physical activity 
categories (45% and 30%, respectively), a quarter of the women were 
classified in the low activity group. Moreover, a relatively large percentage 
(30%) of women reported no leisure-time physical activity and very few 
participants reported any vigorous physical activity (17%). In addition to 
this, the majority of participants (58%) were overweight/obese according to 
their self-reported BMI. Of the demographic and behavioural 
characteristics, only associations were found between physical activity 
levels and family history of breast cancer. Participants with a family history 
of breast cancer were more likely to be sufficiently active than those with 
no family history. The majority of participants were aware of the effects of 
physical activity (75%) and overweight/obesity (80%) on breast cancer 
risk. When comparing awareness across demographic and behavioural 
characteristics, significant differences in awareness were found only for 
family history of breast cancer. Those with a family history were more 
likely to be aware of the effects of physical activity and overweight/obesity 
on breast cancer risk than those with no family history. No differences in 
awareness of the effects of physical activity and overweight/obesity on 
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breast cancer risk were found between physical activity categories and 
BMI categories. However, significant associations were found between 
physical activity categories and whether participants thought they were 
doing enough physical activity. Participants in the low physical activity 
category were more likely to respond that they thought they were doing 
enough physical activity, and those in the high physical activity category 
were more likely to respond that they thought they were not doing enough 
physical activity. 
 
The dominant physical activity reported by the participants was domestic 
physical activity in the current study. This type of activity has been 
consistently linked with reduced breast cancer risk (Friedenreich et al., 
2002; Lahmann et al., 2005; Lynch et al., 2011). However, in the present 
cohort, the number of women who did not report any leisure-time physical 
activity was a concern. Research reveals that leisure-time physical activity 
can attribute to the largest reductions in breast cancer risk (Monninkhof et 
al., 2007; Friedenreich and Cust, 2008). Lynch and colleagues (2011) in a 
recent review of the epidemiological literature reported that greater 
decreases in breast cancer risk were observed with greater duration of 
recreational physical activity. In addition, there was also a low incidence of 
vigorous physical activity in this current study. Vigorous physical activity 
has been associated with a greater risk reduction in breast cancer 
compared to moderate physical activity (Gammon et al., 1998; 
Friedenreich and Cust, 2008; Lynch et al., 2011). Dallal and colleagues 
(2007) reported that long-term strenuous physical activity (>5 h·wk-1 per 
year) is inversely associated with both invasive and in situ breast cancer 
risk. Leitzmann and co-workers (2008) observed that vigorous intensity 
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physical activities almost entirely contributed to a reduction in breast 
cancer risk, although, these beneficial effects of vigorous physical activity 
were limited to those with a normal BMI (18-25 kg·m2). Our findings of a 
lack of reported leisure-time and vigorous physical activity in a relatively 
large number of participants suggests that these participants are not 
currently exposed to the possible greater breast cancer reductions 
associated with these forms of physical activity. In addition, a high 
prevalence of overweight/obesity suggests that the majority of our sample 
would benefit from both physical activity and weight management 
guidance to promote breast cancer risk reducing behaviours. 
 
Although, the majority of the screening population were aware that 
physical activity reduces breast cancer risk and overweight/obesity 
increases risk, there were still a sizable percentage of women who 
responded “no effect” or “don’t know” that physical activity or being 
overweight/obese can influence breast cancer risk (24% and 19%, 
respectively). Despite this high awareness of the effects of physical activity 
and overweight/obesity on breast cancer risk, there was no association 
between the awareness of these factors and physical activity and BMI. 
Therefore, the participants who were aware that physical activity can 
reduce the risk of breast cancer were no more active than those who were 
unaware. Similarly, overweight/obese women were no more or less aware 
of overweight/obesity as a breast cancer risk factor. This finding is 
consistent with the general view that awareness and knowledge alone are 
insufficient for promotion and maintenance of long-term behavioural 
change (Carleton et al., 1996; Marcus et al., 2006; Williams et al., 2008). 
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Although, they do represent an important first step towards a future 
change in behaviour (Marcus et al., 2006; Ferrari et al., 2007).  
 
Women with a family history of breast cancer were more likely to be 
sufficiently active and aware of physical activity and obesity/overweight 
effects on breast cancer risk than those without. There is evidence that 
most women with a family history of breast cancer are aware of their own 
increase in risk and, indeed, tend to overestimate this risk (Audrain-
McGovern et al., 2003). In support of our finding that women with a history 
of breast cancer were more active than those without, Ochoa and 
colleagues (2010) found that women with a family history of breast cancer 
had twice the probability of performing more intense physical exercise. 
However, other studies (Townsend et al., 2013; Madlensky et al., 2005) in 
contrast have not shown differences in health behaviours between those 
with and without a family history of breast cancer.  
 
The women in our sample who were aware of the benefits of physical 
activity but were not sufficiently active may not have been aware that their 
physical activities were low. We found that participants in the low physical 
activity category were significantly more likely to perceive that they were 
performing sufficient amounts of physical activity. This finding is consistent 
with previous research that has shown that adults who are not currently 
meeting recommended guidelines overestimate their own levels of 
physical activity (Ferrari et al., 2007). Participant’s awareness of whether 
they were doing sufficient physical activity was poor regardless of physical 
activity category. This finding is perhaps unsurprising given that a recent 
survey reported that only 6% of men and 9% of women could correctly 
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define the minimum recommended targets, the majority underestimated 
(69% men and 68% women) or overestimated (25% men and 23% 
women) the amount of physical activity recommended (Townsend et al., 
2012). Furthermore, evidence suggests that participants who are not 
aware of their inadequate physical activity level have a less positive 
intention to increase their level of physical activity than those who rate 
their own physical activity level as low (Ronda et al., 2001). People may 
only consider changing their behaviour when they consider their behaviour 
to be inappropriate and is potentially putting their health at risk, which may 
help to explain the findings that women with a family history of breast 
cancer engage in more intense exercise than women without a family 
history (Ochoa et al., 2010; Cavill and Bauman, 2004). Those at greatest 
risk of health problems may fail to recognise their inactivity and therefore, 
are unlikely to perceive a need to change and may be less susceptible to 
health promotion campaigns. Alternatively, some respondents with a high 
level of awareness and knowledge who do not engage in sufficient 
physical activity levels may lack the necessary skills or require additional 
information and/or support on how to make behavioural changes (Carleton 
et al., 1996). Therefore, strategies to increase that awareness of physical 
activity benefits may not be necessary; rather awareness of the 
recommended physical activity guidelines and the promotion of strategies 
that facilitate the achievement of these guidelines may be required. 
 
This study has a number of limitations that need to be considered when 
reviewing these results. Self-report measures of physical activity which 
require participants to recall past activity, such as IPAQ, are a subjective 
means of estimating individual physical activity levels, and are reliant on 
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the individuals’ ability to remember levels of exposure (Watkinson et al., 
2010). Over reporting of physical activity, especially of time and intensity 
and activities in the occupational and domestic domains may be a problem 
in this type of assessment (Weinstein et al., 1998). There is evidence to 
suggest that up to 60% of adults who do not meet recommended 
guidelines for physical activity overestimate their own level of physical 
activity (van Sluijs et al., 2007).  
 
The number of women categorised in the “moderate” and “high” physical 
activity categories were surprisingly high compared to the much lower 
levels of physical activity reported in the Health Survey for England in 
2008 (Roth, 2009). Using the “moderate” category of the IPAQ to identify 
those meeting current recommended guidelines for physical activity may 
be troublesome. The creators of the IPAQ acknowledge challenges with 
interpreting these physical activity categories (Bauman et al., 2009). 
Respondents categorised as moderately active are those whose total 
physical activity exceeds 600 MET-min·wk-1 or those who reported 30 min 
of “moderate” (4-MET intensity) activity or equivalent at least 5 days a 
week. This category is described as “moderate” in the IPAQ scoring 
protocol because it would be achieved by most adults through background 
activity, such as occupational activity, gardening and housework, and 
family care that adults accumulate daily. Bauman and colleagues (2009) 
recommend using the “high” IPAQ category to account for this limitation in 
using self-report total activity scores to identify those meeting physical 
activity recommendations. Use of the “high” category to identify those 
meeting current recommended guidelines for physical activity would have 
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brought the results in line with the findings of the Health Survey for 
England (Roth, 2009).  
 
We used a self-designed questionnaire to assess participant’s awareness 
of physical activity and overweight/obesity and the sufficiency of their 
physical activity. The two questions were not validated and therefore, may 
be at risk of response bias if there was a lack of comprehension on the 
part of respondents. The use of vague and ambiguous terms imposes a 
cognitive burden on respondents, and thus increase the risk of questions 
being interpreted idiosyncratically by respondents, which in turn can 
introduce a systematic bias into the questionnaire data (Sturgis and Smith, 
2010). Systematic bias can lead to measurement error which may result in 
misclassification. Therefore, we attempted to avoid the use of vague and 
ambiguous terms in the two questions and explained the meaning of the 
questions to respondents before completion.    
 
The use of self-reported BMI has been criticised as an inappropriate tool 
for precise measures of obesity prevalence (McAdams et al., 2007). The 
available literature consistently points toward an underreporting of mass 
and overreporting of height, leading to an underreporting of BMI (Ziebland 
et al., 1996; Nawaz et al., 2001; Connor Gorber et al., 2007; McAdams et 
al., 2007; Elgar and Stewart, 2008; Bes-Rastrollo et al., 2011). However, 
there is evidence that self-reported BMI values tend to overestimate 
measured BMI values at the low end of the BMI scale (<22 kg·m2) and 
underestimate BMI values at the high end, particularly at values > 28 
kg·m2 (Stommel and Schoenborn, 2009). In this current study, it is likely 
that there were fewer participants with BMI values in the lower end of the 
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scale than the higher end, and considering the general trend in the 
literature towards an underestimation of BMI, it is perhaps more probable 
that our mean self-reported BMI represents an underestimation rather than 
an overestimation. 
 
The ability to generalise our findings to the entire NHSBSP population is 
limited due to its relative small sample size and the use of a single mobile 
screening unit based at one site in the West Midlands. Currently, there is 
limited demographic data on breast screening attendees to compare our 
sample against, so it was not possible to assess how representative the 
sample was post-hoc. However, the BMI of this current sample was similar 
to self-reported BMI in a previous study of breast screening populations 
(Fisher et al., 2007) and the 58% prevalence of overweight/obesity in the 
current study was also close to the 60% of adult women in the West 
Midlands reported in The Health Survey for England in 2010 (Joint Health 
Surveys Unit, 2011). 
 
 Nevertheless, our findings can only be generalised to breast cancer 
screening attendees within the Black Country area of the West Midlands, 
UK. Future larger scale multi-site studies are required to confirm the 
findings of this current study. 
 
5.1.6 CONCLUSIONS 
To the authors’ knowledge, this current study is the only study that has 
assessed the levels of physical activity and awareness of the influence of 
physical activity and overweight/obesity on breast cancer risk amongst 
breast screening populations in the UK. In this current study, a relatively 
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large number of women reported no leisure-time or vigorous physical 
activity which are important lifestyle choices to reduce the risk of breast 
cancer. Most of the participants were aware that physical activity can 
reduce breast cancer risk and overweight/obesity can increase risk, but no 
differences were found between awareness and physical activity and self-
reported BMI levels. However, participants who performed low physical 
activity were unaware that they were not performing sufficient physical 
activity. Poor awareness of inadequate physical activity levels has been 
associated with less positive intention to change behaviour and increased 
physical activity levels. Therefore, this population may benefit from 
strategies aimed to increase awareness and knowledge of the 

















5.2 Physical activity behaviour of women attending breast screening, 
receiving chemotherapy and post-breast cancer treatment; a cross-
sectional study 
5.2.1 ABSTRACT 
Introduction: A lack of physical activity is a well-recognised risk factor in 
the development of breast cancer and evidence-based research on the 
impact of physical activity on breast cancer survival is consolidating. 
However, evidence reveals that breast cancer survivors have low levels of 
physical activity, suggesting the need of targeted interventions to enhance 
the physical activity behaviour of breast cancer survivors. Unfortunately, 
there is lack of data from the UK about the physical activity behaviours of 
women at various stages of diagnosis and treatment of breast cancer. 
Therefore, the aim of the present study was to assess physical activity 
levels in women at different stages of breast cancer pathway.  
Methods: A convenient sample of patients was selected at various stages 
of presentation and treatment of breast cancer. Patients attending breast 
screening for NHSBSP (n=188), post-operative patients attending for 
chemotherapy (n=41) and breast cancer patients within one year’s post-
treatment (n=80) were invited to take part in this cross-sectional study.  
Results: Based on the odds ratio, the likelihood of a chemotherapy 
participant not meeting physical activity guidelines (i.e., being in the low 
activity category) were three times higher than the odds of a NHSBPS 
attendee not meeting physical activity guidelines, and compared to post-
treatment participants, the chemotherapy patient’s odds of not meeting 
physical activity guidelines was four times higher. The odds of NHSBPS 
attendees being in the high activity category compared to the moderate 
category were three times higher than that of a post-treatment participant. 
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Conclusion: The current study suggests the need to establish robust 
physical activity interventions to enhance the physical activity behaviour of 
breast cancer survivors. 
 
5.2.2 INTRODUCTION 
Worldwide, breast cancer is the most frequently diagnosed cancer and the 
leading cause of cancer death among females (Jemal et al., 2011). In the 
UK, female breast cancer had the highest incidence rate of all cancers, 
with an average European age standardised rate of 124.2 cases per 
100,000 population each year between 2007 and 2009 (ONS, 2012). As a 
large consequence of early detection and improved treatment strategies, 
UK breast cancer mortality rates are falling and in turn survival rates are 
improving (Nur et al., 2011) and thus there are now more breast cancer 
survivors than ever before. However, due to the chronic side-effects of 
breast cancer treatment, survivors may require diagnostic, therapeutic, 
supportive or palliative services many years post-diagnosis, which poses a 
major burden to already stretched healthcare resources. Therefore, 
interventions are required that can not only reduce the risk of developing 
breast cancer, but in addition, can benefit breast cancer survivors. 
 
Lack of physical activity is a well-recognised risk factor in the development 
of breast cancer and evidence on the impact of physical activity on breast 
cancer survival is consolidating (World Cancer Research Fund/American 
Institute for Cancer Research, 2009). In prospective studies, an average 
25% reduction in the risk of developing breast cancer was seen in the 
most physically active women compared to the least active women while 
this risk reduction is shown to be dose-dependent (Lynch et al., 2011). 
310 
 
Evidence also suggests that achieving recommended physical activity 
levels can improve disease-specific mortality after breast cancer diagnosis 
(Beasley et al., 2012). In addition, a recent Cochrane review demonstrated 
that physical activity can significantly improve the quality of life of breast 
cancer survivors (Mishra et al., 2012). However, despite these positive 
effects of physical activity, evidence reveals that breast cancer survivors 
have low levels of physical activity and many women decrease their 
physical activity following diagnosis (Irwin et al., 2003; Irwin et al., 2004). 
As such, targeting behaviours that may increase levels of physical activity 
may be beneficial for breast cancer patients. Unfortunately, there is a lack 
of data from the UK about the physical activity behaviours of women at 
various stages of diagnosis and treatment of breast cancer. Therefore, the 
aim of the present study was to assess physical activity levels in women at 
different stages of the breast cancer pathway, that is, during breast 
screening (i.e. pre-diagnosis of breast cancer), during chemotherapy and 
within one year post- breast cancer treatment. 
 
5.2.3 METHODS 
A convenience sample of patients at various stages of presentation and 
treatment of breast cancer was selected. Patients attending breast 
screening for NHSBSP (n=188), post-operative patients attending for 
chemotherapy (n=41) and breast cancer patients within one year’s post-
treatment (n=80) were invited to take part in this cross-sectional study. 
The chemotherapy patient group were recruited from breast clinics by the 
consultant breast surgeon and consultant oncologist to take part in an 
audit of physical activity. This required permission from the head of 
Research and Development at the hospital but not ethics approval. 
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Participants within each group completed an assessment which included 
demographics, physical activity questionnaires and anthropometric 
measurements. The height and mass of patients receiving chemotherapy 
and the patients within one-year post-treatment were measured directly in 
breast clinics at Russells Hall Hospital, Dudley. The assessment of the 
breast cancer screening attendees was carried out in a mobile screening 
unit located in Sandwell, West Midlands, and because mass and height 
could not be measured directly the self-reported height and mass were 
taken from these participants. Participant’s height and mass were then 
used to calculate BMI. Each participant was facilitated to complete the 
validated long form International Physical Activity Questionnaire (IPAQ) 
(Craig et al., 2003). The IPAQ assessed moderate and vigorous physical 
activity in four life domains: occupational, active transportation, domestic 
and leisure-time, and walking in the occupational, active transport and 
leisure-time domains. IPAQ was administered during face-to-face 
interviews by specifically trained researchers (Hallal et al., 2010). 
 
Physical activity categories were classified based on IPAQ manual 
recommendations (http://www.ipaq.ki.se/scoring.pdf). Using MET-min·wk-1 
as a means to combine aerobic activities of different types and intensities 
into a single measure of amount of activity, the IPAQ physical activity 
categories allow the categorisation of individuals into those who are 
meeting the current recommended physical activity guidelines (i.e. a ≥150 
minutes of moderate-intensity physical activity per week) and those who 
are not (i.e. <150 min/week) (Bull and the Expert Working Groups, 2010). 
The IPAQ categorises physical activity into low (not achieving 
recommended levels), moderate and high activity categories. Based on 
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recent recommendations (Bauman et al., 2009), separate analysis were 
included using either moderate-to-high or high activity category alone to 
identify those meeting recommended physical activity guidelines 
 
Statistical analysis 
The physical activity data were explored to identify outliers. Outliers were 
identified by converting all scores to z-scores. Z-scores greater than 3.29 
were classed as outliers. All outliers above this score were converted to 
one unit above the next highest score with a z-score below 3.29 
(Tabachnik and Fidell, 1996). The distribution of all continuous outcomes, 
including body mass, BMI, IPAQ MET-min·wk-1 scores (work, active 
transport, domestic and leisure domain totals, walk, moderate, vigorous 
and overall physical activity) and IPAQ time variables (walk, moderate, 
vigorous, and overall physical activity time) were assessed. Distributions 
of these data were explored by first observing histograms and P-P plots 
for each variable. The z-score of skewness (zskewness=skewness-
0/SEskewness) and kurtosis (zkurtosis=skewness-0/SEkurtosis) was then 
calculated for each variable, a z-score of greater than 1.96 was used to 
signify significant skewness and kurtosis, and therefore. If a variable’s z-
scores were lower than 1.96, that variable was deemed to be normally 
distributed. Data that was normally distributed were reported as mean (±s), 
while data not normally distributed were expressed as median (IQR). 
Height differences (only normally distributed variable) between groups 
were analysed with one-way Analysis of Variance (ANOVA) using 
Bonferoni post-hoc analysis for individual comparisons. Kruskal-Wallis 
tests were performed on all other variables of interest. These tests were 
analysed post hoc using the critical difference method as described by 
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Siegel and Castellan (1988). The level of significance was set at p<0.05 
for between groups analysis. 
 
Physical activity categorical data were expressed as number of 
participants and percentages, and were analysed via χ2 analysis. We first 
compared the number of participants in the three physical activity 
categories between the three groups. If significant associations were 
found, we planned a number of comparisons to identify which 
comparisons were significant. There were nine planned comparisons, 
including the number of participants in the low activity category vs. 
moderate activity plus high activity category, number of participants in the 
high activity category vs. low activity plus moderate activity category, and 
the number of participants in the moderate activity vs. high activity 
category in the NHSBSP participants vs. the chemotherapy patients, the 
NHSBSP participants vs. the post-treatment patients, and the 
chemotherapy patients vs. the post-treatment patients. In order to counter 
the inflation of type I error caused by multiple comparisons, a Bonferoni 
correction was applied to the alpha level. In this case we planned nine 
comparisons, which gave us an alpha level of p<0.0056 (i.e. 
α 0.05/9=0.0056). Statistical analyses were performed using IBM® 




Characteristics of the participants in each group are presented in table 
5.2.1. In brief, there was a slightly larger percentage (42%) of participants 
with a normal BMI (18-24.9 kg·m2) in the NHSBPS attendees compared to 
the chemotherapy and post-treatment group. All of the groups had a 
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similar majority of white British participants. There were less 
premenopausal women in the NHSBPS group compared to the other two 
groups. In addition, a larger percentage of the post-treatment group was 
current or previous smokers compared to the other two groups.  
 









 N % N  % N  % 
BMI (kg·m2)* 
o Obese (BMI= > 30) 
o Overweight (BMI=25-
29.9) 
o Normal (BMI=18-24.9) 






































Ethnic Origin  
o White British 
o Pakistani 
o Indian 
o Black Caribbean 
o White Irish 
















































































































































































Key: NR=not reported 
* NHSBSP participants’ BMI was computed from self-reported height and mass 
† For post-treatment participants premenopausal status was determined as those 
participants who were currently or recently menstruating  
ǂ  Figure represents those participants who were employed, both part-time and 
full-time, no separate figures were available for each  
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The descriptive statistics of the anthropometric and physical activity 
variables for each group are presented in table 5.2.2. There were no 
significant differences in height (p=0.077), body mass (p=0.626) or BMI 
(p=0.854) between the participant groups. Kruskal-Wallis tests revealed 
significant differences in overall (p<0.01) (Figure 5.2.1), domestic 
(p<0.01), leisure (p<0.01), moderate (p<0.01) and vigorous (p<0.05) 
physical activity (MET-min·wk-1), and overall (p<0.05), moderate (p<0.01) 
and vigorous (p<0.05) physical activity time (min) between groups. 
 
Post-hoc analysis revealed significantly lower overall (p<0.001), domestic 
(p<0.001), leisure (p<0.001) and moderate (p<0.001) physical activity 
(MET-min·wk-1) and overall (p<0.01) and moderate (p<0.001) physical 
activity time (min) in the breast cancer patients undergoing chemotherapy 
compared to the NHSBSP participant group. The chemotherapy 
participants also performed significantly less overall (p<0.001), domestic 
(p<0.001), leisure (p<0.001), moderate (p<0.05) and vigorous (p<0.01) 
physical activity (MET-min·wk-1) and overall (p<0.01), moderate (p<0.01) 
and vigorous (p<0.05) physical activity time (min) than the post-treatment 
participant group. The post-treatment breast cancer survivors performed 
significantly less overall, domestic (p<0.05) physical activity (MET-min·wk-




Table 5.2.2 Mean ± s or median (interquartile range) for anthropometric measures and physical activity (PA) variables for 
NHSBPS participants, breast cancer patients undergoing chemotherapy, and breast cancer patients within one-year post-
treatment (PA in MET-min·wk-1 unless stated otherwise) 
 NHSBSP Chemotherapy Post-treatment   
Variable N Median (IQR) N Median (IQR) N Median (IQR) F/H statistic p-value 
Height (m) mean ± s 179 1.63 ± 0.06 34 1.63 ± 0.07 80 1.61 (0.07) 3.494 0.077 
Body mass (kg) 145 68.9 (19.6) 34 70.0 (21.6) 80 67.7 (14.2) 0.937 0.626 
BMI (kg∙m2) 143 26.4 (7.3) 34 27.5 (5.3) 80 26.0 (6.1) 0.315 0.854 
Overall PA 188 1689 (2345)* 41 933 (2127)† 80 1463 (1501)ǂ 12.286 0.002 
Work PA  188 0 (0) 41 0 (0) 80 0 (0) 0.329 0.848 
Active transport PA 188 66 (387) 41 50 (479) 80 132 (264) 1.133 0.567 
Domestic PA  188 774 (1281)* 41 297 (897)† 80 541 (987)ǂ 14.52 0.001 
Leisure PA 188 330 (1031)* 41 0 (314)† 80 350 (693) 11.253 0.004 
Walk  188 396 (974) 41 297 (693) 80 396 (565) 0.838 0.658 
Moderate PA  188 965 (1612)* 41 396 (1370)† 80 693 (1060) 17.642 0.000 
Vigorous PA 188 0 (0) 41 0 (0)† 80 0 (0) 6.059 0.048 
Overall PA time (min) 188 420 (571)* 41 270 (602)† 80 416 (390) 7.366 0.025 
Walk time (min) 188 120 (295) 41 90 (210) 80 120 (171) 0.838 0.658 
Moderate PA time (min) 188 235 (300)* 41 120 (385)† 80 178 (297)ǂ 11.679 0.003 
Vigorous PA time(min) 188 0 (0) 41 0 (0)† 80  0 (0) 5.992 0.049 
Key: * Significantly higher in the NHSBPS group vs. the chemotherapy group;  
† Significantly lower in the chemotherapy group vs. the post-treatment group;  




Figure 5.2.1 Box-plots (showing minimum value, 1st quartile, median, 3rd quartile 
and maximum values excluding outliers) for overall physical activity (MET-min·wk-
1) of NHSBPS attendees, chemotherapy breast cancer patients and post-
treatment breast cancer survivors (circles above each boxplot represent values 
that are 1.5 IQRs above the 3rd quartile) 
 
Figure 5.2.2 Percentage of participants in each physical activity category 
in the NHSBPS attendees, chemotherapy breast cancer patients and post-




According to IPAQ physical activity categories, there was a higher 
proportion of participants (20 out of 41) categorised as low activity in the 
chemotherapy participant group compared to the NHSBSP group (44/188) 
and the post-treatment group (15/80) (Figure 5.2.2). A greater proportion 
of participants in the NHSBPS participant group were in the high activity 
category (50/188) compared to the chemotherapy and post-treatment 
groups (7/41 and 10/80, respectively), while a larger proportion of the 
post-treatment group were categorised as moderate activity (55/80) 
compared to the NHSBSP and chemotherapy groups (14/41 and 94/188, 
respectively). 
 
There was a significant association between the population groups and 
the categories of activity χ2 (4) =22.887, p<0.001. Post-hoc analysis with a 
Bonferoni correction applied (p<0.0056) revealed that chemotherapy 
patients were more likely to be categorised as low activity (i.e. not meeting 
recommended physical activity guidelines) than moderate or high category 
compared to the NHSBSP attendees (p=0.001) and post-treatment breast 
cancer patients (p=0.001), while post-treatment patients were less likely to 
be categorised in the high category than the moderate category compared 
to the NHSBPS participants (p=0.004). When we categorised those only in 
the high category as meeting recommended physical activity guidelines 
we found no association between participant groups. 
 
 Based on the odds ratio, the odds of a chemotherapy participant not 
meeting physical activity guidelines (i.e. being in the low activity category) 
were 3.1 times higher than the odds of a NHSBPS attendee not meeting 
physical activity guidelines, and compared to post-treatment participants, 
319 
 
the chemotherapy patient’s odds of not meeting physical activity 
guidelines was 4.1 times higher. The odds of NHSBPS attendees being in 
the high activity category compared to the moderate category were 2.9 
times higher than that of a post-treatment participant.  
 
5.2.5 DISCUSSION  
Results revealed that women receiving chemotherapy for breast cancer 
performed significantly lower physical activity in a number of IPAQ 
domains compared to the women attending NHS breast screening, and 
breast cancer patients who were within one year post-treatment. The post-
treatment breast cancer patients also performed significantly less physical 
activity compared to the breast screening participants. Chemotherapy 
patients were less likely to be meeting the recommended guidelines when 
compared to the other two groups.  
 
The finding of relatively low levels of physical activity in the two breast 
cancer patient groups is supported by past research. Previous studies 
have reported low levels of physical activity in patients receiving 
chemotherapy (Clark et al., 2007; Demark-Wahnefried et al., 1997), and 
have ascribed this finding largely to the side-effects of treatment, and 
treatment-related fatigue in particular (Clark et al., 2007). In the US, Irwin 
and colleagues (2004) surveyed the self-reported physical activity levels of 
806 breast cancer patients within three years post-diagnosis, and found 
that when household and gardening activities were excluded, only 32% of 
breast cancer survivors achieved recommended levels of physical activity. 
Similarly, in the current UK based study there were relatively few 
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participants in the post-treatment group who reported high moderate-to-
vigorous activity (i.e. categorised as high activity). 
 
Although, it was not possible to ascertain in this current study, previous 
studies comparing breast cancer patients pre-diagnosis physical activity 
levels to their post-diagnosis levels, have found decreases in physical 
activity from pre- to post-treatment (Irwin et al., 2003; Littman et al., 2010). 
In a prospective cohort study (Irwin et al., 2003) that compared the self-
reported physical activity of 812 breast cancer patients, reported an 11% 
decrease in total physical activity (hours/week) from pre- to post-diagnosis 
in women treated for radiation and chemotherapy. Subsequent studies 
have also found a similar decrease in physical activity in the 12 months 
after diagnosis relative to before diagnosis (Littman et al., 2010). These 
observed decreases have been attributed to persistent negative side-
effects of breast cancer treatment including fatigue, nausea, and pain 
(Hartvig et al., 2006; Schwartz, 2000). Consistent with the findings of the 
current UK study, the results of the above US-based studies suggest that 
pre-breast cancer diagnosis physical activity levels are higher than the 
physical activity levels of patients post-diagnosis. 
 
However, while the general finding in the literature supports lower in 
physical activity in pre-diagnosis to during treatment to post-treatment 
breast cancer populations, a recent finding from a Swedish study suggests 
that this may not be true for all women (Johnsson et al., 2013). The 
authors (2013) observed that breast cancer patients who had been 
physically active before their cancer diagnosis and women who had 
received information about physical activity were more physically active 
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during chemotherapy. Therefore, further research is required to establish 
how pre-breast cancer diagnosis physical activity along with other possible 
factors can mediate the levels of physical activity post-treatment. 
 
Our study has several limitations. As is the case with all cross-sectional 
studies, it was not possible to attribute a temporal relationship between the 
group treatment status (i.e. breast screening, chemotherapy and post-
treatment) and physical activity. That is, although we have found an 
association between physical activity levels and the treatment status of the 
participants, there is no evidence that the treatment status of participants 
was the cause of the reported physical activity. Furthermore, the cross-
sectional design of the current study provided a “snap shot” of physical 
activity behaviour within the three UK based study groups. Hence, it is 
possible that this “snap shot” of physical activity reported by the 
participants in each group were not representative of their usual levels of 
physical activity. Moreover, we assessed physical activity via the self-
report IPAQ questionnaire, which requires participants to recall past 
activity, and is therefore, a subjective means of estimating individual 
physical activity levels that may be influenced by recall bias and social 
desirability bias. However, this design provides real-time information 
regarding the physical activity status of breast cancer populations, which 
can facilitate the design of pragmatic interventions that can be delivered 
within the NHS. A further limitation of our study is that we cannot be sure 
that these findings are generalizable to women attending breast screening 
and women who are receiving or have completed breast cancer treatment 
because our sample included only women from the Black Country area of 
the West Midlands in the UK. Our samples of chemotherapy and post-
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treatment breast cancer patients were also relatively small, which further 
limits our ability to generalise. The NHSBSP sample was chosen as a 
“pre-diagnosis” comparison group based on their status as an “at risk of 
breast cancer” group. However, clearly not all of the patients sampled will 
develop breast cancer, and therefore, this group may not be 
representative of breast cancer patients pre-diagnosis. Finally, BMI for the 
group of screening attendees was self-reported. This may have influenced 
the data of the present study; however, the effects of physical activity on 
BMI and/or the effects of the different stages of breast cancer were not 
amongst the main aims of the present study. 
 
5.2.6 CONCLUSIONS 
In summary, we found that breast cancer patients receiving chemotherapy 
had lower levels of physical activity compared to women attending breast 
screening and breast cancer patients within one-year post-treatment, while 
post-treatment breast cancer survivors had lower levels of physical activity 
group compared to the breast screening group. The relatively low physical 
activity levels of the post-treatment breast cancer survivors means that a 
large proportion of this group were not sufficiently exposed to the potential 
benefits of physical activity on breast cancer survival. The findings of this 
current study, highlights the need to establish robust physical activity 
interventions to enhance the physical activity behaviour of post-treatment 
breast cancer survivors in the UK at a time when the negative effects of 
chemotherapy begin to resolve and patients are more receptive to 




5.3 A home-based physical activity intervention in breast cancer 
survivors; a randomised controlled trial 
5.3.1 ABSTRACT 
Introduction: Randomised controlled trials have demonstrated that 
adherence to supervised physical activity interventions may result in 
improved in health outcomes and HRQoL in breast cancer survivors. 
However, the findings of supervised facility-based physical activity 
interventions may not generalise to patients who have limited access to 
exercise facilities because of financial, transportation or time-related 
difficulties. Home-based physical activity interventions are potentially 
advantageous as they may mitigate many of the difficulties associated with 
facility-based physical activity interventions. Therefore, the purpose of this 
study was to investigate the effects of a home-based physical activity 
intervention on physical activity levels, anthropometric measures, HRQoL 
and blood biomarkers in post-adjuvant therapy breast cancer survivors.  
Methods: Eighty post-adjuvant therapy breast cancer survivors 
(age=53.6±9.4y; height=161.2±6.8cm; mass=68.7±10.5kg) were randomly 
allocated to a six-month home-based physical activity intervention or a 
usual care group. End points included changes in self-reported physical 
activity levels assessed via the IPAQ, mass, BMI, body fat %, HRQoL 
measured by the FACT-B questionnaire and fasting insulin, glucose, 
insulin resistance (HOMA), TC, HDL-C, LDL-C and TG between baseline 
and 6-months. The intervention group received an intervention aimed at 
encouraging the achievement of current recommended physical activity 
guidelines of 150 min·wk-1 of moderate physical activity. The intervention 
consisted of a face-to-face physical activity consultation during the first 
visit, followed by support telephone calls at the end of months one, two 
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and three, and a physical activity reminder postcard during the last two 
months. Ethical approval was obtained from the Black Country NHS 
Research Ethics Committee (West Midlands, UK). Pre-post intervention 
differences were analysed using linear mixed model analysis.  
Results: Self-reported total and moderate physical activity significantly 
increased from baseline to post-intervention in the intervention compared 
to usual care (mean difference, MD=580 MET-min·wk-1, P=0.04, d=0.48 
and MD=112 MET-min·wk-1, P<0.01, d=0.57, respectively). Both body 
mass and BMI decreased significantly from baseline to post-intervention in 
the intervention compared to usual care (MD, -1.6 kg, P=0.03, and MD, -
0.6 kg·m2, P=0.02, respectively). There was no significant change in body 
fat % scores (P=0.16). Of the HRQoL variables only the trial outcome 
index and breast cancer subscale improved significantly in the physical 
activity group compared to the usual care group (MD=5.2, P=0.016, 
d=0.55 and MD=2.9, P=0.002, d=0.71, respectively). Of the blood 
biomarkers only TC and LDL-C was significantly reduced in the physical 
activity group compared to the usual care group (MD, -0.45 units, 
P=0.006, and -0.308 units, P=0.046, respectively).  
Conclusion: We found that a home-based physical activity intervention 
resulted in significant improvements in self-reported physical activity, mass 
and BMI, breast cancer specific HRQoL and TC and LDL-C. The 
portability, feasibility and relatively low cost of this current intervention 
makes it a promising intervention that could benefit a large number of 
breast cancer survivors, therefore, it will be important to assess whether 
modifications would be needed when employed in older and perhaps less 





Worldwide, breast cancer is the most frequently diagnosed cancer and a 
leading cause of cancer death among females (Jemal et al., 2011). In the 
UK, female breast cancer had the highest incidence rate of all cancers, 
with an average rate of 124.2 cases per 100,000 population (European 
age-standardised) each year between 2007 and 2009 (ONS, 2012). In 
2006, there were 296,037 (790.8 per 100,000) UK women diagnosed and 
living with breast cancer within a ten-year period. Furthermore, the number 
of women with breast cancer has been predicted to increase in the future, 
with recent projections estimating a 44% increase in breast cancer 
incidence in England from 2001 figures by 2020 (Moller et al., 2007).  
 
As a large consequence of early detection and improved treatment 
strategies, UK breast cancer mortality rates are falling and in turn survival 
rates are improving (Nur et al., 2011). As a result there are now more 
breast cancer survivors than ever before. Breast cancer survivors may 
experience side-effects of treatment years after diagnosis, such as fatigue, 
pain, cognitive dysfunction, neuropathy, sexual problems, cardiotoxicity 
and reduced quality of life (Azim et al., 2011; Bovelli et al., 2010; van 
Dalen et al., 2010). In addition, breast cancer survivors are at an 
increased risk of weight gain, obesity, recurrence, new primary cancer, 
CVD and diabetes (Azim et al., 2011; Bovelli et al., 2010). Therefore, 
breast cancer survivors may require diagnostic, therapeutic, supportive or 
palliative services many years post-diagnosis which poses a major 
challenge to already stretched healthcare services. Accordingly, simple, 
effective and inexpensive interventions for breast cancer survivors that 
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can reduce the side-effects of treatment, improve the health and quality of 
life and possibly reduce the risk of early mortality are needed. 
 
Encouraging breast cancer survivors to adopt a healthy lifestyle post-
treatment may be important for improving health and quality of life of 
survivors and in turn reduce the healthcare burden (Demark-Wahnefried et 
al., 2005). In particular, higher levels of physical activity, may reduce 
breast cancer-related and all-cause mortality (Schmidt et al., 2013; 
Cadmus Bertram et al., 2011; Chen et al., 2011; Irwin et al., 2011; 
Friedenreich et al., 2009; Holmes et al., 2005). However, physical activity 
levels are generally low among breast cancer survivors and many women 
decrease their physical activity following diagnosis (Irwin et al., 2003; Irwin 
et al., 2004). Therefore, interventions are required to improve the physical 
activity levels of breast cancer survivors post-diagnosis. 
 
RCTs have found beneficial effects of physical activity, including 
improvements in cardiorespiratory fitness, enhanced quality of life, 
reduced fatigue and lower weight gain compared to control groups 
(Cadmus et al., 2009; Rogers et al., 2009; Payne et al., 2008; Daley et al., 
2007; Matthews et al., 2007; Herrero et al., 2006; Pinto et al., 2005; 
Courneya et al., 2003).  However, most physical activity intervention trials 
consist of either entirely or partly facility-based interventions, and 
therefore, the findings of these trials may not generalise to patients who 
have limited access to exercise facilities because of transportation or time-
related difficulties. To overcome this problem some trials have provided 
entirely home-based physical activity interventions (Musanti et al., 2012; 
DeNysschen et al., 2011; Rogers et al., 2009; Payne et al., 2008; Heim et 
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al., 2007; Matthews et al., 2007; Vallance et al., 2007; Pinto et al., 2005). 
In addition to mitigating transport and time-related difficulties, home-based 
interventions are also advantageous because they are less expensive 
than supervised, facility-based interventions and do not require 
participants to attend classes or maintain a health club membership to 
sustain physical activity.  
 
Trials employing home-based interventions appear to show good 
adherence to physical activity programmes and significant increases in 
physical activity in intervention patients compared to controls (Rogers et 
al., 2009; Matthews et al., 2007; Vallance et al., 2007; Pinto et al., 2005). 
As reported in the systematic review and meta-analysis of interventions 
(section 2.8), these trials have found positive effects on cardiorespiratory 
fitness, physical condition domain of self-esteem, quality of life, fatigue 
and sleep when comparing intervention groups to controls. However, all of 
the above studies were either based in North America or Germany (Heim 
et al., 2007), therefore, there is currently no data regarding the 
effectiveness of home-based physical activity interventions in UK breast 
cancer survivor populations. As a consequence it is unclear how 
generalisable the findings of these trials are to breast cancer survivors in 
the UK. 
 
Few studies have given consideration to the long-term implications of 
individuals’ adherence and motivation to exercise. Most of the trials 
investigating the effects of physical activity in breast cancer survivors have 
not included a physical activity counselling component designed to 
promote physical activity behaviour change within the physical activity 
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interventions. Without the support to change beyond what is provided by 
the exercise facilities or the physical activity programmes provided, it is 
unlikely breast cancer survivors will be able to maintain their participation 
once the specified intervention period lapses (Daley et al., 2004). Only 
three home-based intervention trials consisted of a physical activity 
specific counselling component, which included either both face-to-face 
counselling and support telephone calls (Rogers et al., 2009; Matthews et 
al., 2007) or support telephone calls alone (Pinto et al., 2005). Although 
the findings of these home-based physical activity trials are promising, 
there were a number of limitations which limit the generalizability of the 
results. Matthew and colleagues (2007) involved a small sample of 
postmenopausal breast cancer survivors (n=36), Rogers et al. (2009) 
consisted of a relatively small (n=41) number of sedentary breast cancer 
survivors receiving hormone therapy, while the sample in Pinto et al. 
(2005) consisted of a number of patients diagnosed with less severe, non-
invasive stage 0 breast cancer (16%) and none diagnosed with stage III 
breast cancer, and a large proportion of highly educated and affluent 
patients (40% of patients with a bachelor’s degree or graduate degree and 
61% of patients with a household income of more than $50,000). In 
addition, all of these trials were relatively short in duration (12 weeks) and 
based in the USA. Hence, trials with a larger sample size and longer 
duration that examine the effect of home-based physical activity 
interventions with an additional counselling component in a more 
representational sample of UK breast cancer survivors are required. 
 
Therefore, the aim of this current study was to investigate whether post-
adjuvant therapy breast cancer survivors can adopt a relatively 
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inexpensive home-based physical activity programme and determine the 
effects of adherence to such a programme on physical activity levels, 
weight gain, HRQoL, insulin resistance and blood lipid profiles. The main 
hypothesis was that breast cancer survivors who received the home-
based physical activity intervention would have increased self-reported 
total physical activity from baseline to post-intervention compared to the 
usual care participants. We also hypothesised that breast cancer survivors 
in the intervention group would have higher HRQoL, better weight 
maintenance, lowered insulin resistance and improved blood lipid profiles, 
when compared with usual care participants post-intervention. 
 
5.3.3 METHODS  
Trial design  
This current study was a two-armed, parallel design RCT that compared a 
six month home-based physical activity intervention to usual care. 
Individualised face-to-face consultations and telephone counselling to 
individualise goal-setting and assess progress formed the key components 
of this programme. The present study reports data collected at baseline 
and six months. Recruitment of participants took place between January 
2010 and March 2013.  
 
One hundred and fifty female breast cancer patients who had completed 
adjuvant therapy were invited to take part in the current trial. Of these 
women, 53% (n=80) were found to fully meet the study criteria, were 
interested in participating and were willing to be randomised to a treatment 
or usual-care control group. Seventy breast cancer patients were excluded 
due to reasons including not meeting eligibility criteria, not wanting to 
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participate in exercise or have blood taken, and felt they did not need 
exercise advice. Six of the 70 patients were excluded because they did not 
attend the initial assessment, and these patients could not be contacted to 
establish the reasons for their non-attendance. 
 
Participants 
Women attending breast cancer clinics at Russells Hall Hospital (The 
Dudley Group of Hospitals, NHS Foundation Trust, UK), were invited to 
enrol on the study by cancer care nurses working within these clinics. 
Interested patients were given a study information booklet and were 
contacted by the primary researcher via telephone a week later. 
Participants were eligible to take part in the current study if they 1) were 
female, 2) were aged less than 69 y, 3) were diagnosed with invasive 
breast cancer (Stage I-III) within two years of enrolment, 4) were post-
surgery and had no surgery planned for the next six months at least, 5) 
had fully completed adjuvant therapy (radiotherapy and/or chemotherapy) 
not including hormonal therapy, 6) were willing to be randomised 7) and 
willing to maintain contact with the investigators over the six months. 
Exclusion criteria included 1) the inability to participate in physical activity 
because of severe disability (e.g., severe arthritic conditions), 2) 
psychiatric illness and 3) vulnerable subjects, such as pregnant women or 
any other patient where physical activity was not approved by their 
oncologist. The study was reviewed, approved and monitored by the 
investigational review boards of the Russells Hall Hospital and all 




Volunteers were asked to visit the testing venue (Research and 
Development Unit, Russells Hall Hospital, Dudley) early in the morning 
following a 12 hour overnight fast. Participants were asked not to change 
their normal physical activity patterns from when the appointment was 
arranged to the day of the appointment. All participants were subjected to 
the same data collection procedures overseen by the same investigator. 
Upon arrival, participants’ height, mass and body composition were 
assessed. Participants were then asked to complete a demographics 
questionnaire, which included questions relating to ethnicity, time since 
diagnosis and end of treatment, co-morbidities and medical history, family 
history of breast cancer and reproductive and menstrual history.  
 
Home-based physical activity Intervention 
Following consent and randomisation, breast cancer patients in the 
intervention group received an intervention (Figure 5.3.1) aimed at 
encouraging the adoption of a more physically active lifestyle. Participants 
received a face-to-face consultation, followed by a support telephone call 
at the end of months one, two and three. During the last two months (4 
and 5) patients received physical activity reminder leaflets encouraging 
their participation in home-based physical activity. The intervention was 
based on the findings from previous research (Rogers et al., 2008; Jones 
and Courneya, 2002), which found that breast cancer survivors had strong 
preferences for the receipt of face-to-face counselling from exercise 
professionals that were associated with a cancer centre, either at the 
cancer centre or at home. Both of the above studies (2008; 2002) also 
found clear preferences for walking, moderate-intensity activity and for 
exercising at home or outdoors. This current study has been developed 
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based on the preferences of breast cancer survivors, and therefore, may 
be a promising model for delivering physical activity promotion 
programmes for these individuals. 
 
Months of the Intervention 0 1 2 3 4 5 6 
Initial assessment and face-
to-face consultation 
√       
Support telephone call  √ √ √    
Mailed physical activity 
prompts 
    √ √  
Post-intervention 
assessment 
      √ 
Figure 5.3.1 Plan of the Six Month Home Based Physical Activity 
Intervention 
 
The face-to face consultation was conducted by the primary researcher 
within the Research and Development unit of Russells Hall Hospital 
immediately after the initial baseline measurements were taken. To ensure 
consistency in intervention delivery across sessions and participants, a 
semi-structured motivational interviewing-based intervention protocol was 
developed to guide intervention delivery. The topics covered in the 
consultation were similar to other trials that incorporated a physical activity 
counselling component (Rogers et al., 2009; Matthews et al., 2007; Pinto 
et al., 2005). These topics included current physical activity behaviour 
(e.g. activities the participants enjoyed and felt they could do on a regular 
basis, ways of fitting physical activity into daily life and previous 
experiences of physical activity), decision balance exercise (e.g. possible 
gains and losses that might occur with increased physical activity levels), 
benefits of physical activity in general and specific to breast cancer 
survivors, perceived barriers (e.g. greatest barriers to being more active 
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and suggestions on how to overcome these), prompts to seek social 
support (e.g. family, friends, workmates and others who might encourage 
exercise, someone to talk to while doing physical activity to provide 
encouragement), goal setting (e.g. participants own goals, goals of 
intervention and determination of short term goals), types and intensities 
of physical activity (e.g. explanation of light, moderate and vigorous 
intensity physical activity with examples specific to participants, such as, 
taking a brisk walk so that you are mildly breathless but can still hold a 
conversation), safety advice (e.g. walking/cycling in dark, ensuring they 
could be seen and someone knows where they’re going, avoid 
busy/dangerous roads etc.) and basic lifestyle information (e.g. basic 
dietary information, portion size, fat intake, smoking and hydration in 
generally and during activity) (see Appendix S). 
 
During the face-to-face consultation, the four core motivational 
interviewing principles, namely, expressing empathy, developing 
discrepancy, rolling with resistance and supporting self-efficacy, were 
applied (Rosengren, 2009; Miller and Rollnick, 1991). Motivational 
interviewing can be defined as a person-centred method of guiding to elicit 
and strengthen personal motivation for change (Resnicow and McMaster, 
2012). This approach aims to assist individuals to work through their 
ambivalence or resistance about behaviour change. Specific therapeutic 
techniques, including open-ended questions, affirmation, reframing, 
reflective listening, importance and confidence rulers, values-sort 
exercises and summarising, that are in line with motivational interviewing 
principles were used as needed. The consultations lasted approximately 
30 to 45 minutes. Patients were given a physical activity pack consisting of 
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an interactive information booklet and a DVD (previously developed by 
Breast Cancer Care) that provided further information of topics such as 
exercising safety, exercise intensity, dealing with fatigue and exercising 
with lymphedema. Patients who did not have access to a DVD were 
encouraged to watch it with a friend or family member. Information about 
local physical activity opportunities were also provided, including an 
exercise initiative run by Dudley Council in local parks. 
 
To facilitate behaviour change over the longer term, the participants were 
contacted by the primary researcher by telephone one, two and three 
months after randomisation. The focus of these calls was to prevent 
relapse back to sedentary behaviour and/or improve maintenance of a 
physically active lifestyle, and covered topics similar to the face-to-face 
consultation such as enhancing motivation, goal setting, self-efficacy for 
activity, overcoming barriers, providing positive reinforcement and 
developing appropriate activity plans for home-based physical activity. 
Calls lasted approximately 15 to 20 minutes, were guided by standardised 
phone call scripts and as with the face-to-face counselling session the 
principles of motivational interviewing were applied. Participants were 
encouraged to telephone the research team should they encounter any 
problems or relapse in their efforts to increase their physical activity. 
Participants were also sent physical activity reminder leaflets that 
encouraged participation in regular physical activity at the end of the fourth 
and fifth months of the intervention (see Appendix T).  
 
The intervention was developed to promote enjoyment, motivation, 
confidence and compliance, as well as minimising the possibility of injuries 
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and discomfort. The initial goal of the intervention (months 1-3) was for 
participants to progress towards accumulating 30 minutes of moderate 
intensity exercise on three to five days per week. During months 3 to 6, 
the intervention participants were encouraged to work towards 
accumulating at least 30 minutes of moderate-intensity physical activity on 
five to seven days per week in broad agreement with current public health 
guidelines (Bull and the Expert Working Groups, 2010). If participants 
were already achieving this on trial entry they were, as a minimum, 
actively encouraged to maintain their level of physical activity. Participants 
were encouraged to first focus on the frequency of their physical activity 
and then duration. Physical activity in the form of walking was particularly 
encouraged. The impact due to walking is low and strain on the feet and 
joints is minimised. Moreover, it does not require any specialized 
equipment. However, we did not preclude and encouraged participants to 
perform other activities that they enjoyed. Participants were advised to 
refrain from activity if they felt unwell. They were told to immediately 
contact their doctor (GP) and notify the research site if they had problems 
breathing, developed chest pain, felt faint or dizzy, developed a joint 
problem, developed high blood pressure or became pregnant. In these 
circumstances, the clinician (consultant surgeon) of the research team 
made a clinical decision as to whether the patient should refrain from 
physical activity temporarily or withdraw from the intervention. 
 
Usual Care Group 
Since not informing patients about the benefits of physical activity may be 
considered unethical, participants randomised to the usual care arm 
received standard information regarding physical activity (i.e. the current 
336 
 
recommended physical activity guidelines), as provided to all breast 
cancer patients treated at the site. Participants completed the same 
baseline and post-six month intervention assessments as the physical 
activity intervention group. 
 
Outcomes  
After randomisation, participants completed the International Physical 
Activity Questionnaire (IPAQ) followed by the Functional Assessment of 
Cancer Therapy-Breast (FACT-B) HRQoL questionnaire. Questionnaires 
were administered in this order to all participants and questionnaire 
completion was facilitated by the same trained researcher via a face-to-
face interview, in order to minimise participant bias. The primary outcome 
of the current study was total physical activity (MET-min·wk-1). Secondary 
outcomes included body mass, body mass index (BMI) body fat 
percentage (%), all other IPAQ physical activity, FACT-B variables and 
total cholesterol (TC), high-density lipoprotein (HDL-C), low-density 
lipoprotein (LDL-C), triglycerides (TG), blood glucose and insulin 
concentrations and insulin resistance via HOMA. All assessments were 
made at baseline and within two weeks of completing the six-month 
intervention. The details of assessments are described in chapter 4.3. 
 
Sample size calculation 
Power calculations were based on total physical activity as the primary 
outcome. A similar trial (Matthews et al., 2007) reported that the mean 
difference from baseline to 12 weeks follow-up using self-reported physical 
activity was 16.5 MET-h·wk-1 greater in the intervention group compared to 
the usual care group. Power calculations were carried out using the 
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equation below (Equation 5.1) (Noordzij et al., 2010). With at least 36 
participants in each group (N=72), the trial would have 80% power at 
p<0.05. To allow for 10% attrition we aimed to recruit 80 participants (40 in 
each group). 
 
Equation 5.1 Sample size calculation 
 
 
Where, n=sample size in each group, a=normal deviate for different 
significance levels (Type I error or alpha) for two tailed alternative 
hypothesis (i.e. 1.96), b=normal deviate for different power, probability of 
rejecting null hypothesis when it is not true or one minus probability of type 
II error (i.e. 0.842), σ2=population variance (i.e. combined s for the 
intervention and control groups), μ1=population mean in intervention 
group, μ2=population mean in control/comparison group. 
 
Randomisation    
Randomisation of participants in this current study was conducted via the 
Cancer Research UK Clinical Trials Unit of the University of Birmingham. 
A computer generated random numbers list was used to allocate all 
participants into intervention groups and allocate 40% of participants in 
each group into a substudy. The substudy consisted of a separate 
exercise tolerance test and blood pressure assessment carried out on a 
separate day to the outcomes outline above. The findings from the 
substudy will be presented in section 5.4. The random allocation sequence 
was kept concealed from the primary researcher. Patients were allocated 
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to intervention and usual care groups on a 1:1 allocation ratio. The 
patients were stratified into the two groups (intervention and usual care) 
after taking into consideration adjuvant chemotherapy. This stratification 
can add to the credibility of a trial, as it ensures treatment balance, 
allowing easy interpretation of outcomes without adjustment (Beller et al., 
2002). The results of randomisation were explained to the participants 
after they completed the demographics questionnaire. The primary 
researcher who carried out both the initial and post-intervention 




Only data from breast cancer survivors who had attended their initial 
assessments were included in the analysis. All data was inputted onto to a 
Microsoft Excel™ spreadsheet (Microsoft Corporation) and transferred to 
Statistical Package for Social Sciences (SPSS) (IBM™) for windows 
version 20.0 for analysis. For all analyses, we employed the intention-to-
treat (ITT) approach (Newell et al., 1992).  
 
Physical activity data outliers were identified by converting all scores to z-
scores. Z-scores greater than 3.29 were classed as outliers. All outliers 
above this score were converted to one unit smaller than the next highest 
score with a z-score below 3.29 (Tabachnik and Fidell, 2007). The 
distribution of all continuous, baseline and post-intervention outcomes 
were assessed. Distributions of these data were explored by first 
observing histograms and P-P plots for each variable. The z-score of 
skewness (zskewness=skewness-0/SEskewness) and kurtosis (zkurtosis= 
339 
 
skewness-0/SEkurtosis) was then calculated for each variable, a z-score of 
greater than 1.96 was used to signify significant skewness and kurtosis, 
and thus, data not normally distributed. Of all variables, only total 
cholesterol, HDL-C and LDL-C were normally distributed at both baseline 
and post-intervention. Normally distributed variables were expressed as 
mean±s, while all other variables were described using medians and 
interquartile ranges (IQR). Categorical data were presented as number of 
participants and percentages.  
 
To correct for non-normal distributions, variables not normally distributed 
were log transformed. Anthropometric data and blood biomarkers (TG, 
glucose, insulin and HOMA) were positively skewed, and were therefore, 
log transformed to base 10, log10(X). Because the physical activity data 
contained zero values, they were transformed to log10(X+1). FACT 
variables data were negatively skewed, and therefore, were first reverse 
log transformed (highest score+1–X) and then log10(X) transformed. 
Repeated-measures linear mixed model analysis was performed on all 
continuous trial outcomes to assess differences in group changes from 
baseline to post-intervention (i.e. 6-months from baseline). Linear mixed 
models use all available data and provide a valid analysis when data are 
missing at random (Diggle et al., 2002). Time (baseline and post-
intervention) was selected as the repeated effects variable. Treatment 
group alone was considered as fixed effects and participants as the 
random factor.  
 
For each outcome variable, we tested a model with a scaled identity 
structure for a random effect and an autoregressive [AR(1)] structure for 
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the repeated effect versus a model that had a compound symmetry 
structure for the random effect and an unstructured matrix for the repeated 
effect. To compare the adequacy of smaller models versus more complex 
models the likelihood ratio (LLR) test was used. The null hypothesis of this 
test states that the smaller model provides as good a fit for the data as the 
larger model. If the null hypothesis was rejected, then the alternative, 
larger model was chosen as this would provide significant improvement 
over the smaller model. The LLR test statistic was computed by 
subtracting the Maximum Log Likelihood (MLE) of the larger model from 
the MLE of the smaller model.  Degrees of freedom were then computed 
by subtracting the total number of parameters in the smaller model from 
the total parameters in the larger model. The significance of the test 
statistic was established by comparing it to critical values for the chi-
square statistic with the computed degrees of freedom. If the test statistic 
was greater than the critical values for a chi-square statistic (i.e. ≥ χ2 value 
for 0.05) with the computed degrees of freedom then the difference 
between models is significant. That is, the new model (unstructured 
variance) presented a significant improvement over the original AR(1) 
model. A non-significant difference between models meant the null-
hypothesis could be accepted and the simpler model could be chosen. In 
all cases there was no significant improvement in models, therefore, the 
less complex, AR(1) covariance structure results were presented. Results 
of the linear mixed model analysis on log transformed data are presented 
in tables 5.3.5, 5.3.6 and 5.3.7. We also provide the mean difference, 
standard error and 95% confidence intervals (CI) of the untransformed 




Chi-square analysis was performed on categorical IPAQ data. The breast 
cancer subscale score (BCS), FACT-General, FACT-Breast and trial 
outcome index (TOI) FACT HRQoL variables were categorised based on 
whether participants experienced a minimum clinically important increase 
in these variables from baseline to post-intervention. These minimum 
important clinically improvements were categorised based on a previous 
study, which suggested minimum clinically important increases of two 
points for the BCS, seven points for the FACT-B total score and five points 
for the FACT-G and the TOI scores (Eton et al., 2004). Chi-square 
analysis was then performed to examine intervention and usual care 
groups for differences in the number of participants who experienced a 
minimum important clinically increase in these variables. Statistical tests 
and corresponding p values were two-sided; a p value of less than 0.05 
was reported as statistically significant. Cohen’s d effect sizes for linear 
mixed model analysis was calculated based on the estimate comparing 
baseline values of the intervention group to the 6-month values in the 
intervention group and the baseline and 6-month values for the usual care 
group. Effect sizes for the t-values of each comparison were calculated by 
converting the t value to d using the formula below: 
 
Equation 5.1 Conversion of t values to effect sizes (Cohen’s-d) (Rosenthal 
and Rosnow, 1991) 
 
 
According to Cohen (1992) a small effect would be denoted as d=0.2, 
medium effect d=0.5 and large effect d=0.8. For the purposes of this 
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report, effect sizes of <0.20 were interpreted as small, 0.2 to <0.5 as small 
to moderate, 0.5 to <0.8 as moderate to large, and ≥0.8 as large. 
 
5.3.4 RESULTS 
Flow of participants through the trial and recruitment 
Eighty participants were recruited for this trial between January 2010 and 
March 2013.  Flow of participants through the study is provided in Figure 
5.3.2. Participants were randomised to either the intervention or usual care 
group (40 participants in both groups). Seventy participants completed the 
trial, with 37 and 33 completers in the intervention group and usual care 
group, respectively. Of the three participants assigned to the intervention 
group, one participant dropped out of the trial due to a recurrence of 
breast cancer, while another participant cited sciatica as the reason for 
dropping out, and the third participant discontinued the trial due to 
unspecified personal reasons. Two of the participants in the usual care 
group dropped out of the trial because they did not want to attend the 
hospital for re-assessment, another patient dropped out due to a hip 
operation, and four participants could not be contacted to arrange re-
assessment and therefore, did not give reasons for dropping out. 
 
Participant characteristics at baseline 
Table 5.3.1 provides the baseline characteristics overall and by group 
assignment. Baseline data was collected from 80 breast cancer survivors 
(age=53.6±9.4 y; height=161±6.8 cm; mass=68.7±10.5 kg) who have 
completed the six month study duration. Both the intervention group 
(age=52.4±10.3 y; height=162±6.2 cm; mass=70.9±11.8 kg) and the usual 
care group (age=54.7±8.3 y; height =160±7 cm; mass=68.2±11.2 kg) 
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consisted of 40 participants. The number of patients who had undergone 
chemotherapy was 42 (52.5%). The same number of patients completed 
chemotherapy in the intervention as the usual care group (n=21; 52.5%). 
Patients had received their breast cancer diagnosis an average of 38±20.8 
weeks before their initial assessment. The mean number of weeks since 
the patients completed treatment (i.e. surgery/radiotherapy/chemotherapy) 
was 10.5±9.0 weeks for the 80 patients. 
 
 







Table 5.3.1 Personal characteristics of the participants at baseline 












Mean±s age (y) 53.6±9.4 52.4±10.3 54.7±8.3 
Mean±s time since diagnosis 
(wk) 
38.0±20.8 42.2±20.0 34.4±21.1 
Mean±s time since end of 
treatment (wk) 
10.5±9.0 8.9±7.3 12.0±10.3 
Ethnic Origin:  
• White British 
• White Irish 
• Other white background 

















• Obese (BMI=> 30) 
• Overweight (BMI=25-29.9) 
• Normal (BMI=18-24.9) 
































• Mean±s cigarettes/day 





















• No  
Mean±s no. of days/week when 
alcohol is drank 
Mean±s no. glasses on days 







































• High Cholesterol 
• Heart disease 
• Vascular disease 
• Asthma or chronic bronchitis 
• Osteoarthritis 
• Rheumatoid arthritis 
• Kidney disease 














































































Mean±s age at birth of 1st child 
(y): 
26.8±4.9 27.2±4.8 26.4±5.0 






























































• Married  
• Not married, living with 
partner 
• Not married, not living with 
partner 






























• O-levels or GCSE 
• A-level or equivalent 
• NVQ 
• College degree or diploma 
• Bachelor degree 
• Post-graduate degree  
• Other or not listed 




























Employment status:  
• Employed full-time 
• Employed part-time 
• Homemaker 
• Unemployed 





























The baseline characteristics of participants in the intervention and usual 
care groups were similar in terms of age, BMI, presence of family history 
of breast cancer, alcohol drinking behaviour, number of children, age at 
first birth, numbers who had breastfed, numbers still menstruating, oral 
contraceptive pill use, HRT use, education and employment status (see 
table 5.3.1). There were a greater number of participants in the usual care 
group who reported co-morbidities (hypertension, asthma and 
osteoarthritis), nulliparity and being divorced or separated compared to the 
intervention group.  
 
The anthropometric characteristics of participants in the intervention group 
were similar to that of participants in the usual care group (see table 
5.3.2). However, those in the usual care group were more active 
compared to the intervention group at baseline (see table 5.3.2). The 
difference in median physical activity time was almost 160 min between 
the intervention and usual care group. However, most of the additional 
activity of the usual care group can be attributed to a greater amount of 
domestic physical activity in this group. Regarding IPAQ physical activity 
categories, 19% (n=15/80) of the participants were classified as low 
activity, while 69% (n=55/80) and 13% (n=10/80) were categorised as 
moderate and high activity, respectively, at baseline. In the intervention 
group, 20% (n=8/40), 75% (n=30/40) and 5% (n=2/40) of participants were 
categorised as low, moderate and high activity, respectively, while in the 
usual care group 5% (n=2/40), 75% (n=30/40) and 13% (n=5/40) of 
participants were categorised as low, moderate and high activity, 
respectively, at baseline. Therefore, at baseline 15% (n=6) more 
participants were categorised in the low activity category in the 
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intervention group compared to the usual care group. There were no 
evident differences in HRQoL variables or blood biomarkers between 
groups at baseline (see Tables 5.3.3 and 5.3.4, respectively). Twenty nine 
participants were characterised as dyslipidaemic at baseline, based on 
increased concentrations of TC (>6.2 mmol·L-1), 22 had increased TG 
(>1.7 mmol·L-1), 21 had increased LDL-C (>4.13 mmol·L-1) and two had 
decreased levels of HDL-C (<1.03 mmol·L-1). The number of participants 
characterised as dyslipidaemic were similar across groups (data not 
shown). Twenty-nine participants (intervention, n=14; usual care, n=15) 
had undetectable insulin concentrations (i.e. insulin <14.0 pmol·L-1). Ten 
participants, five in each group, were characterised as insulin resistant (i.e. 
HOMA ≥2.5).  
 
Physical activity outcomes 
Self-reported total physical activity (both MET-min·wk-1 and time variables) 
significantly increased from baseline to post-intervention in the intervention 
group compared to usual care group (mean difference, 580 MET-min·wk-1; 
p=0.04, and mean difference, 169 min; p=0.03, respectively). In particular, 
moderate physical activity (both MET-min·wk-1 and time variables) and 
domestic physical activity increased in the intervention group compared to 
the usual care group over the intervention period (p=0.004 and 0.04, 
respectively). No significant differences were found for any of the other 
physical activity variables (see Table 5.3.5). 
 
Chi-square analysis was not possible on physical activity categorical data 
because greater than 20% of the expected counts were less than five and 
some of the expected frequencies were below one. Collapsing the 
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moderate and low categories into one category did not remedy this.  
Therefore, the physical activity data are presented as frequencies in those 
who completed post-intervention assessments. Post-intervention, only 5% 
(n=2/37) of the intervention group participants were categorised as low 
activity compared to 10% (n=4/33) in the usual care group. The majority of 
the intervention group (75%, n=30/37) and 50% (n=20/33) of the usual 
care were categorised as moderate activity, while 13% and 23% were 
categorised as high activity in the intervention and usual care groups, 
respectively. Of the participants in the intervention group categorised as 
low activity at baseline, 88% (n=7/8) and 12% (n=1/8) moved to the 
moderate and high activity category, respectively, post-intervention. While 
in the usual care group, 50% (n=2/4) remained in the low activity category 
while one participant each moved from low to moderate and low to high 
activity categories, post-intervention. Of the intervention participants 
categorised as moderate activity at baseline, 85% (n=23/27), 7.5% 
(n=2/27) and 7.5% (n=2/27) did not change, increased to the high activity 
category or decreased from the moderate to low category, respectively. 
While, 80% (n=16/22) 18% (n=4/22) and 9% (n=2/22) of usual care 
participants categorised as moderate activity at baseline, did not change, 
increased to the high activity category or decreased from the moderate to 
low category, respectively. The two participants in the intervention group 
who were categorised as high activity remained in the high category post-
intervention, however, 43% (n=3/7) of the usual care participants 
categorised as high activity dropped down to the moderate category and 





Table 5.3.2 Median (IQR) for anthropometric and physical activity (PA) 
variables at baseline for all participants and for intervention and usual care 
groups at baseline and post-intervention (6-months) (all physical activity 
data reported as MET-min·wk-1 unless stated otherwise) 













67.7 (14.2) 67.3 (15.8) 66.9 (17.7) 68.5 (12.3) 67.3 (6.3) 
BMI (kg·m2) 26.0 (6.1) 26.0 (6.3) 25.1 (7.2) 26.0 (5.8) 26.0 (4.9) 
Body fat (%) 35.3 (7.3) 35.1 (8.3) 35.3 (8.6) 35.3 (6.9) 36.6 (6.2) 
Total PA 1463 (1276) 998 (1390) 1746 (1291) 1617 (1394) 1802 (1450) 
Work PA  0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Active 
transport PA 
132 (264) 140 (223) 198 (157) 83 (446) 198 (380) 
Domestic PA  541 (987) 396 (1043) 462 (1056) 636 (892) 657 (651) 
Leisure PA  350 (693) 350 (594) 706 (1056) 367 (842) 594 (833) 
Walk-cycle-
leisure PA* 
572 (979) 501 (502) 1072 (1077) 627 (502) 792 (887) 
Walk  396 (565) 338 (437) 594 (462) 479 (780) 578 (660) 
Moderate PA  693 (1059) 396 (1062) 660 (1040) 792 (890) 918 (1258) 
Vigorous PA  0 (0) 0 (0) 0 (320) 0 (0) 0 (0) 
Total PA 
time (min) 
441 (389) 300 (377) 455 (353) 459 (401) 440 (296) 
Walk time 
(min) 
120 (172) 103 (133) 170 (223) 145 (236) 175 (200) 
Moderate PA 
time (min) 
178 (297) 120 (298) 152 (315) 207 (252) 197 (196) 
Vigorous PA 
time (min) 
0 (0) 0 (0) 0 (40) 0 (0) 0 (5) 
* Computed by summing occupational walking, active transport (walking and 








Table 5.3.3 Median (IQR) HRQoL (FACT-B) variables at baseline for all 
participants and for intervention and usual care groups at baseline and 
post-intervention (6-months) 











Physical well-being (PWB) 
(0-28) 
24 (7) 24 (8) 26 (5) 
 
24 (7) 26 (5) 
Social well-being (SWB) (0-
28) 
25 (4) 26 (3) 24 (6) 24 (6) 26 (5) 
Emotional well-being 
(EWB) (0-24) 
21 (6) 21 (7) 22 (4) 21 (5) 21 (5) 
Functional well-being 
(FWB) (0-28) 
23 (6) 23 (8) 23 (6) 24 (7) 24 (8) 
Breast cancer subscale 
(BCS) (0-36) 
24 (9) 24 (7) 27 (10) 28 (9) 25 (10) 
FACT-General (FACT-G) 
(0-108) 
92 (21) 92 (23) 93 (19) 92 (17) 95 (22) 
FACT-Breast (FACT-B) (0-
144) 
116 (26) 116 (30) 118 (28) 117 (23) 119 (30) 
Trial Outcome Index (TOI) 
(0-92) 
72 (21) 71 (21) 75 (19) 73 (16) 76 (21) 
Key: FACT-G=PWB+SWB+EWB+FWB; FACT-B=FACT-G + BCS; 
TOI=PWB+FWB+BCS 
Higher scores represent better quality of life 
 
Table 5.3.4 Mean±s and median (IQR) blood biomarkers at baseline for all 
participants and for intervention and usual care groups at baseline and 
post-intervention (6-months)  











Total cholesterol 5.77±1.17 5.75±1.30 5.42±1.09 5.79±1.04 5.93±0.91 
High-density 
lipoprotein  
1.62±0.32 1.65±0.30 1.62±0.33 1.58±0.34 1.60±0.30 
Low-density 
lipoprotein  
3.50±1.00 3.44±1.15 3.18±1.01 3.56±0.84 3.64±0.84 
Triglycerides 1.25 (0.93) 1.20 (1.05) 1.20 (0.78) 1.30 (1.75) 1.4 (0.78) 
Glucose 4.80 (0.70) 4.85 (0.68) 4.7 (0.88) 4.70 (0.98) 4.8 (0.58) 
Insulin 31.5 (34.4) 29.5 (32.9) 30.0 (33.4) 33.0 (35.9) 21.5 (27.9) 
Insulin 
resistance* 
1.39 (1.10) 1.30 (1.10)  1.45 (1.45) 1.5 (1.40) 1.2 (1.13) 
* Measured via HOMA 
Units of measurement: Total cholesterol, high-density lipoprotein, low-density 




Table 5.3.5 Linear mixed model results of log transformed data and delta values (6-months minus baseline) of untransformed 
data for anthropometric and physical activity (PA) variables comparing intervention group to usual care group at baseline to post-
intervention (6-months) (6-months) (all physical activity data reported as MET-min·wk-1 unless stated otherwise) 
















Body mass (kg) -0.010 0.004 -0.019 to -0.001 0.026 0.51 -1.61 0.79 -3.18 to -0.04 
BMI (kg·m2) -0.010 0.005 -0.019 to -0.001 0.023 0.50 -0.62 0.30 -1.22 to -0.01 
Body fat (%) 0.006 0.008 -0.021 to 0.010 0.495 0.16 0.36 0.65 -0.94 to 1.66 
Total PA 0.234 0.110 0.139 to 0.454 0.037 0.48 579.77 281.54 17.96 to 1141.58 
Work PA  0.027 0.197 -0.365 to 0.419 0.892 0.03 -45.85 44.95 -135.54 to 43.85 
Active transport PA -0.185 0.303 -0.789 to 0.419 0.544 0.14 23.16 62.65 -101.86 to 148.18 
Domestic PA  0.477 0.233 0.014 to 0.940 0.044 0.46 152.41 209.81 -266.26 to 571.08 
Leisure PA  0.255 0.308 -0.358 to 0.868 0.410 0.19 382.46 153.49 76.19 to 688.74 
Walk-cycle-leisure PA 0.120 0.213 -0.304 to 0.544 0.575 0.13 436.28 166.39 104.26 to 768.30 
Walk  0.176 0.256 -0.335 to 0.687 0.494 0.16 172.94 124.90 -76.30 to 422.18 
Moderate PA  0.518 0.205 0.109 to 0.928 0.014 0.57 111.87 235.22 -357.5 to 581.25 
Vigorous PA  0.313 0.305 -0.293 to 0.919 0.307 0.23 265.17 106.79 52.08 to 478.26 
Total PA (min) 0.224 0.098 0.0289 to 0.418 0.025 0.52 168.81 69.78 29.57 to 308.06 
Walk (min) 0.161 0.211 -0.260 to 0.582 0.449 0.17 52.47 37.84 -23.04 to 127.97 
Moderate PA (min) 0.502 0.169 0.165 to 0.839 0.004 0.67 114.41 64.41 -14.11 to 242.94 
Vigorous PA (min) 0.107 0.179 -0.250 to 0.464 0.553 0.13 17.04 8.76 -0.43 to 34.51 
* Anthropometric data were log transformed to base 10, log10(X), while all physical activity data were transformed to log10(X+1) 
† Delta descriptive statistics were only available for the 37 participants in the intervention and the 33 participants in the usual care who had 
both baseline and post-intervention values  
ǂ  Significant results in bold  
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Table 5.3.6 Linear mixed model results of log transformed data and delta values (6-months minus baseline) of untransformed 
data for HRQoL FACT-B variables comparing intervention group to usual care group at baseline to post-intervention  














Physical well-being  0.002 0.070 -0.137 to 0.141 0.977 0.01 0.68 2.01 -3.34 to 4.69 
Social well-being  -0.058 0.080 -0.216 to 0.101 0.471 0.16 -0.72 0.70 -2.11 to 0.67 
Emotional well-being  0.011 0.066 -0.121 to 0.142 0.873 0.04 -0.27 0.55 -1.37 to 0.82 
Functional well-being  0.037 0.066 -0.094 to 0.167 0.581 0.13 1.90 0.93 0.06 to 3.75 
Breast cancer subscale  0.169 0.053 0.062 to 0.275 0.002 0.71 2.91 1.11 0.70 to 5.11 
FACT-General  0.155 0.074 -0.119 to 0.177 0.695 0.09 2.68 3.74 -4.77 to 10.15 
FACT-Breast  0.112 0.068 -0.023 to 0.246 0.103 0.37 5.42 2.76 -0.09 to 10.94 
Trial Outcome Index 
(TOI) 
0.146 0.059 0.027 to 0.264 0.016 0.55 5.23 2.30 0.64 to 9.82 
* FACT variables data were first reverse log transformed (highest score+1–X) and then log transformed base 10, log10(X) 
† Delta descriptive statistics were only available for the 37 participants in the intervention and the 33 participants in the usual care who had 
both baseline and post-intervention values 
ǂ  Significant results in bold 












Table 5.3.7 Linear mixed model results of log transformed data and delta values (6-months minus baseline) of untransformed 
data for blood biomarker variables comparing intervention group to usual care group at baseline to post-intervention  
 Mean Difference† SE difference 95% CI 
 
p-valueǂ Effect size (d) 
Total cholesterol  -0.447 0.156 -0.136 to -0.760 0.006 0.65 
High-density lipoprotein  0.138 0.159 -0.178 to 0.455 0.378 0.20 
TC/HDL ratio* -1.27 0.066 -0.121 to 0.142 0.873 0.46 
Low-density lipoprotein  -0.308 0.151 -0.006 to -0.610 0.046 0.46 
Triglycerides* 0.102 0.100 -0.098 to 0.302 0.242 0.27 
Glucose* 0.079 0.185 -0.291 to 0.449 0.626 0.11 
Insulin* -7.511 11.322 -30.061 to 15.039 0.333 0.22 
Insulin resistance* -0.459 0.628 -1.716 to 0.798 0.096 0.38 
* Variables log transformed base 10, log10(X), untransformed descriptive statistics are presented with p-values and d of log-transformed 
comparisons 
† Delta descriptive statistics were only available for the 37 participants in the intervention and the 33 participants in the usual care who had 
both baseline and post-intervention values 
ǂ  Significant results in bold
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Anthropometric outcomes  
Both body mass and BMI decreased significantly from baseline to post-
intervention in the intervention group compared to usual care group (mean 
difference, -1.6 kg; p=0.03, and mean difference, -0.6 kg·m2; p=0.02, 
respectively). There was no significant change in body fat % scores 
(p=0.16) (see Table 5.3.5).  
 
HRQoL outcomes 
Analyses highlighted a significant moderate to large improvement in TOI 
scores in the physical activity group compared to the usual care group 
over the 6-month intervention period (mean difference, 5.2 units; p=0.016). 
A significant moderate to large improvement for BCS scores was also 
recorded for the physical activity group compared to the usual care group 
over the study period (mean difference, 2.9; p=0.002). No significant 
differences between physical activity and usual care groups for PWB 
(p=0.98), SWB (p=0.47), EWB (p=0.87), FWB (p=0.58), FACT-G (p=0.70) 
and FACT-B (p=0.10) were recorded (Table 5.3.6). 
 
Chi-square analysis of the BCS, FACT-G, FACT-B and TOI variables 
revealed significant associations between intervention and usual care 
groups and the number of participants who experienced minimum clinically 
important increases in BCS, χ2 (1)=6.19, p=0.013, and TOI , χ2 (1)=8.34, 
p=0.004. Significantly more participants in the intervention group 
experienced minimum clinically important improvements in BSC and TOI 
between baseline and post-intervention compared to the usual care group 
(n=21/37 vs. n=9/33 or 57% vs. 27%; and n=24/37 vs. n=10/33, or 65% 
vs. 30%). No significant associations were found between intervention and 
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usual care groups and the number of participants who experienced 
minimum clinically important changes in FACT-G, χ2 (1)=0.31, p=0.63, and 
FACT-B, χ2 (1)=1.67, p=0.23, variables. 
 
Blood biomarker outcomes 
We found significant reductions TC and LDL-C in the physical activity 
group compared to the usual care group over the 6-month intervention 
period (mean difference, 0.45 units; p=0.006) -0.308 0.151 -0.006 to -
0.610 0.046 0.46. However, no significant changes were observed in TG, 
HDL-C, glucose, insulin or HOMA between the groups over the 
intervention period (see Table 5.3.7).  
 
5.3.5 DISCUSSION 
As hypothesised, breast cancer survivors who received the home-based 
physical activity intervention significantly increased our primary outcome, 
self-reported total physical activity (MET-min·wk-1 and time) when 
compared with usual care post-intervention. We also found further 
significant improvements in body mass, BMI, domestic (MET-min·wk-1) and 
moderate (both MET-min·wk-1 and time) physical activity, HRQoL (BCS 
and TOI) and TC and LDL-C concentrations in the intervention compared 
to usual care. All of the significant improvements above were found to 
have moderate to large effect sizes, apart from the small to moderate 
effect observed for domestic physical activity. Significantly more 
participants in the intervention group experienced minimum clinically 
important improvements in BSC (increases of ≥2 points) and TOI 
(increases of ≥5 points) between baseline and post-intervention compared 
to the usual care group. However, we observed no significant 
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improvements in body fat, and other physical activity, HRQoL and blood 
biomarker variables. 
 
Our findings of increases in total and moderate physical activity are 
consistent with previous home-based physical activity interventions with 
an additional physical activity counselling element (Rogers et al., 2009; 
Matthews et al., 2007; Pinto et al., 2005). Two previous similar trials 
(Matthews et al., 2007; Pinto et al., 2005) found improvements in self-
reported physical activity in the intervention groups compared to usual 
care, while another study (Rogers et al., 2009) found increases in 
objective physical activity but not self-reported physical activity. Unlike one 
of the previous studies (Matthews et al., 2007), we found no significant 
increases in self-reported walking from baseline to post-intervention in the 
intervention group compared to the usual care group. However, while in 
the current study we encouraged walking as an effective way of meeting 
recommended physical activity guidelines, we also encouraged other 
moderate activities, such as other aerobic exercise (e.g. running, 
stationary cycling, elliptical trainers, rowing machines, swimming, etc.) and 
the use of fitness DVD’s. In addition, the IPAQ assesses walking in 
occupational and active transport domains as well as leisure domains, so 
it is also probable that the usual care engaged in this type of activity as 
much as intervention participants as part of general daily activities. 
 
Unlike similar previous studies, we found significant reductions in body 
mass and BMI (Rogers et al., 2009; Matthews et al., 2007; Pinto et al., 
2005). Although the mean pre-post differences in the intervention 
compared to usual care could be considered modest for both outcomes (-
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1.6 kg and -0.6 m·kg-1), it does represent at the least more effective weight 
management. The significant reductions in mass and BMI were surprising 
given that the intervention did not focus on weight loss and did not involve 
any calorie restriction. However, previous research (Pate et al., 1996) has 
found positive associations between physical activity and healthy eating 
behaviours; therefore, it is possible that participants in the intervention 
group changed to healthier eating behaviours when becoming more 
physical activity, which in turn may have had a beneficial effect on mass 
and BMI. The reasons for our significant improvements compared to the 
lack of improvements seen in earlier studies (Rogers et al., 2009; 
Matthews et al., 2007; Pinto et al., 2005) could be due in part to the longer 
duration of the current study compared to the earlier studies (6-months vs. 
12-weeks). However, we found no significant improvements in body fat % 
despite the improvements in mass and BMI. It is possible that the method 
of assessing body fat %, bioelectrical impedance, was not a precise 
enough method to measure small changes in body fat over time (Dehghan 
and Merchant, 2008). 
 
The findings of significant increases in the HRQoL variables, BCS and 
TOI, indicate that our intervention may have specific benefits for breast 
cancer survivors given that higher BCS scores indicates fewer breast 
cancer-specific symptoms, and higher TOI scores indicates greater 
physical and functional well-being and fewer breast cancer-specific 
symptoms. One previous study (Courneya et al., 2003) investigated the 
effects of a physical activity intervention on HRQoL in breast cancer 
survivors, and found similar significant improvements in the TOI and BCS 
scores (mean difference=6.3 and 3.6, respectively; both p<0.001). Only 
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one of the previous home-based physical activity interventions with an 
additional physical activity counselling element measured HRQoL (Rogers 
et al., 2009). Using the same FACT questionnaire, the authors (2009) 
reported significantly greater improvements social well-being in the 
intervention group versus usual care group, but no significant 
improvements were found in the other HRQoL variables. Unfortunately, 
the TOI was not calculated for this study (Rogers et al., 2009) so it was not 
possible to make a comparison with this current study. Significant 
improvements in the FACT-B variable in the intervention group versus 
usual care group was reported by an earlier home-based physical activity 
trial involving breast cancer survivors, which did not have a counselling 
component (Vallance et al., 2007). The authors (2007) only reported the 
FACT-B variable.  
 
The reasons for the differences in HRQoL between previous studies are 
unclear. However, it is likely that the breast cancer stage, treatment 
received and both the time since diagnosis and the end of treatment may 
influence participant’s responses to the items with the FACT 
questionnaire. For instance, given that our sample was on average 38 
weeks post-treatment, it is possible that items such as “I have nausea” 
may no longer be relevant. Nevertheless, we did find minimum clinical 
significant improvements in BSC and TOI in the intervention versus usual 
care, which can be interpreted in part as fewer reported breast cancer-
specific symptoms such as “shortness of breath”, “change in weight” and 
“effect of stress on illness” in the intervention group compared to the usual 




The significant reductions observed in TC and LDL-C as a result of home-
based physical activity were encouraging given that the recent findings of 
Santos et al. (2014) suggesting that LDL-C promotes breast cancer cell 
proliferation, migration and loss of adhesion, which are hallmarks epithelial 
to mesenchymal transition. In addition, existing literature investigating the 
prevention of CVD emphasize the role of TC and LDL-C with a 
supplementary role for HDL-C and a modest role for TG (ECS and EAS, 
2011; O’Keefe et al., 2004; Edwards and Moore, 2003). Every 1.0 mmol·L-
1 reduction in TC and LDL-C has been associated with a corresponding 
50% and 22% reduction in CVD mortality and morbidity, respectively 
(CTTC, 2010; Stamler et al., 1993). Extrapolating from the available data, 
the observed 0.33 mmol·L-1 and 0.26 mmol·L-1 mean reductions in TC and 
LDL-C, respectively, in the intervention group in the current study, would 
equate to CVD mortality risk reductions of 16.5% and 5.72%. Evidence 
supports our finding of the role that physical activity can play in favourably 
altering lipid profiles. In a recent meta-analysis, aerobic exercise was 
found to result in significant mean reductions in TC and LDL-C, a small but 
significant mean increase in HDL-C and unaltered TG concentrations 
(Pattyn et al., 2013). Previous studies involving breast cancer survivors 
have also observed favourable effects of physical activity on lipid profiles. 
Fairey and colleagues (2005) found significant reductions in TG and non-
statistically significant but clinically important changes in TC, HDL-C and 
LDL-C after an aerobic exercise intervention compared to usual care. 
Similarly, two other studies employing combined aerobic exercise and 
resistance training interventions in breast cancer survivors found 
favourable effects of lipid profiles. Mefferd and co-workers (2007) 
observed reductions in TC to a level no longer at risk for CVD and 
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significant changes in the ratio of TC to HDL-C and TG concentrations, 
while Nuri et al. (2012) found significant increases in HDL-C and 
reductions in TG.   
 
Hyperinsulinemia may play a role in facilitating breast cancer recurrence 
and progression (Goodwin et al., 2002b). Insulin may have a mitogenic 
effect on breast cells, inhibit sex hormone binding globulin and promote 
the release of adipokines, leptin, TNF-α and IL-6, which stimulate 
aromatase activity, angiogenesis, proliferation, invasion and metastasis 
and inhibits apoptosis (Lann and LeRoth, 2008; Rose et al., 2004; Kaaks, 
1996). However, we found no significant changes in glucose, insulin and 
insulin-resistance, which was consistent with several previous studies 
involving physical activity interventions in breast cancer survivors and non-
diabetic participants (Pattyn et al., 2013; Schmitz et al., 2005; Fairey et al., 
2003). Conversely, other physical activity interventions in breast cancer 
survivors found significant reductions in insulin (Nuri et al., 2012; Irwin et 
al., 2009; Ligibel et al., 2008) and glucose (Nuri et al., 2012). However, 
only one of these studies involved an aerobic exercise only intervention 
(Irwin et al., 2009), the other studies consisted of aerobic exercise and 
resistance training combined (Nuri et al., 2012; Ligibel et al., 2008). 
Therefore, the effect of aerobic exercise on glucose-insulin dynamics is 
unclear due to a lack of agreement between available studies (Fairey et 
al., 2003; Irwin et al., 2009). There are perhaps alternative reasons for the 
lack of reductions in glucose, insulin and insulin-resistance in the current 
study, including an insufficient sample size to detect differences between 
groups, an insufficient reduction in body fat (Ross et al., 2004) and the fact 
that the majority of participants did not have diabetes (Pattyn et al., 2013). 
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In order to interpret the findings of this current study, the strengths and 
limitations must be carefully considered. The strengths of the current study 
include its randomised design, the use of an independent clinical trials unit 
to randomise patients and conceal the allocation sequence from the 
principle investigator and an analysis plan that adhered to intention-to-
treat principles. We reported moderate to large effect sizes for all but two 
of our statistically significant findings. We recruited participants over two 
full calendar years; therefore, it is unlikely that our results were influenced 
by the seasonal changes in physical activity suspected in previous 
research (Vallance et al., 2007). The generalisability of our findings is 
increased by the recruitment of breast cancer survivors diagnosed with 
stage I to III rather than only early-stage breast cancer and the fact that we 
included both pre- and post-menopausal breast cancer survivors. The 
results of the trial were promising given that the intervention was relatively 
brief, inexpensive and highly feasible given that it was home-based and 
consisted of a single in-person counselling session followed by three 
support telephone calls. The fact that this intervention was home-based 
increases the portability of the intervention. Intervention portability is 
important so that the intervention can be implemented in health care and 
community settings so that the maximum number of breast cancer 
survivors can benefit. Further enhancing the ability to translate this 
intervention into these settings is the fact that it did not require specialist 
exercise equipment or face-to-face physical activity supervision by 
exercise professionals. Moreover, support staff in a health care setting or 
community volunteers could successfully deliver the intervention after 
appropriate training, and because the telephone calls were relatively brief 
they represent a minimal burden to staff. Thus, this intervention represents 
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an important step toward developing cost-effective and feasible 
interventions that can help a large number of breast cancer survivors to 
engage in sufficient levels of physical activity.  
 
This study was not without its limitations. We did not control for the 
increased risk of type I errors when making multiple comparisons. 
Moreover, given the 26 secondary comparisons, our study is subject to at 
least one false discovery by chance if all of these comparisons were 
actually null. The reliance of self-report physical activity rather than 
objective measures to assess changes in physical activity can be seen as 
a limitation. Self-report measures, such as IPAQ, require participants to 
recall past activity, are a subjective means of estimating individual physical 
activity levels and are reliant on the individuals’ ability to remember levels 
of exposure (Watkinson et al., 2010). The IPAQ assesses physical activity 
performed in the seven days prior to assessment, therefore, it is possible 
that the monitoring period at baseline and post-intervention may not have 
been representative of physical activity during the entire 6-month 
intervention. Self-report measures are also at risk of social desirability 
bias, which describes when participant responses reflect a social desirably 
outcome. In this case, participants self-reported physical activity levels 
may be higher than the actual levels performed. However, we would have 
expected this bias across both groups given that the participants in the 
usual care group were not discouraged from taking part in physical 
activity. Furthermore, recent research has suggested that there is minimal 
evidence of social desirability for self-reported physical activity measures 
(Motl et al., 2005). 
363 
 
The higher physical activity levels reported by the usual care group at 
baseline were a concern. Although our eligibility criteria ensured both 
groups completed treatment a similar number of weeks before the initial 
assessment, and our stratified randomisation process allocated the same 
number of participants who had completed chemotherapy into each group, 
we did not have specific eligibility criteria or did not apply stratification to 
randomisation based on physical activity levels. Therefore, the study was 
at risk of having groups with differing physical activity levels at baseline. 
However, the higher self-reported physical activity levels of the usual care 
group were not indicative of a generally higher physical activity level 
across all participants in the usual care group compared to the intervention 
group; rather, it was largely the result of three participants in this group 
who reported much higher activity levels (≥5000 MET-min·wk-1) compared 
to other participants. Therefore, with the exception of these three 
participants the levels of physical activity were similar in both groups, as 
evidenced by the number of participants in the low and moderate activity 
physical activity categories in each group.  
 
In addition to the higher physical activity levels at baseline, there was 
evidence of contamination of the usual care group. Six of the usual care 
group increased their physical activity levels enough to move to a higher 
physical activity category from baseline to post-intervention. This 
contamination may have been because we informed participants in the 
usual care of the current recommended physical activity guidelines and did 
not discourage them from engaging in physical activity. We felt that it 
would be unethical to prevent participants from engaging in a physical 
activity, given the disease risk associated with sedentary lifestyles. In 
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addition, it is likely that because ours was a physical activity trial it would 
attract breast cancer survivors who were interested in commencing or 
increasing their physical activity levels. Therefore, the usual care 
participants who increased their physical activity levels may have done so 
because of a greater state of “readiness” to engage in physical activity. 
This finding is consistent with a previous study, which found that breast 
cancer patients beginning adjuvant therapy increased physical activity 
more when given physical activity recommendations compared to patients 
who did not receive such recommendations (Jones et al., 2004). 
Nevertheless, despite possible usual care group contamination, we found 
significant improvements in total physical activity in the intervention group 
compared to the usual care group and more participants moved to a 
higher physical activity category in the intervention group compared to the 
usual care group over the study period.  
 
It is possible that the significant changes in HRQoL found in the 
intervention group compared to the usual care group could in part be 
explained by the greater attention we gave the intervention group 
participants. Participants in this group received approximately 75 minutes 
more attention in the form of face-to-face and telephone counselling, 
compared to the participants in the usual care. Subsequent studies should 
attempt to balance the attention given to both groups in order to minimise 
the possibility of attention bias influencing results. 
 
It is unclear whether the hormone therapy status of the breast cancer 
survivors influenced our finding that physical activity favourably altered 
lipid profiles. Evidence suggests that Tamoxifen may favourably alter lipid 
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profiles, while aromatase inhibitors may have a negative effect on lipid 
profile, although the evidence for this is less clear (Hozumi et al., 2011). 
We did not gather data on the hormone therapy status of participants, and 
therefore, we cannot rule out that this may have influenced our findings. 
However, because we balanced the groups in regard to chemotherapy 
treatment and the group were similar in age and most other 
characteristics, it is probable that the groups did not differ in regards to 
hormone therapy status.  
 
Although the randomisation was performed by an independent clinical 
trials unit, the outcome assessor was not blinded to the allocation of 
participants. This would have been difficult as the primary investigator was 
responsible for delivering both the face-to-face and telephone counselling 
sessions and for performing the outcome assessments. Therefore, we 
cannot rule out the possibility that measurement bias influenced our 
results. Measurement bias can be introduced if the outcome assessor 
consciously or unconsciously provides more encouragement during 
assessments to the participants in the intervention group than those in the 
usual care group, which may result in more favourable scores in the 
intervention group. However, every attempt was made to standardise 
protocols across groups and the outcome assessor was carefully trained 
and monitored for objective and consistent administration of protocols. 
While attempts were made to reduce measurement bias attributed to the 
outcome assessor, the inability to blind participants to group allocation 
was not possible. This inability to blind participants is an inherent limitation 
of physical activity studies, which may bias participant responses and 
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behaviours because of their awareness of the study purpose and desire to 
please the study research staff.  
 
There is a suggestion that the trial may have potentially been influenced 
by recruitment (selection) bias. Our trial attracted breast cancer survivors 
with an average younger age compared to the average age of breast 
cancer survivors (53 y vs. 61 y) (Howlader et al., 2013). Furthermore, 
when using the self-report IPAQ “moderate” and “high” physical activity 
categories to identify participants meeting current recommended physical 
activity guidelines, a greater number of participants in this current trial 
were meeting these guidelines compared to the general English 
population (~82% vs. 40%) (Roth, 2009). However, Bauman and 
colleagues (2009) recommend using the “high” IPAQ category to identify 
those meeting physical activity recommendations. Use of the “high” 
category in this way would have resulted in a much lower number of 
participants not meeting physical activity guidelines compared to the 
general English population (13% vs. 40%) (Roth, 2009). This finding would 
be consistent with US-based research reporting generally lower physical 
activity among breast cancer survivors (Irwin et al., 2003; Irwin et al., 
2004).  
 
However, because participants knew they were being recruited to a 
physical activity trial it is possible that the participants who were eligible 
and consented to taking part were those participants who were already 
interested in physical activity and thus, more susceptible to change. This 
may limit the generalizability of our results to breast cancer survivors 
ready to perform higher levels of physical activity. Further limiting the 
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generalisability of our results was the homogeneity of our sample. The 
majority of participants were white British (95%), non-smoking (94%), 
married (74%) women with children (86%) who did not have a family 
history of breast cancer (81%). Therefore, further research is required to 
establish the generalisability of results to non-white breast cancer 
survivors, in particular. 
 
Future studies are needed to investigate the generalizability of findings 
observed in this current study and similar previous studies to, in particular, 
ethnic minority populations, for which the cultural barriers to engaging in 
physical activity may differ from those of the predominantly Caucasian 
samples used in previous research. Objective assessments of physical 
activity should be used in combination with self-report to allow for a more 
precise measurement of physical activity patterns amongst participants in 
future trials. Subsequent studies should attempt to balance the attention 
given to both intervention and usual care groups to minimise the effects of 
attention bias. It is also important to establish the cost-effectiveness of 
such physical activity interventions given the increased burden on health 
care services. The cost-effectiveness of physical activity trials could be 
assessed by comparing the costs of running these interventions to the 
possible cost-saving effects of such trials, which may include outcomes 
such as reduced hospital admissions and usage of health care services in 
the years following treatment. In addition, assessment of physical activity 
maintenance after study completion are required to understand whether 
breast cancer survivors adhere to physical activity guidelines once they 
have left the study interventions. This type of longitudinal physical activity 
follow-up study is also required to measure to effects of consistent 
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physical activity on recurrence, late treatment effects, such as 
cardiotoxicity, and breast cancer-related and all-cause mortality in a 
randomised controlled study design.  
 
5.3.6 CONCLUSIONS 
Within the context of the limitations of this study, we found that a home-
based physical activity intervention resulted in significant favourable 
effects on self-reported physical activity, body mass, BMI, HRQoL, TC and 
LDL-C. Future research will be needed to establish the generalisability and 
maintenance of physical activity post-intervention. Further investigation is 
required to elucidate to impact of aerobic exercise interventions on 
glucose-insulin dynamics within breast cancer survivors. The portability 
and feasibility of this current intervention makes it a promising intervention 
that could benefit a large number of breast cancer survivors, therefore, it 
will be important to assess whether modifications would be needed when 
employed in older and perhaps less motivated breast cancer survivors. 
Future prospective longitudinal studies are needed to determine the 











5.4 The effects of a home-based physical activity intervention on 
cardiorespiratory fitness in breast cancer survivors 
5.4.1 ABSTRACT 
Introduction: Low cardiorespiratory fitness is inversely correlated with 
breast cancer-related deaths and cardiovascular and all-cause mortality. 
Breast cancer survivors have presented lower cardiorespiratory fitness 
compared to their age matched healthy, sedentary non-cancer peers. 
Meta-analyses have found significant improvements in cardiorespiratory 
fitness in breast cancer populations participating in physical activity 
interventions. However, these physical activity interventions typically 
involve supervised exercise programmes, which are costly to run and 
time-consuming. Therefore, the aim of this current study was to investigate 
the effects of a home-based intervention aimed at improving the physical 
activity levels of breast cancer survivors on cardiorespiratory fitness. 
Methods: Thirty two (40%) breast cancer survivors (height=162±5.4 cm; 
mass=70.6±10.3 kg; BMI=27.2±4.4 kg·m2) were randomly allocated from 
the parent study (study 5.3).In addition to the outcomes described in study 
5.3, the cardiorespiratory fitness (peak oxygen uptake, VO2 peak) of 
participants allocated to the substudy was assessed by a graded exercise 
test using gas exchange analysis. Primary outcomes were change in VO2 
peak, body mass and self-report physical activity levels. The intervention 
group received an intervention aimed at encouraging the achievement of 
current recommended physical activity guidelines of 150 min·wk-1 of 
moderate physical activity. The intervention consisted of a face-to-face 
physical activity consultation during the first visit, followed by support 
telephone calls at the end of months one, two and three, and a physical 
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activity reminder postcard during the last two months. Ethical approval 
was obtained from the Black Country NHS Research Ethics Committee 
(West Midlands, UK). 
Results: Mean VO2 peak (25.3±4.7 ml·kg-1·min-1) of the breast cancer 
survivors was classified as “poor” compared age and gender group 
matched normative values. We observed a significant moderate to large 
improvement in relative VO2 peak (ml·kg-1·min-1) (mean difference, MD, 
2.1; p=0.035, d=0.8), but not in absolute VO2 peak (L·min-1) (mean 
difference, 107.4; p=0.086, d=0.7) from baseline to post-intervention in the 
intervention group compared to usual care group. We found non-
significant in other test variables, body mass and self-report physical 
activity outcomes. Although, based on the effect size, 64% of the pre-post-
intervention increases in total physical activity in the intervention group 
would be above the average increase in the usual care group. 
Conclusion: We found significant moderate to large increases in relative 
cardiorespiratory fitness as a result of a home-based physical activity 
intervention, but future adequately powered trials are required to confirm 
this finding. Our data highlights the potential efficacy of a home-based 
physical activity intervention coupled with face-to-face counselling and 
telephone support in providing beneficial effects on cardiorespiratory 
fitness, which may influence breast cancer outcomes and CVD risk. 
 
5.4.2 INTRODUCTION 
Breast cancer is the most common malignancy in UK women, with an 
average of 48,988 new cases diagnosed per year during 2008 and 2010 
(ONS, 2012). Although the incidence rates of breast cancer in UK have 
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increased by 4.4% (2,148 new cases) from 2006 to 2008, improvements in 
early detection and treatment have resulted in substantial survival gains 
with breast cancer-specific mortality decreasing by 3% between 2006-08 
and 2008-10 and by 9.3% from 2000 to 2010 (ONS, 2012; 2011). As a 
result, 296,037 (790.8 per 100,000 women) UK women are now living with 
a previous history of breast cancer within the past 10 years (NCIN, 2010), 
with survival times in most breast cancer patients sufficient to increase 
their risk for CVD. 
 
Women diagnosed with breast cancer experience an excess of 
cardiovascular mortality (Eloranta et al., 2012). A recent retrospective 
cohort study, consisting of 63,566 breast cancer patients followed up for a 
median of nine years, found that CVD was the primary cause of death 
(15.9%, 95% CI 15.6-16.2) followed closely by breast cancer (15.1%, 95% 
CI 14.8-15.4) (Patnaik et al., 2011). The authors (2011) reported that CVD 
increased breast cancer-specific mortality by 24%, which may have been 
due to the cardiac toxicity associated with chemotherapy in breast cancer 
patents (Jones et al., 2007), and potentially under-diagnosis and under-
treatment of CVD for breast cancer patients, because their primary cancer 
diagnosis may be perceived as the overriding medical priority. In addition 
to this, the increased mortality due to CVD could be attributed to the 
higher number of women who survive breast cancer, who as they grow 
older are more likely to have comorbidities, and women with more 
comorbidities are more likely to die as a result of causes other than breast 




Higher levels of physical activity are associated with improved survival and 
fewer recurrences in women diagnosed with breast cancer (Beasley et al., 
2012; Ibrahim and Al-Homaidh, 2011) and has also been recommended 
as an intervention to improve CVD risk profile (Knobf and Coviello, 2011; 
Thompson et al., 2003). Furthermore, low cardiorespiratory fitness, usually 
measured by oxygen uptake at maximal or peak exercise (VO2 max or 
peak), has been shown to be inversely correlated with breast cancer-
related deaths and cardiovascular and all-cause mortality (Blair et 
al., 1996; Blair et al., 1989; Peel et al., 2009). Women with low 
cardiorespiratory fitness of below eight maximal metabolic equivalents 
(METs, where 1 MET=VO2 of 3.5 ml·kg-1·min-1) or a VO2 max of 28 ml·kg-
1·min-1 had a nearly three-fold increase in breast cancer deaths compared 
to those who reached 10 METs (VO2 max of 35 ml·kg-1·min-1) or greater 
(Peel et al. 2009). Therefore, it is worrying that a recent study indicated 
breast cancer survivors had a 22% lower VO2 max compared to their age 
matched healthy, sedentary non-cancer peers (Jones et al., 2012). 
 
Previous systematic reviews and meta-analyses have found significant 
improvements in cardiorespiratory fitness in breast cancer populations 
participating in physical activity interventions (Fong et al., 2012; McNeely 
et al., 2006). The results of the systematic review and meta-analysis 
conducted as part of the current thesis (see section 2.8) found greater 
improvements in the cardiorespiratory fitness of breast cancer survivors 
within aerobic exercise interventions. However, physical activity 
interventions involving breast cancer populations typically involve 
supervised exercise programmes, which are costly to run and time-
consuming. Therefore, given that health care resources are finite, cost-
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effective interventions that can improve the health of patients are more 
desirable to those making clinical, managerial and policy decisions. 
Several studies have found encouraging increases in cardiorespiratory 
fitness in breast cancer survivors utilising low-cost home-based physical 
activity interventions (Rogers et al., 2009; Fillion et al., 2008; Pinto et al., 
2005). Therefore, the aim of this current study was to investigate the 
effects of a home-based intervention focused on improving physical 
activity levels of breast cancer survivors on cardiorespiratory fitness. 
 
5.4.3 METHOD 
Trial design  
This current study was a two-armed, parallel design RCT that compared a 
six month home-based physical activity intervention to usual care. 
Individualised face-to-face consultations and telephone counselling to 
personalise goal-setting and assess progress formed the key components 
of our intervention. The current study presents the data from a substudy 
within the trial outlined in section 5.3. Forty per cent of the patients 
randomised to intervention and usual care groups in the parent study were 
randomised to a substudy involving an exercise tolerance test and blood 
pressure assessment in addition to all of the same outcome assessments 
administered as part of the parent study. The current study reports data 
collected at baseline and six months. Recruitment of participants took 
place between January 2010 and March 2013. 
 
Participants  
Women attending breast cancer clinics at Russells Hall Hospital (The 
Dudley Group of Hospitals, NHS Trust, UK), were invited to enrol on the 
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study by cancer care nurses working within these clinics. Interested 
patients were given a study information booklet and were contacted by the 
primary researcher via telephone a week later. The eligibility criteria have 
been described earlier in the methods of study 5.3 (please see pg. 330). 
The study was reviewed, approved and monitored by the investigational 
review boards of the Russells Hall Hospital and all subjects provided 
written consent prior to data collection. 
 
Participants were asked to visit the testing venue (Research and 
Development Unit, Russells Hall Hospital, Dudley) on two separate 
occasions at baseline and post-intervention. On the initial visit participants 
reported to the testing venue early in the morning following a 12 hour 
overnight fast. Upon arrival on the initial assessment day, participants’ 
height, mass and body composition were assessed. Participants were 
then asked to complete a demographics questionnaire, followed by the 
IPAQ and the FACT-B HRQoL questionnaire. Upon completion of the 
questionnaires participants had a venipuncture blood sample taken. For 
those participants who had been allocated to the cardiorespiratory fitness 
substudy an additional day and time (within 5 days of first assessment) 
was organised in order to complete an exercise tolerance test. Prior to 
exercise tolerance testing patient notes were reviewed by the author (IL) 
and the patients’ breast surgeon in order to establish whether they were 
any contraindications to engage in physical testing and activity. Before 
exercise testing, participants were asked to refrain from vigorous exercise 
the day before, to have eaten at least three hours before the test and to be 
normally hydrated pre-test. Participants were asked not to change their 
normal physical activity patterns from when the appointment was arranged 
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to the day of the two appointments. All participants were subjected to the 
same data collection procedures overseen by the same investigator. 
 
Home-based physical activity Intervention 
Following consent and randomisation, breast cancer patients in the 
intervention group received an intervention aimed at encouraging the 
adoption of a more physically active lifestyle. This intervention was 
described in detail in study 5.3. In brief, participants received a face-to-
face consultation, followed by a support telephone call at the end of 
months one, two and three. During the last two months (4 and 5) patients 
received physical activity reminder leaflets encouraging their participation 
in home-based physical activity. The initial goal of the intervention (months 
1-3) was for participants to progress towards accumulating 30 minutes of 
moderate intensity exercise on three to five days per week.  During 
month’s three to six, the intervention participants were encouraged to work 
towards accumulating at least 30 minutes of moderate-intensity physical 
activity on five to seven days per week in broad agreement with current 
public health guidelines (Bull and the Expert Working Groups, 2010). 
 
Since not informing patients about the benefits of physical activity may be 
considered unethical, participants randomised to the usual care arm 
received standard information regarding physical activity (i.e. the current 
recommended physical activity guidelines), as provided to all breast 
cancer patients treated at the site. Participants completed the same 
baseline and post-six month intervention assessments as the physical 




Study outcomes  
The outcomes reported in the current study include cardiorespiratory 
fitness as assessed via an exercise tolerance test, blood pressure and 
self-reported physical activity (assessed via IPAQ). The primary outcome 
of the current study was cardiorespiratory fitness (VO2 peak). Secondary 
outcomes included time to exhaustion (TTE), peak heart rate (HR peak), 
blood pressure at rest and total, leisure, moderate and vigorous physical 
activity (MET-min·wk-1). All assessments were made at baseline and within 
two weeks of completing the six-month intervention. The details of these 
assessments are described in chapter 4.3. 
 
Statistical analysis 
Only data from breast cancer survivors who had attended their initial 
assessments were included in the analysis. All data was inputted onto to a 
Microsoft Excel™ spreadsheet (Microsoft Corporation) and transferred to 
Statistical Package for Social Sciences (SPSS) (IBM™) for windows 
version 20.0 for analysis. For all analyses, we employed the intention-to-
treat (ITT) approach (Newell et al., 1992). Physical activity data outliers 
were identified by converting all scores to z-scores. Z-scores greater than 
3.29 were classed as outliers, values above this score were converted to 
one unit smaller than the next highest score with a z-score below 3.29 
(Tabachnik and Fidell, 2007). The distribution of all continuous, baseline 
and post-intervention outcomes were assessed using the same method 
outlined in study 5.3. Of the variables, all exercise tolerance test variables 
and blood pressure were normally distributed at both baseline and post-
intervention. Normally distributed variables were expressed as mean ± s, 
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while all other variables were described using medians (IQR). Categorical 
data were presented as number of participants and percentages.  
 
To correct for non-normal distributions, variables not normally distributed 
were log transformed. The physical activity data contained zero values, 
and were therefore, transformed to log10(X+1). Repeated-measures linear 
mixed model analysis was performed on all continuous trial outcomes to 
assess differences in group changes from baseline to post-intervention 
(i.e. 6-months from baseline). The rationale and description of this 
statistical test were provided in study 5.3. Statistical tests and 
corresponding p values were two-sided; a p-value of less than 0.05 was 
reported as statistically significant. Cohen’s d effect sizes for linear mixed 
model analysis was calculated based on the estimate comparing baseline 
values of the intervention group to the 6-month values in the intervention 
group and the baseline and 6-month values for the usual care group. 
Effect sizes for the t-values of each comparison were calculated by 
converting the t value to d using the formula provided in study 5.3 (pg. 
341). According to Cohen (1992) a small effect is denoted as d=0.2, 
medium effect d=0.5 and large effect d=0.8. For the purposes of this 
report, effect sizes of <0.20 were interpreted as small, 0.2 to <0.5 as small 
to moderate, 0.5 to <0.8 as moderate to large, and ≥0.8 as large. 
 
5.4.4 RESULTS 
Flow of participants through the trial and recruitment 
Eighty participants were recruited for the parent trial between January 
2010 and March 2013 (see section 5.3). Flow of participants through the 
study is provided in Figure 5.4.1. Forty participants each were randomised 
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to the intervention and usual care groups, and of the forty participants in 
each group 40% (16 in each group) were randomly allocated to the 
cardiorespiratory fitness substudy presented here. Twenty nine of the 
substudy participants completed the trial, with 15 and 14 completers in the 
intervention group and usual care group, respectively. One participant 
assigned to the intervention group dropped out of the trial due to a 
recurrence of breast cancer, while of the two participants assigned to the 
usual care group, one dropped out of because she did not want to return 
to the hospital for reassessment and the other participant was not 
contactable and as such was lost to follow-up. 
 
 




Table 5.4.1 Personal characteristics of the participants at baseline 
(intervention, n=16; usual care, n=16) 




N (%) usual 
care 
Mean±s age (y) 52.3±9.6 52.5±10.7 52.0±8.6 
Mean±s time since diagnosis (wk) 40.6±24.5 41.3±25.5 39.9±25.4 
Mean±s time since end of 
treatment (wk) 
10.9±9.2 10.1±9.4 11.6±11.6 
Ethnic Origin:  








o Obese (BMI=> 30) 
o Overweight (BMI=25-
29.9) 
o Normal (BMI=18-24.9) 




































o Mean±s cigarettes/day 





















o No  
Mean±s no. of days/week when 
alcohol is drank 







































o High Cholesterol 
o Heart disease 
o Vascular disease 
o Asthma or chronic 
bronchitis 
o Osteoarthritis 
o Rheumatoid arthritis 
o Kidney disease 











































































N (%) usual 
care 
Mean±age at birth of first child (y): 24.3±10.4 25.4±8.3 23.3±12.3 




























































o Married  
o Not married, living with 
partner 




















o O-levels or GCSE 
o A-level or equivalent 
o NVQ 
o College degree or 
diploma 
o Bachelor degree 
o Post-graduate degree  
o Other or not listed 
































Employment status:  
o Employed full-time 
o Employed part-time 
o Homemaker 
o Unemployed 































Physical activity:    
o Low 9 (28) 4 (25) 5 (31) 
o Moderate 19 (59) 12 (75) 7 (44) 
o High 4 (13) 0 4 (25) 
381 
 
Table 5.4.2 Linear mixed model results for exercise tolerance test (ETT), body mass and physical activity (PA, MET-min·wk-1) 
variables comparing intervention group to usual care group at baseline to post-intervention† 
 Intervention group (n=16) Usual care group (n=16)    













VO2 peak (ml·min-1) 1749±311 1795±315 46 1816±264 1852±223 36 -107.4 -231.2 to 16.4 0.09 (0.7) 
VO2 peak (ml·kg-1·min-1) 24.5±4.6 25.8±5.6 1.3 26.6±4.4 26.6±3.3 0 -2.1 -4.1 to -1.6 0.04 (0.8) 
Time to Exhaustion (sec) 471±105 531±100 60 523±76 545±49 22 -34.2 -84.6 to 16.3 0.18 (0.5) 
Peak Heart rate (bpm) 176±11 181±9 5 174±16 174±16 0 -4.1 -9.2 to 1.0 0.11 (0.6) 
Resting SBP (mm·Hg-1) 125±10 126±14 1 127±13 126±12 -1 -3.0 -10.5 to 4.6 0.41 (0.3) 
Resting DBP (mm·Hg-1) 78±6 78±8 0 81±9 78±6 -3 -3.8 -8.6 to 1.2 0.13 (0.6) 
Resting MAP (mm·Hg-1) 97±10 98±14 1 99±11 96±9 -3 -4.4 -11.1 to 2.3 0.20 (0.5) 
Mass (kg) 72.5±12.4 71.0±12.7 -1.5 69.0±8.3 70.1±7.0 1.1 1.04 -1.9 to 4.0 0.48 (0.3) 
Total PAǂ 604 (1058) 1388 (661) 784 1313 (2023) 1497 (1623) 184 -0.16 -0.42 to 1.0 0.21 (0.5) 
Leisure PAǂ 308 (569)  792 (572) 484 428 (930) 594 (896) 166 -0.38 -1.41 to 0.72 0.51 (0.2) 
Walk PAǂ 404 (637) 752 (726) 348 347 (404) 545 (743) 198 0.19 -0.57 to 0.96 0.61 (0.2) 
Moderate PAǂ 202 (961) 586 (636) 384 599 (946) 819 (1651) 220 -0.39 -1.05 to 0.28 0.25 (0.4) 
Vigorous PAǂ 0 (0) 0 (320) 0 0 (270) 0 (180) 0 -0.59 -1.80 to 0.62 0.33 (0.4) 
Ave diff= average difference; Descriptive statistics presented as either mean±s or median (interquartile range) depending on distribution of data; 
† Post-intervention data were only available for the 15 participants in the intervention and the 14 participants in the usual care 
*The effect estimate represents the statistical difference between intervention and usual care groups pre-post-intervention, therefore, positive values 
represent higher than scores at baseline in the intervention group, while negative values represent lower scores at baseline in the intervention group. 
ǂ  Physical activity effect estimates, 95% CI, p-value and Cohen’s d based on linear mixed model analysis on data log transformed base 10, log10(X) 
Significant results in bold
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Participant characteristics at baseline 
Table 5.4.1 provides the baseline characteristics overall and by group 
assignment. Baseline data was collected from 32 breast cancer survivors 
(height=162±5.4 cm; mass=70.6±10.3 kg; BMI=27.2±4.4 kg·m2) who have 
completed the 6-month study duration. Both the intervention group 
(height=160±4.5 cm; mass=72.2±12.0 kg; BMI=28.2±4.9 kg·m2) and the 
usual care group (height=163±6.0 cm; mass=68.9±8.3 kg; BMI=26.1±3.6 
kg·m2) consisted of 40 participants. Sixteen (50%) patients had undergone 
chemotherapy, with an equal number of participants who had received 
chemotherapy in each group. The baseline characteristics of participants 
in the intervention and usual care groups were similar in terms of age, 
mean time since diagnosis and end of treatment, and other demographic 
and lifestyle factors (see table 5.4.1). 
 
Cardiorespiratory, body mass and physical activity outcomes 
Analysis of cardiorespiratory fitness revealed that the breast cancer 
survivor’s baseline mean VO2 peak was 25.3±4.7 ml·kg-1·min-1, with a 
median percentile of 20 (IQR=23.8) when each participants scores were 
compared to age and gender group matched normative values (ACSM, 
2009). The 20th percentile is described as a poor cardiorespiratory fitness. 
We observed a significant moderate to large improvement in 
cardiorespiratory fitness in relative terms (ml·kg-1·min-1) from baseline to 
post-intervention in the intervention group compared to usual care group 
(mean difference, 2.1; p=0.035, d=0.8). The interpretation of the Cohen’s d 
indicates that 79% of the usual care group’s change in relative VO2 peak 
was below that of the average VO2 peak change in the intervention group. 
However, no significant improvement was observed for cardiorespiratory 
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fitness in absolute terms (L·min-1) (mean difference, 107.4; p=0.086, 
d=0.7). Although, the large effect size indicates that 76% of participants in 
the usual care group increased their absolute VO2 peak by less than the 
participants in the intervention group. We found no significant differences 
between groups in TTE, HR peak or blood pressure at baseline versus 
post-intervention (see Table 5.4.2). Similarly, no differences were found in 
the physical activity group compared to the usual care group over the 6-
month intervention period for body mass and total, leisure, walking, 
moderate and vigorous physical activity (p>0.05). Although, based on the 
effect size, 64% of the increases in total physical activity from baseline to 
post-intervention in the usual care group would be below the average 
increase in the intervention group. 
 
5.4.5 DISCUSSION 
In our subset of breast cancer survivors, we found significant 
improvements in cardiorespiratory fitness (VO2 peak, ml·kg-1·min-1) in a 
physical activity intervention group compared to a usual care group. 
However, we found no significant improvements in absolute VO2 peak 
values, TTE, HR peak, blood pressure or physical activity levels in 
participants in the intervention group compared to usual care. 
 
The mean VO2 peak values of the breast cancer survivors in this current 
study are similar to that reported in previous studies in which 
cardiorespiratory fitness was measured directly (Burnett et al., 2013; 
Jones et al., 2012; Mehnert et al., 2011; Peel et al., 2009; Fillion et al., 
2008; Herrero et al., 2006; Hutnick et al., 2005; Courneya et al., 2003). 
The low VO2 peak values reflect the poor physical condition of our breast 
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cancer survivors, and were lower than the values (28 ml·kg-1·min-1) Peel et 
al. (2009) associated with a three-fold increase in risk of breast cancer 
mortality. Therefore, the values reported in the current study may indicate 
an increased risk of breast cancer mortality and the need for this 
population to engage in physical activity to improve cardiorespiratory 
fitness and overall health status. 
 
In the current study, breast cancer survivors in the intervention group 
significantly improved cardiorespiratory fitness compared to the usual care 
group. We found increases in VO2 peak values of 5.3% in the physical 
activity intervention group, compared to no change (0%) in the usual care 
group. The magnitude of this treatment effect was lower compared to the 
9% to 17% increases observed in previous studies assessing the effect of 
physical activity on VO2 peak in breast cancer survivors (Mehnert et al., 
2011; Fillion et al., 2008; Herrero et al., 2006; Hutnick et al., 2005; 
Courneya et al., 2003). However, all of the studies above consisted of 
supervised exercise interventions; therefore, the improvements observed 
in cardiorespiratory fitness in the current study are encouraging given the 
home-based nature of the intervention. Moreover, we observed non-
significant increases in physical activity levels in the intervention compared 
to usual care, thus, it is likely that improvements in cardiorespiratory 
fitness may have been greater if larger increases in physical activity levels 
were observed. In addition, the participants in the usual care maintained 
VO2 peak values, which suggest that the exercise tolerance test may have 
acted as a source of motivation to engage in physical activity over the 
study period. Nevertheless, the improvements in VO2 peak in our 
intervention group may improve participants’ ability to perform normal day 
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to day activities, increase independence, promote a sense of well-being 
and ultimately confer a positive influence on breast cancer mortality (Peel 
et al., 2009; Herrero et al., 2006). 
 
In the current study, the lack of improvement in relative VO2 peak 
observed in the usual care group, despite a slight non-significant 
improvement in absolute VO2 peak can almost entirely be attributed to 
non-significant increase in body mass (i.e. the increase in absolute VO2 
peak was equivalent to the increase in body mass). However, the 
significant increase in relative VO2 peak observed in the intervention group 
can only partially be explained by a reduction in body mass, given the non-
significant improvements in absolute VO2 peak (i.e. the increase in relative 
VO2 peak was higher than that expected for the reduction in body mass 
observed). Therefore, mechanisms other than reduced body mass may be 
responsible for the improvements in relative VO2 peak observed in the 
intervention group. The mechanisms by which physical activity can 
increase VO2 peak in breast cancer survivors remains to be elucidated. 
However, previous studies of postmenopausal women attributed physical 
activity-induced increases in VO2 peak to adaptations in skeletal muscles 
(Spina et al., 1993; 2000).  Adaptations associated with prolonged aerobic 
exercise, such as a greater left ventricular ejection fraction resulting from a 
more compliant cardiac chamber, increased oxidative enzyme activity, 
capillary density, myoglobin concentrations, muscle glycogen and higher 
percentage of type I fibre types, facilitate improvements in cardiac output 
and arterial-venous oxygen difference, which can in turn improve VO2 
peak (Levine, 2008; Bassett and Howley, 2000; Holloszy and Coyle, 
1984). Thus, it is probable that both increases in cardiac output and 
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arterial-venous oxygen difference contributed to the physiologic 
adaptations observed in this current trial. However, because we measured 
VO2 peak and not VO2 max, we cannot discount the possibility that 
psychological factors, such as increased motivation, self-confidence and 
tolerance, influenced the pre-post intervention changes in VO2 peak. 
 
The strengths and limitations of our trial merit comment. Strengths include 
the RCT design, validated measures of VO2 peak and the relatively brief 
and inexpensive, highly feasible and home-based nature of the 
intervention. The limitations of the parent study have been described in 
study 5.3, therefore, only the specific limitations of the substudy will be 
discussed in this section. The outcome assessor was not blinded to the 
allocation of participants, which was not possible as the primary 
investigator was responsible for delivering the face-to-face and telephone 
counselling sessions and for performing the outcome assessments. 
Therefore, we cannot rule out the possibility that measurement bias 
influenced our results. Measurement bias can be introduced if the 
outcome assessor consciously or unconsciously provided more 
encouragement during exercise tolerance tests to the participants in the 
intervention group than those in the usual care group, which may have 
resulted in more favourable scores in the intervention group. Breath-by-
breath systems can have a typical measurement error of approximately 
2%, and therefore, may account for a portion of the 5% improvement in 
VO2 peak observed in the intervention group (Lamberts et al., 2009). 
However, every attempt was made to standardise protocols across groups 
and the outcome assessor was carefully trained and monitored for 
objective and consistent administration of exercise test protocols. While 
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attempts were made to reduce measurement bias attributed to the 
outcome assessor, the blinding of participants to group allocation was not 
possible. This inability to blind participants is an inherent limitation of 
physical activity studies, which may bias participant responses and 
behaviours because of their awareness of the study purpose and desire to 
please the research staff.  
 
In the parent study (see study 5.3) 36 participants were needed in each 
group to detect a change in physical activity with a power of 0.80 and a 
two-tailed alpha less than 0.05. Therefore, the substudy was not powered 
to detect changes in cardiorespiratory fitness in the subsample of 32 
breast cancer survivors. Our finding of no significant improvements in 
physical activity levels despite greater increases in physical activity levels 
in the intervention group compared to the usual care group over the study 
period may have been a result of insufficient statistical power and a higher 
probability of type II errors. Therefore, future studies with sufficient 
statistical power to detect differences are required to confirm the effect of 
home-based physical activity on cardiorespiratory fitness in particular. 
 
5.4.6 CONCLUSIONS 
In the context of the limitations outlined above, we found significant 
moderate to large increases in cardiorespiratory fitness as a result of a 
home-based physical activity intervention. Our data highlights the potential 
efficacy of a home-based physical activity intervention coupled with face-
to-face counselling and telephone support in providing beneficial effects 
on cardiorespiratory fitness, which may influence breast cancer outcomes 
and CVD risk. Sufficiently powered future studies are required to detect 
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differences between groups to confirm our finding of improved 
cardiorespiratory fitness in our home-based physical activity intervention. 
Prospective longitudinal RCTs are needed to determine the impact of 
physical activity and improvements in cardiorespiratory on breast cancer 





























CHAPTER SIX: GENERAL DISCUSSION 
The aim of the current thesis was to investigate physical activity in breast 
cancer patients. Specifically, this project explored the awareness of the 
role of physical activity in breast cancer risk in an “at risk” of breast cancer 
population and levels of physical activity of women at different stages of 
the breast cancer pathway, namely, breast screening attendees (i.e. pre-
diagnosis), during adjuvant therapy and post-treatment breast cancer. 
Subsequently, the project investigated the effects of physical activity on 
outcomes associated with the health and well-being of breast cancer 
patients’ post-treatment (i.e. breast cancer survivors). The main findings of 
this current thesis expand our knowledge of physical activity among 
women at different stages of the breast cancer pathway and emphasises 
the role of physical activity in improving the lives of breast cancer patients 
survivors. 
 
As highlighted in the literature review, higher levels of physical activity are 
associated with a lower risk of developing breast cancer and both lifetime 
and recent (1 to 3 y) pre-diagnosis can reduce the risk of all-cause and 
breast cancer-related mortality. However, as indicated in the first study a 
relatively high proportion of the breast cancer screening attendees we 
sampled, were categorised as being low to moderately physically active 
and found to engage in low levels of recreational physical activity, despite 
a high level of awareness of the potential beneficial role of physical activity 
in reducing breast cancer risk. Furthermore, in the second study we found 
that physical activity was reduced in patients undergoing chemotherapy, 
and that the physical activity levels of breast cancer survivors were below 
the levels observed in breast screening attendees. Given the strong
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association found, in our systematic review and meta-analysis of 
epidemiological studies, between post-diagnosis physical activity and 
reductions in all-cause and breast cancer-related mortality.  
 
Our systematic review and meta-analysis of controlled trials investigating 
the effect physical activity interventions in breast cancer survivors, 
emphasized the beneficial effect that physical activity can have on 
outcomes such as self-reported physical activity, cardiorespiratory fitness, 
BMI, body fat %, muscular strength, systolic blood pressure, HRQoL, 
fatigue, self-esteem, depression and anxiety among breast cancer 
survivors. However, due to few available trials assessing particular 
outcomes, small number of participants and substantial heterogeneity of 
interventions implemented and measures used to assess outcomes, we 
could not draw conclusions on the impact of a number of outcomes such 
as mass, plasma glucose, insulin, HOMA and lipid concentrations. 
Furthermore, there was a paucity of data regarding the effectiveness of 
home-based physical activity interventions and interventions 
compromising of specific physical activity counselling in breast cancer 
survivors. To this author’s knowledge, no UK-based trials investigating this 
type of intervention in British breast cancer survivors exist. Overall, the 
findings from the review of physical activity interventions provided a strong 
rationale for investigating the effects of a home-based physical activity 
intervention on the health and well-being of breast cancer survivors.  
 
We conducted a RCT to explore whether a home-based physical activity 
intervention could be beneficial to breast cancer survivors. In this study we 




physical activity counselling component resulted in significant favourable 
effects on self-reported physical activity, body mass, BMI, HRQoL, TC and 
LDL-C. In a substudy involving 40% of the participants from the parent 
RCT, we observed significant increases in cardiorespiratory in the physical 
activity intervention compared to usual care over the study period. The 
results of the RCT are encouraging given the home-based nature of the 
intervention coupled with its counselling component. Home-based physical 
activity interventions are appealing in health care settings because they 
are relatively brief, inexpensive and highly feasible. One particular benefit 
of this type of intervention is its portability, it did not require specialist 
exercise equipment or face-to-face physical activity supervision by 
exercise professionals, which means that it can be implemented in a 
variety of health care and community settings to maximise the number of 
breast cancer survivors who can benefit.  
 
Physical activity counselling aims to promote physical activity behaviour 
change within the physical activity interventions. Few previous physical 
activity interventions in breast cancer survivors have included this 
component in their interventions, and therefore, it can be argued that 
these trials have neglected to consider the long-term implications of 
individuals’ adherence and motivation to exercise. Without the support to 
change physical activity behaviours beyond what is provided by the 
exercise facilities or the physical activity programmes, it is unlikely breast 
cancer survivors will be able to maintain their participation once the 
specified intervention period lapses. Therefore, the inclusion of a single 
face-to-face counselling session followed by three support telephone calls 
focused on promoting physical activity behaviour change and facilitating 
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adherence by providing encouragement and advice on overcoming 
barriers to physical activity. One of the key benefits of our intervention in 
regards to its portability was that support staff in a health care setting or 
community volunteers could successfully deliver the intervention after 
appropriate training, and because the telephone calls were relatively brief 
they represent a minimal burden to staff. Thus, this intervention may 
represent an important step toward developing cost-effective and feasible 
interventions that can help a large number of breast cancer survivors to 
engage in sufficient levels of physical activity. 
 
The portability and feasibility of this current intervention makes it a 
promising intervention that could benefit a large number of breast cancer 
survivors, therefore, it will be important to assess whether modifications 
would be needed when employed in older and perhaps less motivated 
breast cancer survivors. Further investigation is required to elucidate to 
impact of aerobic exercise interventions on glucose-insulin dynamics 
within breast cancer survivors. Given the increases in CVD mortality in 
breast cancer survivors, our finding of low cardiorespiratory fitness within 
our sample of breast cancer survivors was worrying. Studies with sufficient 
power to detect differences between groups are required to confirm our 
finding of improved cardiorespiratory fitness in our home-based physical 
activity intervention group versus usual care. The cost-effectiveness of 
home-based physical activity should be assessed in future research. This 
can be achieved by comparing the costs of running this type of 
interventions to the possible cost-saving effects of such trials, which may 
include outcomes such as reduced hospital admissions and usage of 
health care services in the years following treatment. Future prospective 
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longitudinal RCTs are needed to determine the impact of physical activity 
and improvements in cardiorespiratory fitness on breast cancer-related 
mortality, recurrence and development of CVD in breast cancer survivors. 
 
Overall, higher levels of physical activity were associated with lower all-
cause and breast cancer-related mortality, with post-diagnosis physical 
activity providing the strongest risk reductions. Physical activity 
interventions may have beneficial effects on the health and well-being of 
post-treatment breast cancer patients. Our observational studies 
discovered relatively low levels of physical activity, and in particular 
recreational physical activity, in women at different stages of the breast 
cancer pathway. In particular, women undergoing chemotherapy and 
those who had completed breast cancer treatment had lower levels of 
physical activity compared to women attending breast screening. We 
found that a home-based physical activity intervention with an additional 
specific physical activity counselling component resulted in significant 
improvements in self-reported physical activity, body mass, BMI, HRQoL 
and TC and LDL-C concentrations, and significant improvements in 
cardiorespiratory fitness and TC concentrations in a subsample of 
participants. Our data supports the inclusion of physical activity promotion 
as an integral component for the management breast cancer survivors. 
The home-based physical activity intervention with an additional 
counselling and support component utilised in this current study provides a 
promising, portable and highly feasible tool that could be applied in health 
and community settings to improve the health and well-being of large 
numbers of breast cancer survivors, and potentially reduce their risk of 
breast cancer-related, all-cause and CVD mortality. 
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CHAPTER SEVEN: LIMITATIONS 
Although the methodology of the present study was carefully designed, 
several potential limitations may have influenced our findings. Limitations 
are discussed in detail within each study, therefore, in this section an 
overview of the key limitations are presented. Limitations were listed as 
either general or study specific, depending on whether they affected the 
project as a whole or individual studies, respectively. 
 
7.1 General limitations 
• A cross-sectional design was utilised in the first and second study 
in the current project. Although the associations observed in these 
studies are interesting and can serve to generate hypotheses, they 
do not provide definitive evidence for causality and directionality, 
which can be best addressed via RCTs. 
• Physical activity levels were assessed in each study via self-report 
(IPAQ), which requires participants to recall past activity, and is 
therefore, a subjective means of estimating individual physical 
activity levels that relies on the individuals’ ability to remember 
levels of exposure (Watkinson et al., 2010). The IPAQ assesses 
physical activity performed in the seven days prior to assessment; 
therefore, it is possible that the monitoring period may not have 
been representative of participants’ typical physical activity. 
Furthermore, physical activity questionnaires are at risk of social 
desirability bias, which describes when participant responses reflect 
a social desirably outcome. In this case social desirability bias 
would be manifested as higher reported physical activity. However, 
physical activity questionnaires tend to result in over-reporting of 
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physical activity rather than under-reporting (Weinstein et al., 1998), 
therefore, the physical activity levels presented in our studies would 
represent over-reported values. However, recent research has 
suggested that there is minimal evidence of social desirability for 
self-reported physical activity measures (Motl et al., 2005).  
• All of the samples used in the current project were convenience 
samples, and therefore, expose all of the studies to selection bias, 
and as such our samples may not be representative of the 
population they were taken from. Selection bias refers to a 
systematic difference between a study sample and the population 
from which they were recruited or a systematic difference between 
the comparison groups within a controlled trial. Randomised 
recruitment sampling strategies can be used in place of 
convenience sampling to reduce selection bias. Furthermore, 
because we recruited participants to take part in physical activity 
studies, the group may have included participant’s interested or 
already engaged in physical activity. Therefore, our participants 
may not be representative of all post-treatment breast cancer 
patients. However, this would likely lead to higher levels of physical 
activity than what might be typical for this population.  
• Finally, the generalisability of our findings is limited due to the lack 
of ethnic diversity in our samples. Each of the participant groups 
consisted of 95% or more white British women, therefore, our 
findings are not generalisable to other ethnic groups. Furthermore, 
we recruited from only one geographical location, the Black Country 
region of the West Midlands, and thus, it cannot be assumed that 
findings in women from this area can be applied to all of the UK 
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population. However, the physical activity levels, BMI and other 
demographic variables were consistent with a sample of breast 
cancer patients taken from another location within the UK (Daley et 
al., 2007).    
 
7.2 Study specific limitations 
7.2.1 Study one and two 
• The generalisability of our findings regarding physical activity levels 
of women attending breast screening and women who are receiving 
or have completed breast cancer treatment is limited, because our 
sample included only women from the Black Country area of the 
West Midlands in the UK. Our samples of chemotherapy and post-
treatment breast cancer patients were also relatively small, which 
further limited our ability to generalise. Furthermore, the NHSBSP 
sample included in studies one and two was chosen as a “pre-
diagnosis” comparison group based on their status as an “at risk of 
breast cancer” group. However, clearly not all of the patients 
sampled will develop breast cancer, and therefore, this group may 
not be representative of breast cancer patients pre-diagnosis. 
• In study one, the BMI for the group of screening attendees was 
computed from self-reported height and mass. This may have 
influenced the data of the present study. However, self-reported 
BMI values tend to overestimate measured BMI values at the low 
end of the BMI scale (<22 kg·m2) and underestimate BMI values at 
the high end, particularly at values >28 kg·m2 (Stommel and 
Schoenborn, 2009). Therefore, because most of our sample had 
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BMI’s at the higher end and considering the general trend in the 
literature towards an underestimation of BMI, it is perhaps more 
probable that our mean self-reported BMI represents an 
underestimation rather than an overestimation. Furthermore, effects 
of physical activity on BMI and/or the effects of the different stages 
of breast cancer were not amongst the main aims of the project. 
 
7.2.2 Study three and four 
• Although we utilised a stratified randomisation process to reduce 
selection bias (i.e. systematic differences between intervention and 
usual care groups) and allocate the same number of participants who 
had completed chemotherapy into each group, we did not have specific 
eligibility criteria or did not apply stratification to randomisation based 
on physical activity levels. Unfortunately, higher physical activity levels 
were reported by the usual care group compared to the intervention 
group at baseline. However, the higher self-reported physical activity 
levels of the usual care group were largely the result of three 
participants in this group who reported much higher activity levels 
(≥5,000 MET-min·wk-1) compared to other participants. Therefore, with 
the exception of these three participants the levels of physical activity 
were similar in both groups, as evidenced by the number of participants 
in the low and moderate physical activity categories in each group.  
• There was a suggestion of contamination within the usual care group, 
that is, six of the usual care group increased their physical activity 
levels enough to move to a higher physical activity category from 
baseline to post-intervention. This contamination may have been 
because we informed participants in the usual care of the current 
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recommended physical activity guidelines and did not discourage them 
from engaging in physical activity. We felt that it would be unethical to 
prevent participants from engaging in a physical activity, given the 
disease risk associated with sedentary lifestyles. In addition, it is 
possible that the initial consultation may have acted as a minimal 
intervention, and increased the awareness of physical activity in breast 
cancer survivors who may already have been in a higher state of 
‘readiness’ to engage in increased levels of physical activity. 
Nevertheless, despite possible usual care group contamination, we 
found significant improvements in total physical activity in the 
intervention group compared to the usual care group and more 
participants moved to a higher physical activity category in the 
intervention group compared to the usual care group over the study 
period.  
• The trial results may have been influenced by attention bias. 
Participants in this group received approximately 75 minutes more 
attention in the form of face-to-face and telephone counselling, 
compared to the participants in the usual care. Therefore,  it is possible 
that the significant changes in HRQoL, in particular, found in the 
intervention group compared to the usual care group could in part be 
explained by the greater attention we gave the intervention group 
participants.  
• Furthermore, because the outcome assessor was not blinded to the 
allocation of participants, the trial is at risk of assessment bias. Blinding 
the assessor to the allocation of participants was not possible because 
the primary investigator was responsible for delivering both the face-to-
face and telephone counselling sessions and for performing the 
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outcome assessments. Assessment bias can be introduced if the 
outcome assessor consciously or unconsciously provides more 
encouragement during assessments to the participants in the 
intervention group than those in the usual care group, which may result 
in more favourable scores in the intervention group. However, every 
attempt was made to standardise protocols across groups and the 
outcome assessor was carefully trained and monitored for objective 
and consistent administration of protocols. In addition, assessment bias 
could have been introduced by the inability to blind participants to 
group allocation. This inability to blind participants is an inherent 
limitation of physical activity studies, which may bias participant 
responses and behaviours because of their awareness of the study 






CHAPTER EIGHT: CONCLUSIONS 
In summary, our two systematic reviews with meta-analyses revealed 
firstly, significant associations between higher levels of pre-diagnosis 
(lifetime and recent) and post-diagnosis physical activity and reduced risk 
of mortality, and secondly, significantly improved outcomes related to the 
health and quality of life of breast cancer survivors due to a physical 
activity intervention. Consistent with our first hypothesis, in study one we 
found relatively low levels of recreational physical activity in a population 
of breast cancer attendees and those with lower activity levels were 
unaware that their levels were below recommended levels of physical 
activity. However, contrary to our original predictions there was high 
awareness of the role of physical activity on the risk of breast cancer 
regardless of physical activity level. Therefore, the results suggest that 
strategies to improve awareness of how much physical activity is 
sufficient, and in turn the recreational physical activity levels of breast 
screening attendees. In study two our findings were consistent with our 
hypotheses, we observed lower levels of physical activity in both breast 
cancer patients undergoing adjuvant chemotherapy and patients post-
treatment compared to breast cancer attendees. The results of the above 
two studies provided a rationale for an intervention aimed to promote 
adherence to current UK recommended physical activity guidelines in 
post-treatment breast cancer patients. 
 
We tested the efficacy of a home-based physical activity intervention with 
an additional counselling component to increase physical activity in breast 
cancer survivors within a randomised controlled design setting. In 
agreement with our hypotheses, we found that a home-based physical 
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activity intervention resulted in significant favourable effects on self-
reported physical activity, body mass, BMI, elements of HRQoL, TC and 
LDL-C concentrations, but not body fat %, TG, HDL-C, glucose, insulin or 
HOMA. In addition, within a random subsample of breast cancer survivors 
from within the main RCT, we found significant improvements in 
cardiorespiratory fitness in the intervention group compared to the usual 
care group. These results were encouraging given the highly feasible, 
portable and home-based nature of the intervention. 
 
The results of each of the studies in this current project must be 
interpreted within the contexts of the limitations of each study. The 
limitations of the current project include the cross-sectional design of the 
first two studies, which does not provide definitive evidence for causality 
and directionality. The use of convenience samples increased the risk of 
results being influenced by recruitment bias. The homogeneity of our 
sample limited the generalisability of our findings to ethnic groups other 
than white British women. In addition, self-reported physical activity was 
measured as an outcome in this project, and as such our results could 
have been influenced by recall bias and/or social desirability bias. 
Furthermore, the inability to blind both the outcome assessor and trial 
participants exposed the RCT to assessment bias.   
 
Future research will be needed to establish the generalisability and 
maintenance of physical activity in the time post-intervention. Given the 
potential of our intervention to reach a large population of breast cancer 
survivors within health and community settings, it will be important to 
assess whether modifications would be needed when employed in older 
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and perhaps less motivated breast cancer survivors. Further investigation 
is required to elucidate the impact of home-based physical activity 
interventions on glucose-insulin dynamics and confirm our beneficial 
effects on cardiorespiratory fitness in a sufficiently large sample of breast 
cancer survivors. The cost-effectiveness of home-based physical activity 
could be explored by comparing the costs of running this type of 
interventions to the possible cost-saving effects of such trials, which may 
include outcomes such as reduced hospital admissions and usage of 
health care services in the years following treatment. Perhaps most 
importantly, future prospective longitudinal RCTs are needed to determine 
the impact of physical activity and improvements in cardiorespiratory on 
breast cancer-related mortality, recurrence and development of CVD in 
breast cancer survivors. 
 
Overall, this project highlighted the potential beneficial effects that a home-
based physical activity intervention coupled with face-to-face counselling 
and telephone support can have on the health and well-being of breast 
cancer survivors, and its potential in positively impacting factors that can 
influence the risk of CVD and breast cancer mortality. Our findings 
highlight the importance of including physical activity promotion in the 
management and post-treatment care of breast cancer survivors. The 
portability and feasibility of our intervention makes it a promising 
intervention that could benefit a large number of breast cancer survivors in 
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Appendix A: Tumour, Node, Metastasis (TNM) classification system, 7th Edition 




• Tis – Carcinoma in situ 
o Tis (Ductal): Intraductal carcinoma in situ 
o Tis (LCIS): Lobular carcinoma in situ 
o Tis (Paget): Paget disease of the nipple is not associated with 
invasive carcinoma and/or carcinoma in situ (DCIS and/or 
LCIS) in the underlying breast parenchyma (specialized 
human tissue located on the chest between the pectoralis 
muscle). Carcinomas in the breast parenchyma associated 
with Paget disease are categorized based on the size and 
characteristics of the parenchymal disease, although the 
presence of Paget disease should still be noted 
• N0 – No regional lymph node metastases 
o pNO: No regional lymph node metastasis identified 
histologically 
o pNO(i-): No regional lymph node metastases histologically, 
negative IHC 
o pNo(i+): Malignant cells in regional lymph node(s) no greater 
than 0.2 mm 
o pNO(mol-): No regional lymph node metastases 
histologically, negative molecular findings  
o pNO(mol+): Positive molecular findings, but no regional 
lymph node metastases detected by histology or IHC 
• M0 – No clinical or radiographic evidence of distant metastases 
o M0: No evidence of distant metastases 
Stage 
IA 
• T1 - Tumor ≤2 mm in greatest dimension 
o T1mi — Tumor ≤1 mm in greatest dimension 
o T1a — Tumor >1 mm but ≤5 mm in greatest dimension 
o T1b — Tumor >5 mm but ≤10 mm in greatest dimension 
o T1c — Tumor >10 mm but ≤20 mm in greatest dimension 
• N0: No regional lymph node metastases (see stage 0 for sub 
groupings) 
• M0: No clinical or radiographic evidence of distant metastases 
Stage 
IB 
• T0 — No evidence of primary tumour 
• pN1mi — Micrometastases (greater than 0.2 mm and/or more than 
200 cells, but none greater than 2.0 mm)  
• MO: cMO(i+) – No clinical or radiographic evidence of distant 
metastases, but deposits of molecularly or microscopically detected 
tumour cells in circulating blood, bone marrow or other non-regional 
nodal tissue that are no larger than 0.2 mm in a patient without 
symptoms or signs of metastases 
OR  
• T1 – Tumor ≤2 mm in greatest dimension (see Stage IA for 
subgroups) 
• pN1mi — Micrometastases (greater than 0.2 mm and/or more than 
200 cells, but none greater than 2.0 mm)  





• T0 — No evidence of primary tumour 
• N1 – Metastasis to movable ipsilateral level I, II axillary lymph 
nodes(s) 
o pN1 — Micrometastases; or metastases in 1 to 3 axillary 
lymph nodes; and/or in internal mammary nodes with 
metastases detected by sentinel lymph node biopsy but not 
clinically detected (i.e. not detected by imaging studies 
excluding lymphoscintigraphy, or by clinical examination) 
o pN1mi — Micrometastases (greater than 0.2 mm and/or more 
than 200 cells, but none greater than 2.0 mm)  
o pN1a — Metastases in 1 to 3 axillary lymph nodes, at least 
one metastasis greater than 2.0 mm 
o pN1b — Metastases in internal mammary nodes with 
micrometastases or macrometastases detected by sentinel 
lymph node biopsy but not clinically detected 
o pN1c — Metastases in 1 to 3 axillary lymph nodes and in 
internal mammary lymph nodes with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but 
not clinically detected 
• MO: see stage IB 
OR 
• T1 – Tumor ≤2 mm in greatest dimension (see Stage IA for sub 
groupings) 
• N1 – Metastasis to movable ipsilateral level I, II axillary lymph 
nodes(s) (see above for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases 
OR  
• T2 – Tumour >20 mm but ≤50 mm in greatest dimension 
• N0 – No regional lymph node metastases 
• M0 – No clinical or radiographic evidence of distant metastases 
Stage 
IIB 
• T2 – Tumour >20 mm but ≤50 mm in greatest dimension 
• N1 – Metastasis to movable ipsilateral level I, II axillary lymph 
nodes(s) (see IIA  for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases 
OR  
• T3 – Tumor >50 mm in greatest dimension 
• N0 – No regional lymph node metastases 
• M0 – No clinical or radiographic evidence of distant metastases 
Stage 
IIIA  
• T0 – No evidence of primary tumour 
• N2 – Metastasis to ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted; or in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically evident axillary node 
metastases 
o pN2 – Metastases in 4-9 axillary lymph nodes; or in clinically 
detected internal mammary lymph nodes in the absence of 
axillary lymph node metastases 
o N2a – Metastasis to ipsilateral level I, II axillary lymph nodes 
fixed to one another (matted) or to other structures 
o pN2a – Metastases in 4 to 9 axillary lymph nodes (at least 
one tumor deposit greater than 2.0 mm) 
o N2b – Metastasis only in clinically detected ipsilateral internal 
mammary nodes and in the absence of clinically evident 
axillary node metastases 
o pN2b – Metastases in clinically detected internal mammary 




• M0 – No clinical or radiographic evidence of distant metastases 
OR 
• T1 – Tumor ≤2 mm in greatest dimension (see Stage IA for sub 
groupings) 
• N2 – Metastasis to ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted; or in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically evident axillary node 
metastases (see above for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases  
OR 
• T2 – see above for sub groupings 
• N2 – Metastasis to ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted; or in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically evident axillary node 
metastases (see above for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases  
OR 
• T3 – Tumor >50 mm in greatest dimension 
• N1 – Metastasis to movable ipsilateral level I, II axillary lymph 
nodes(s) (see IIA  for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases  
• OR 
• T3 – Tumor >50 mm in greatest dimension 
• N2 – Metastasis to ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted; or in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically evident axillary node 
metastases (see above for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases 
Stage 
IIIB  
• T4 – Tumor of any size with direct extension to the chest wall and/or 
the skin (ulceration or skin nodules) 
o T4a — Extension to chest wall, not including only pectoralis 
muscle adherence/invasion 
o T4b — Ulceration and/or ipsilateral satellite nodules and/or 
edema (including peau d'orange) of the skin which do not 
meet the criteria for inflammatory carcinoma 
o T4c — Both (T4a and T4b) 
o T4d — Inflammatory carcinoma 
• N0 – No regional lymph node metastases 
• M0 – No clinical or radiographic evidence of distant metastases  
OR 
• T4 – Tumor of any size with direct extension to the chest wall and/or 
the skin (ulceration or skin nodules) (see above for subgroups) 
• N1 – Metastasis to movable ipsilateral level I, II axillary lymph 
nodes(s) (see IIA  for sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases  
OR 
• T4 – Tumor of any size with direct extension to the chest wall and/or 
the skin (ulceration or skin nodules) (see above for subgroups) 
• N2 – Metastasis to ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted; or in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically evident axillary node 
metastases (see above for IIIA  sub groupings) 
• M0 – No clinical or radiographic evidence of distant metastases  
Stage 
IIIC  
• Any T 
• N3 – Metastases in ipsilateral infraclavicular  (level III axillary) lymph 
node(s) with or without level I, II axillary lymph node involvement 
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(N3a); or in clinically detected ipsilateral internal mammary lymph 
node(s) with clinically evident level I, II axillary lymph node 
metastases (N3b); or metastases in ipsilateral supraclavicular lymph 
node(s) with or without axillary or internal mammary lymph node 
involvement (N3c) 
o pN3 – Metastases in 10 or more axillary lymph nodes; or in 
infraclavicular (level III axillary) lymph nodes; or in clinically 
detected ipsilateral internal mammary lymph nodes in the 
presence of 1 or more positive level I, II axillary lymph nodes; 
or in more than 3 axillary lymph nodes and in internal 
mammary lymph nodes with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but 
not clinically detected; or in ipsilateral supraclavicular lymph 
nodes 
o pN3a — Metastases in 10 or more axillary lymph nodes (at 
least one tumour deposit greater than 2.0 mm); or 
metastases to the infraclavicular (level III axillary lymph) 
nodes 
o pN3b – Metastases in clinically detected ipsilateral internal 
mammary lymph nodes in the presence of 1 or more positive 
axillary lymph nodes; or in more than 3 axillary lymph nodes 
and in internal mammary lymph nodes with micrometastases 
or macrometastases detected by sentinel lymph node biopsy 
but not clinically detected 
o pN3c – Metastases in ipsilateral supraclavicular lymph nodes 
Stage 
IV 
• Any T 
• Any N 
• M1 – Distant detectable metastases as determined by classic 
clinical and radiographic means and/or histologically proven 

















Appendix B: epidemiological systematic review; MEDLINE (via PubMed) search 
strategy and results 
 Query Items 
found 
1 Search physical activity [mh] 171397 
2 Search physical activ* [tiab] 52380 
3 Search physical* activ* [tiab] 25569 
4 Search exercise [mh] 101067 
5 Search exercis* [tiab] 188821 
6 Search motor activity [mh] 171397 
7 Search training [tiab] 226754 
8 Search sports [mh] 103589 
9 Search sport* [tiab] 39560 
10 Search fitness [tiab] 36630 
11 Search cardiovascular [tiab] 256395 
12 Search cardiorespiratory [tiab] 10078 
13 Search cardio-respiratory [tiab] 1563 
14 Search resistance training [mh] 2478 
15 Search aerobic [tiab] 51706 
16 Search walk* [tiab] 66214 
17 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR 
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16) 
940761 
18 Search breast neoplasms [mh] 203202 
19 Search cancer* 132892
0 
20 Search carcinom* 607735 
21 Search neoplas* 209289
4 
22 Search malignan* 392824 
23 Search tumour* 201740 
24 Search tumor* 108354
0 
25 Search (#19 OR #20 OR #21 OR #22 OR #23 OR #24) 292403
2 
26 Search breast 331449 
27 Search (#25 AND #26) 269050 
28 Search (#17 AND #27) 7028 
29 Search mortality [tiab] 432127 
30 Search survival [tiab] 548430 
31 Search recurrence [tiab] 170324 
32 Search survivor* [tiab] 59666 
33 Search death [tiab] 433653 
34 Search relapse* [tiab] 100590 
35 Search recurrence* [tiab] 190541 
36 Search weight* [tiab] 626769 
37 Search BMI [tiab] 66114 
38 Search "body mass index" [tiab] 90181 
39 Search fat [tiab] 163914 
40 Search adipo* [tiab] 84934 
41 Search overweight [tiab] 33710 
42 Search obes* [tiab] 159094 
43 Search prognos* [tiab] 344526 
44 Search loss [tiab] 572098 
45 Search gain[tiab] 143606 
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46 Search reduc* [tiab] 202356
5 
47 Search biomarkers [tiab] 53154 
48 Search blood [tiab] 132471
2 
49 Search bio-marker* [tiab] 263 
50 Search biomarker* [tiab] 78349 
51 Search progress* [tiab] 674582 
52 Search (#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 
OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR 




53 Search (#28 AND #52) 4516 
54 Search (#28 AND #52) Filters: English 4168 























Appendix C: details of multivariate analysis in epidemiological studies included 
in systematic review 
1. Abrahamson et al. 2006 
• Estimates for physical activity adjusted for stage and income 
 
2. Borugian et al. 2004 
• Estimates adjusted for age and stage at diagnosis, treatment, 
oestrogen receptor status, WHR, and family history of breast 
cancer 
 
3. Cadmus-Bertram et al. 2011 
• All analyses adjusted for age at randomization, race, fruit and 
vegetable consumption, BMI at randomization, menopausal status, 
tumour type, tumour grade, tumour stage, anti-oestrogen use, 
clinical site, time from diagnosis to randomization, hot flashes, and 
study group 
 
4. Chen et al. 2011 
• Estimates adjusted for date of birth, BMI at baseline, waist-to-hip 
ratio at baseline, menopausal status, income, education, QOL, 
cruciferous vegetable intake, soy protein intake, tea consumption, 
chemotherapy, radiotherapy, tamoxifen use, TNM status, and 
ER/PR status. Exercise was treated as a time-dependent variable 
 
5. Cleveland et al. 2012 
• Estimates adjusted for age at diagnosis, BMI and menopausal 
status 
 
6. Dal Maso et al. 2008 
• Estimates were adjusted for region of residence, age and year at 
breast cancer diagnosis, and for major tumour characteristics (i.e., 
TNM stage and ER/PR status) 
 
7. Emaus et al. 2010 
• Estimates adjusted for age at diagnosis, pre-diagnostic 
observation time, tumor stage, region of residence (strata), year at 
diagnosis before and after 1995 (strata), and BMI or leisure time 
physical activity, respectively 
 
8. Enger and Bernstein, 2004 
• Estimates adjusted for age, stage at diagnosis and BMI 
 
9. Friedenreich et al. 2009 
• Recurrences: Estimates for total physical activity were adjusted for 
age, tumour stage, treatment (chemotherapy, hormone therapy 
and radiation therapy), SBR grade, BMI and other comorbidity 
conditions. Estimates for recreational activity, occupational activity 
and household activity were adjusted for other types of physical 
443 
 
activity, age, tumour stage, treatment (chemotherapy, hormone 
therapy and radiation therapy), SBR grade, BMI and other 
comorbidity conditions 
• Breast cancer-related mortality: Estimates for total physical activity 
were adjusted for age, tumour stage, treatment (chemotherapy, 
hormone therapy and radiation therapy), SBR grade, PR status, 
WHR and HRT use. Estimates for recreational activity, 
occupational activity and household activity were adjusted for 
other types of physical activity, age, tumour stage, treatment 
(chemotherapy, hormone therapy and radiation therapy), SBR 
grade, PR status, WHR and HRT use 
• All-cause mortality: Estimates for total physical activity were 
adjusted for age, tumour stage, treatment (chemotherapy, 
hormone therapy and radiation therapy), SBR grade, WHR, HRT 
use, oral contraceptive use, weight gain since age 20 and total 
pack-years of smoking for current and former smokers. Estimates 
for recreational activity, occupational activity and household 
activity were adjusted for other types of physical activity types, 
age, tumour stage, treatment (chemotherapy, hormone therapy 
and radiation therapy), SBR grade, WHR, HRT use, oral 
contraceptive use, weight gain since age 20 and total pack-years 
of smoking for current and former smokers. Multivariable model is 
adjusted for recreational physical activity, occupational physical 
activity, age, tumour stage, treatment (chemotherapy, hormone 
therapy and radiation therapy), SBR grade, WHR, HRT use, oral 
contraceptive use, weight gain since age 20 and total pack-years 
of smoking for current and former smokers 
 
10. Hellmann et al. 2010 
• Estimates adjusted for age, disease stage, adjuvant treatment, 
menopausal status, parity, alcohol intake, smoking, body mass 
index and hormone replacement therapy 
 
11. Holick et al. 2008 
• Estimates adjusted for age at diagnosis, stage of disease at 
diagnosis, state of residence at diagnosis, and interval between 
diagnosis and physical activity assessment. Additionally adjusted 
for postdiagnosis BMI, postdiagnosis menopausal status, 
postdiagnosis hormone therapy use, total energy intake year 
before enrollment in the CWLS, education level at diagnosis, 
family history of breast cancer at diagnosis, and initial treatment 
modality (radiation, chemotherapy, tamoxifen) 
 
12. Holmes et al. 2005 
• Estimates adjusted for age (months); interval between diagnosis 
and physical activity assessment (28-33, 34-40, ≥41 mo); smoking 
status (never, current, past); body mass index (≤21, 21-22.9, 23-
24.9, 25-28.9, ≥29), menopausal status and hormone therapy use 
(premenopausal, postmenopausal, and never use; 
postmenopausal and current use; postmenopausal and past use; 
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uncertain menopausal status; missing); age at first birth and parity 
(nulliparous, <25 y and 1-2 births, <25 y and ≥3 births, ≥25 y and 
1-2 births, ≥25 y and ≥3 births); oral contraceptive use (never, 
ever, missing); energy intake (quintiles); energy-adjusted protein 
intake (quintiles); disease stage (I, II, III); radiation treatment (yes 
or no); chemotherapy (yes or no); and tamoxifen treatment (yes or 
no) 
 
13. Irwin et al. 2011 
• Pre-diagnosis physical activity: Adjusted for age, ethnicity, WHI 
study arm, previous hormone therapy use, BMI, diabetes, alcohol, 
smoke, total calories, percentage calories from fat, and servings of 
fruit and vegetables 
• Post-diagnosis physical activity: Adjusted for age, stage, ER, PR, 
grade, HER2, ethnicity, WHI study arm, previous hormone therapy 
use, time from diagnosis to physical activity assessment, BMI, 
diabetes, alcohol, smoke, total calories, and percentage calories 
from fat, and servings of fruit and vegetables 
 
14. Irwin et al. 2008 
• Adjusted for age, race, disease stage, initial treatment and 
tamoxifen use 
 
15. Keegan et al. 2010 
• Estimates adjusted for study center (Ontario, Northern California, 
Australia), age of diagnosis (continuous), race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic, non-Hispanic Asian, 
other, missing), number of affected nodes (0, 1-3, 4+, missing), 
BMI (<25.0, 25.0-29.9, ≥30.0, missing), time since last full term 
pregnancy (nulliparous, <2 yrs, 2-4 yrs, ≥5 yrs, missing), ER status 
(negative, positive, missing), PR status (negative, positive, 
missing), tumor grade (1,2,3, missing), tumor size (≤20, >20, 
missing), and tumor type (invasive ductal, invasive lobular, other, 
missing) 
 
16. Rohan et al. 1995  
• Estimates adjusted for stage and multiple breast cancer risk 
factors, including BMI and energy intake, but not treatment 
 
17. Smidth et al. 2013 
• All models were adjusted for tumor size, nodal status, tumor 
grading, ER/PR status, radiotherapy, screening-detected tumor, 
HT use at diagnosis, age at diagnosis, BMI pre-diagnosis, 
smoking status and pack years and pre-existing angina pectoris. 
In addition, models for overall mortality and for other deaths were 







18. Sternfield et al. 2009 
• Recurrence and breast cancer-related death: adjusted for age, 
number of positive nodes, stage, weight at 18 y, type of treatment 
(chemotherapy/radiation) and type of surgery (mastectomy or 
conserving) 
• All-cause death: adjusted for age, number of positive nodes, 
stage, weight at 18 y, education level and smoking status 
 
19. West-Wright et al. 2009 
• Estimates adjusted for age (in years) and adjusted for race, BMI, 
total caloric intake, oestrogen receptor status, number of comorbid 





























PA categories Comparisons Outcome 
Schmidt et 
al. (2013) 
1) Level of 
recreational PA 
(MET-h/wk): 
• 0 MET-h/wk 
• ≥0 MET-h/wk 
a) BMI <25:  
Any PA vs. No PA category 
All-cause deaths: 
HR = 1.63 (1.23-2.17) 
Breast cancer-
related death: 
HR = 1.38 (0.97-1.95) 
 
b) BMI ≥25:  
Any PA vs. No PA category 
All-cause deaths: 








1) Level of 
recreational PA 
(MET-h/wk): 
• 0 MET-h/wk 
• ≥9 MET-h/wk 
a) BMI <25:  
≥9 MET-h/wk PA (n=226/ 
all-cause deaths=18; 
n=189/breast cancer 
deaths=15) vs. 0 MET-h/wk 
(n=147/17; n=175/34) 
All-cause death: 




a) HR = 0.67 (0.32-
1.40) 
b) BMI ≥25: 
≥9 MET-h/wk PA 









b) HR = 0.59 (0.32-
1.08) 
2) Level of 
recreational PA 
(MET-h/wk): 
• 0 MET-h/wk 
>0 MET-h/wk 
a) BMI <25:  
≥0 MET-h/wk PA 
(n=493/all-cause 
deaths=39; n=416/breast 








a) 0.57 (0.30-1.09) 
b) BMI ≥25: 
≥9 MET-h/wk PA 








b) HR = 0.63 (0.40-
0.99) 







first 36 mo 
• No exercise 
• <8.3 
• ≥8.3 
a) BMI <25:  
≥8.3 (n=1,027/all-cause 
deaths=78; n=967/breast 
cancer events=87) vs. no 
exercise (n=1,102/113; n= 
1,015/98) category 
All-cause death: 




metastasis or breast 
cancer-related 
death: 
a) HR = 0.66 (0.47-
0.94)* 
b) BMI ≥25:  
≥8.3 (n=522/51; n=609/72) 
vs. no exercise (n=496/61; 
n=565/76) category 
All-cause death: 




metastasis or breast 
cancer-related 
death: 














a) BMI <25:  
>0 MET-h/wk (n=780/all-




a) HR = 0.49 (0.27-
0.91) 
b) BMI 25-29.9:  
>0 MET-h/wk (n=696/27) 
vs.0 MET-h/wk (n=305/28) 
 
All-cause death: 
b) HR = 0.43 (0.24-
0.76) 
  c) BMI >30: 
>0 MET-h/wk (n=512/31) 
vs.0 MET-h/wk (n=393/32) 
All-cause death: 






1) Recent PA (3 
y pre-diagnosis) 
(MET-h/wk): 
• 0 (sedentary) 
• >0 (active) 
a) BMI <25 (n=2,220):  
Sedentary (all-cause 




a) HR = 1.46 (1.10-
1.94) 
b) BMI ≥25 (n=1,806):  
Sedentary and BMI ≥25 




b) HR = 1.46 (1.10-
1.93) 
c) BMI ≥25 (n=1,806): 
Active and BMI ≥25 (213)  
vs. Active and BMI <25 
(234) 
All-cause death: 









a) BMI <25 (n=749):  




a) HR = 0.38 (0.17–
0.85)** 
b) BMI 25-29.9 (n=656):  




b) HR = 0.95 (0.47–
1.94)  
 
c) BMI ≥ 30 (n=518): 




c) HR = 0.90 (0.38–
2.16) 
West-Wright 







• Low PA 
• Intermediate 
PA 
• High PA 
a) BMI <25:  
High (n=701/ all-cause 
deaths= 220 and breast 
cancer deaths=99) vs. low 








a) HR = 1.15 (0.58-
2.29) 
b) BMI ≥25:  
High (n=460/100 and 191)  
vs. low (n=227/100 and 
191) recent PA category 
All-cause death: 
















• <8  
• ≥8 




h/wk (n=657/11) total 








b) BMI ≥25:  
≥8 MET-h/wk (n=1,157/28) 
vs. <8 (n=1,372/47) MET-
h/wk total recreational PA 
quartile 
b) HR = 0.63 (0.39-
1.02) 
Irwin et al. 
2008 (HEAL) 





a) BMI <25:  
>0 MET-h/wk (n=293/all-




a) HR = 0.74 (0.36-
1.55) 
b) BMI ≥25:  
>0 MET-h/wk (n=780/all-
cause deaths=44) vs.0 
MET-h/wk (n=201/20) 
All-cause death: 
b) HR = 0.31 (0.13-
0.74) 
Abrahamson 
et al. 2006 
1) Level of PA: 
• Low PA (< 
median)  
• High PA (> 
median) 
a) BMI <25:  
High (cohort, n=401) vs. 
low (n=347) PA category 
All-cause deaths: 
a) HR = 1.08 (0.77-
1.52) 
b) BMI ≥25:  
High (n=174) vs. low 
(n=299) PA category 






Prior to Diagnosis 
(MET-h/wk): 
• <3 MET-h/wk 
• ≥24 MET-
h/wk 
a)BMI <25:  
≥24 MET-h/wk 
(n=246/breast cancer 








b) BMI ≥25:  
≥24 MET-h/wk  (n=157/10) 
vs. <3 MET-h/wk 
(n=522/51) 







PA categories Comparisons Outcome 







first 36 mo 
• No exercise 
• <8.3 
• ≥8.3 
a) ER+PR+ (positive):  
≥8.3 MET-h/wk (all cause 
death cohort 
n=756/deaths=52; breast 
cancer events cohort 
n=722/events=63) vs. no 








metastasis or breast 
cancer-related death: 
a) HR = 0.79 (0.53-
1.19) 
b) ER-PR- (negative):   
≥8.3 MET-h/wk (n=416/ 45; 
n=393/ 48) vs. no exercise 
(n=478/76; n= 428/62)  
 
All-cause death: 




metastasis or breast 
cancer-related death: 




c) ER+PR-/ER-PR+ (mixed): 
≥8.3 MET-h/wk (n=349/28; 
n=321/34) vs. no exercise 
(n=338/31; n= 308/28)  
 
All-cause death: 




metastasis or breast 
cancer-related death: 
c) HR = 0.51 (0.27–
1.00) 












cause deaths=64) vs.0 MET-
h/wk (n=688/57) 
All-cause death: 




cause deaths=23) vs.0 MET-
h/wk (n=123/14) 
All-cause death: 




cause deaths=9) vs.0 MET-
h/wk (n=97/7) 
All-cause death: 




cause deaths=19) vs.0 MET-
h/wk (n=369/21) 
All-cause death: 











a) ER+ (n=2553)  
>38.2 MET-h/wk (all-cause 




a) HR = 0.67 (0.48-
0.94)** 
b) ER- (n=881):  
>38.2 MET-h/wk (44) vs.0 
MET-h/wk (36) 
All-cause death: 
b) HR = 1.05 (0.66-
1.68) 
Sternfield 
et al. 2009 
(LACE) 




a) ER+PR+ (positive) 
(n=1,327):  




a) HR = 0.59 (0.34–
1.04)** 
b) ER- and/or PR- 
(negative) (n=614):   




















• Low PA 
(>0.5) 




a) ER+ (n=2,549):  










a) HR = 0.46 (0.26-
0.80)** 
b) ER- (n=450):  












b) HR = 0.33 (0.13-
0.83)* 





• Low PA 
(>0.5) 




a) ER+ (n=2,549):  










a) HR = 1.06 (0.62-
1.81) 
b) ER- (n=450):  










b) HR = 1.18 (0.51-
2.74) 
Irwin et al. 
2008 
(HEAL) 







cause deaths=86) vs.0 MET-
h/wk (n=86/18) 
All-cause death: 




cause deaths=10) vs.0 MET-
h/wk (n=15/1) 
All-cause death: 









• <9 MET-h/wk 
• ≥9 MET-h/wk 
a) ER+PR+ (positive):  
≥9MET-h/wk (n=609/breast 
cancer deaths= 38) vs. <9 
MET-h/wk (n=955/99) 
Breast cancer death: 




b) ER-PR- (negative):   
≥9 MET-h/wk  (n=149/13) vs. 
<9 MET-h/wk (n=272/27) 





Study authors  PA categories Comparisons Outcome 
Chen et al. 2011 
(SBCSS) 
1) Exercise energy 
expenditure (MET-
h/wk) in first 36 mo 
• No exercise 
• <8.3 
• ≥8.3 
a) TNM I-IIa: 
≥8.3 MET-h/wk (all 
cause death cohort 
n=1,096/deaths=55; 
breast cancer events 
cohort 
n=1,048/events=71) 










a) HR = 0.62 (0.41–
0.92) 
  b) TNM IIb-III: 
≥8.3 MET-h/wk 
(n=382/66; n=351/ 
68) vs. no exercise 
All-cause death: 











b) HR = 0.45 (0.32–
0.64)** 















a) HR = 0.65 (0.42–
0.99) 







b) HR = 0.46 (0.27–
0.78) 







• Low PA (>0.5) 







































• Low PA (>0.5) 
































b) HR = 1.09 (0.67-
1.79) 
























recreational PA  
 
b) Regional stage: 
≥8 MET-h/wk 




b) HR = 0.56 (0.34-
0.94) 
Irwin et al. 2008 
(HEAL) 











a) HR = 0.53 (0.23 
to 1.20) 






b) HR = 0.65 (0.42–
0.99) 
Holmes et al. 2005 
(NHS) 
Physical Activity 
Prior to Diagnosis 
(MET-h/wk): 
• <9 MET-h/wk 
• ≥9 MET-h/wk 
a) Stage I: 
≥9MET-h/wk 
(n=685/breast cancer 









b) Stage II: 
≥9MET-h/wk 
(n=405/breast cancer 
deaths=45) vs. <9 
MET-h/wk 
(n=609/94) 
b) HR = 0.62 (0.43-
0.90) 
c) Stage III: 
≥9MET-h/wk 
(n=76/breast cancer 
deaths=15) vs. <9 
MET-h/wk 
(n=129/48) 






Menopause status sub-analyses 
Study authors  PA categories Comparisons Outcome 
Chen et al. 2011 
(SBCSS) 
1) Exercise energy 
expenditure (MET-
h/wk) in first 36 mo 




≥8.3 MET-h/wk (all 
cause death cohort 
n=760/deaths=61; 
breast cancer events 
cohort 
n=715/events=72) 










a) HR = 0.69 (0.47–
1.00) 
  b) Postmenopause: 
≥8.3 MET-h/wk 
(n=789/68; n=748/ 





















(< 55 y, includes 
perimenopause): 
Regular exercise (n 
= 51/17) vs. 
sedentary category 
(n = 106/39) 
All-cause deaths: 








(≥ 55 y): 
Regular exercise (n 
= 86/22) vs. 
sedentary category 













• <8  
• ≥8 
a) Age at diagnosis 






recreational PA  
Breast cancer-
related death: 











b) HR = 0.85 (0.47-
1.54) 
Irwin et al. 2008 
(HEAL) 












a) HR = 0.18 (0.05 
to 0.60) 







b) HR = 0.29 (0.14–
0.60) 
Holmes et al. 2005 
(NHS) 
Physical Activity 
Prior to Diagnosis 
(MET-h/wk): 
• <9 MET-h/wk 

















vs. <9 MET-h/wk 
(n=1,406/140) 
b) HR = 0.73 (0.54-
0.98) 






 >4,000 (n=33/breast 
cancer deaths=10) 









cancer death=12) vs. 
0 kcal/min (n=90/29) 



































































Lifetime pre-diagnosis recreational physical activity and breast cancer-related 


































































Recent pre-diagnosis recreational physical activity and breast cancer-related 





































































































Meeting recommended physical activity guidelines post-diagnosis and all-cause 



















Appendix F: search strategy and results of the systematic review of physical 
activity interventions in breast cancer patients after adjuvant therapy 
1. Cochrane Central Register of Controlled Trials (The Cochrane Library 
2012, Issue 10): 
 
#1. MeSH descriptor: [Breast Neoplasms] explode all trees   7465    
#2. breast near cancer*          13765          
#3. breast near neoplasm*          7805          
#4. breast near carcinoma*          1421          
#5. breast near tumour*          323          
#6. breast near tumor*          565          
#7. Masectom*           1          
#8. Axillary near dissection*         431          
#9. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8       15054          
#10. MeSH descriptor: [Exercise] explode all trees    11452    
#11. Enter terms for search Exercis*        37884          
#12. MeSH descriptor: [Motor Activity] explode all trees   13162    
#13. MeSH descriptor: [Sports] explode all trees    7301    
#14. Sport*            10268          
#15. MeSH descriptor: [Resistance Training] explode all trees  697    
#16. training            29927          
#17. fitness            3919          
#18. Physical near activit*          6223          
#19. Activ*            98579          
#20. MeSH descriptor: [Behavior] explode all trees    41168    
#21. Behaviour*           12733          
#22. Behavior*           35381          
#23. #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or  
        #18 or #19 or #20 or #21 or #22        189077          
#24. #9 and #23           2964       
 
 
2. MEDLINE search strategy and results (1966- 11th Oct 2012) 
  
#1. Breast neoplasm*        195998 
#2. Breast cancer*        156009  
#3. Breast tumour*        2613 
#4. Breast tumor*        12073 
#5. Masectomy        7 
#6. Masectom*        7 
#7. Axillary dissection*       2234  
#8. Breast carcinoma*       
 23293 
#9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8   235994 
#10. Exercise          245000 
#11. Exercis*         238638 
#12. Motor control        59781 
#13. Sports         129732 
#14. Sport*         82040 
#15. Resistance training       9172 
#16. Training         969792 
#17. Fitness         47194 
#18. Physical activity        269678 
#19. Physical activ*        229752 
#20. Activ*        
 1097721 
#21. Behaviour         176148 
459 
 
#22. Behavior         862178 
#23. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16  
        OR #17 OR #18 OR #19 OR #20 OR #21 OR #22  
 3252048 
#24. #9 AND #23        31415 
#25. Randomised [tiab]       53641 
#26. Randomized controlled trial* [pt]     331679 
#27. Controlled clinical trial [PT]      84496 
#28. Randomised controlled trial*      16591 
#29. Randomized [tiab]       272572 
#30. Randomly [tiab]        186951 
#31. Drug therapy [sh]      
 1547923 
#32. Trial [tiab]        313924 
#33. Groups [tiab]       
 1230493 
#34. Placebo [tiab]        143615 
#35. #25 OR #26 OR #27 OR #28 OR #29 OR #31  
        OR #32 OR #33 OR #34      
 3057911 
#36. #24 AND #35        7688 
#37. #24 AND #36 Filters: Humans      7206 
 
 
3. Embase (1980 to 2012 Week 40), Global Health (1973 to Sept 2012) 
HMIC Health Management Information Consortium (1979 to Sept 2012) 
and PsycINFO search strategy and results 
 
1. exp Breast Neoplasms       313324 
2. (breast adj6 cancer$).mp.      469398 
3. (breast adj6 neoplasm$).mp.       28150 
4. (breast adj6 carcinoma$).mp.      103000 
5. (breast adj6 tumour$).mp.      
 17652 
6. (breast adj6 tumor$).mp.        147389 
7. Masectom$.mp.        15 
8. (Axillary adj6 dissection*).mp.      11811 
9.  Searches 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8     543869 
10. exp Exercise/         207246 
11. Exercis$.mp.         688418 
12. exp Motor control/        18944 
13. exp Sports/         97571 
14. Sport$.mp.         280439 
15. exp Resistance training/        3072 
16. Training.mp.        
 1002911 
17. Fitness.mp.         126469 
18. (Physical adj6 activit$).mp.       251625 
19. Activ$.mp.        
 6840274 
20. exp Behavior/        
 2884760 
21. Behavio?r$.mp.        
 2813736 
22. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17  
or 18 or 19 or 20 or 21       
 11199449 
23. 9 and 22          221520 
460 
 
24. random:.tw.        
 1997422 
25. clinical trial:.mp.        
 1441746 
26. exp health care quality/       
 1739857 
27. 24 or 25 or 26        
 4318113 
28. limit 27 to human        30042 
Results: 
Embase (1980 to 2012 Week 40)    
 (29089) 
Global Health (1973 to September 2012)     (391) 
HMIC Health Management Information  
Consortium (1979 to September 2012)      (51) 
PsycINFO (1967 to October Week 2 2012)     (511) 
 
 
4. CINAHL search strategy and results: 
 
1. Randomized controlled trial OR randomised controlled trial  
OR controlled clinical trial OR Clinical trial OR random  
OR health care quality OR Trial       169826 
2. Exercise OR motor control OR sport OR resistance training  
OR Fitness OR Physical activity OR behaviour OR  
Behavior OR Training        305387 
3. Breast cancer OR Breast neoplasms OR breast tumour OR breast  
tumor OR mastectomy OR axillary dissection OR breast carcinoma 44708 
4. 2 AND 3          3137 
5. 1 AND 4         425 
 
 
5. PeDRO search strategy and results: 
 
1. Cancer (clinical trials only)      536 
2. Breast cancer        377 
3. Breast neoplasms        1 
4. Breast carcinoma        7 
5. Breast tumor        15 
6. Breast tumour        3 
7. Mastectomy        0 
8. Mastectomies        0 
9. Axillary dissection       0 
Total: 939 
 
6. SPORTdiscus search strategy and results: 
 
1. Randomized controlled trial OR randomised controlled trial  
OR controlled clinical trial OR Clinical trial OR random  
OR health care quality OR Trial       17503 
2. Exercise OR motor control OR sport OR resistance training  
OR Fitness OR Physical activity OR behaviour OR  
Behavior OR Training        923600 
3. Breast cancer OR Breast neoplasms OR breast tumour OR breast  
tumor OR mastectomy OR axillary dissection OR breast carcinoma 3180 
461 
 
4. 2 AND 3          1040 





1. Breast cancer        389  
2. Breast Neoplasms       5  
3. Breast carcinoma        47  
4. Breast tumor        11 
5. Breast tumour        22 
6. Mastectomy         0 
7. Mastectomies        0  
8. Axillary dissection       0  
Total: 474 
 
8. ProQuest (Dissertations and Theses and Conference Papers and 
Proceedings Index, 1861 to October 2012) 
          
1. Breast cancer AND exercise      477 
2. Breast cancer AND physical activity OR fitness    636 
3. Breast cancer AND sport OR resistance training   355 
4. Breast cancer AND behaviour OR behavior    716 
5. Breast neoplasms AND exercise      23 
6. Breast neoplasms AND physical activity OR fitness    28 
7. Breast neoplasms AND sport OR resistance training   13 
8. Breast neoplasms AND behaviour OR behavior    34 
9. Breast carcinoma AND exercise OR physical activity   79 
10. Breast carcinoma AND sport OR fitness     35 
11. Breast carcinoma AND behaviour OR behavior    83 
12. Breast carcinoma AND resistance training    22 
13. Breast tumor AND exercise OR physical activity   139 
14. Breast tumor AND sport OR fitness     58 
15. Breast tumor AND behaviour OR behavior    135 
16. Breast tumor AND resistance training     38 
17. Breast tumour AND exercise OR physical activity   139 
18. Breast tumour AND sport OR fitness     58 
19. Breast tumour AND behaviour OR behaviour    135 
20. Breast tumour AND resistance training     38 
21. Mastectomy        2 




9. Web of knowledge search strategy and results: (Science Citation Index 
Expanded, 1970 to October 2012; Social Sciences Citation Index, 1970 to 
October 2012; Arts and Humanities Citation Index, 1975 to October 2012; 
and Conference Proceedings Citation Index of Science and Social 
Science, 1990 to October 2012) 
 
# 1 TS=randomised controlled trial      
 196,124 
# 2 TS=randomized controlled trial      
 196,124 
# 3 TS=controlled clinical trial       
 136,465 




# 5 TS=random*         
 981,749 
# 6 TS=trial         
 850,451 
# 7 #6 OR #5 OR #4 OR #3 OR #2 OR #1     
 1,492,151 
# 8 TS=breast neoplasms        12,537 
# 9 TS=breast cancer        
 293,160 
# 10 TS=breast carcinomas       92,647 
# 11 TS=(breast Near Cancer)         
 277,285 
# 12 TS=breast tumour        
 123,180 
# 13 TS=breast tumor        
 123,180 
# 14 TS=mastectomy         3 
# 15 #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8   
 316,601 
# 16 TS=exercise         
 241,089 
# 17 TS=physical activity        
 119,741 
# 18 TS=resistance training        11,622 
# 19 TS=activit*         
 2,426,049 
# 20 TS=fitness          65,538 
# 21 TS=training         
 415,379 
# 22 TS=motor control        89,644 
# 23 TS=sport*         65,588 
# 24 #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 
 3,116,690 
# 25 #24 AND #15         51,596 




















Appendix G: Details of excluded studies from systematic review of physical activity 
interventions 
Trial Reason 
Andersen 2006 This study was excluded as it was not an RCT or a CTT 
Banasik 2009 This study was excluded because it contained patients with 
metastatic disease 
Basen-Engquist 2006 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Bennet 2007 This study was excluded because breast cancer population was 
not analysed separately 
Bloom 2008 This study was excluded because it contained patients with 
metastatic disease 
Burnham 2002 This study was excluded because breast cancer population was 
not analysed separately 
Cadmus Bertram 2011 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Campbell 2012 This study was excluded as it was not an RCT or a CCT 
Carson 2009 This study was excluded because it contained patients with 
metastatic disease 
Carter 2012 This study was excluded because it did not compare an 
exercise with no exercise or control or usual care 
Cheema 2006 This study was excluded because it did not compare an 
exercise with no exercise or control or usual care 
Classen 2008 This study was excluded because exercise was not promoted or 
measured  
Cohen 2010 This study was excluded because all patients were pre-
treatment 
Courneya 2003 This study was excluded because it did not include a separate 
analysis of breast cancer patients 
Crane-Okada 2012 This study was excluded because the intervention did not 
involve physical activity  
Cruess 2000 This study was excluded because exercise was not promoted or 
measured  
Culos Reed 2006 This study was excluded because it contained multiple cancers 
Cunningham 1998 This study was excluded because groups contained participants 
with metastatic disease 
D’Attilio 2007 This study was excluded because it lacked a non-exercising 
comparison group 
Danhauer 2009 This study was excluded because it included breast and ovarian 
cancer patients and breast cancer population was not analysed 
separately  
Damush 2006 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
De Backer 2007 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Demark-Wahnefried 
2006 
This study was excluded because it did not include a separate 
analysis of breast cancer patients 
Dimeo 2008 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Djuric 2002 This study was excluded because it included a combined 
exercise and diet intervention where the effects of exercise 
could not be isolated. 
Eyigor 2010 This study was excluded because it included the comparison 
group were recommended walking exercise 
Galantino 2012 This was excluded because it was a qualitative study 
Gielissen 2012 This study was excluded because breast cancer population was 
not analysed separately 
464 
 
Gordon 2005 This study was excluded because it included exercises 
restricted to stretching and local muscular endurance (i.e. 
training of shoulders) 
Graves 2005 This study was excluded because exercise was not promoted or 
measured  
Haas 2001 This study was excluded as it was not an RCT or a CTT 
Hanna 2008 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Hayes 2009 This study was excluded because it included a therapeutic 
exercise regimen that addressed only specific impairments 
related to the shoulder and arm 
Haykowsky 2009 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Headley 2004 This study was excluded because groups contained participants 
with metastatic disease 
Hislop 2006 This study was excluded because exercise was not promoted or 
measured  
Hojan 2011 This study was excluded because it did not contain a 
comparison group 
Hong 2007 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Hsieh 2008 This study was excluded because it included participants 
undergoing chemotherapy and radiotherapy 
Hunt-Shank 2006 This study was excluded because it did not contain a 
comparison group 
Ibfelt 2011 This study was excluded because breast cancer population was 
not analysed separately 
Ingram 2001 This study was excluded because it did not contain a 
comparison group 
Johnsson 2011 This study was excluded because it did not contain a 
comparison group 
Jonsson 2009 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Kilbreath 2006 This study was excluded because it included exercises 
restricted to stretching and local muscular endurance (i.e. 
training of shoulders) 
Kilgour 2008 This study was excluded because it included exercises 
restricted to stretching and local muscular endurance (i.e. 
training of shoulders) 
Kilka 2008 and 2009 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Kim Soo 2011 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Kovacic 2011  
LaStayo 2011 This study was excluded because breast cancer population was 
not analysed separately 
Loprinzi 2012 This study was excluded because breast cancer population was 
not analysed separately 
Luctkar Faude 2007 This study was excluded because breast cancer population was 
not analysed separately 
May 2008 and 2009 This study was excluded because breast cancer population was 
not analysed separately 
McClure 2010 This study was excluded because it included exercises 
restricted to stretching and local muscular endurance (i.e. 
training of shoulders) 
McGuire 2008 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
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McKenzie 2003 This study was excluded because it included only quality of life 
assessment and outcomes related to only specific impairments 
related to the shoulder and arm 
McTiernan 1998 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Moadel 2007 This study was excluded because it included patients 
undergoing adjuvant cancer therapy (chemotherapy) 
Mustian 2009 This study was excluded because it included participants 
undergoing radiotherapy 
Noble 2012 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Oh 2010 and 2012 This study was excluded because breast cancer population was 
not analysed separately 
Oldervoll 2011 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Pinto 2008 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Portela 2008 This study was excluded because groups contained participants 
with metastatic disease 
Rabin 2006 This study was excluded because it lacked a non-exercising 
comparison group 
Rabin 2009 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Sandel 2005  This study was excluded because it included patients 
undergoing adjuvant cancer therapy (chemotherapy and 
radiotherapy) 
Schmidt 2012 This study was excluded because it lacked a non-exercising 
comparison group 
Schmitz 2010 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care (PAL pilot) 
Schneider 2007 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Schwartz 1999 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Segar 1998 This study was excluded because it included patients 
undergoing adjuvant cancer therapy (chemotherapy and 
radiotherapy) 
Sherman 2010 This study was excluded because the intervention group 
contained participants with metastatic disease 
Speed-Andrews 2010 This study was excluded because it did not contain a 
comparison group 
Sprod 2005 This study was excluded because it lacked a non-exercising 
comparison group 
Stan 2012 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Stevinson 2006 This study was excluded because breast cancer population was 
not analysed separately 
Stolley 2009 This study was excluded because it lacked a comparison group 
Szczepanska 2010 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Tang 2010 This study was excluded because breast cancer population was 
not analysed separately 
Thorsen 2005 This study was excluded because breast cancer population was 
not analysed separately 
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Tidhar 2010 This study was excluded because it involved therapeutic 
exercise regimens addressing only specific impairments related 
to the shoulder, arm or both. 
Turner 2004 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Twiss 2009 This study was excluded because it included and medication 
combined group compared to a comparison group on 
medication exercise 
Ulger 2010 This study was excluded because it did not contain a 
comparison group 
Van Puymbroeck 2011 This study was excluded because it lacked a non-exercising 
comparison group 
Van Weert 2005 This study was excluded because breast cancer population was 
not analysed separately 
Vos 2006 Trial did not promote physical activity as a part of the 
intervention and/or measure physical activity as an outcome 
Waltman 2003 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Wilson 2006 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Wong 2012 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Wu 2008 This study was excluded as it did not compare an exercise with 
no exercise, another intervention, or usual care 
Yuen 2007 This study was excluded because it included two patients 
undergoing adjuvant cancer therapy (chemotherapy or 
radiotherapy) in each of the two intervention groups and one 
patient in the control group 
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Appendix H: Funnel plots from RCT systematic review 
 
Funnel Plot: Physical activity 
 




Funnel plot: Body mass 
 





Funnel plot: Body fat percentage 
 
 
Funnel plot: Upper body strength 
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FFunnel Plot: General health-related quality of life 
 
 




Funnel plot: Mental well-being 
 
 





















































Appendix K: PHAST awareness study demographic information 
Name  .................................................  
Hospital reference .................................................   
Today’s date  .................................................  
Date of birth .............................................................   
Height:                                         Weight:                                    BMI:                              
BF%: 
Ethnicity: 
White – British 
White - Irish 
Other white background 
Black – Caribbean 
Black – African 
 






Asian – other 
White and black Caribbean 
White and black African 
Other mixed background 
Other 
On what date were you diagnosed with Breast cancer?  ...................   
How long ago did you complete your treatment?  ...................   
Have you ever been diagnosed with or are you taking treatment for 
: (Please circle the appropriate answer) 
Diabetes Yes No 
Hypertension (high blood 
pressure) Yes No 
High cholesterol Yes No 
Do you have a first degree relative (parents and brothers and sisters) who 




 Yes             No  
Do you smoke? (Please circle the appropriate answer)  
Currently Previously Never 
 
If you do or did smoke, how many cigarettes on average a day, and for 
how many years?  
Number a day: ……………………. Number of years: 
…………………………… 
How many days a week do you drink alcohol? 
……………………………………… 
On the days you drink the most how many glasses do you drink? 
…………………………. 
What do you normally drink? (circle the appropriate answer) 
Wine                                    Beer                                                 Spirits 
Do you have a past history of :  (please circle the appropriate answer) 
Heart disease (any) Yes No 
Vascular disease e.g. 
stroke 
Yes No 
Rheumatic fever Yes No 
Asthma or chronic 
bronchitis 
Yes    No 
Gout Yes No 
Rheumatoid arthritis Yes No 
Osteoarthritis Yes No 
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Kidney disease Yes     No 
Liver disease Yes No 
Your marital status (please tick the box closest to your situation) 
              Single 
 Married 
 Living with a partner  
 In a partnership, but not living together 
 Divorced/separated 
 Widowed 
How many children do you have?  ........................  
What are were you when you had your first child?…………………… 
Did you breastfeed your children?                              Yes  No 
Are you menstruating     Yes  No 
 
If yes,  
Are you using a contraception pill   Yes  No 
Are you menstruating regularly   Yes  No 
When did your last period start: …………  
Do you or have you ever taken the oral contraceptive pill?             Yes 
 No     
If yes how long have/had you taken the oral contraceptive pill (years)? 
………………. 
Do you take hormone replacement therapy                Yes  No     
Have you ever taken HRT?                                           Yes  No 
 




What is the highest qualification you hold? (tick the box that applies 
to you) 
 O-levels or GCSEs 
 A-levels 
 NVQ 
 College degree or diploma 
 Bachelor’s degree 
 Postgraduate degree or diploma 
 Other (please give details)  .........................................................................      
How old were you when you left school or full-time education? ..........    
Occupation now or before 
retirement 





 ......................  






Unable to work due to illness 
Retired 




  Do you think you do enough physical activity? 
 
    No….         Yes….   Unsure…. 
 







No effect Don’t 
know 
Physical activity     




















Appendix L: PHAB-PILOT Randomisation Form 
Randomisation :  0800 371 969 or 0800 731 7625 or  0800 328 6412 (Monday – Friday 9 am to 5 pm) 
 
Caller’s Details  
Caller’s name: Ian Lahart (please print) 
 : 01384 244015 Ext: __________      
 : 01384 244072 
 
Patient’s Details  
Patient’s initials:   (forename & surname)  Date of birth: DD / 
MON / YYYY 
Gender: Female    Male  




All questions must be answered YES for patient to be eligible                                          No Yes 
Within 2 years post-diagnosis of invasive breast cancer?                 
Has the patient given written informed consent?                                  
Date informed consent obtained?                                         DD / MON / YYYY 
Post-surgery and no surgery planned for the next 6 months                     
Completed adjuvant therapy                                                                          
Willing to be randomised                                                                                
Unable to participate in physical activity because of  
severe disability (e.g., severe arthritic conditions)                                      
Psychiatric illness                                                                                            
Vulnerable population group                                                                           
Any other patient where physical activity  






Stratifying Variables   
Has chemotherapy been given?                                   No                   Yes  
 
Allocation   
Randomisation 1 
Allocation 1: Control  Intervention  
Randomisation 2 
Allocation 2: No  Yes  
Patient’s Trial Number:   
Completed by: ________________________ 

























Appendix M: Patient Information Sheet 
PHAB-Pilot 
Physical activity and Breast cancer-pilot study 
 
You are being invited to take part in a research project.  But before you 
decide whether you would like to take part it is important for you to 
understand why the research is being conducted and what it will involve.  
Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP, if you wish. 
 
Ask us if there is anything that is not clear or if you would like more 
information.  Please take your time to decide whether you wish to take 
part. 
 
In order to make sure that you have some general information about this 
study we have compiled a list of questions and answers.  We hope that 
this will allow you to make an informed decision as to whether you would 
like to become involved in this project. 
 
Q: What is the purpose of this study? 
A:  There are some studies, which show that women who take regular 
exercise after the treatment of breast cancer may do better and live longer 
compared to those who are not involved in regular physical activity. 
Recovering from breast cancer can be a difficult experience both 
physically and psychologically for many women and they may not feel like 
doing much exercise. For these reasons, we would like to carry out 
research to see if we can change the behaviour of women from inactive to 
active after they have been treated for breast cancer. This research 
projects will also consider whether exercise can help to improve the 
general health and well-being of women who have had breast cancer.  We 
hope that this study will provide health professionals with information 
regarding the benefits of exercise in women who have been treated for 
breast cancer.  This study would last 6 months.  
 
Q: Why have I been chosen? 
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A: In order to take part in this study you must have completed some form 
of breast cancer treatment within last 2 months and no longer undergoing 
active treatment.  Women who fulfil these criteria are being invited to 
participate in this project.   
 
Q:  Do I have to take part? 
A:  No. You are under no obligation to take part in this study. It is up to you 
to decide whether to take part.   If you do decide to take part, you will be 
given this information sheet to keep and we will ask you to sign a consent 
form.  If you decide to take part in this study and changed your mind 
afterwards, you are still free to withdraw at any time and without giving a 
reason.  This will not affect the standard of care you receive from the 
Dudley Group of Hospitals or any other health professional. 
 
Q: What will be involved if I agree to take part in the study? 
A. Once the consent form has been signed you will be asked to complete 
questionnaires to assess the amount of physical activity you do. If the 
results of the questionnaire show that you already do a lot of physical 
activity, we will allocate you into the observational group. The details about 
the observational group are given on page 4 paragraph 1.  If the result of 
the questionnaire shows that you do some physical activity then you will 
be allocated to take part in one of 2 groups.  The requirements of each of 
these groups are outlined below.  It is important to understand that you will 
be allocated to one of the 2 groups randomly, as if decided by the toss of a 
coin. We have to do this in order to make sure the results that we get from 
this are reliable.  
 
Over the course of the study, we would ask you to (irrespective of the 
group that you are in), to complete a series of assessments at the 
beginning and at the end (after 6 months) of the trial.  
In detail these assessments are:  
a) questionnaires that evaluate your levels of physical activity (20 
minutes to complete them) 
b)  body fat and muscle that we measure with an apparatus identical 
to scales that measure body weight (30 second to complete)  
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c)  We will need a blood sample from you  
 
In addition, some of you will be invited to perform an exercise tolerance 
test, which is the gold standard (the best possible way of) measuring 
your fitness (the actual test takes only 8-12 minutes to complete).  
 
 
Group 1: PHAB-intervention group 
If you are randomly allocated to this group, you will be given support and 
encouragement to do regular exercise. You will be offered a face to face 
consultation for 30 minutes, 2 telephonic consultations for 15 minutes 
each and 2 reminders by post to become physically active (Figure 1). We 
will ask you to build up to regular physical activity equalling to brisk 
walking for 30 minutes for 5 days a week. All these sessions will be on a 
'one-to-one' basis with a trained specialist/researcher. An important 
feature of the contact session will be exercise counselling; the specialist 
will encourage you to discuss your thoughts and feelings about exercise 
and other aspects of your lifestyle. We would also ask you to give a blood 
sample for the purpose of this research. Finally, some of you will be asked 
to take a test to check your cardio-respiratory fitness. Both the blood 
sample and the exercise test will have to be performed at the beginning 
and at the end of this trial (6 months). If for any reason you feel that you 




Recruitment    1 & 2 month  3 month  4 month    5 month 
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Group 2:  Standard care Group 
If you are allocated to this group, you will not receive regular 
encouragement to exercise. You will complete the questionnaire about 
physical activity and quality of life at the beginning and at 6 months into 
the study. We would also like to take from you a blood sample. Finally, you 
may be asked to take a test to check your cardio-respiratory fitness at the 
beginning and one at the end of the study at 6 months. Throughout the 
course of the study, you should continue to live your life as normal.  
 
Q: What are the side effects? 
A: Sometimes when people have not exercised for a long time they can 
experience shortness of breath during exercise and muscle soreness after 
exercise. During the exercise you may experience fatigue, which stop 
immediately after you finish with your exercise testing.  
 
Q: What are the possible benefits of taking part? 
A:  If you are assigned to the physical activity group, you will be able to 
take part in regular exercise, which is known to have benefits for general 
fitness.  If you are assigned to the control group, we will give you advice 
about exercise at the end of your involvement in the project, if you wish. 
 
Q: Can I withdraw from the study at any time? 
A:  Yes you can.  You are free to refuse to join the study and may 
withdraw at any time or choose not to answer certain questions.  You will 
receive the same quality of care from the hospital whether you join the 
project or not.  If you think you might be pregnant, you should inform the 
exercise researcher. 
 
Q: When and where will the project take place? 
A:  The physical activity recommended is brisk walking for 30 minutes for 
5 days a week, any time of the day that is suitable to you. We encourage 
you to do this exercise in and around your home to minimise 
inconvenience.   
 
Q: What other information will be collected in the study? 
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A:  With your agreement, we may wish to obtain additional information 
about the type of treatment you received at the Dudley Group of Hospitals, 
and your hospital admissions from your medical records. 
 
Q: Will there be any effects on my follow-up screening? 
A:  No, your participation in the study is not connected to your follow-ups. 
 
Q: What happens when the research stops? 
A: Once you have completed the physical activity training, you will be 
given advice about how to exercise safely on your own.  You may choose 
to join your local gym or exercise club. The exercise specialist will give you 
help regarding this issue nearer the time. 
 
Q: Will the information obtained in the study be confidential? 
A:  Anything you say will be treated in confidence.  Your name will not be 
mentioned in any reports of the study and care will be taken so that you 
cannot be identified from details in reports. 
 
Q: Will anyone else be told about my participation in the project? 
A:  With your agreement, we will inform your family doctor that you are 
helping with this study. 
 
Q:  What will happen to the results of the research project? 
A:  We hope to publish the findings from this research project in health 
science research journals.  We will also present the results to Medical 
conferences and seminars.  Only individuals who are directly related to 
this project will have access to the research data.  All data will be kept in a 
locked cupboard.  
 
Q:  Who is organising and funding the research? 
A:  The study is been conducted by the Breast Unit, Russells Hall Hospital 
by a team led by Mrs AR Carmichael, Consultant Breast Surgeon.  
 
Q: Who has reviewed the study? 
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A:  Consultants, doctors, exercise physiologists and psychologists. Also, 
the study is approved from the Research Ethics Committee of our 
Hospital.   
 
Q: Where can I get some independent information about medical 
research? 
A: You can also get some independent information about Medical 
Research from a leaflet published by the UK Clinical Research 
Collaboration. The leaflet is entitled "Clinical trials: What they are and what 
they’re not”.  This leaflet gives more information about medical research 
and considers some of the questions you may want to ask.  A copy can be 
obtained from UK Clinical Research Collaboration, 20 Park Crescent, 
London W1B 1AL. 
 
 
Q: What if I wish to complain about the way in which this study has 
been conducted?  
A: If you have any cause to complain about any aspect of the way in 
which you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are 
available to you and are not compromised in any way because you have 
taken part in a research study. 
 
If you have any complaints or concerns please contact either the project 
co-ordinator 
Mrs AR Carmichael, Consultant Surgeon, Russells Hall Hospital 
Dudley; Tel: 01384 244015 
OR 
Otherwise you can use the normal hospital complaints procedure and 
contact the following person: 
Maria Smith, Business Support Manager, Complaints & Claims 
Department, Russells Hall Hospital; Tel:  01384 456111 Ext 3548 
 
Thank you for taking the time to consider your participation in this study.  
 















CONSENT FORM  
 
Title of Project: PHAB-Pilot Physical activity and Breast cancer; a 




1. I confirm that I have read and understand the information sheet. I have 
had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from the Russells Hall Hospital, University of Birmingham, University of 
Wolverhampton and from regulatory authorities, where it is relevant to 
my taking part in this research. I give permission for these individuals 
to have access to my records. 
 
4. I agree to my GP being informed of my participation in the study 
 
 





_______________  ________________  _________________  
Name of Patient  Date     Signature  
 
 
_________________ ________________ ___________________  
Name of Person  Date     Signature  











Appendix O: Demographic information questionnaire 
PHAB DEMOGRAPHIC  INFORMATION 
Name  .................................................  
Hospital reference .................................................   
Today’s date  .................................................  
Date of birth  .................................................  
Height:                                         Weight:                                    BMI:                              
BF%: 
Ethnicity: 
White – British 
White - Irish 
Other white background 
Black – Caribbean 
Black – African 
 






Asian – other 
White and black Caribbean 
White and black African 
Other mixed background 
Other 
On what date were you diagnosed with Breast cancer?  ...................   
How long ago did you complete your treatment?  ...................   
Have you ever been diagnosed with or are you taking treatment for 
: (Please circle the appropriate answer) 
Diabetes Yes No 
Hypertension (high blood 
pressure) 
Yes No 
High cholesterol Yes No 
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Do you have a first degree relative (parents and brothers and 
sisters) who have been diagnosed with breast cancer? (Please circle 
the appropriate answer)  
 Yes             No  
Do you smoke? (Please circle the appropriate answer)  
Currently Previously Never 
 
If you do or did smoke, how many cigarettes on average a day, and 
for how many years?  
Number a day: …………………….     Number of years: 
…………………………… 
How many days a week do you drink alcohol? 
……………………………………… 
On the days you drink the most how many glasses do you drink? 
…………………………. 
What do you normally drink? (circle the appropriate answer) 
Wine                                                    Beer                                                 
Spirits 
Do you have a past history of :  (please circle the appropriate answer) 
Heart disease (any) Yes No 
Vascular disease e.g. 
stroke 
Yes No 
Rheumatic fever Yes No 
Asthma or chronic 
bronchitis 
Yes No 
Gout Yes No 
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Rheumatoid arthritis Yes No 
Osteoarthritis Yes No 
Kidney disease Yes No 
Liver disease Yes No 
Your marital status (please tick the box closest to your situation) 
 Single 
 Married 
 Living with a partner  
 In a partnership, but not living together 
 Divorced/separated 
 Widowed 
How many children do you have? ........................   
What age were you when you had your first child?  
……………………….. 
Did you breastfeed your children?.......................                              
Yes  ........................ No 
Are you menstruating     Yes  No 
 
If yes,  
Are you using a contraception pill   Yes  No 
Are you menstruating regularly   Yes  No 
When did your last period start: …………  
Do you or have you ever taken the oral contraceptive pill?             Yes 
 No     
If yes how long have/had you taken the oral contraceptive pill 
(years)? ………………. 
Do you take hormone replacement therapy                Yes  No     
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Have you ever taken HRT?                                           Yes  No 
 
If yes how long have/had you taken HRT (years)? 
…………………………… 
What is the highest qualification you hold? (tick the box that applies 
to you) 
 O-levels or GCSEs 
 A-levels 
 NVQ 
 College degree or diploma 
 Bachelor’s degree 
 Postgraduate degree or diploma 
 Other (please give details)  .........................................................................      
How old were you when you left school or full-time education? 
…………  
Occupation now or before 
retirement 





 .....................  
504 
 






Unable to work due to illness 
Retired 























Appendix P: International Physical Activity Questionnaire 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(October 2002) 
 
LONG LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires. Long (5 activity domains asked independently) and short (4 
generic items) versions for use by either telephone or self-administered methods 
are available. The purpose of the questionnaires is to provide common 
instruments that can be used to obtain internationally comparable data on 
health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in 
Geneva in 1998 and was followed by extensive reliability and validity testing 
undertaken across 12 countries (14 sites) during 2000. The final results suggest 
that these measures have acceptable measurement properties for use in many 
settings and in different languages, and are suitable for national population-
based prevalence studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is 
encouraged. It is recommended that no changes be made to the order or wording 
of the questions as this will affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is encouraged to facilitate worldwide use of IPAQ. 
Information on the availability of IPAQ in different languages can be obtained at 
www.ipaq.ki.se. If a new translation is undertaken we highly recommend using 
the prescribed back translation methods available on the IPAQ website. If 
possible please consider making your translated version of IPAQ available to 
others by contributing it to the IPAQ website. Further details on translation and 
cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical 




More detailed information on the IPAQ process and the research methods used 
in the development of IPAQ instruments is available at www.ipaq.ki.se and 
Booth, M.L. (2000). Assessment of Physical Activity: An International 
Perspective. Research Quarterly for Exercise and Sport, 71 (2): s114-20. Other 




INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people 
do as part of their everyday lives. The questions will ask you about the time you 
spent being physically active in the last 7 days. Please answer each question 
even if you do not consider yourself to be an active person. Please think about 
the activities you do at work, as part of your house and yard work, to get from 
place to place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 
days. Vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder than normal. Moderate activities refer to 
activities that take moderate physical effort and make you breathe somewhat 
harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer 
work, course work, and any other unpaid work that you did outside your home. 
Do not include unpaid work you might do around your home, like housework, 
yard work, general maintenance, and caring for your family. These are asked in 
Part 3. 
 




 No                                 Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days 
as part of your paid or unpaid work. This does not include traveling to and from 
work. 
 
2.  During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, heavy construction, or climbing up 
stairs as part of your work? Think about only those physical activities 
that you did for at least 10 minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity                      Skip to 
question 4 
 
3. How much time did you usually spend on one of those days doing 
vigorous physical activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
4. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate physical activities like carrying light loads as part of your 
work? Please do not include walking. 
 
_____ days per week 
 




5. How much time did you usually spend on one of those days doing 
moderate physical activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time as part of your work? Please do not count any walking 
you did to travel to or from work. 
 
_____ days per week 
 




7. How much time did you usually spend on one of those days walking as 
part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to 
places like work, stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor 
vehicle like a train, bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle                           Skip to question 
10 
 
9. How much time did you usually spend on one of those days traveling in a 
train, bus, car, tram, or other kind of motor vehicle? 
 
_____ hours per day 
_____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to 
and from work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 
minutes at a time to go from place to place? 
 
_____ days per week 
 




11. How much time did you usually spend on one of those days to bicycle 
from place to place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time to go from place to place? 
 
_____ days per week 
 




AND CARING FOR 
FAMILY 
 
13. How much time did you usually spend on one of those days walking from 
place to place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the 
last 7 days in and around your home, like housework, gardening, yard work, 
general maintenance work, and caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
vigorous physical activities like heavy lifting, chopping wood, shoveling 
snow, or digging in the garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard                                Skip to 
question  
 
15. How much time did you usually spend on one of those days doing 
vigorous physical activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate activities like carrying light loads, sweeping, washing windows, 
and raking in the garden or yard? 
 
_____ days per week 
 




17. How much time did you usually spend on one of those days doing 
moderate physical activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at 
least 10 minutes at a time. During the last 7 days, on how many days did 
you do moderate activities like carrying light loads, washing windows, 
scrubbing floors and sweeping inside your home? 
 
_____ days per week 
 







19. How much time did you usually spend on one of those days doing 
moderate physical activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days 
solely for recreation, sport, exercise or leisure. Please do not include any 
activities you have already mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 
days, on how many days did you walk for at least 10 minutes at a time in 
your leisure time? 
 
_____ days per week 
 
 No walking in leisure time                        Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in 
your leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
vigorous physical activities like aerobics, running, fast bicycling, or fast 
swimming in your leisure time? 
 
_____ days per week 
 





23. How much time did you usually spend on one of those days doing 
vigorous physical activities in your leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do 
moderate physical activities like bicycling at a regular pace, swimming at 
a regular pace, and doubles tennis in your leisure time? 
 
_____ days per week 
 




25. How much time did you usually spend on one of those days doing 
moderate physical activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, 
while doing course work and during leisure time. This may include time spent 
sitting at a desk, visiting friends, reading or sitting or lying down to watch 
television. Do not include any time spent sitting in a motor vehicle that you have 
already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a 
weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a 
weekend day? 
 
_____ hours per day 
_____ minutes per day 
 
 










Appendix Q: FACT-B (Version 4) 
 
English (Universal) 16 November 2007 
 
This a list of statements that other people with your illness have said are 
important. Please circle or mark one number per line to indicate your 

































Appendix S: Physical activity: Script for face to face and telephonic consultation 
Please emphasise moderate intensity physical activity message 
 
Current PA Behaviour 
 
• Activities the patients enjoyed & felt they could do on a regular basis 
 
• Ways of fitting PA into daily life; previous experiences 
 
 
Decision Balance Sheet 
  





 What are the greatest barriers and how they might be overcome? 
 
 Suggest exercise benefits patients may not be aware of 
  
Prompts to seek social support 
  
• Family, friends, workmates, others who might encourage exercise 
 




• Patients states own goals 
 




• Walking/cycling in dark, ensure can be seen and someone knows  
 
• Where you’re going. Avoid busy/dangerous roads etc. 
 
Go for brisk walk 
 
• Brisk walk so that you are mildly breathless but can still hold a 
conversation 
 
Basic lifestyle information 
 








Appendix T: Post card physical activity prompt  
 
